2016 American Transplant Congress » 2016 ATC Sessions

Date & Time:
None. Available on demand

Location: None listed

Session Type:

Meeting: 2016 American Transplant Congress

25-Hydroxyvitamin D Insufficiency Is Associated with Higher Risk of BK Virus Re-Activation After Kidney Transplantation.

N. Elfadawy,¹ S. Flechner,² E. Poggio,² B. Stephany,² R. Fatica,² J. Schold,² S. Mossad.²
A Kidney Paired Donation Standard Acquisition Charge Pilot Program.

M. Rees,¹ L. Reece,² S. Rees,² B. Crandall,² A. Leichtman.⁴
A Virtual Crossmatch Algorithm That Mimics the Sensitivity of Flow Cytometric Crossmatch.

P. Rao, D. Deo, C. Rhodes, D. King, P. Bowe, J. Napoleon, I. Okere.
Activated Cytoprotective Mechanisms in DBD Kidneys Correlate with Kidney Function in Transplant Recipients: A Study Using Clinical Samples from the UK QUOD Biobank.

M. Kaisar,¹ L. van Dullemen,² Z. Akhtar,¹ M. Lo Faro,¹ H. Huang,¹ H. Leuvenink,² B. Kessler,¹ R. Ploeg.¹
Clinical Significance of Isolated v1 Arteritis in Renal Transplantation.

D. Mikhail,^1,3 J. Wei,³ D. Kleinsteuber,² M. Gabril,^2,3 A. Sener,^1,3 M. Moussa,^2,3 P. Luke.^1,3
Combination of Delayed Kidney Transplant (KT) and Better Quality Kidneys Offers Excellent Patient Survival in Combined Liver-Kidney Transplantation (CLKT).

B. Ekser, R. Mangus, J. Fridell, C. Kubal, D. Bayt, S. Nagaraju, P. Mihaylov, J. Powelson, W. Goggins, A. Tector.
Complement-Binding Donor-Specific Anti-HLA Antibodies Are Associated with Severe Kidney Allograft Arteriosclerosis.

A. Loupy,¹ D. Viglietti,² J. Duong Van Huyen,¹ D. Glotz,² C. Legendre,¹ A. Zeevi,³ C. Lefaucheur.²
Early Hospital Readmission Following Kidney Re-Transplantation.

E. King, B. Orandi, S. Bae, X. Luo, D. Segev.
Early Post-Transplant Immunosuppression (IS) Withdrawal – Final Outcomes of the ITN030ST AWISH Study.

A. Shaked,¹ S. Feng,² J. Punch,³ J. Reyes,⁴ J. Levitsky,⁵ G. Klintmalm,⁶ H. Kopetskie,⁷ M. DesMarais,² A. Priore,⁸ N. Bridges,⁸ P. Sayre.²
Effect of mTOR Inhibitors on the Risk of Cancer Development After Kidney Transplantation in Chinese Population.

C.-C. Kao,¹ J.-S. Liu,² M.-H. Lin,² F.-C. Chang,¹ Y.-C. Lin,¹ H.-H. Chen,¹ T.-W. Chen,¹ C.-C. Hsu,² M.-S. Wu.¹
Evaluation of a Novel Global Immunity Assay to Predict Infections in Organ Transplant Recipients.

M. Mian, A. Humar, S. Keshwani, S. Husain, P. Ashton, S. Han, L. Singer, J. Kim, E. Renner, M. Bhat, D. Kumar.
Everolimus with Low-Dose Tacrolimus vs. a Standard Immunosuppressive Regimen: Renal Histology at 6 Months in De Novo Renal Transplant Patients.

S. Yilmaz,¹ D. Shaffer,² F. Shihab,³ K. McCague,⁴ D. Patel,⁴ Y. Qazi,⁵ F. Vincenti.⁶
Financial Burdens and Coping Mechanisms of Living Kidney Donors.

S. Li,¹ C. Thiessen,¹ J. Gannon,¹ D. Dobosz,¹ D. Gray,³ A. Mussell,³ K. Kennedy,² P. Reese,³ E. Gordon,¹ S. Kulkarni.²
First Bilateral Hand Transplant in a Child: Short-Term Medical Outcomes and Challenges.

S. Amaral,¹ M. Levine,² B. Chang,² S. Lopez,¹ C. McAndrew,² S. Kessler,¹ A. Shaked,² L. Levin.²
Foxp3 Controls Oxidative Phosphorylation in Regulatory T Cells.

U. Beier,¹ A. Angelin,² J. Jiao,¹ H. Xiao,¹ L. Wang,³ S. Dahiya,³ A. Wells,³ D. Wallace,² W. Hancock.³
Identification of MicroRNAs in EBV⁺ B Cell Lymphomas and Secreted Exosomes.

V. Kaul, A. Harris-Arnold, C. Esquivel, O. Martinez, S. Krams.
Implementation of Telehealth Is Associated with Improved Timeliness of Kidney Transplant Waitlist Evaluation at a VA Center.

R. Forbes,^1,2 K. Kummerow Broman,^1,2 T. Johnson,² D. Rybacki,² M. Hagemann,² A. Hannah-Gillis,² I. Feurer,¹ D. Hale.^1,2
Initial Experience Treating Hepatitis C Positive Kidney Transplant Recipients with Non-Interferon-Containing Regimens: Successes and Challenges.

M. Aull, A. Watkins, J. Kim, K. Rhee, D. Dadhania, J. Lee, S. Kapur.
Is C3d-fixing Donor Specific HLA Antibody Detection Really Necessary?

P. Malvezzi,¹ M. Villemaire,¹ A. Bourdin,² T. Jouve,¹ R. Tetaz,¹ B. Janbon,¹ N. Terrier,³ D. Masson.²
Ischemia Reperfusion Induced Murine Heart Transplant Rejection Is Complement Dependent.

N. Chun,¹ M. Zhang,² R. Fairchild,³ P. Heeger.¹
Live Donor Liver Transplantation for NASH: The Toronto Experience.

A. Barbas, N. Goldaracena, M. Dib, M. Marquez, G. Sapisochin, D. Al-Adra, I. McGilvray, M. Cattral, P. Greig, D. Grant.
Microfluidics to Characterize Leukocyte Trafficking into Allografts and the Resolution of Inflammation.

L. Boneschansker,^1,2 D. Irimia,² D. Briscoe.¹
Mining the Human Proteome for Monitoring Renal Transplant Injury.

T. Sigdel,¹ Y. Gao,² J. He,² A. Wang,¹ C. Nicora,² D. Smith,² W. Qian,² D. Camp,² M. Sarwal.¹
Pediatric Access to Kidney Transplantation Under KAS.

W. Cherikh,¹ D. Stewart,¹ A. Kucheryavaya,¹ M. Aeder,² E. Brewer.³
Polyclonal Treg Adoptive Therapy for Control of Subclinical Kidney Transplant Inflammation (TASK Pilot Trial).

S. Chandran, Q. Tang, M. Sarwal, Z. Laszik, A. Putnam, T. Sigdel, E. Tavares, J. Bluestone, F. Vincenti.
Pre-Transplant IgM to Post-Transplant IgG DSA Conversion May Be Affected by Immunosuppression.

A. Nguyen,¹ M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,² C. Morgan,² A. Maldonado,² P. Terasaki.¹
Pregnancy Excludes Women from Successful Living Donor Transplantation.

P. Porrett,¹ B. Bromberger,² S. Hashmi,¹ A. Morrison,¹ D. Sawinski.³
Pregnancy Outcomes in 17 Female Heart Transplant Recipients with the Initial Diagnosis of Congenital Heart Defect.

L. Coscia,¹ D. Armenti,¹ S. Constantinescu,^1,2 M. Moritz.^1,3
Prolongation of Graft Survival by Anti-TIM1 Is Specifically Mediated by IL-10+ Bregs and Is Not Dependent on IL-35 or Plasma Cell Differentiation.

Y. Zhou,^1,2 Q. Ding,¹ A. Cherukuri,¹ D. Rothstein.¹
Rapamycin Encapsulated Nanoparticles as Pre-Treatment in Lung Transplantation.

G. Bazzle,¹ S. Dixit,² K. Patel,³ A.-M. Broome,² S. Nadig,^1,3 C. Atkinson.^1,3
Relationship Between Mean Fluorescence Intensity and C1q/C3d-Fixing Capacities of Anti-HLA Antibodies.

G. Claisse,¹ L. Absi,² E. Alamartine,¹ N. Maillard,¹ C. Mariat.¹
Serial Peripheral Blood Mononuclear Cell Expression Profiling Reveals Inflammatory Genomic Storm Following Mechanical Circulatory Support Surgery.

G. Godoy,¹ G. Bondar,¹ A. Esmaeili,¹ E. Arellano,¹ E. Chang,¹ M. Bakir,¹ J. Chittoor,¹ R. Togashi,¹ N. Fazli,¹ C. Starling,¹ E. Oh,¹ S. Toluie,¹ Z. Yang,² D. Tran,¹ M. Cadeiras,¹ N. Wisniewski,¹ M. Kwon,¹ J. Schaenman,¹ Y. Korin,¹ M. Rosetti,¹ E. Reed,¹ M. Deng.¹
Short-Term Post-Donation Renal Function in Living Kidney Donors.

L. Fahmy, A. Massie, A. Muzaale, S. Sandal, E. Chow, D. Segev.
Successful Treatment of Hepatitis C in Renal Transplant Recipients with Directly Acting Antiviral Agents.

M. Lubetzky,¹ S. Chun,¹ A. Joelson,¹ E. Akalin,¹ P. Gaglio,² G. DeBoccardo.¹
Survival Benefit of DCD Livers.

X. Luo, A. Massie, D. Segev.
Toll-Like Receptor (TLR) 9-Induced Resistance to Murine Cardiac Allograft Tolerance Is Dependent Upon C3a and C5a Receptor (C3aR/C5aR) Signaling.

J. Sheen, P. Heeger.
Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.

M. Bowring, L. Kucirka, A. Massie, X. Luo, M. Sulkowski, D. Segev, C. Durand.
Validation of a Simplified Cost-Effective Clinical Risk Stratification That Predicts Myocardial Ischemic Events in Kidney Transplant Candidates.

T. Jiamjariyapon,^1,2 N. Townamchai,^2,3 N. Garg,² M. Pavlakis,² A. Chandraker.²
Where Are the KDPI 0-20% Kidneys Going in the New KAS? A Major Allocation Shift.

M. Aeder,¹ N. Turgeon,² A. Kucheryavaya,³ D. Stewart.³
A Molecular Biopsy Test for Probability of Non-Adherence.

P. Halloran,^1,3 G. Einecke,² J. Reeve.¹
A P2X7R Mutation with Hypermetabolic T Cells, Th1/Th17 Skewing and Reduced Cardiac Allograft Survival.

F. D'Addio,^1,2 A. Vergani,³ L. Potena,⁴ A. Maestroni,² S. Tezza,¹ M. Ben Nasr,¹ V. Usuelli,² M. Sbolli,¹ L. Borgese,⁴ A. Iacovoni,⁵ D. Corradi,⁶ R. Abdi,⁷ A. Secchi,² R. Starling,⁸ M. Sayegh,^7,9 W. Harmon,¹ D. Briscoe,¹ P. Heeger,¹⁰ A. Chandraker,⁷ F. Grigioni,⁴ P. Fiorina.^1,2
African-American Primary Renal Transplant Recipients Are at a Significantly Higher Risk to Develop De Novo DSA.

M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,³ C. Morgan,² A. Maldonado,⁴ A. Nguyen,¹ P. Terasaki.¹
Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation.

J. Mansur, G. Basso, M. Cristelli, G. Mata, T. Sandes-Freitas, G. Kirsztajn, H. Tedesco-Silva, J. Medina-Pestana.
BK Polyomavirus Seroreactivity of Kidney Donors Predicts Viremia and Nephropathy in Recipients.

H. Wunderink,¹ E. van der Meijden,¹ C. van der Blij-de Brouwer,¹ M. Mallat,² G. Haasnoot,³ E. van Zwet,⁴ E. Claas,¹ J. de Fijter,³ A. Kroes,¹ F. Arnold,⁵ A. Touzé,⁵ F. Claas,³ J. Rotmans,³ M. Feltkamp.¹
C5a Induces CSF1-Dependent Regulatory Macrophage (Mreg) Development Required for Murine Allograft Tolerance.

I. Llaudo, P. Conde, J. Ochando, P. Heeger.
Clinical and Subclinical Cardiac Events After Kidney Transplantation (KTX).

F. Cosio,¹ H. Amer,¹ M. Keddis,² A. Jaffe.³
Common Molecular Features of Human Kidney Transplant Rejection Reflect Mechanistic Sharing Between T Cell-Mediated and Antibody-Mediated Rejection.

J. Venner,^1,2 P. Halloran.²
Direct IL-33 Stimulation of T Regulatory Cells via Suppression of Tumorigenicity 2 (ST2) Is Required for Effective Control of Alloimmune Responses.

X. Zhang,^1,3 B. Matta,¹ D. Reichenbach,² B. Blazar,² H. Turnquist.¹
Diversity of Influenza Antibody Repertoire in Transplant Recipients with Natural Influenza Infection.

V. Ferreira, A. Chruscinski, S. Han, A. Humar, D. Kumar.
Early Hospital Readmission Following Pediatric Kidney Transplantation.

E. King, L. Kucirka, M. McAdams-DeMarco, S. Bae, D. Segev.
Enhanced Recovery After Kidney Transplantation: 48 Hour Length of Stay in Living and Deceased Donor Transplant Recipients.

O. Ojogho, J. Mejia, S. Bani-Hani, B. Dieter, R. Carson.
Examining the Risk for Post-Transplant Viral Infections and Lymphoproliferative Disorder (PTLD) in Kidney Transplant Patients (Pts) Receiving Calcineurin Inhibitor-Based Immunosuppression (CNI-IS) Compared to Belatacept (CTLA4Ig).

B. Shin, J. Choi, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.
Fate of Endogenous Alloreactive B Cells in Transplant Tolerance.

J. Chen,¹ J. Yang,¹ A. Akl,¹ Q. Wang,¹ D. Yin,¹ R. Sciammas,² A. Chong.¹
Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation.

E. Woodle, A. Girnita.
First Clinical Experience with Belatacept in 3 Hand Transplanted Patients.

J. Grahammer,¹ B. Zelger,² B. Zelger,³ M. Ninkovic,¹ A. Muehlbacher,⁴ D. Oefner-Velano,¹ S. Schneeberger,¹ A. Weissenbacher.⁵
HLA Antibody in Transplant Recipients During Transition from Paediatrics.

S. Kaki,¹ A. Lunn,² J. Goodwin,³ T. Key,³ W. McKane.¹
HO-1/SIRT1/p53 Axis Regulates Macrophage Activation and Attenuates Liver Ischemia-Reperfusion Injury in Mice.

K. Nakamura,¹ M. Zhang,² B. Ke,¹ S. Kageyama,¹ R. Busuttil,¹ J. Araujo,² J. Kupiec-Weglinski.¹
Hepatitis E Virus (HEV) Infection Among Kidney Transplant Patients in a Northeast US Center.

M. Lim,¹ S. Kamili,² T. Greene,² A. Tejada-Strop,² J. Drobeniuc,² M. Vanderveen,¹ R. Bloom.¹
Impact of Early Calcineurin Inhibitor Withdrawal on Renal Function and Urinary Protein Excretion: 24 Month Analyses of the ELEVATE Study.

J. de Fijter,¹ H. Holdaas,¹ M. Seelen,¹ S. Sundar,¹ F. Bemelman,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ M. van der Giet.¹
Impact of Proximity MELD/PELD Points on Liver Redistricting Scenarios.

S. Gentry,^1,2 J. Pyke,¹ D. Schladt,¹ J. Zeglin,¹ W. Kim,³ J. Lake,⁴ R. Hirose,⁵ D. Mulligan,⁶ A. Israni.¹
Kidney Transplantation in HIV Patients: Effect of Race on the Choice of Anti-Thymocyte Globulin Induction Immunosuppression.

M. Casey, T. Aijaz, X. Wen, S. Rehman, A. Santos, E. Thomas, K. Andreoni, K. Womer.
Live Donor Champion Program: Time to Redefine Living Liver Donation.

D. Maluf, A. Sites, M. Donovan, J. Wang, E. Lyster, C. Argo.
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.

F. Al Ammary, S. Bae, A. Massie, N. Desai, N. Dagher, E. Kraus, A. Wiseman, D. Segev.
Molecular Assessment of Kidney Transplant Biopsies Performs Similarly in Medulla and Cortex.

K. Madill-Thomsen,¹ J. Reeve,¹ G. Bohmig,² F. Eskandary,² P. Halloran.^1,3
Molecular Significance of Microvascular Inflammation and C4d Negative Transplant Glomerulopathy.

M. Lubetzky,¹ P. O Broin,² Y. Bao,¹ E. Akalin.¹
Normothermic Ex Vivo Liver Perfusion (NEVLP) Using Steen Solution as Preservation Technique for Liver Transplantation-First Clinical Results.

M. Selzner, N. Goldaracena, J. Echeverri, I. Linares, M. Kaths, N. Selzner, M. Cattral, E. Renner, A. Ghanekar, L. Lilly, P. Greig, I. McGilvray, D. Grant.
Obesity Is Associated with Increased Risk of ESRD Among Living Kidney Donors.

J. Locke,¹ C. Lewis,¹ R. Reed,¹ V. Kumar,¹ D. Sawinski,² A. Massie,³ P. MacLennan,¹ R. Mannon,¹ R. Gaston,¹ D. Segev.³
Primary Outcome of iWITH: A Multi-Center Clinical Trial of Complete Immunosuppression Withdrawal (ISW) in Stable Pediatric Liver Transplant (LT) Recipients.

S. Feng,¹ J. Bucuvalas,² A. Demetris,³ K. Spain,⁴ S. Kanaparthi,⁵ J. Magee,⁶ G. Mazariegos,³ The iWITH Investigators.⁷
Provider Attitudes Toward Shared Mobile Decision Aid Utilized Among Patients Evaluated for Kidney Transplantation: iChoose Kidney Randomized Trial.

M. Basu,¹ S. Pastan,¹ S. Mohan,² M. Wolf,³ J. Friedewald,³ D. Ladner,³ K. Smith,¹ L. McPherson,¹ A. Russell,³ M. Chiles,² R. Patzer.¹
Receptor Tyrosine Kinase Mer Mediates Expansion of MDSCs Critical for Transplantation Tolerance.

L. Zhang,¹ M. DeBerge,² X. Zhang,³ J. Wang,³ Z. Zhang,³ E. Thorp,² X. Luo.^1,2,3
Removing Geographic and Financial Barriers for Directed Living Kidney Donations: Lessons from Kidney Paired Donation.

M. Aeder,¹ R. Leishman,² D. Stewart.²
Return on Investment for Financial Assistance for Living Kidney Donors in the United States.

A. Mathur,¹ J. Xing,² D. Dickinson,² P. Warren,³ K. Gifford,³ B. Hong,⁴ A. Ojo,⁵ R. Merion.^2,5
Short UK Dialysis Does Not Significantly Impact on Live Donor Kidney Allograft Survival.

A. Bentall,^1,2 M. Jesky,^1,2 R. Borrows,^1,2 R. Johnson,³ S. Ball.^1,2
The Effect of DRI and KDPI on Outcomes of High MELD Patients Undergoing Simultaneous Liver Kidney Transplant.

E. Chan,¹ M. Hertl,¹ J. Perkins.²
The Quilty Effect in Pediatric Heart Transplant Recipients.

A. Joong,¹ M. Richmond,¹ K. Stack,² R. Rodriguez,¹ J. McAllister,² W. Zuckerman,¹ T. Lee,¹ S. Law,¹ L. Addonizio.¹
U.S. Dialysis Facility Characteristics Associated with Racial Disparities in Access to the Kidney Deceased Donor Transplant Waiting List.

J. Gander, L. Plantinga, S. Paul, S. Pastan, R. Patzer.
Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS.

D. Stewart,¹ A. Kucheryavaya,¹ R. Brown,¹ D. Klassen,¹ N. Turgeon,² M. Aeder.³
mTORC2 Negatively Regulates Dendritic Cell (DC) Metabolism and the Allostimulatory Function of Donor DCs in Organ Transplantation.

A. Watson,^1,2 D. Raïche-Regué,¹ H. Dai,¹ K. Fabian,^3,4 G. Delgoffe,^4,5 W. Storkus,^3,4 A. Thomson.^1,2
Adherence Patterns in Adolescent and Young Adult Kidney Transplant Recipients.

J. Boucquemont,^1,2 B. Foster,^1,2 The TAKE-IT Investigators.
An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.

W. Ju, A. Yang, Q. Ren, D. Wang, Z. Guo, Y. Ma, A. Hu, Q. Tai, X. Zhu, X. He.
Analysis of Broken Chains in Kidney Paired Donation During an 8 Year Period within the National Kidney Registry.

N. Cowan,¹ J. Sinacore,² H. Gritsch,¹ J. Veale.¹
B Lymphocytes Prevent Transplantation Tolerance in NOD Mice by Limiting CD4 Treg Function.

B. Stocks, C. Wilson, D. Meehan, A. Marshall, D. Moore.
Beyond the Bones – The Association Between Vitamin D, Graft Outcomes and Vascular Disease.

A. Cherukuri,¹ S. Balasubramanian,² R. Molyneux,² R. Baker.
Blindspots in HLA Antibody Testing: Recognition Is First Step to Nirvana.

A. Kher, P. Dorwal, V. Kher.
Blockade of HLA Antibody-Triggered Classical Complement Activation by High-Affinity Humanized Monoclonal Anti-C1s Antibody TNT009 – Results of a First-in-Human Phase 1 Trial.

J. Mühbacher,¹ B. Jilma,² M. Wahrmann,³ L. Marinova,³ F. Eskandary,³ J. Gilbert,⁴ S. Panicker,⁴ G. Böhmig.³
CD57+ CD4 T Cells Persist in the Periphery Following Kidney Transplantation.

J. Espinosa,^1,2 L. Stempora,¹ R. Townsend,³ A. Kirk.¹
Center-Level Variation in Association Between Early Hospital Readmission and Survival Following Kidney Transplantation.

S. Cramm, E. King, D. Segev.
DSA After Transplant Increases Risk of Renal Allograft Failure Independent of Concurrent Biopsy Results: The DEKAF Study Data.

J. Cecka,¹ J. Grande,² F. Cosio,² R. Leduc,³ The DeKAF Study Group.
Deceased Organ Donor Management: Does Hospital Volume Matter?

M. Patel,¹ J. Mohebali,¹ M. Sally,² T. Groat,² P. Vagefi,¹ D. Chang,¹ D. Malinoski.²
Development of a Vascularized Thymus-Sternum Composite Tissue Allograft Model in Non-Human Primates.

N. O'Neill, S. Sendil, Y. Zhao, A. Hershfield, I. Tatarov, G. Braileanu, W. Hassanein, D. Parsell, A. Azimzadeh, L. Burdorf, R. Pierson, A. Nam.
Donors with Isolated Anti-HBc (“HBcAb Only”) Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb.

Y. Chang,^1,3 C. Chinchilla-Reyes,² M. Koss,^1,2 M. Nowicki.^1,2
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.

H. Hirsch,¹ J. De Fijter,¹ M. van der Giet,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ H. Holdaas,¹ J. Cruzado.¹
Efficacy and Renal Function in Kidney Transplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination with Everolimus (EVR) versus Mycophenolate (MPA).

A. Brigido, H. Tedesco, C. Felipe, M. Cristelli, M. Franco, J. Medina-Pestana.
Evaluation of Scoring Systems Predicting Patient Survival at Time of Kidney Transplantation.

O. Staeck, D. Khadzhynov, A. Kleinsteuber, L. Lehner, M. Duerr, K. Budde, F. Halleck.
Everolimus (EVR) versus Mycophenolate Sodium (MPS) for Recipients of Kidney Transplants from Expanded Criteria Donors (ECD) Receiving Anti-Thymocyte Globulin (r-ATG) and Tacrolimus (TAC).

H. Tedesco-Silva,¹ C. Felipe,¹ A. Brigido,¹ A. Bessa,¹ M. Paula,¹ P. Ruppel,¹ M. Cristelli,¹ L. Viana,¹ G. Basso,¹ M. Franco,² W. Aguiar,¹ J. Medina-Pestana.¹
Gsk3β Regulates Macrophage Pro-Inflammatory Immune Activation via AMPK-Mediated Induction of Small Heterodimer Partner (SHP).

H. Zhou,^1,2 J. Zhu,^1,3 S. Yue,¹ R. Busuttil,¹ J. Kupiec-Weglinski,¹ X. Wang,² Y. Zhai.¹
Hepatic Hemodynamics (HD) and Portal Flow Modulation (PM): Tactical Use in Small for Size (SFS) Live Donor Liver Transplantation (LDLT).

T. Mansour,¹ J. Pisa,¹ E. Przybyszewski,¹ J. Guarrera,¹ K. Tomoaki,¹ B. Samstein,¹ K. Halazun,² A. Griesemer,¹ J. Emond.¹
IL-2 Therapy Restores the Impaired Function of Regulatory T Cells Induced by Calcineurin Inhibitors in Liver Transplantation.

G. Whitehouse, E. Gray, S. Mastoridis, E. Kodela, A. Sanchez-Fueyo, M. Martinez-Llordella.
Immune Response to BK Virus in Renal Transplant Recipients.

D. DeWolfe,¹ J. Gandhi,¹ M. Mackenzie,¹ T. Broge,¹ E. Bord,¹ D. Mandelbrot,¹ R. Viscidi,² F. Cardarelli,¹ M. Pavlakis,¹ C. Tan.¹
Incidence and Renal Consequences of Type 2 Diabetes Mellitus in Kidney Donors.

H. Ibrahim, A. Matas, D. Berglund, S. Reule, A. Kukla, N. Issa, R. Spong, R. Foley.
Insights into the Treatment of Post-Transplant Focal Glomerulosclerosis: Experience Gained from a Concise Diagnostic and Management Protocol.

K. Koutroutsos,¹ R. Charif,¹ L. Moran,² J. Moss,² T. Cook,² C. Roufosse,² D. Taube,¹ M. Loucaidou.¹
Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.

E. Maloney, E. Bongen, F. Vallania, N. Kotecha, P. Khatri, O. Martinez.
Intervention Development for the Allocation System Changes for Equity in kidNey Transplantation (ASCENT) Study.

K. Smith,¹ J. Gander,¹ M. Basu,¹ S. Pastan,¹ S. Mohan,² C. Escoffery,¹ L. Plantinga,¹ S. Kalloo,² G. Green,³ A. Berlin,⁴ G. Renville,⁵ T. Browne,⁶ N. Turgeon,¹ S. Caponi,⁷ J. Krisher,⁸ R. Patzer.¹
Kidney Donor Profile Index Trend Analyses.

D. Vikraman, K. Ravindra, S. Sanoff, W. Irish, U. Patel, D. Sudan.
Lymph Node Stromal Laminins Differentially Regulate T Cell Immunity and Tolerance.

T. Simon, J. Bromberg.
Malignancies Contribute to Presensitization with Alloreactive T-Cells in Kidney Transplant Recipients.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
NK Cells Are Required in B-Cell Dependent, Antibody Mediated Islet Transplant Tolerance.

C. Schuetz, K. Lee, L. Kojima, L. Washburn, L. Liu, W.-H. Liu, J. Kim, J. Markmann.
Natural Killer CD16/FcR Profiles May Associate with Enhanced Humoral Responsiveness in Heart Transplant Recipients with Cardiac Allograft Vasculopathy.

P. Paul,^1,2 C. Picard,^3,4 E. Sampol,⁵ L. Lyonnet,¹ J. Di Cristofaro,^3,4 G. Lano,^6, B. Dussol,^6, F. Collart,⁷ F. Sabatier,^1,2 F. Dignat George,^1,2 A. Mouly Bandini.⁷
Predicting Obstructive Coronary Artery Disease in Asymptomatic Patients Undergoing Renal Transplantation Using a Simple Risk Score.

D. Moutzouris, C. Baker, M. Willicombe, N. Duncan, J. Galliford, A. McLean, D. Taube.
Racial Disparities in Perioperative Complications After Live Kidney Donation.

K. Lentine,¹ N. Lam,² D. Axelrod,³ M. Schnitzler,¹ A. Garg,⁴ J. Schold,⁵ D. Brennan,⁶ H. Randall,¹ D. Segev.⁷
Relationship Between Clinical Events and Everolimus Exposure at 12 Months in De Novo Renal Transplant Recipients.

F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
Seven Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients.

J. Leventhal,¹ J. Galvin,¹ D. Stare,¹ L. Gallon,¹ J. Miller,¹ J. Mathew,¹ M. Abecassis,¹ S. Ildstad.²
Skipping Comparable Local Waitlist Candidates Under Share 35.

E. Chow,¹ A. Massie,¹ X. Luo,¹ C. Wickliffe,¹ S. Gentry,² A. Cameron,¹ D. Segev.¹
Solid Phase Assay Demonstrates High Rates of Allosensitization in Pediatric Heart Recipients.

W. Zuckerman,¹ B. Feingold,² A. Zeevi,² C. Bentlejewski,² L. Addonizio,¹ E. Blume,³ C. Canter,⁴ A. Dipchand,⁵ D. Hsu,⁶ R. Shaddy,⁷ W. Mahle,⁸ K. Much,⁹ B. Armstrong,⁹ D. Ikle,⁹ H. Diop,¹⁰ J. Odim,¹⁰ S. Webber.¹¹
Subnormothermic Machine Perfusion (SNMP) Leads to Increased Bile Production and Secretion of Hydrophilic Bile Acids After Liver Transplantation When Compared to Cold Storage (CS).

B. Banan, R. Lopez, Z. Khan, C. Hughes, G. Michalopoulos, P. Fontes.
Utility in Treating Renal Failure in End-Stage Liver Disease with Simultaneous Liver-Kidney Transplantation.

X. Cheng,¹ M. Stedman,¹ W. Kim,² J. Tan.¹
Who Should Decide? Potential Living Kidney Donor Preferences for Making Decisions About Risk.

C. Thiessen,¹ J. Gannon,¹ K. Kennedy,² D. Dobosz,¹ S. Li,¹ D. Gray,³ A. Mussell,³ E. Gordon,² P. Reese,³ S. Kulkarni.¹
A Retrospective Study of Simultaneous Bilateral Nephrectomies and Renal Transplantation in Recipients with Polycystic Kidney Disease.

E. Grodstein, D. Kaufman.
A Risk Quantification Score for Heart Transplants: A Heart Donor Risk Index.

A. Israni,^1,2 D. Zaun,¹ J. Snyder,¹ N. Salkowski,¹ H. Xiong,¹ B. Kasiske,^1,2 M. Colvin,^1,3 M. Colvin.^1,3
Acute Kidney Injury After Liver Transplantation Is Set in Motion Early After Reperfusion of the Liver Graft: A Prospective Cohort Study.

I. Jochmans,¹ N. Meurisse,² D. Monbaliu,¹ J. Pirenne.¹
An Improved Method for the Evaluation of Microvascular Inflammation in Renal Allograft Biopsies.

M. Rooney,¹ Z. Ping,² D. Samarapungavan,³ R. Hennigar.⁴
Angiotensin II Type 1 Receptor Antibodies Are Associated with Allograft Loss in Pediatric Renal Transplantation.

M. Pearl,¹ Q. Zhang,² M. Palma Diaz,³ J. Grotts,⁴ J. Brook,⁴ D. Gjertson,² P. Weng,¹ E. Reed,² E. Tsai.¹
Assessment of Chikungunya IgM Prevalence Among Deceased Organ and Tissue Donors Using Two Enzyme Immunoassay (EIA) Kits.

H. Prince, M. Altrich, M. Nowicki.
Characteristics of Compatible Pair Participants in Living Donor Kidney Transplant Exchanges.

F. Weng, T. Grogan, A. Patel, S. Mulgaonkar, M. Morgievich.
Clinical Significance of Non-HLA Antibodies in the Development of Microcirculation Inflammation in Allograft Tissue After Kidney Transplantation.

J. Min,^1,3 H. Lee,^2,3 B. Chung,^1,3 E.-J. Oh,^2,3 C. Yang.^1,3
Does DCD Donor Time-to-Death After Withdrawal of Support Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United States.

J. Scalea, L. Fernandez, A. D'Alessandro, M. Anderson, D. Foley, J. Mezrich.
Durable Clinical and Immunologic Advantage of Living Donor Liver Transplantation (LDLT) in Children.

E. Przybyszewski,¹ S. Lobritto,¹ M. Martinez,¹ J. Vittorio,¹ A. Fox,¹ B. Samstein,² T. Kato,¹ A. Griesemer,¹ J. Emond.¹
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.

M. Willicombe, D. Goodall, A. McLean, D. Taube.
Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.

Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.
Expansion of Regulatory B-Cells and Their Potential Role in Transplantation Tolerance.

B. Amundsen, H. Deirawan, J. Kim, J. Markmann.
HLA Identical or Haploidentical Combined Kidney and Bone Marrow Transplantation for Multiple Myeloma with End-Stage Renal Failure.

T. Kawai,¹ Y.-B. Chen,¹ M. Sykes,² C. Benedict,¹ N. Tolkoff-Rubin,¹ B. Day,¹ S. McAfee,¹ K. Ballen, S. David,¹ T. Spitzer.¹
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.

M. Charlton,¹ E. Yoshida,² M. Bouliere,³ S. Flamm,⁴ A. Muir,⁵ M. Fried,⁶ N. Terrault,⁷ S. Arterburn,⁸ C. Yun,⁸ P. Pang,⁸ A. Osinusi,⁸ J. Spellman,⁸ M. Natha,⁸ D. Brainard,⁸ J. McHutchison,⁸ M. Manns,⁹ N. Afdhal.¹⁰
High PD-L1/CD86 MFI Ratio and IL-10 Secretion Characterize Maturation-Resistant Human Regulatory Dendritic Cells (DCregs) Generated for Clinical Testing in Transplantation.

A. Zahorchak,¹ L. Butterfield,^2,3 C. Macedo,¹ D. Hamm,⁴ D. Metes,^1,3 A. Thomson.^1,3
Immunogenic HLA-DR Eplet Mismatches as Predictors of Transplant Glomerulopathy.

D. Blum,¹ K. Tinckam,² M. Marrari,³ J. Kim,² R. Sapir-Pichhadze.¹
Influence of the Tacrolimus Metabolism Rate on BKV Infection After Kidney Transplantation.

G. Thölking,¹ C. Schmidt,¹ K. Schuette-Nuetgen,¹ D. Pabst,¹ R. Koch,² H. Wolters,³ S. Reuter,¹ B. Suwelack.¹
Investigating Geographic Variation in the Number of Deceased Donor Transplants Performed in the U.S.

R. Carrico, D. Stewart, R. Ehrensberger, B. Shepard, D. Klassen.
Investigating Posttransplant Allo-Donor Specific CD57⁺ Cells in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.

H. Xu, F. Feng, A. Kirk.
Kidney Retransplantation Is Associated with Higher Mortality Risk Among HIV+ vs. HIV- Recipients.

B. Shelton,¹ S. Mehta,¹ D. Sawinski,² R. Reed,¹ P. MacLennan,¹ S. Gustafson,³ C. Durand,⁴ D. Segev,⁴ J. Locke.¹
Machine Perfusion (MP) at 21[deg]C Simulates Hibernation Metabolic Pathways in a Non-Hibernator Mammal.

B. Banan, S. Dobrowolski, G. Michalopoulos, P. Fontes.
Macrophage Specific Deletion of RhoA Impedes Macrophage Functions and Abrogates Chronic Rejection of Cardiac Allograft.

Y. Liu, W. Chen, X. Li, R. Ghobrial, M. Kloc.
Monitoring of De Novo DSA Post Alemtuzumab Induction in Renal Transplant Recipients: One Year Follow Up.

Y. Nigatu, C. Estrada, F. Darras, H. Suh, M. Abate, E. Nord.
Offering HCV-Positive Kidneys to HCV-Negative Patients on the Kidney Transplant Waitlist Is Lifesaving: Results of a Markov Model.

D. Goldberg, P. Reese, V. Potluri, F. Scott.
Post-Transplant T-Cell Alloreactive Perturbation Precedes the Advent of Humoral Immunity in Kidney Transplant Patients.

E. Crespo,¹ S. Luque,¹ J. Cruzado,² E. Melilli,² J. Grinyo,² M. Lucia,¹ O. Bestard.²
Pre-Transplant Panel of Reactive T Cells (PRT) as an Independent Predictor of 2-Year Kidney Graft Function.

I. Gandolfini,¹ E. Crespo,² M. Baweja,¹ U. Maggiore,³ P. Cravedi,¹ P. Heeger,¹ O. Bestard.²
Predictors of Patient Uncertainty Regarding Treatment Options Among End Stage Renal Disease Patients Evaluated for Kidney Transplantation.

L. McPherson,¹ M. Basu,¹ S. Pastan,¹ S. Mohan,² M. Wolf,³ J. Gander,¹ R. Patzer.¹
Primary Graft Failure following Cardiac Transplantation Is Associated with Elevated Pre-Transplant Levels of Pro-Inflammatory Factors.

D. Chatterjee,¹ K. Clerkin,¹ K. Rogers,¹ D. Mancini,¹ Y. Naka,¹ H. Takayama,² K. Takeda,² P. Colombo,² G. Vlad,³ R. Vasilescu,³ B. Levin,⁴ M. Farr,¹ S. Restaino,¹ E. Zorn.¹
Recurrence of FSGS Post Kidney Transplantation: Salvage Therapy with ACTHAR® Gel.

P. Vaitla, D. Daswatta, A. Guasch.
Risk of ESRD in Potential HIV+ Live Kidney Donors.

A. Muzaale,¹ L. Kucirka,¹ A. Massie,¹ C. Durand,¹ J. Locke,² G. Lucas,¹ D. Segev.¹
Sphingosine 1-Phosphate (S1P) Receptors Differentially Regulate Murine and Human CD4 T Cell Migration Across Lymphatic Endothelium.

Y. Xiong,¹ C. Brinkman,¹ K. Hippen,² B. Blazar,² J. Bromberg.¹
T-Bet Regulates nTreg Stability and Suppression in an Islet Allograft Model.

Y. Xiong, S. Ahmad, D. Iwami, C. Brinkman, J. Bromberg.
Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas.

A. Sang, G. Ivison, C. Esquivel, S. Krams, O. Martinez.
The “PHS Increased Risk” Label Is Associated with Non-Utilization of Hundreds of Organs Per Year.

M. Volk,¹ A. Wilk,² C. Wolfe,³ D. Kaul.⁴
Use of Small (<10kg) Kidney Donors in the US.

J. Smith,^1,2 J. Snyder,¹ A. Israni,¹ B. Kasiske,¹ R. Perez.³
Using Predictive Modeling to Manage Cardiovascular Risk and Improve Kidney Transplant Outcomes.

W. Moran, J. Zhang, Z. Su, D. Taber, P. Mauldin, T. Srinivas.
Vascularized Composite Allograft Tolerance with Transient High-Dose Tacrolimus Across a Full MHC Mismatch in a Large Animal Model.

H. Wang, E. Swanson, H.-T. Cheng, J. Walch, J. Alonso-Esclante, K. Kolegraff, J. Lopez, G. Furtmuller, B. Oh, A. Quan, J. Budihardjo, S. AlFadil, S. Mulla, P. Akre, J. Sacks, S. Bonawitz, G. Raimondi, J. Shores, D. Cooney, W. Lee, G. Brandacher.
What Are the Charges and Costs of Transplanting High MELD Patients?

K. Bortecen, B. Gelb, A. Winnick, G. Morgan, L. Teperman.
“Day 2 Discharge” After Kidney Transplantation: Complications, Health Care Utilization, and Long-Term Clinical Outcomes.

A. Mathur, N. Katariya, A. Welu, J. Chang, R. Heilman, A. Singer, H. Khamash, H. Chakkera, W. Hewitt, D. Haakinson, M. Maningo-Salinas, E. Oakley, A. Moss, K. Reddy.
A New Diagnostic Score for Microvascular Inflammation in Antibody-Mediated Rejection in Heart Transplantation.

M. Racapé,¹ A. Loupy,² R. Guillemain,¹ A. François,³ P. Rouvier,⁴ C. Toquet,⁵ X. Jouven,¹ J. Venner,⁶ L. Hidalgo,⁶ J. Reeve,⁶ P. Bruneval,¹ J. Duong Van Huyen,² P. Halloran.²
AT1R Antibodies at 1-Year Negatively Impact 5-Year Native Renal Function in Liver Transplant Recipients.

J. O'Leary,¹ A. Philippe,² H. Heidecke,² R. Freeman,¹ L. Jennings,¹ R. Catar,² G. Klintmalm,¹ D. Dragun.²
Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.

J. Choi, A. Vo, M. Haas, D. Puliyanda, S. Louie, A. Peng, J. Kahwaji, R. Villicana, I. Kim, J. Mirocha, S. Jordan.
Are We Refusing Good Organs? Outcomes of Ventilator Management of Sub-Optimal Lung Donors.

B. Scully,¹ D. Horne,¹ J. Heinle,¹ E. McKenzie,¹ K. Hosek,² W. Zhang,² G. Mallory,³ E. Melicoff.³
Association of Ultrastructural Changes in Renal Allograft Biopsies with Antibody-Mediated Rejection (AMR) and Graft Outcomes.

A. Haririan,¹ M. Chaudhry,² J. Papadimitriou,² N. Costa,¹ B. Thomas,¹ M. Mavanur,¹ R. Ugarte,¹ C. Cangro,¹ C. Drachenberg.²
BK Nephropathy, but Not Isolated BK Viremia Associated with De Novo DSA Despite Similar Immunosuppression Reduction.

W. Cheungpasitporn,¹ D. Mitema,¹ H. Amer,¹ F. Cosio,¹ M. Stegall,² C. Schinstock.¹
Blocking Fc Receptor in Flow Cytometric Crossmatch: Refining an Old Assay to Improve Patient Management.

N. Brown, J. Wang, S. Marino.
Clinical Prediction Tool to Guide Referral of Elderly Dialysis Patients for Kidney Transplant Evaluation.

L.-X. Chen,¹ M. Josephson,¹ N. Stankus,¹ K. Campbell,¹ D. Hedeker,² M. Saunders.¹
Cold Storage Stabilization of Gap Junctions Reduces Post Transplant Ischemia Reperfusion Injury.

R. Finnegan,¹ P. Zhu,¹ S. Stephenson,¹ K. Patel,² S. Nadig,^1,2,3 C. Atkinson.^1,2,3
Complexity of Hylinosis in Renal Transplant Biopsies: Donor Age, Glomerular Disease, and Time.

G. Einecke,¹ J. Reeve,² P. Halloran.^2,3
Crisis on the Waiting List for Children Listed in Low Volume Solid Organ Transplant Centers.

A. Rana, E. Brewer, W. Winkelmayer, C. O'mahony, J. Goss.
DEPTOR Inhibits mTORC1 in CD4⁺ T Cells and Increases Treg Function by Stabilizing Foxp3 Expression.

J. Wedel,^1,2 S. Bruneau,^1,2 D. Briscoe.^1,2
Donor-Derived Monocytes Migrate to the Contralateral Lung and Cause Neutrophilia Following Single Lung Transplant.

S. Chiu, Z. Zheng, H. Sun, M. DeCamp, Jr, G. Budinger, H. Perlman, A. Misharin, A. Bharat.
Donor-Recipient Absolute Weight Mismatch and the Risk of Graft Loss in Renal Transplantation.

A. Miller,¹ B. Kiberd,¹ I. Alwayn,² K. Tennankore.¹
Effects of Immunosuppression and Sun Exposure on Immune Cell Populations in Skin and Blood of Kidney Transplant Recipients.

M. Burke,¹ L. Nahum,⁴ N. Isbel,¹ R. Carroll,³ H. Soyer,¹ R. Francis,¹ J. Bridge,¹ C. Staatz,² J. Wells.¹
Human B Cell Cytokines Predict Renal Allograft Rejection and Early Transplant Outcomes.

A. Cherukuri, R. Mehta, S. Ogunde, S. Hariharan, D. Rothstein.
Impact of Early Allograft Dysfunction (EAD) and Its Components on Patient Survival Following Liver Transplantation (LT): Long-Term Outcomes Up to 10 Years.

B. Ekser, R. Mangus, J. Fridell, C. Kubal, J. Davis, J. Salisbury, T. Salisbury, S. Nagaraju, P. Mihaylov, A. Tector.
Impact of Low Dose Tacrolimus with Everolimus Regimen on Renal Pathology and T-Regulatory Cells in Kidney Transplant.

A. Shetty,¹ T. Opas,¹ J. Mathew,¹ V. Mas,² J. Leventhal,¹ N. Sustento-Reodica,¹ L. Gallon.¹
Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin^®) vs Basiliximab After Kidney Transplantation: A Health Economic Analysis from a German Perspective.

L. Cremaschi,¹ R. Thissen,² T. Benzing,² M. Wiesener,³ N. Zink,³ T. Paivanas,⁴ J. Reitan,⁴ M. Gallagher,⁵ F. Thaiss.¹
Living Donor Liver Transplant Has Similar Outcome to Deceased Donor Liver Transplant for MELD > 25.

M. Al Sebayel,¹ F. Abaalkhail,^1,2 M. Shoukri,¹ H. Albahili,^1,2 S. Alabbad,¹ W. AlHamoudi,^1,2,3 H. Albeshbeshy,¹ H. Elsiesy.^1,2
Long-Lasting Skin Allograft Tolerance Induced and Maintained by Short-Term Vascularized Bone Marrow Transplant in a Mouse Model.

C.-H. Lin,¹ M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher.²
Mycophenolic Acid Product Discontinuation Prior to Conception: Analysis of Pregnancies in Kidney Transplant Recipients.

S. Constantinescu,^1,2 L. Coscia,² D. Armenti,² M. Moritz.^2,3
Predictors of Early Rejection and Allograft Failure in Pediatric Kidney Transplantation: Impact of Histology and Behavior.

M. Seifert, M. Yanik, R. Mannon.
Reciprocity for Compatible Pair Participation in Kidney Paired Donation.

J. Gill,¹ M.-C. Fortin,² C. Rose,¹ E. Cole,³ K. Tinckam,³ J. Gill.¹
Renal Outcome with Eculizumab in Patients with aHUS with Native and Transplanted Kidneys: Pooled Analysis of 100 Patients.

C. Legendre,¹ J. Campistol,² T. Feldkamp,³ J. Wang,⁴ G. Remuzzi,⁵ L. Weekers,⁶ N. Sheerin.⁷
Risk Prediction of End-Stage Renal Disease in Living Kidney Donors.

A. Massie, E. Chow, D. Segev.
Sociodemographic and Comorbidity Differences Between Dialysis, Waitlisted and Transplant Patients in the UK: Findings from the ATTOM Study.

D. Wu,¹ M. Robb,² C. Watson,³ R. Ravanan,⁴ J. Forsythe,¹ A. Bradley,³ G. Oniscu.¹
Systematic Pathological Component Scores for Skin-Containing Vascularized Composite Allografts.

I. Rosales,¹ M. DeFazio,² R. Foreman,¹ D. Sachs,² C. Cetrulo,² D. Leonard,^2,3 R. Colvin.¹
The Effect of Donor Age on Acute Rejection Age – The Clinical Impact of Donor Immuno-Senescence in the Modern Immunosuppressive Era.

U. Khalid, P. Donato, L. Szabo, R. Chavez, E. Ablorsu, A. Asderakis.
The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation.

J. Patel, M. Kittleson, D. Chang, T. Aintablian, A. Velleca, D. Ramzy, L. Czer, J. Kobashigawa.
The Impact of Readmission following Kidney Transplantation: Is Readmission Becoming More Risky?

E. King, L. Kucirka, M. McAdams-DeMarco, A. Massie, D. Segev.
The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.

N. Polanco Fernandez,¹ A. García Santiago,¹ M. Fernández Ruiz,² R. Muñoz,³ C. Alvarez Vazquez,⁴ A. Hernandez,¹ V. Mercado,¹ E. González Monte,¹ I. Fernández,³ J. Aguado,² M. Praga,¹ A. Andres.¹
Thymus Is Required for T Cells Reconstitution Following Antibody-Mediated Lymphoablation.

K. Ayasoufi, R. Fan, A. Valujskikh.
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.

S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹
Tolerance Induction with Donor Bone Marrow Transplantation in Kidney Transplantation.

H. Park,¹ N. Lee,¹ S. Lee,¹ G. Choi,¹ C. Kwon,¹ S. Kim,¹ J.-W. Joh,¹ M. Kim,² Y. Kwon,² S.-K. Lee.¹
Tracking Endogenous B Cells Recognizing Allogeneic MHC Class II in Mice.

J. Yang,^1,2 J. Chen,¹ A. Akl,¹ R. Sciammas,³ A. Chong.¹
Utilization and Post-Transplant Outcomes Associated with Hepatitis C+ Donor Kidneys in the Advent of Direct-Acting Antivirals.

M. Bowring, L. Kucirka, A. Massie, X. Luo, M. Sulkowski, D. Segev, C. Durand.
Viral Gastroenteritis in Adult and Pediatric Solid Organ Transplant (SOT) Patients.

C. Hernández Garcia,¹ B. Lee,¹ X. Pang,² H. Yuan Zhou,¹ J. Preikisatis.¹
A Nationwide Analysis of Reoperation After kidney Transplant.

Z. Moghadamyeghaneh, M. Alameddine, G. Burke, G. Ciancio, L. Chen.
A Novel Murine Orthotopic Forelimb Transplantation Model That Allows for Reliable Assessment of Post-Transplant Upper Extremity Function.

J. Budihardjo,¹ B. Kern,^1,2 S. Mermulla,¹ A. Quan,¹ C. Cadmi,¹ J. Lopez,¹ J. Park,¹ A. Hoke,¹ W. Lee,¹ S. Tuffaha,¹ G. Brandacher.¹
Acute Kidney Injury (AKI) Associated with Chronic Kidney Disease (CKD) in Paediatric Non-Kidney Transplant Recipients.

C. Williams,^1,2 K. Borges,² T. Banh,² J. Vasilevska-Ristovska,² R. Chanchlani,^1,2 V. Ng,^1,2 A. Dipchand,^1,2 M. Solomon,^1,2 D. Hebert,^1,2 S. Kim,^1,3 B. Astor,⁴ R. Parekh.^1,2,3
Acute Kidney Injury and Chronic Kidney Disease in Donation After Circulatory Death Liver Transplantation: UK Single Centre Study.

I. Umbro,^1,2 F. Tinti,^1,2 F. Evison,³ A. Sharif,⁴ B. Gunson,⁵ A. Mitterhofer,² J. Ferguson,¹ P. Muiesan.¹
Antibody Mediated Rejection and Mixed Acute Rejection: Long Term Results and Predictive Factors for Graft Loss Following Proteasome Inhibitor Therapy.

A. Lichvar,¹ A. Leino,¹ S. Tremblay,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,^1,2 F. Paterno,¹ A. Shields,^1,2 D. Witte,¹ R. Alloway,¹ E. Woodle.¹
Belatacept Does Not Inhibit Plasmablast Formation Supported by Follicular T Helper Cells, but Favors the Development of Transitional Regulatory B Cells in Kidney Transplant Patients.

G. de Graav, D. Hesselink, M. Dieterich, R. Kraaijeveld, W. Weimar, C. Baan.
Clonal Expansion of Donor-Specific Tregs Following Combined Kidney and Bone Marrow Transplantation.

T. Savage,¹ S. Dewolf,¹ A. Obradovic,¹ S. Lau,¹ J. Zuber,¹ L. Turka,^2,3 Y. Shen,¹ M. Sykes.¹
Decline of HCV RNA and Core Antigen: Predictors of Achieving SVR in Transplant Recipients Undergoing DAA-Therapy.

S. Pischke,³ V. Proske,¹ S. Polywka,⁴ M. Lütgehetmann,⁴ M. Lang,¹ S. Stauga,¹ L. Fischer,¹ A. Lohse,³ B. Nashan,² M. Sterneck.¹
Dilution of Patient Sera Improves MFI Correlation with Complement Fixation in Solid Phase Assay Assessment.

C. Castleberry,¹ D. Phelan,² K. Simpson,¹ T. Mohanakumar,³ C. Canter.¹
Donor-Specific Antibody Is a Major Independent Predictor of Accelerated Heart Allograft Vasculopathy (CAV).

M. Bories,¹ S. Varnous,² C. Lefaucheur,³ P. Rouvier,² R. Guillemain,¹ P. Bruneval,¹ J. Duong Van Huyen,⁴ A. Loupy.⁴
Early Alloantibody Responses Against Donor MHC Class I and Class II Molecules Are Differentially Affected by Prolonged Cold Ischemia Storage of Renal Allografts.

V. Gorbacheva, R. Fan, W. Baldwin, A. Valujskikh.
Early Post Renal Transplant aHUS in Patients with Heterozygous CFHR3-CFHR1 Deletion.

S. Rhazouani, A. Malone, T. Alhamad, T. Maw, D. Brennan, R. Delos Santos.
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.

C. Lefaucheur,¹ L. Hidalgo,² J. Reeve,² D. Viglietti,¹ C. Gosset,¹ O. Aubert,³ C. Ulloa,³ C. Legendre,³ D. Glotz,¹ P. Halloran,² A. Loupy.³
Efficacy and Safety of Direct Antiviral Agents (DAA)-Based Therapies for Hepatitis C Virus (HCV) Infection in Kidney Transplant (KT) Recipients.

M. Fernandez Ruiz,¹ A. García Santiago,² N. Polanco Fernandez,² R. Muñoz,³ A. Hernandez,² E. González Monte,² V. Mercado,² I. Fernández,³ J. Aguado,¹ M. Praga,² A. Andrés.²
Elevated Intragraft Expression of Innate Immunity and Cell Death-Related Markers Characterizes Deceased Donor Conditions and Is a Risk Factor for Adverse Graft Outcome.

M. Eikmans,¹ J. Yang,¹ G. Haasnoot,¹ C. van Kooten,² M. Mallat,² H. de Fijter,² I. Bajema,³ F. Claas.¹
Establishing the Relationship Between Receptor Occupancy, Serum Exposure and Pathway Inhibition by the Blocking, Non-Depleting Anti-CD40 Antibody CFZ533 to Inform Dose Selection in Clinical Transplantation.

P. Espie, J. Munz, T. Flandre, B. Haraldsson, P. Ulrich, J. Rush.
Evaluation of a Risk-Stratified Induction Immunosuppression Protocol Utilizing Low-Dose Antithymocyte Globulin in Renal Transplantation.

A. Diamond, Z. Khawaja, M. Simpson, S.-C. Kung, M. Akoad, J. Pomposelli, E. Pomfret.
Factors Associated with Mortality Among a Large Population of Patients with Cirrhosis and a Low MELD (<15).

K. Atiemo, L. Zhao, A. Skaro, L. VanWagner, S. Goel, A. Kho, B. Ho, R. Kang, S. Montag, J. Holl, M. Abecassis, D. Ladner.
Functional Status and Comorbidity Are Associated with High Costs After Liver Transplantation.

M. Serper, M. Rossi, T. Bitterman, A. Shaked, K. Olthoff.
Global Kidney Exchange.

M. Rees,¹ T. Dunn,¹ S. Rees,¹ J. Rogers,¹ L. Reece,¹ A. Roth,² C. Kuhr,¹ O. Ekwenna,¹ D. Fumo,¹ K. Krawiec,³ S. Jain,¹ C. Marsh,¹ M. Tan,¹ S. Paloyo.⁴
Human and Mouse Treg Use Lymphotoxin for Migration Across Lymphatic Endothelium.

C. Brinkman,¹ K. Hippen,² B. Blazar,² J. Bromberg.¹
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study.

M. Carmellini,¹ P. Todeschini,² A. Secchi,³ S. Sandrini,⁴ E. Minetti,⁵ L. Furian,⁶ G. Spagnoletti,⁷ F. Pisani,⁸ G. Piredda,⁹ G. Cappelli,¹⁰ G. Tisone.¹¹
Impact of Donor-Recipient Relationship on Development of CKD.

A. Matas, D. Vock, H. Ibrahim.
Impact of Induction Therapy on Cardiovascular Events in Kidney Transplant Recipients.

S. Sandal,^1,2 S. Bae,² A. Massie,² M. Cantarovich,¹ D. Segev.²
Impact of Preoperative Body Composition on Outcomes After Living Donor Liver Transplantation.

Y. Hamaguchi, T. Kaido, A. Kobayashi, S. Okumura, S. Yagi, H. Okajima, S. Uemoto.
Latest VCA Statistics in the U.S.

W. Cherikh,¹ H. McGehee,¹ C. Wholley,¹ L. Levin,² S. McDiarmid.³
Modification of DC Phenotype and Function via Targeted Porous Silicon Nanoparticles.

S. Stead,¹ S. McInnes,² S. Kireta,³ P. Rose,¹ D. Rojas-Canales,³ S. Jesudason,³ S. Grey,⁴ R. Carroll,³ N. Voelcker,² P. Coates.^1,3
One Year Post VZV Booster: Still Equal Response in Renal Transplant Recipients Compared to Healthy Persons.

M. Kho,¹ W. Weimar,¹ M. Boer-Verschragen,¹ A. van der Eijk,² N. van Besouw.¹
Outcomes of Solid Organ Transplant Recipients with Pre-Existing Malignancies.

S. Acuna,^1,2,3 R. Sutradhar,^1,2 J. Kim,^1,2,4 N. Baxter.^1,2,3
Pancreas Transplantation from Pediatric Donors: A UNOS Registry Analysis.

M. Spaggiari, I. Tzvetanov, H. Jeon, E. Benedetti, J. Oberholzer.
Potential Applications of Viral miRNA Assays in the Management of Transplant Patients with Polyomavirus BK Infection.

P. Randhawa, G. Zeng, Y. Huang.
Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results.

R. Esmeraldo, M. Oliveira, P. Pinheiro, C. Girao, T. Freitas.
Pulse Pressure and GFR Decay in Kidney Transplant Recipients.

O. Sanchez, S. Reule, R. Spong, N. Issa, A. Kukla, A. Matas, H. Ibrahim.
Reversibility of Acute Kidney Rejection According to the Banff 2013 Classification: A Retrospective Cohort Study.

A. Poulin,¹ M. Dorais,² L. Sénécal,³ S. Colette,³ H. Cardinal.¹
Role of NRP1 in CD4+ T Cell Allo-Activation.

E. Lee, H. Kim, G. Demirci.
Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.

J. Sageshima,¹ A. de Mattos,² C. Troppmann,¹ C. Santhanakrishnan,¹ J. McVicar,¹ B. Gallay,² M. Gandhi,² M. Alnimri,² R. Perez.¹
The Association of Life Expectancy by Resident Zip Code and Kidney Transplant Outcomes – What Is True Baseline Risk?

L. Buccini, D. Goldfarb, E. Poggio, S. Flechner, J. Schold.
The Impact of Body Mass Index > 35 on Kidney Transplant Outcomes: A Systematic Review.

D. Walczak, E. Benedetti.
The Impact of Early Acute Rejection and Delayed Graft Function on Graft Outcomes at Six Months in Adult Deceased Donor Kidney Recipients.

D. Keith, G. Vranic, A. Nishio Lucar.
Accumulation of Highly Sensitized Patients in a KPD Registry.

S. Stepkowski, B. Mierzejewska, D. Bekbolsynow, M. Rees.
Are Prior Living Kidney Donors with ESRD Being Listed and Receiving Transplantation Priority in a Timely Manner?

J. Wainright, A. Kucheryavaya, D. Klassen, D. Stewart.
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.

A. Benitez,¹ T. Milford,² K. Torralba,³ K. Payne,² M. De Vera.¹
Better Long-Term Renal Function with Lower Incidence of Acute Rejection and Lower CMV Infection in Renal Transplant Patients Treated with a Combination of Tacrolimus and Everolimus.

G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli, F. Citterio.
C1-Inhibitor in Acute Antibody-Mediated Rejection Non-Responsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.

C. Lefaucheur,¹ D. Viglietti,¹ C. Gosset,¹ A. Loupy,² A. Zeevi,³ D. Glotz.¹
Comparison of Three Approaches for Laparoscopic Donor Nephrectomy: Transvaginal, Transumbilical Single Site and Retroperitoneal.

M. Miura, H. Higashiyama.
Composite Score to Define the Risk of Allograft Loss After Standard-of-Care Treatment of Antibody-Mediated Rejection in Kidney Transplantation.

D. Viglietti,¹ A. Loupy,² J. Duong Van Huyen,² J. Verine,¹ A. Zeevi,³ C. Legendre,² D. Glotz,¹ C. Lefaucheur.¹
DAAs Rapidly Clear HCV Viremia in Recipients of HCV+ Donor Kidneys.

D. Sawinski, R. Bloom, N. Patel.
Distinct Phenotype and Function of Plasmacytoid Dendritic Cells from Kidney Allografts in Tolerant Recipients.

N. Oh,^1,2 C. Yang,^1,2,3 M. Tonsho,^1,2 D. Ndishabandi,^1,2,3 P. Russell,^1,2 R. Colvin,^1,3 J. Madsen,^1,2 A. Alessandrini.^1,2
Elevated Urinary 11-Dehydrothromboxane B2 Is Associated with Increased Bleeding Risk in Left Ventricular Assist Device Patients.

W. Schultz,⁴ A. Pekarek,³ R. Cole,¹ A. Duncan,⁵ S. Laskar,¹ A. Smith,¹ D. Nguyen,² J. Vega, D. Gupta.¹
Evaluation of the Major Adverse Cardiac Events Risk with Everolimus-Based Calcineurin Inhibitor Reduction or Withdrawal Regimen in Liver Transplant Recipients: 3-Year Post-Hoc Analysis of the Randomized H2304 Extension Study.

P. Bernhardt,¹ G. Dong,² P. Lopez,¹ G. Hustache,¹ G. Bader.¹
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.

A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
Ex Situ Perfusion of a Human Limb for 24 Hours.

N. Werner,¹ F. Alghanem,¹ S. Rakestraw,¹ B. Nicely,² A. Olszewksi,² S. Rudich,² A. Rojas-Pena,¹ J. Magee,¹ K. Ozer.³
Factors Associated with Acute Rejections in Kidney Transplant Recipients: Time for HLA-DR Matching in Elderly Recipients?

D. Khadzhynov, F. Halleck, L. Lehner, M. Duerrr, A. Kleinsteuber, D. Schmidt, K. Budde, O. Staeck.
Graft Outcomes in Pediatric Kidney Transplants Are Better with Laparoscopic Donor Nephrectomy and High Volume Centers.

J. Burg,¹ D. Scott,¹ K. Roayaie,¹ E. Maynard,¹ J. Barry,² C. Enestvedt.¹
HLA Class II and BK Virus Reactivation in Renal Transplant Recipients.

P. Shah,¹ K. Anderson,² M. Aubrey,² C. Roark,² B. Freed,² A. Wiseman.¹
Have We Gone Too Far Defining Performance Outliers? One-Third of Kidney Transplant Programs Now Identified for Low Performance within Three Years.

J. Schold,¹ C. Miller,¹ M. Henry,² L. Buccini,¹ S. Flechner,¹ D. Goldfarb,¹ E. Poggio,¹ K. Andreonni.³
Hematopoietic Cell Transplant and Solid Organ Transplantation: A First Report of the U.S. Experience.

M. Gupta, M. Levine, P. Abt.
High Incidence of Herpes Zoster After Kidney, Liver, Heart and Lung Transplantation.

N. van Besouw, S. Roest, D. Bovée, H. Metselaar, R. Hoek, J. van Weezel, A. van der Eijk, W. Weimar, O. Manintveld, M. Kho.
IFTA Is Linked to Urinary Microbiome Changes.

B. Modena, R. Milam, F. Harrison, S. Kurian, D. Salomon, A. Kirk.
Impact of Pretransplant Non-Donor-Specific HLA Immunization: Mainly Class 1 Immunization Leads to Poor Immunologic Outcome and Graft Loss.

O. Staeck, F. Halleck, A. Staeck, L. Lehner, M. Duerr, E. Schrezenmeier, K. Budde, D. Khadzhynov.
Improving the Efficiency, Safety and Cost of Evaluating Living Donor Liver Candidates Using Single Sequence MRI.

M. Schilsky,^1,2 K. Cartiera,¹ S. Boga,¹ S. Schilsky,³ S. Emre,¹ D. Mulligan,¹ J. Weinreb,¹ G. Israel.¹
Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.

M. van der Giet,¹ J. de Fijter,¹ F. Oppenheimer,¹ L. Toselli,¹ G. Russ,¹ P. Lopez,² J. Aguilar,² P. Bernhardt,² Z. Wang,³ J. Cruzado,¹ H. Holdaas.¹
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.

J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Molecular Profiles of Renal Allograft Rejection.

Z. Hajjiri, P. Finn, D. Perkins.
Mortality and Graft Loss Attributable to Readmission Following Kidney Transplantation.

E. King, M. Bowring, L. Kucirka, M. McAdams-DeMarco, A. Massie, D. Segev.
NAD⁺Promotes Allograft Survival Independently of CD4⁺CD25⁺Foxp3⁺ Regulatory T Cells.

A. Elkhal, H. Rodriguez Cetina Biefer, H. Uehara, M. Quante, M. Seyda, J. Schuitenmaker, S. Tullius, A. Elkhal.
Profiling Metabolic Differences Between Graft- vs. Pathogen-Elicited CD8⁺ T Cell Responses.

A. Karp, M. Wagener, J. Robertson, M. Ford.
Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients.

A. Skaro,¹ A. LeFever,² J. Mathew,¹ L. Gallon,¹ J. Hie,¹ C. Hansen,² D. Stare,¹ G. Johnson,³ J. Leventhal.¹
Role of Cardiac Evaluation and Management in Kidney and Liver Transplant Candidates.

W. Bannister, C. Wu, M. Schnitzler, A. Bonagura, B. Laihinen, F. Irwin.
Serelaxin Decreases the Severity of Cold Ischemia-Reperfusion Injury After Liver Transplantation in Mice.

S. Kageyama, K. Nakamura, R. Busuttil, J. Kupiec-Weglinski.
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.

A. Santos, M. Casey, X. Wen, S. Rehman, K. Womer.
TGFb in Regulatory B Cells-Dependent Tolerance.

H. Deirawan, L. Kojima, L. Washburn, J. Markmann, J. Kim.
Targeting IFN-g-Expressing TIM-4⁺B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.

Q. Ding,¹ K. Mohib,¹ S. Xiao,² V. Kuchroo,² D. Rothstein.¹
The Impact of CMS Policy on Delisting of "Too Sick" Liver Transplant Candidates.

N. Dolgin, B. Movahedi, P. Martins, A. Bozorgzadeh.
The Largest Single Center Experience with Total Artificial Heart Implantation: Characterization of Outcome.

F. Arabia, M. Kittleson, L. Czer, D. Chang, T. Aintablian, E. Passano, G. Rodriguez, C. Runyon, J. Kobashigawa, J. Moriguchi.
Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience.

K. Hatahet,¹ M. Ghanta,¹ A. Gillespie,¹ I. Lee,¹ H. El-Halawany,² K. Qureshi,² K. Lau,³ S. Karhadkar,³ A. Di Carlo,³ S. Constantinescu,¹ S. Rao.¹
Twenty Years of Evolving Trends in Racial Disparities for Adult Kidney Transplant Recipients.

D. Taber, M. Gebregziabher, K. Chavin, T. Srinivas, P. Baliga, L. Egede.
Utilization of HCV-Positive Donors' Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy.

B. Amundsen,¹ M. Sise,² M. Lin,³ H. Deirawan,¹ E. Heher,² B. Kimball,¹ J. Markmann,¹ N. Elias.¹
Initial Experience with Donor Specific Tregs in Kidney Transplantation.

J. Markmann,¹ E. Guinan,² E. Geissler,³ G. Cole,² S. Germana,¹ J. Kim,¹ B. Sawitzki.⁴
99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.

A. Kucheryavaya,¹ M. Aeder,² N. Turgeon,³ D. Klassen,¹ D. Stewart.¹
A Non-Invasive Blood Transcriptional Assay, Ksort, Monitors Alloimmune Response in the Sailor Randomized Multicenter Trial.

J. Ekberg,¹ B. Jespersen,² K. Skov,² M. Sarwal,³ T. Sigdel,³ S. Hsieh,³ P. Lindner.¹
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.

A. Guasch,¹ H. Xu,² A. Mehta,¹ A. Ghali,¹ S. Mead,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson,¹ A. Kirk.²
A Prospective Carfilzomib-Based Desensitization Trial: Phase 1 Results.

S. Tremblay,¹ A. Shields,¹ R. Alloway,¹ P. Brailey,¹ B. Abu Jawdeh,¹ T. Latif,¹ J. Driscoll,¹ M. Pando,² A. Girnita,¹ E. Woodle.¹
Allo-Specific Memory B Cell Recall Responses Are Dependent on B Cell Autophagy.

J. Leventhal,¹ M. Fribourg,² J. Ni,¹ P. Heeger.¹
Big Data Predictive Solution to Optimize Kidney Transplant Outcome and Resource Utilization.

T. Srinivas, D. Northrup, P. Mauldin, D. Taber, Z. Su, J. Zhang, M. Daniels, W. Moran.
CD4 T Cell Mediated Help Is Required for Intra-Allograft Proliferation of Endogenous Memory CD8 T Cells and Their Ability to Mediate Rejection of Cardiac Allografts Subjected to Prolonged Ischemia.

H. Tsuda, T. Tanaka, C. Su, A. Valujskikh, R. Fairchild.
CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients.

S. Ball, A. Small, C. Waite.
Circulating Angiotensin II Receptor: Possible Marker for Antibody Mediated Tissue Injury?

P. Kimball, F. McDougan, G. Gupta.
Combination of Veto Cell Transfer and iNKT Cell Therapy Establishes Complete Hematopoietic Chimerism in Non-Myeloablative BMT Recipients.

R. Ishii,¹ T. Hirai,¹ Y. Ishii,² K. Tanabe.¹
Controlled Oxygenated Rewarming and Subnormothermic Machine Perfusion of Steatotic Livers: First Clinical Results.

D. Hoyer,¹ A. Gallinat,¹ J. Treckmann,¹ T. Benkoe,¹ S. Swoboda,¹ U. Rauen,² A. Paul,¹ T. Minor.¹
De Novo Anti-HLA DSA Characteristics and Subclinical Antibody Mediated Kidney Allograft Injuries.

T. Yamamoto, Y. Watarai, A. Takeda, M. Okada, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, K. Morozumi, K. Uchida, T. Kobayashi.
Delays in the Live Kidney Donor Evaluation Process.

J. Leanza, K. Kumar, J. Tonascia, E. King, A. Massie, D. Segev.
Denosumab Prevents Bone Mineral Density Loss in De Novo Kidney Transplant Recipients: Results from a Randomized Controlled Trial.

M. Bonani,¹ D. Frey,² J. Brockmann,³ T. Fehr,¹ T. Müller,¹ N. Graf,⁴ R. Wüthrich.¹
Erythropoietin (EPO) Mediates Spontaneous Kidney Transplant Tolerance in Mice.

P. Cravedi,¹ C. Purroy,¹ J. Madsen,² R. Fairchild,³ T. Tanaka,³ W. Baldwin 3rd,³ A. Alessandrini,² P. Heeger.¹
Exosomes with Lung Associated Self-Antigens (Collagen V and K alpha 1 Tubulin): Role in Rejection Following Human Lung Transplantation.

M. Gunasekaran,^1,2 Z. Xu,^1,2 D. Nayak,^1,2 M. Sharma,^1,2 R. Hachem,¹ T. Mohanakumar.^1,2
Factors and Outcomes Associated with Daptomycin Non-Susceptible Enterococcal Infections in Solid Organ Transplant Recipients.

K. Younan,¹ R. Lee,¹ T. McCarty,¹ D. Kunz,² J. Locke,³ B. Camins,¹ P. Pappas,¹ J. Baddley,¹ A. Nellore.¹
Frailty in KT Recipients of All Ages.

M. McAdams-DeMarco, H. Ying, I. Olorundare, E. King, D. Segev.
Increased Waitlist Death and Removal in Pediatric Liver Transplant Recipients Denied Exception Requests.

H. Braun,³ J. Dodge,² S. Rhee,¹ J. Roberts,² E. Perito.¹
Informing Informed Consent for High KDPI Kidneys.

A. Nishio Lucar, D. Keith, G. Vranic.
Intestinal Retransplantation in Children: Single Center Experience.

N. Celik,¹ F. Vyas,¹ G. Bond,¹ K. Soltys,¹ J. Rudolph,² R. Sindhi,¹ G. Mazariegos.¹
Is Facilitated Pancreas Allocation Effective?

R. Carrico,¹ J. Fridell,² J. Odorico,³ S. Niederhaus.⁴
Learning Curve of Laparoscopic Donor Nephrectomy for Abdominal Transplant Surgery Fellows.

O. Serrano,¹ A. Bangdiwala,² D. Vock,³ V. Kirchner,¹ T. Dunn,¹ E. Finger,¹ T. Pruett,¹ A. Matas,¹ R. Kandaswamy.¹
Long-Term Death-Censored Graft Loss in the DeKAF Study.

A. Matas,¹ A. Fieberg,¹ R. Leduc,¹ F. Cosio,² R. Gaston,³ R. Mannon,³ M. Cecka,⁴ D. Rush,⁷ B. Kasiske,⁵ S. Gourishankar,⁶ J. Connett,¹ J. Grande.²
Modified Normothermic Extracorporeal Liver Perfusion for Discarded Human Livers.

B. Banan,¹ R. Watson,² M. Xu,¹ Y. Lin,¹ W. Chapman.¹
Mothers Are Often Sensitized and Sensitive: Antibody Mediated Rejection in Child to Mother Living Donor Liver Transplantation.

B. Movahedi,¹ N. Yu,² P. Martins,¹ A. Ahearn,¹ J. Stoff,¹ A. Bozorgzadeh.¹
Outcomes of Pediatric en Bloc Kidney (PeB) Grafts After Loss of a Single Kidney.

C. Santhanakrishnan, R. Perez, J. McVicar, J. Sageshima, C. Troppmannn.
Pediatric Heart Transplantation Across a Positive Cross-Match Is Associated with High Rates of AMR but No Difference in Short Term Graft Loss, Dysfunction and Death (CTOTC-04 study).

S. Webber,¹ L. Addonizio,² E. Blume,³ A. Dipchand,⁴ R. Shaddy,⁵ B. Feingold,⁶ C. Canter,⁷ D. Hsu,⁸ W. Mahle,⁹ A. Zeevi,⁶ K. Much,¹⁰ D. Ikle,¹⁰ H. Diop,¹¹ J. Odim, MD, PhD, for CTOTC-04 Investigators.¹¹
Potent Induction Therapy Improves Graft Outcome in Younger Pancreas Transplant Recipients (<30 Years of Age).

A. Gruessner, V. Whittaker, S. Narsipur, V. Aggarwal, C. Hubbel, R. Gruessner.
Potential Kidney Donors with Asymptomatic Micorsocpic Hematuria: Histopathological Findings & Outcomes.

E. Hassan,^1,2 H. Aleid,¹ T. Zulfiquar,¹ I. Ibrahim,^1,3 H. Almana.⁴
Pre-Listing Prescription Narcotic Use: Survival Implications in Liver Transplantation.

H. Randall,^1,6 K. Lentine,⁶ D. Segev,^2,1 H. Yuan,⁶ J. Tuttle-Newhall,³ M. Nazzal,⁶ C. Varma,⁶ G. Hess,⁵ B. Kasiske,¹ M. Schnitzler.^6,1
Predicting the Timing of Graft Failure in De Novo DSA Positive Patients.

M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,³ C. Morgan,² A. Maldonado,⁴ A. Nguyen,¹ P. Terasaki.¹
Predictive Model for Medication Errors in a Chronic Kidney Transplant Clinic.

K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma in Cirrhotic Livers.

M. Samoylova, N. Mehta, J. Roberts, F. Yao.
Rapamycin Nanotherapy Delays Heart Transplant Rejection.

M. Braza,¹ M. Lameijer,¹ C. Perez-Medina,¹ T. Reiner,³ M. Nahrendorf,⁴ Z. Fayad,¹ R. Duivenvoorden,¹ J. Ochando,² W. Mulder.¹
The Impact of Ritonavir-Boosted Protease Inhibitors and Non-Depleting Antibody Induction on Outcomes in HIV-Infected Kidney Transplant Recipients.

B. Rollins, S. Lerner, M. Rana, S. Huprikar, L. Miko, V. Nair, S. Florman, R. Shapiro.
The Impact of Sequential Gene Modifications on Cardiac Xenograft Survival.

K. Horvath,¹ A. Singh,¹ J. Chan,¹ M. Thomas,² B. Lewis,² D. Ayares,³ P. Corcoran,¹ M. Mohiuddin.¹
The Role of PI3kγ and PI3kδ in Alloimmunity.

M. Uehara,¹ A. Jamil,¹ Z. Solhjou,¹ M. McGrath,¹ N. Banouni,¹ C. Evans,² J. Dinitto,² D. Winkler,² R. Abdi.¹
Understanding the Drivers Behind an Early Post-KAS Rise in Delayed Graft Function (DGF) Rates.

D. Stewart, A. Kucheryavaya, D. Klassen.
YKL-40 Predicts Renal Recovery in Deceased-Donor Transplantation.

J. Puthumana,¹ I. Hall,¹ P. Reese,² B. Schröppel,³ F. Weng,⁴ H. Thiessen-Philbrook,¹ M. Doshi,⁵ V. Rao,¹ C. Lee,⁶ J. Elias,⁶ L. Cantley,¹ C. Parikh.¹
miR-21 in Chronic Allograft Vasculopathy.

V. Usuelli,¹ M. Ben Nasr,^1,2 F. D'Addio,^1,2 L. Kaifeng,² L. Borgese,³ L. Potena,³ A. Solini,⁴ C. Rossi,⁴ A. Secchi,¹ D. Corradi,⁵ N. Chau,⁶ P. Fiorina.^1,2
A Multidisciplinary Approach to Reviewing Patient Care in Abdominal Transplantation.

S. Lerner, M. Resta-Flarer, R. Shapiro, S. Florman, L. Kim-Schluger, V. Nair.
A Users Guide to Maximizing Utility and Outcome in >70 Year Old Donors.

K. Halazun, E. Przybyszewski, B. Samstein, E. Verna, A. Fox, R. Brown, J. Emond.
Absence of Receptors for C3a or C5a Prevent Alloreactive CD8 T Effector Cell (Teff) Expansion but Differentially Impact Memory (Tmem) Persistence Posttransplantation.

D. Mathern, P. Heeger.
Acute Operative Complications and 1,5,& 10 Year Outcomes in Living Donors by Type of Live Donor Nephrectomy – UK Cohort Study.

N. Krishnan,¹ L. Bradbury,² N. Raymond.¹
Ameliorating Progression of Allograft Vasculopathy by Targeting the T Follicular Helper Cell Subset.

M. Chhabra, J. Ali, J. Alsughayyir, S. Qureshi, J. Bradley, E. Bolton, R. Motallebzadeh, G. Pettigrew.
Clinical Rejection-Risk Assessment with Allospecific CD154+T-Cytotoxic Memory Cells (CD154+TcM) After Pediatric Liver or Intestine Transplantation (LTx, ITx).

K. Soltys, G. Bond, G. Mazariegos, L. O'Toole, C. Trautz, L. Remaley, A. Zeevi, C. Ashokkumar, R. Sindhi.
Deceased Donor Urine C5a Predicts Donor and Recipient Acute Kidney Injury.

B. Schroppel,¹ P. Heeger,² I. Hall,³ M. Doshi,⁴ F. Weng,⁵ P. Reese,⁶ C. Parikh.³
Designing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Longterm Heart Allograft Acceptance While Inducing Immune Cell Exhaustion, Treg Induction and Memory Cell Suppression.

E. Sula Karreci,¹ A. Mihali,¹ M. Uehara,¹ A. Kurdi,¹ L. Riella,¹ R. Abdi,¹ H. Fan,² P. Singh,² C. Nathan,² G. Lin,² J. Azzi.¹
Designing and Synthesizing a Novel Highly Selective Immunoproteasome Inhibitor That Promotes Long Term Heart Allograft Acceptance While Reducing Plasma Cells and Donor Specific Antibodies.

A. Mihali,¹ E. Sula Karreci,¹ A. Kurdi,³ L. Riella,¹ Y. Kawano,³ H. Fan,² P. Singh,² I. Ghobrial,³ C. Nathan,² G. Lin,² J. Azzi.¹
Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10.

J. Ho,¹ A. Sharma,² R. Mandal,³ D. Wishart,³ C. Wiebe,¹ L. Storsley,¹ M. Karpinski,¹ I. Gibson,⁴ P. Nickerson,¹ D. Rush.¹
Evolution of Body Composition and Associations to Glucose Metabolism During the First Year After Kidney Transplantation.

M. von Düring,¹ A. Hartmann,^1,2 J. Bollerslev,^2,4 A. Åsberg,^1,3 K. Godang,⁴ I. Eide,¹ D. Dahle,¹ T. Jenssen.^1,5
How Did the New Kidney and Pancreas Allocation Systems Effect Pancreas Utilization in the First Six-Months?

R. Carrico,¹ J. Fridell,² J. Odorico,³ Z. Stewart.⁴
Hypothermic Machine Perfusion Is Also Beneficial for Deceased Donor Kidneys When Cold Ischemic Time Is Short and a Short Cold Ischemic Time Is Also Beneficial When Kidneys Are Machine Perfused.

J. Kox,¹ C. Moers,² D. Monbaliu,³ A. Strelniece,⁴ J.-W. Treckmann,⁵ I. Jochmans,³ H. Leuvenink,² L. van Heurn,¹ J. Pirenne,³ A. Paul,⁵ R. Ploeg.^2,6
Improved Health Related Quality of Life Also in Older Recipients Following Kidney Transplantation.

K. Lønning,¹ K. Heldal,^2,3 T. Bernklev,^2,3 M. Andersen,^1,4 A. Hartmann,^1,3 N. Von der Lippe,³ A. Reisæter,¹ K. Midtvedt.¹
Incidence of Depression Following Live Kidney Donation.

J. Leanza,¹ S. Anjum,¹ L. Fahmy,¹ S. Bae,¹ R. Reed,² J. Locke,² A. Massie,¹ D. Segev.¹
Inclusion of Human Tissue Factor Pathway Inhibitor or Thrombomodulin Transgenes Attenuates Critical Consumptive Thrombocytopenia in Cardiac Xenotransplantation.

J. Chan,¹ A. Singh,¹ P. Corcoran,¹ M. Thomas III,² B. Lewis,² D. Ayares,³ K. Horvath,¹ M. Mohiuddin.¹
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.

N. Bossini,¹ S. Sandrini,¹ R. Tardanico,² F. Valerio,¹ G. Setti,¹ C. Salviani,¹ S. Possenti,¹ P. Foini,¹ E. Marta,¹ G. Cancarini.¹
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).

J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.

R. Patel,¹ I. Feurer,¹ S. Karp,¹ L. Gillis,¹ H. Katzenstein,¹ H. Lovvorn III,¹ J. Pietsch,¹ D. Chung, G. Tiao,² D. Hanto.¹
Mapping Heterogeneity in Antibody-Mediated Rejection Using Molecular Phenotypes and Archetype Analysis.

J. Reeve,¹ P. Halloran.^1,2
Mechanistic Insights into How Targeting of HDAC10 Promotes Foxp3+ Treg Cell Suppressive Activity, Gene Expression and Metabolism, and Enhances Allograft Survival.

S. Dahiya,¹ L. Wang,¹ U. Beier,^1,2 A. Angelin,¹ R. Han,¹ D. Wallace,^1,2 W. Hancock.^1,2
Microarray Analysis of Transbronchial and Mucosal Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-Cell Mediated Inflammation.

K. Halloran,¹ J. Chang,² V. Ramassar,² J. Weinkauf,¹ A. Kapasi,¹ D. Lien,¹ J. Reeve,² P. Halloran.^1,2
Non-Invasive – Minimalistic Approach Using Cell-Free MicroRNAs in Paired Plasma and Urine Samples for Early Diagnosis of Chronic Renal Allograft Dysfunction.

S. Bontha,¹ R. Gehrau,¹ E. Rhone,¹ A. King,² L. Gallon,³ K. Brayman,¹ D. Maluf,¹ V. Mas.¹
Non-Invasive Biomarkers for Graft Quality and Outcome Post-Liver Transplantation.

R. Gehrau, V. Mas, S. Bontha, D. Maluf.
Normothermic Ex-Vivo Perfusion of the Intestine: The Introduction of an Innovative Physiologic Model with Novel Biomarkers.

B. Soliman, T. Okamoto, C. Quintini, Q. Liu, M. Fujiki, A. Khanna, K. Hashimoto, J. Fung, K. Abu-Elmagd.
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.

K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
Post Transplantation High-Dose Cyclophosphamide Treatment Promotes Immune Tolerance After Skin, Solid Organ, and Vascularized Composite Allotransplantation.

G. Furtmüller,¹ B. Oh,¹ M. Fryer,^1,4 P. Akre,¹ S. Ganguly,² J. Dodd-o,³ D. Cooney,¹ G. Raimondi,¹ W. Lee,¹ L. Luznik,² G. Brandacher.¹
Post-Transplant Monitoring of Donor-Specific Anti-HLA Antibodies and Their Characteristics Improves Risk Stratification of Kidney Allograft Loss.

D. Viglietti,¹ A. Loupy,² C. Bentlejewski,³ C. Legendre,² D. Glotz,¹ A. Zeevi,³ C. Lefaucheur.¹
Pre-Donation Weight Loss Postpones Living Kidney Donation without Attaining the Desired Weight Maintenance in the Midterm.

P. Ventura-Aguiar, E. De Sousa-Amorim, J. Campistol, F. Diekmann, F. Oppenheimer, I. Revuelta.
Pre-Transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-Transplant Outcomes: A National Study.

M. Nazzal,¹ J. Chen,¹ K. Lentine,¹ M. Schnitzler,¹ J. Tuttle-Newhall,² C. Varma,¹ A. Taha,¹ A. Said,¹ H. Xiao,¹ H. Randall.¹
Prior Infection or Colonization with Carbapenem-Resistant Enterobacteriaceae Is Not an Absolute Contraindication for Solid Organ Transplantation.

S. Huprikar,¹ L. Casner,¹ S. Pouch,² M. Pinheiro Freire,³ R. Madan,⁴ E. Kwak,⁵ M. Satlin,⁶ P. Hartman,⁷ L. Pisney,⁸ P. Henrique Mourão,⁹ R. La Hoz,¹⁰ G. Patel.¹
Share35 Liver Allocation Is Associated with Increased Early Graft Failure Rate.

T. Wong,¹ N. Koizumi,² J. Ortiz.³
Significant Association of Vitamin-D Receptor (VDR) Gene Polymorphism and Incidence of De Novo DSA in Renal Transplantation.

L. Das, K. Ide, Y. Tanaka, N. Tanimine, S. Verma, H. Ohdan.
Significant Increase in Wait List Removals for Candidates Considered Too Sick from the US Kidney Transplant Waiting List.

E. Poggio, L. Buccini, S. Flechner, D. Goldfarb, J. Schold.
The First Impressions: A Study in Pre and Post-Implantation Renal Grafts for Early Detection Markers of Delayed Graft Function and Recovery.

S. Bontha,¹ L. Suh,¹ P. Dormish,¹ R. Gehrau,¹ E. Rhone,¹ L. Gallon,³ A. King,² C. Dumur,² D. Maluf,¹ V. Mas.¹
The Impact of One Year Individual or Dual Organ Rejection in Simultaneous Pancreas-Kidney Transplant on Kidney Graft Survival – A UNOS Registry Analysis 2000-2013.

I. Moinuddin,¹ T. Taber,¹ M. Yaqub,¹ O. Adebiyi,¹ M. Mujtaba,¹ J. Chen,² M. Goble,² D. Mishler,¹ J. Fridell,² A. Sharfuddin.¹
The Optimal Time Point for Steroid Withdrawal After Kidney Transplantation Is One Year After Engraftment.

M. Haller,¹ M. Kammer,^1,2 A. Kainz,² G. Heinze,¹ R. Oberbauer.^1,2
The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
The Relationship Between Kidney Donor Profile Index and Six Month eGFR in Deceased Donor Recipients.

D. Keith, A. Nishio Lucar, G. Vranic.
Transfer of Donor-Derived Exosomes to Recipient Ag-Presenting Cells Is Critical for Allograft Recognition.

Q. Liu,¹ D. Rojas-Canales,¹ S. Divito,¹ W. Shufesky,¹ A. Larregina,² A. Morelli.¹
Treatments Against Renin-Angiotensin-Aldosterone System Could Influence FGF23 and Klotho Levels in Renal Transplant Recipients.

S. Sezer,¹ E. Tutal,¹ Z. Bal,¹ M. Uyar,¹ M. Haberal.²
Acute Inflammation, Chronic Damage and Renal Dysfunction in Renal Transplant Recipients with Delayed Graft Function (DGF).

A. Cherukuri, R. Mehta, P. Sood, P. Randhawa, A. Tevar, S. Hariharan.
An Interventional Study Evaluating Cell Mediated Immunity to Guide Therapy for CMV Viremia.

M. Mian, A. Humar, S. Keshwani, S. Husain, P. Ashton, S. Han, L. Singer, J. Kim, E. Renner, D. Kumar.
Analysis of Local versus Imported Expanded Criteria Donor (ECD) Kidneys: A Single Center Experience with 497 ECD Kidney Transplants.

M. Khan,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Aquaporin 4 Blockade Is a Novel Strategy to Prevent T Cell Activation and Effector Functions.

K. Ayasoufi,¹ N. Kohei,¹ G. Farr,² P. McGuirk,² M. Pelletier,² R. Fairchild,¹ A. Valujskikh.¹
Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years.

A. Santos, X. Wen, M. Casey, S. Rehman, K. Womer.
Automated Web-Based Monitoring Identifies Significant Clinical Changes in Patients Awaiting Kidney Transplant.

H. Braun, M. Parente, R. Hirose, G. Roll.
Characteristics and Outcomes of Vancomycin Resistant Enterococcus Bacteremia After Liver Transplant.

R. Odrobina,¹ C. Kovacs,¹ R. Butler,² C. Koval.¹
Combined CD122 and Costimulation Blockade Prolongs Allograft Survival by Controlling Expansion and Effector Function of Memory CD8 T Cells.

D. Mathews,¹ Y. Dong,¹ L. Higginbotham,¹ S. Kim,¹ C. Breeden,¹ J. Tso,² A. Adams.¹
Conditional Deletion of mTOR in Myeloid Cells Inhibits Chronic Allograft Rejection – A Novel Role for Macrophages in Transplant Vasculopathy.

Y. Zhao, W. Chen, P. Lan, X. Xiao, W. Liu, M. Kloc, Y. Liu, R. Ghobrial, O. Gaber, X. Li.
Costimulation Blockade by Anti CD40 Antibody Prevents Humoral and Cellular Rejection of Heterotopic Pig Cardiac Xenograft.

A. Singh,¹ J. Chan,¹ P. Corcoran,¹ B. Lewis,² M. Thomas,² D. Ayares,³ K. Horvath,¹ M. Mohiuddin.¹
Development and Validation of a Molecular Microscope Diagnostic System (MMDx) for Heart Transplant Biopsies.

P. Halloran,¹ D. Kim,¹ A. Loupy,² J.-P. Duong Van-Huyen,² P. Bruneval,³ L. Potena,⁴ O. Leone,⁴ J. Reeve.¹
Effect of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blockade (ARB) Exposure on Intragraft Gene Expression of Kidney Transplant Patients.

C. Suarez-Fuentes,^1,2,4 P. O Broin,³ Y. Bao,¹ E. Akalin.^1,2
Financial Cost of Cold Ischemia Time in Kidney Transplantation.

O. Serrano,¹ D. Vock,² W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ R. Feldman,³ E. Finger.¹
Graft Survival of Steroid-Avoidance Protocols in Pediatric Kidney Transplantation[mdash]A Propensity Score Analysis.

E. Nehus,¹ Y. Wang,² B. Lu,³ C. Liu,² M. Macaluso,² M.-O. Kim.²
High-Risk Age Window for Graft Loss in Pediatric Lung and Heart Transplant Recipients.

B. Orandi, X. Luo, K. Van Arendonk, R. Higgins, D. Segev.
High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients.

D. Berglund,¹ D. Schladt,² K. Sanghavi,¹ W. Guan,¹ B. Wu,¹ C. Dorr,³ R. Remmel,¹ R. Mannon,⁴ A. Matas,¹ W. Oetting,¹ A. Israni,³ P. Jacobson,¹ DeKAF Genomics Investigators.
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States: Epidemiology, Outcomes, and Costs.

A. Mathur, Y.-H. Chang, D. Steidley, N. Khurmi, N. Katariya, A. Singer, W. Hewitt, K. Reddy, A. Moss.
IL-17-Producing CCR6⁺CD4⁺ Th17 Cells Drive Intestinal Allograft Rejection in Humans.

J. Kaiser, C. Cosentino, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
IgG Dilutions, Subclasses, C1q, and IgM: Determining Relevant Testing for De Novo DSA and Outcome Prediction.

M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,³ C. Morgan,² A. Maldonado,⁴ A. Nguyen,¹ P. Terasaki.¹
Impact of Early Acute Rejection (AR) on Pancreas Transplant (PT) Outcomes.

V. Kirchner, T. Dunn, A. Kukla, R. Kandaswamy, E. Finger.
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).

A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
Inhibitory FcγRIIB Functionally Inhibits Donor-Reactive CD8⁺ Memory T Cell Responses Following Transplantation.

D. Pinelli, M. Wagener, D. Liu, I. Badell, M. Ford.
Kidney Waitlist Management with Lean Six Sigma.

V. Arelin,¹ J. Schaefer,³ H. Haller,¹ I. Ackermann,² H. Schrem.²
Levels of VEGF-C, PLGF and Follistatin at 12 Months Post Transplantation Are Associated with Increased Risk for Long Term Progressive Renal Dysfunction.

G. Dreyer,¹ J. de Fijter,¹ D. Briscoe,² K. Daly,² M. Reinders.¹
Liver-Intestine Candidates Benefit from National Sharing.

E. Edwards,¹ A. Harper, D. Sudan.
Motivation and Stress Associated with Non-Directed Kidney Donation.

J. Wiseman,¹ D. Berglund,¹ C. Jacobs,¹ D. Larson,¹ C. Garvey,¹ M. Vogues, S. Rein,¹ O. Sanchez,¹ C. Radecki Breitkopf,² H. Ibrahim,¹ A. Matas.¹
Phenotype and Outcome of Antibody-Mediated Rejection Due to Pre-Existing and De Novo DSA in Kidney Recipients.

O. Aubert,¹ A. Loupy,¹ L. Hidalgo,² J. Reeve,³ D. Glotz,¹ C. Legendre,¹ C. Lefaucheur,¹ P. Halloran.³
Positive Lymphocytes Flow Cytometry Crossmatch Due to AT1r Antibodies in Absence of HLA-DSA.

M. Ramirez,¹ D. Kershaw,² Y. Huang,² J. Magee,³ M. Samaniego,² T. Williams,¹ D. Schauss,¹ T. Franks,¹ Y. Kleyman,¹ D. Ramon.¹
Prospective Randomized Controlled Study Evaluating the Impact of an Electronic Feedback System on Medication Adherence in Solid Organ Transplantation.

M. Lockwood, L. Potter, B. Kane, L. Lourenco, A. Bozdin, J. Millis.
Protective Impact of the Kidney in SPK Transplants – Mechanisms for Improved Outcomes Compared with Solitary Transplants.

E. Finger, T. Dunn, A. Kukla, V. Kirchner, R. Kandaswamy.
Proteoforms: Novel Biomarkers for Acute Rejection in Liver Transplant Recipients.

J. Levitsky,¹ T. Toby,¹ K. Kim,¹ I. Ntai,¹ A. Demetris,² M. Abecassis,¹ P. Thomas,¹ N. Kelleher.¹
SLPI in the Perfusion Liquid: A Predictor Marker of Short and Long Term Clinical Outcomes.

A. Dotta,¹ F. Caro,² K. Peña Ponce,¹ N. Ambrosi,² J. Salaberry,² X. García,¹ E. Minué,¹ L. León,¹ F. Sánchez,² F. Togniolo,¹ C. Incardona,³ E. Chuluyan,² D. Casadei.¹
Selective Deletion of Notch2 on B Cells Abrogates Alloantibody Production in Fully MHC-Mismatched Cardiac and Skin Transplant Models.

N. Murakami, C. Magee, T. Borges, J. Azzi, L. Riella.
Short Term Changes in HRQOL Following Kidney Transplantation.

I. Olorundare, H. Ying, M. McAdams-DeMarco, D. Segev.
Sudden Increase in Allocation Score for Pediatric Liver Transplant Candidates Predicts Waitlist Mortality.

X. Luo, D. Mogul, A. Massie, D. Segev.
Surgical Site Infection Does Not Fully Explain the Impact of Obesity on Post-Transplant Outcomes.

S. Bae, L. Kucirka, A. Massie, D. Segev.
The Oldest and Coldest in Kidney Paired Donation: Experience of the National Kidney Registry.

N. Nassiri,¹ L. Kwan,¹ J. Sinacore,² J. Veale.¹
Tolerogenic Interactions Between Host CD8⁺Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning.

D. Hongo Apum,¹ X. Zhang,² E. Engleman,² S. Strober.¹
Tracking of Endogenous Graft-Reactive Tregs Reveals Their Peripheral Enrichment During Transplantation Tolerance.

J. Young,¹ J. Chen,¹ M. Miller,¹ D. Yin,¹ J. Moon,² M.-L. Alegre,¹ A. Chong.¹
Traditionally Unacceptable Organs Promote Liver Transplantation in Patients with Long Waiting Times in the Share 35 Era.

E. Siskind,¹ T. MacDonald,² R. Barth,¹ J. LaMattina,¹ D. Bruno,¹ S. Hanish.¹
mRNA Expression of BAFF and APRIL Receptors Increases in Acute Rejection in Kidney Transplant Recipients.

M. Minz,¹ R. Dhital,¹ R. Minz,² A. Sharma,¹ R. Nada,³ S. Singh,¹ D. Kenwar.¹
αLFA-1 Monotherapy Induced Tolerance Is Dependent on Indirect CD8 T-Cells and Augments a Population of CD8 Cells with a Suppressor Phenotype.

R. Plenter,¹ M. Coulombe,² T. Grazia,¹ R. Gill,² M. Zamora,¹ B. Pietra.³
Ageing as a Barrier to Transplant Tolerance.

J. Kim, R. Stott, H. Deirawan, L. Kojima, L. Washburn, G. Zhao, H. Yeh, J. Markmann.
Antibody-Mediated Rejection in Pancreas Transplantation.

O. Serrano,¹ D. Vock,² E. Finger,¹ R. Kandaswamy,¹ D. Sutherland,¹ T. Dunn.¹
Association of Pre-Transplant Midodrine Use and Complications After Kidney Transplantation.

T. Alhamad,¹ D. Brennan,¹ Z. Brifkani,¹ H. Xiao,² M. Schnitzler,² V. Dharnidharka,¹ D. Axelrod,³ D. Segev,⁴ K. Lentine.²
Associations Between Deceased-Donor Urine MCP-1 and Kidney Transplant Outcomes.

S. Mansour,¹ J. Puthumana,¹ P. Reese,² I. Hall,¹ M. Doshi,³ F. Weng,⁴ B. Schröppel,⁵ H. Thiessen-Philbrook,^1,6 M. Bimali,¹ C. Parikh.¹
BATF Deficiency in Tolerant Lung Allograft Recipients Are Resistant to Anti-MHC and Anti-Self-Antigen Mediated Pathogenesis of Obliterative Airway Disease.

Z. Xu,^1,2 X. Lin,¹ M. Gunasekaran,^1,2 M. Sharma,^1,2 A. Gelman,¹ T. Mohanakumar.^1,2
Banked EBV-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma in Solid Organ Transplantation Recipients.

S. Prockop,¹ E. Doubrovina,¹ C. Sauter,² S. Suser,¹ R. O'Reilly.¹
CTLA4 Negatively Regulates Donor-Reactive CXCR5+PD1+ T Follicular Helper Cell Responses Following Transplantation.

I. Badell,¹ D. Liu,¹ S. Suchard,² S. Nadler,² M. Ford.¹
Colonization and Risk of Bacteremia by Multi-Drug Resistant Organisms in Intestinal Transplant Recipients.

J. Simkins,¹ J. Camargo,¹ M. Morris,¹ R. Vianna,² T. Beduschi,² L. Abbo.¹
Comparison of Early Engraftment Immunobiology of Xenoislets and Alloislets in a Dual Transplant Model.

K. Samy,¹ B. Martin,² M. Song,¹ B. Collins,¹ E. Gall,¹ J. Cano,² A. Farris,² F. Leopardi,¹ A. Kirk.^1,2
Conditional Long Term Intestine Patient and Graft Survival Is Improving Under rATG Immunosuppression in Pediatric Intestine Transplantation.

N. Celik,¹ F. Vyas,¹ G. Bond,¹ K. Soltys,¹ J. Rudolph,² R. Sindhi,¹ G. Mazariegos.¹
Criteria for the Diagnosis of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx).

J. Grande,¹ R. Leduc,² The DeKAF Study Group.
Cytometric Deep Profiling of the CD8+ T-Cell Compartment in Transplant Patients with CMV Viremia.

V. Ferreira, D. Kumar, S. Husain, M. Bhat, P. Ashton, A. Humar.
Defective Post-Reperfusion Metabolic Recovery Directly Associates with Incident Delayed Graft Function.

L. Wijermars, A. Schaapherder, J. Lindeman.
Delayed Induction of Mixed Chimerism Permits Kidney-Induced Cardiac Allograft Tolerance to be Applied to Recipients of Cadaveric Organs.

M. Tonsho,¹ G. Benichou,¹ R. Yu,¹ S. Boskovic,¹ R. Colvin,^1,2 E. Farkash,² R.-N. Smith,² J. Allan,^1,4 A. Cosimi,¹ T. Kawai,^1,3 J. Madsen.^1,4
Early Steroid Withdrawal in African American Kidney Transplant Recipients: A Propensity Score Matching Analysis.

D. Taber, M. Gebregziabher, T. Srinivas, K. Chavin, P. Baliga, L. Egede.
Epitope Load Is Predictive of De Novo Donor Specific Antibodies Occurrence in Renal Transplant Recipients After Conversion from Cyclosporine to Everolimus.

R. Snanoudj,¹ C. Suberbielle,² N. Kamar,³ E. Cassuto,⁴ S. Caillard,⁵ J.-L. Taupin,² D. Anglicheau,¹ C. Legendre,¹ A. Hertig,⁶ E. Rondeau.⁶
Experience Using a Discharge Calculator for Discharge Planning Post Liver Transplantation (OLT).

K. Kerepesi, A. Waby, K. Eid, J. Plescia, K. Zinn, K. Vass, B. Eghtesad, C. Miller, D. Kelly.
Geographic Differences in Racial Disparity Reduction in Kidney Transplant Rates Before and After the New Kidney Allocation System.

R. Patzer,¹ T. Melanson,¹ M. Basu,¹ L. Plantinga,¹ L. McPherson,¹ S. Mohan,² J. Gander,¹ D. Howard,¹ S. Pastan.¹
Hepatocellular Carcinoma Decreases Chance of Successful HCV Therapy in the Current Era.

S. Prenner, L. VanWagner, L. Kulik.
Impact of Delayed Graft Function Varies by Demographic and Clinical Characteristics in Deceased Donor Kidney Transplantation.

C. Liao, A. Massie, S. Bae, A. Muzaale, D. Segev.
Impact of the Kidney Allocation System with Deceased Donor Kidney Utilization at the DSA Level.

W. Ally,² C. Saunders,¹ K. Brayman,² A. Agarwal.²
Living Donor Kidney Transplant Outcomes Have Improved Over the Last Decade.

A. Nishio Lucar, G. Vranic, D. Keith.
Long Term Outcome of De-Novo Autoimmune Hepatitis in Pediatric Recipients of Liver Transplantation.

Y. Avitzur,¹ P. McKiernan,² M. Martinez,³ S. Lobritto,³ D. Kelly,² V. Ng,¹ E. Alonso,⁴ U. Ekong.⁵
Many Discarded Kidneys Are Similar to Kidneys Accepted for Transplantation as Judged by Their Histologic Lesions and Molecular AKI Scores.

K. Famulski,¹ J. Reeve,¹ O. Aubert,² A. Loupy,² S. Niderhaus,³ J. Bromberg,³ P. Halloran.¹
MicroRNAs in Urinary Sediments as Non-Invasive Tool to Detect Acute Rejection After Kidney Transplantation.

E. Gielis,^1,2 J. Anholts,² H. de Fijter,³ I. Bajema,⁴ F. Claas,² M. Eikmans.²
Morbid Obesity and Functional Status as Predictors of Surgical Complication After Renal Transplantation.

T. Veasey, J. Fleming, S. Strout, R. Miller, N. Pilch, H. Meadows, C. Mardis, B. Mardis, P. Baliga, J. McGillicuddy, D. Taber.
Muscle Function, Mass, and Quality in Obese Liver Transplant Candidates: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study.

C. Wang, I. Lobach, J. Lai.
NK-Activating MCMV Strain Is Associated with Increased Murine Renal Transplant Injury.

M. Shimamura,¹ M. Li,² B. Chen,² J. George,² T. Schoeb.³
Outcomes of Depleting Antibody Induction in Kidney Transplantation: A Paired Kidney Analysis.

M. Sampaio, B. Chopra, K. Sureshkumar.
P-Glycoprotein Function: Association with Race, Gender and Tacrolimus Pharmacokinetics.

K. Tornatore,^1,4 H. Minderman,² K. Attwood,³ K. O'Loughlin,² R. Venuto.⁴
Predictors of eGFR Slope at One Year in Kidney Transplants – A Big Data Approach.

J. Zhang, Z. Su, D. Taber, J. Marsden, W. Moran, P. Mauldin, T. Srinivas.
Profiling Immunologic Risk for Acute Rejection in Liver Transplantation: Recipient Age Is a Robust Risk Factor.

M. Kueht, R. Cotton, C. O'Mahony, J. Goss, A. Rana.
Resolution of Undefined Etiology of Respiratory Infections in Lung Transplant Patients with Unbiased Metagenomic Sequencing.

N. Mueller,¹ D. Lewandowska,² B. Ruehe,² P. Schreiber,¹ O. Zagordi,² F. Geissberger,² M. Schuurmans,³ M. Greiner,¹ A. Zbinden,² J. Boeni,² C. Benden,³ A. Trkola,² M. Huber.²
Serum Bicarbonate and Long-Term Outcomes in Kidney Transplant Recipients.

S. Park,¹ E. Kang,¹ M. Han,¹ J. Park,¹ S. Yang,² S. Park,³ I. Jung,⁴ C. Lim,⁵ Y. Kim,¹ Y. Kim,⁶ J. Lee.⁵
Successful Treatment of Established Acute Allograft Rejection with Delayed CTLA-4Ig.

J. Young,¹ J. Chen,¹ D. Yin,¹ R. Sciammas,² V. Vu,¹ M.-L. Alegre,³ A. Chong.¹
Survival Benefit of High-KDPI Kidneys Among Obese Transplant Candidates.

M. Bowring, A. Massie, X. Luo, D. Segev.
Survival Benefit of Living Donor ABOi Kidney Transplantation.

A. Massie, B. Lonze, S. Anjum, X. Luo, D. Segev.
The Live Donor Champion Program: A Novel Approach to Identying Live Kideny Donors.

E. King, M. Bowring, K. Kumar, J. Garonzik Wang, D. Segev.
The Survival Benefit of Pancreas and/or Kidney Transplantation for Patients with Type 1 Diabetes.

R. Gruessner, V. Whittaker, N. Ozden, A. Gruessner.
Transplant Education Increases Wait-Listing Rates in Dialysis Centers with Supportive Administration and Knowledgeable Staff.

A. Waterman,¹ J. Peipert,¹ H. Xiao,² C. Goalby,¹ K. Lentine.²
2B4 Over-Expression Impairs Donor-Reactive CD8+ T Cell Proliferation and Accumulation Following Transplantation.

S. Laurie, D. Liu, M. Ford.
A Sustained Viral Response Achieved with Sofosbuvir/Ledipasvir May Increase the Incidence of Acute Cellular Rejection Post Liver Transplantation.

K. Bortecen, R. Layman, B. Gelb, A. Winnick, G. Morgan, H. Tobias, L. Teperman.
Analysis of Intra-Graft Anti-HLA Antibodies Suggests That HLA Sensitization Occurs Long After an Allograft Nephrectomy and Is Not Due to a Release of Anti-HLA Antibodies from the Failed Kidney.

D. Milongo,¹ N. Congy-Jolivet,² A. Del Bello,¹ F. Sallusto,³ L. Esposito,¹ L. Rostaing,¹ N. Kamar.¹
Assessing Return of CMV Specific Cellular Immunity Using the T-SPOT.CMV Soon After Kidney Transplant with Thymoglobulin.

C. Kotton.
Barriers to Comprehensive Transplant Education at U.S. For-Profit Dialysis Centers and Associations with Waitlist Access.

A. Waterman,¹ J. Peipert,¹ H. Xiao,² C. Goalby,¹ K. Lentine.²
Blockade of the ASC Coreceptor Enhances Hematopoietic Stem Cell Engraftment.

R. Elahimehr, S. Kasimsetti, A. Shigeoka, D. McKay.
Cognitive Impairment in Kidney Transplant Recipients.

A. Gupta,¹ D. Johnson,¹ G. Chen,¹ D. Subramaniam,¹ T. Polshak,¹ T. Thomas,¹ T. Schmitt,¹ D. Ladner,² A. Yu,¹ J. Burns.¹
Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease.

A. Sharfuddin, J. Chen, M. Yaqub, T. Taber, J. Powelson, D. Mishler, M. Goble, J. Fridell, O. Adebiyi, M. Mujtaba.
Delayed Graft Function (DGF) Does Not Accelerate Progression of Fibrosis During the First Year After Deceased Donor Kidney Transplantation.

R. Heilman, I. Qaqish, M. Smith, H. Khamash, B. Kaplan, K. Reddy.
Differential Regulation of the Microvascular Endothelial Cell Mediated Allogeneic CD4+ T Cell Response by Anti-HLA-DR and -DQ Alloantibodies in an Inflammatory Context.

N. Mooney,^1,2 A. Cross,^1,2 J. Lion,^1,2 A. Haziot,^1,2 D. Glotz.^1,2,3
Early Proteomic Predictors of Late Chronic Kidney Disease in Liver Transplant Recipients.

J. Levitsky,¹ S. Asrani,² L. Zhao,¹ M. Abecassis,¹ L. Jennings,² G. Klintmalm.²
Enhanced Activation of Hemostasis During Kidney Transplantation in Patients on Dialysis Compared to Pre-Emptively Transplanted Patients.

T. van den berg, G. Nieuwenhuijs-Moeke, S. Bakker, R. Pol, T. Lisman.
Enhanced IL-6 Production Impedes Transplant Tolerance Induction in Lupus-Prone Mice.

B. Stocks, C. Wilson, M. Seto, A. Marshall, D. Moore.
Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.

S. Chadban,¹ H. Pilmore,² G. Russ,³ J. Kanellis,⁴ S. Campbell,⁵ P. O'Connell,⁶ W. Lim,⁷ M. Lutherborrow,⁸ N. Kurstjens,⁸ R. Walker.⁹
Glycine Is Graft Protective and Improves Kidney Function After Liver Transplantation: Data from HEGPOL-Trial.

A. Nickkholgh,¹ P. Schemmer,¹ G. Polychronidis,¹ S. Luntz,² E. Mayatepek,³ M. Büchler,¹ E. Klar.⁴
IgM Donor Specific Antibodies Are Frequently Associated with C1q-binding DnDSA in Renal Transplant Recipients.

J. Bamoulid,³ A. Roodenburg,⁴ O. Staeck,¹ C. Schoenemann,² N. Lachmann,² K. Budde.¹
Impact of Early Hospital Readmission Following Simultaneous Pancreas Kidney Transplantation.

E. King, L. Kucirka, M. McAdams-DeMarco, M. Bowring, A. Massie, D. Segev.
Impact of Morbid Obesity on Breakthrough CMV Infection in Kidney Transplant Recipients.

S. Strout, N. Pilch, T. Veasey, R. Miller, J. Fleming, H. Meadows, C. Mardis, B. Mardis, P. Baliga, K. Chavin, D. Taber.
Impact of the Kidney Allocation System with Deceased Donor Kidney Transplantation: A Single Center Experience.

A. Agarwal, W. Ally, D. Maluf, S. Pelletier, K. Brayman.
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).

A. Vo,¹ J. Choi,¹ J. Kahwaji,¹ J. Mirocha,² A. Peng,¹ R. Villicana,¹ S. Jordan.¹
Increasing Tacrolimus Time-in-Therapeutic Range Is Associated with Less Cellular Rejection in Lung Transplant Recipients.

C. Ensor, K. Harrigan, R. Venkataramanan, M. Morrell, C. Moore, J. Hayanga, M. Crespo, J. DCunha, A. Zeevi, J. McDyer.
Induction Immunosuppression and Post-Transplant Outcomes in Kidney Recipients with Hepatitis C Virus.

S. Bae, C. Durand, L. Kucirka, A. Massie, D. Segev.
Innate Lymphoid Cells Play a Key Role in Controlling Antimicrobial Defense in Intestinal Transplant Recipients.

J. Kaiser, C. Cosentino, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
Is Pretransplant Determination of Hepatocellular Carcinoma Tumor Grade Using Needle Biopsy Reliable for Transplant Candidate Selection? Analysis of 217 Liver Transplant Recipients.

C. Court, M. Harlander-Locke, D. Markovic, F. Kaldas, A. Zarrinpar, D. Farmer, S. Sho, J. Tomlinson, J. Hiatt, R. Busuttil, V. Agopian, D. Lu, S. Raman.
Lessons Learned Transplanting High KDPI Kidneys Over a Decade: Improvements in Graft Survival Stem from Lower Rates of Early Graft Loss.

S. Sanoff,¹ K. Ravindra, D. Vikraman, U. Patel, D. Sudan, W. Irish.²
Lower Rates of Living Donor Kidney Transplantation(LD) Among African Americans: What Prevents Higher Rates of Donation?

A. Li, N. Foreman, M. Reissmann, C. Zuttermeister, A. Gilbert, M. Grafals, B. Javaid, S. Ghasemian, P. Abrams, M. Cooper, J. Verbesey.
Lower Renal Graft Function and Accelerated Fibrosis in HIV-Infected Transplant Recipients with Previous HIVAN Compared to Non HIVAN HIV-Positive Transplant Recipients.

M.-N. Peraldi,¹ H. Ayari,¹ M. Burbach,¹ C. Randoux,² E. Pillebout,¹ N. De Castro,³ J.-M. Molina,³ D. Glotz.¹
Natural History of Response to Wounding in Human Kidney Transplants.

K. Famulski,¹ J. Venner,^2,1 J. Reeve,¹ P. Halloran.¹
Nondirected Kidney Donation – Donating More Than a Kidney.

C. Jacobs,¹ J. Wiseman,¹ D. Berglund,¹ D. Larson,¹ C. Garvey,¹ M. Vogues,¹ S. Rein,¹ O. Sanchez,¹ C. Radecki Breitkopf,² H. Ibrahim,¹ A. Matas.¹
Obliterative Bronchiolitis Following Lung Transplantation Is Preceded by Depletion of Airway Submucosal Glands and Basal Stem Cells.

A. Swatek, A. Crooke, P. Anderson, T. Lynch, M. Ivanovic, J. Klesney-Tait, M. Eberlein, T. Pena, J. Engelhardt, K. Parekh.
Porcine Islets Engineered to Display SA-FasL Protein on Their Surface Induce Tolerance in Mice Following Transplantation into the Liver or Under the Kidney Capsule.

H. Zhao,¹ K. Woodward,¹ H. Shirwan,¹ M. Graham,² B. Hering,² E. Yolcu.¹
Probability, Risk Factors, and Long-Term Outcomes of Biliary Complications After Hepatic Artery Thrombosis in Adult Liver Transplant Recipients: 20 Years Experience from a Single Center.

M. Fujiki, K. Hashimoto, T. Diago, C. Quintini, F. Aucejo, D. Kelly, B. Eghtesad, J. Fung, C. Miller.
Role of Regulatory T Cells in Induction of Tolerance in Mouse Vascularized Osteomyocutaneous Allotransplantation Under Combined Costimulation Blockade.

M. Anggelia,¹ H.-Y. Cheng,¹ Y.-L. Wang,¹ W.-Y. Chuang,¹ C.-H. Lin,¹ G. Brandacher,² F.-C. Wei,¹ C.-H. Lin.¹
Subtype-Compatible (A2/A2B–>B) Transplantation Under KAS Increases Access 3-Fold for Blood Type B Patients, yet Very Few Candidates Are Listed as Eligible.

D. Stewart,¹ W. Cherikh,¹ A. Kucheryavaya,¹ C. Bryan,² N. Turgeon,³ M. Aeder.⁴
Surveillance Renal Allograft Biopsies Prognosticate Graft Function.

J. Thompson, D. Taber, P. Baliga, K. Chavin, T. Srinivas.
The 20S Proteasome, Active within Exosome-Like Vesicles Released by Apoptotic Cells Accelerates Rejection.

M. Dieudé,^1,4,5 C. Bell,^2,5 J. Turgeon,^1,5 D. Beillevaire,^1,4,5 S. Qi,^1,5 E. Boilard,^3,5 P. Thibault,^2,5 M.-J. Hébert.^1,4,5
The Impact of Pre-Transplant Infections on Post-Liver Transplant Outcomes.

S. Ngo, J. Levitsky, M. Ison.
The Impact of Share 35 on Liver Allocation and Utilization: One DSA's Experience.

J. Orlowski, C. Muse, J. Whaley, R. Squires.
The Medication Level Variability Index (MLVI), a Behavioral Biomarker, Predicts Late Allograft Rejection in Pediatric Liver Transplant Recipients – A Prospective Multisite Study.

E. Shemesh,¹ J. Bucuvalas,² R. Anand,³ R. Venick,⁴ E. Alonso,⁵ J. Mitchell,³ R. Annunziato,¹ G. Mazariegos,⁶ B. Shneider.⁷
VDJ Immune Repertoire Sequencing Predicts Patients at Risk of Alloimmune Injury.

M. Sirota,¹ T. Sigdel,¹ S. Boyd,² A. Fire,² M. Sarwal.¹
Variation in Co-Medication Use According to Kidney Transplant Immunosuppressive Regimen: Application of Integrated Registry and Pharmacy Claims Data.

K. Lentine,¹ A. Naik,² M. Schnitzler,¹ D. Axelrod,³ J. Chen,¹ D. Brennan,⁴ D. Segev,⁵ B. Kasiske,⁶ H. Randall,¹ V. Dharnidharka.⁴
A Systematic Over View of Five Year Results of Serial Protocol Kidney Transplant Biopsies.

A. Geraedts, M. Tavakol, F. Vincenti, S. Chandran, Z. Laszik, B. Lee, J. Roberts, M. Sarwal.
Abrogating Donor-Derived Myd88 Signaling Impairs the Recruitment of Recipient Neutrophils and CD8 T Cells into Lung Allografts in Mice.

Z. Zheng,¹ J.-J. Wang,¹ X. Yeap,¹ X. Kang,¹ Y. Xie,¹ X. Luo,² Z. Zhang.¹
Administration of IL-33 Before Allogeneic Stem Cell Transplantation Expands Recipient Treg That Prevent Graft- vs. Host Disease.

B. Matta,¹ D. Reichenbach,² X. Zhang,¹ B. Koehn,² L. Mathews,¹ C. Feser,² M. Smith,² Q. Liu,¹ R. Zeiser,³ B. Blazar,² H. Turnquist.¹
Assessing the Impact of the Share35 Liver Allocation Policy: Survival Outcomes Among Liver Re-Transplant Recipients.

J. Ortiz,¹ N. Koizumi,² C. Kwon,² Y. Zhang,² C. Ortiz.³
Association of Cytomegalovirus-Specific T Cell-Mediated Immunity with the Risk of CMV Infection Occurrence in Kidney Transplant Recipients.

D. Dęborska-Materkowska,¹ A. Perkowska-Ptasińska,¹ A. Sadowska,¹ D. Sitarek,¹ J. Gozdowska,¹ M. Ciszek,² M. Serwańska-Świętek,³ A. Jóźwik,³ P. Domagała,³ A. Kwiatkowski,³ M. Durlik.¹
Association of Neighborhood Poverty and Living Donor Kidney Transplant Rates by Donor Relationship to Recipient.

G. Vranic, A. Nishio Lucar, D. Keith.
Biliary Epithelial Damage, Regenerative Capacity and Local Immune Response After Cold Storage of DBD Livers Determine Biliary Complications After Liver Transplantation.

S. Brunner, H. Junger, H. Schlitt, S. Fichtner-Feigl.
Black Ethnicity as a Risk Factor for Poor Kidney Allograft Outcomes Post-Transplantation.

S. Tahir,¹ F. Jackson-Spence,¹ H. Gillott,¹ F. Everson,² J. Nath,² A. Sharif.²
Blocking MHC Class II on Human Endothelium Mitigates Acute Rejection of Vessel Allografts by Effector Memory T Cells.

P. Abrahimi,¹ L. Qin,² W. Chang,¹ A. Bothwell,¹ G. Tellides,² W. Saltzman,³ J. Pober.¹
Clinical Impact of the Verigene® Blood Culture System on Rapid Diagnosis and Antibiotic Optimization in Bacteremic Solid Organ Transplant (SOT) Recipients.

N. Law,¹ G. Malat,^3,4 D. Lee,¹ A. Doyle,² C. Emery,^1,5 K. Kyle,⁵ K. Ranganna,² M. Harhay,² T. Bias.^1,4
Comparison of C4d Deposition in Renal Biopsies with Luminex-Based C3d Single Antigen Bead (SAB) Detection.

R. Pelletier,¹ I. Balazs,² P. Adams,³ P. Steller,³ N. DiPaola,⁴ L. Rankin,³ A. Diez,⁵ M. Henry.¹
Coping with Patient Death on Pediatric Liver Transplant Teams.

S. Duncan,¹ R. Arnon,² C. Dipietroantonio,¹ C. Knight,¹ J. Chu,² R. Annunziato.¹
Dynamics of Delayed Graft Function-Associated Risk in Deceased Donor Kidney Transplantation.

C. Liao, A. Massie, S. Bae, A. Muzaale, D. Segev.
Engineering a “Hybrid Thymus” to Promote Transplant Tolerance.

S. AlFadil,¹ M.-J. Kim,² M. Iglesias Lozano,¹ B. Oh,¹ W. Lee,¹ G. Brandacher,¹ T. Serworld,² G. Raimondi.¹
Evaluation of the Long-Term Outcomes with Everolimus After Calcineurin Inhibitor Withdrawal: 36M Results of the H2304 and PROTECT Extension Studies.

L. Fischer,^1,2 J. Fung,¹ H. Metselaar,¹ G. Kaiser,^1,2 P. Schemmer,² P. Neuhaus,² G. Dong,³ P. Lopez,⁴ P. Bernhardt,⁴ H. Schlitt.²
Everolimus/Low Tacrolimus(TAC) Compared to MPA/RegularTAC for Renal Transplantation in the Elderly Recipient – Preliminary Analysis of the nEverOld Trial.

E. David-Neto,¹ F. Agena,¹ F. Ramos,¹ A. Triboni,¹ M. Altona,² V. Coelho,² N. Galante,¹ F. Lemos.¹
High KDPI Kidneys (>85%) Do Not Adversely Affect HRQOL After Kidney Transplantation.

R. Forbes, I. Feurer, D. LaNeve, C. Gamble, D. Shaffer.
Impact of Machine Perfusion on Long-Term Kidney Transplant Outcomes.

S. Sandal,^1,2 X. Luo,² A. Massie,² M. Cantarovich,¹ D. Segev.²
Impact of Mixed Xenogeneic Porcine Hematopoietic Chimerism on Human NK Cell Recognition in a Humanized Mouse Model.

H. Li,¹ P. Vishwasrao,^1,2 M. Holzl,¹ S. Chen,¹ G. Choi,^2,3 G. Zhao,¹ M. Sykes.¹
Incidence and Indications for Pancreatectomy After Late Pancreas Allograft Failure.

S. Parajuli, A. Djamali, B. Astor, H. Sollinger, D. Kaufman, R. Redfield, J. Odorico, D. Mandelbrot.
Influence of AKIN Stage on the Outcome of Deceased Donor Kidney Transplantation (DDKTx).

I. Qaqish, D. Haakinson, K. Reddy, M. Smith, H. Khamash, H. Raymond.
Intracellular OPN Is an Essential Protective Factor for Cardiac Endothelial Cell and the Long Term Heart Graft Survival.

Y. Su,^1,2,3 Z.-X. Zhang,^1,2,3 Z.-Q. Yin,¹ X.-Y. Huang,¹ A. Jevnikar.^1,2,3,4
Matrix Metalloproteinase-9 in Human Orthotopic Liver Transplant Biopsies.

S. Duarte, N. Datta, J. Baber, R. Busuttil, A. Zarrinpar, A. Coito.
NK Cells Play a Critical Role in Mediating Inflammation and Graft Failure During Antibody-Mediated Rejection of Kidney Allografts.

T. Tanaka,^1,2 N. Kohei,¹ N. Dvorina,¹ A. Valujskikh,¹ W. Baldwin 3rd,¹ R. Fairchild.¹
Non-adherence is associated with increased risk of rejection and graft loss.

R. Pullalarevu,¹ D. Taber,² A. Chokkalingam,² R. Browning,¹ M. Kamel,¹ M. Salazar,¹ T. Srinivas,¹ M. Posadas Salas.¹
Outcomes Following Inguinal Hernia Repair in Kidney Transplant Recipients.

S. DiBrito, I. Olorundare, C. Landazabal, D. Segev, N. Dagher.
Outcomes of Isolated Pediatric Small Intestine Transplants Using Vascular Homografts.

Y. Kwon, N. Llore, R. Girlanda, K. Etesami, C. Desai, C. Matsumoto, T. Fishbein.
Pre-Transplant Bariatric Surgery and One-Year Graft Loss Risk in Kidney Transplants.

G. Mour, J. Zhang, Z. Su, D. Taber, P. Mauldin, T. Srinivas.
Predonation Prescription Narcotic Use: A Novel Risk Factor for Readmission After Living Donor Nephrectomy.

K. Lentine,^1,7 D. Segev,^2,1 D. Axelrod,³ N. Lam,⁴ A. Garg,⁵ G. Hess,⁶ B. Kasiske,¹ D. Brennan,⁸ H. Randall,⁷ M. Schnitzler.^7,1
RNAseq Transcriptome Analysis of Bone Marrow CD138⁺ Plasma Cell Responses to Carfilzomib Monotherapy Desensitization.

J. Driscoll, B. Aronow, S. Tremblay, R. Alloway, E. Woodle.
Randomized Controlled Study Evaluating Adherence Monitoring with Electronic Feedback on Reducing Renal Allograft Rejection.

A. Bodzin, Y. Becker, M. Josephson, P. Witkowski, M. Lockwood, L. Potter, B. Kane, L. Lourenco, J. Millis.
Rapid Detection of Urinary CXCL9 as a Diagnostic and Prognostic Tool for Managing Acute Cellular Rejection (ACR) in Kidney Transplantation.

I. Gandolfini,¹ C. Harris,¹ C. Purroy,¹ V. Nair,¹ J. Reid-Adam,¹ O. Bestard,² P. Heeger.¹
Relative Distribution of Livers from HCV+ Donors in the U.S.

J. Salazar,¹ J. Roberts,¹ N. Mehta,¹ M. Volk,² J. Lai.¹
Simultaneous Pancreas and Kidney Transplantation for Type 2 Diabetes.

K. Wong, W. Bry, H. Mahanty, P. Patel.
Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation.

N. Singh,^1,2 A. Rossi,¹ M. Savic,¹ R. Rubocki,¹ M. Parker,¹ J. Vella.¹
The Influence of Rising Lab MELD on Vascular Invasion in HCC.

K. Halazun, E. Przybyszewski, E. Verna, B. Samstein, A. Fox, R. Brown, J. Emond.
Type-I Interferon Induced Cross-Competition of IL-10 Signaling and Its Role in the Abrogation of Transplant Tolerance.

M. Iglesias, A. Arun, W. Lee, G. Brandacher, G. Raimondi.
Utility of Six-Minute-Walk Distance in Predicting Lung Transplant Benefit in the Lung Allocation Score Era.

S. Shah,¹ D. Tumin,³ B. Whitson,² A. Pope-Harman,¹ S. Kirkby,¹ A. Kilic,² P. Lee,² D. Hayes.^1,3
Utility of a Routine Bench Cholangiogram for Deceased Split Liver Procedure.

N. Battula, R. Anbarasan, V. Thumma, K. Sharif, T. Perera, P. Muiesan, D. Mirza.
Wait List Removals and Transplant Rates Are Significantly Associated with Transplant Center Performance Oversight.

J. Schold, L. Buccini, E. Poggio, S. Flechner, D. Goldfarb.
3D-FLM (First, Last, Max): A Novel Summative Measure of Hepatocellular Carcinoma (HCC) Tumor Burden Predicts HCC Recurrence After Liver Transplantation (LT).

E. Nordstrom,¹ J. Dodge,² J. Gralla,¹ K. Campbell,¹ C. Palmer,¹ S. Biggins.¹
5-Year Follow-Up After Live Donor Nephrectomy – A Prospective Cohort Study.

S. Janki,¹ E. Mulder,¹ L. Dols,¹ M. Betjes,² I. Dooper,³ J. IJzermans.¹
A 30% Decrease in Post-kidney Transplant Estimated Glomerular Filtration Rate (eGFR) from 6 Mo-2 Y Is a Surrogate for 5 Y eGFR: Results from Clinical Trials in Organ Transplantation-(CTOT)-17.

G. Faddoul,¹ G. Nadkarni,¹ D. Hricik,² P. Heeger,¹ CTOT17 Investigators.
A Comparative Intention-to-Treat Analysis of Liver Transplantation for HCC – Living Donor Liver Transplant vs. Deceased Donor Liver Transplant.

K. Tomiyama, N. Goldaracena, A. Barbas, M. Dib, G. Levy, L. Lilly, A. Ghanekar, I. McGilvray, E. Renner, M. Bhat, M. Selzner, M. Cattral, N. Selzner, P. Greig, D. Grant, G. Sapisochin.
A Multi-Center Study of Factors That Increase Cognitive Load in Living Donor Liver Transplants.

A. Lee,¹ R. Khorzad,¹ E. Pomfret,² J. Guarrera,³ R. Fisher,⁴ M. Simpson,² A. Skaro,¹ A. Daud,¹ N. Salehitezangi,¹ D. Woods,¹ D. Ladner.¹
A Novel Quantitative CD45 Immunofluorescence Assay Can Measure Inflammatory Load in Renal Transplant Biopsies with Excellent Reproducibility and Repeatability.

Z. Laszik,¹ D. Dobi,¹ L. Laszik,¹ D. Ikle,² S. Chandran,¹ F. Vincenti.¹
A Quantitative CD45 Assay May Improve Diagnostic Accuracy of the Diagnosis of Acute Cellular Rejection in Transplant Kidney Biopsies.

L. Laszik, S. Bowman, V. Walavalkar, F. Vincenti, Z. Laszik.
A Quantitative CD45 Immunohistochemical Assay Allows Precise and Reproducible Measurement of Inflammation in Renal Transplant Biopsies.

V. Walavalkar,¹ S. Bowman,¹ L. Laszik,¹ D. Ikle,² S. Chandran,¹ F. Vincenti,¹ Z. Laszik.¹
A Selective Biomarker in Blood Cells Identifies IFTA After Kidney Transplantation.

M. Matz,¹ C. Lorkowski,¹ K. Wu,³ H.-H. Neumayer,¹ M.-F. Mashreghi,² K. Budde.¹
A Unique In Vitro Migration Model for Leukocyte Trans-Lymphatic Endothelial Migration.

Y. Xiong,¹ C. Brinkman,¹ K. Hippen,² B. Blazar,² J. Bromberg.¹
A2 Kidneys into B Recipients: Is Postoperative Anti-A1 Titer Monitoring Useful?

A. DeMers, R. Forbes, D. Moore, K. Smith, D. Shaffer.
ABO Incompatible Living Related Kidney Transplantation: Results of a Matched-Pair Analysis with ABO Compatible Living Donation.

T. Vowinkel,¹ H. Wolters,² S. Reuter,³ T. Vogel,¹ N. Senninger,¹ B. Suwelack.³
ABO-Incompatible Living Kidney Transplantation at Multicenter Japanese Case Series: Evolution of Outcomes and Immunosuppressive Management.

K. Tanabe,¹ M. Okumi,¹ M. Furusawa,¹ K. Unagami,¹ T. Hirai,¹ H. Shirakawa,² T. Shimizu,¹ K. Omoto,³ M. Inui,¹ H. Ishida.¹
ASC-Deficient Dendritic Cells Exhibit Activation Defects and a Reduced Ability to Stimulate Allogeneic T Cells.

A. Scheinok, A. Shigeoka, S. Kasimsetty, R. Elahimehr, D. McKay.
Absence of Acute Allograft Rejection in the Early Post Operative Period in a Full Face VCA Recipient with a Positive B-Cell Flow Cytometric Crossmatch Utilizing an Induction Immunosuppression Regimen Including Anti-thymocyte and Anti-CD20 Agents.

B. Gelb,³ M. Plana,¹ D. Dadhania,² M. Suthanthiran,² J. Diaz-Siso,¹ E. Rogriguez.¹
Acute Allograft Glomerulopathy: A Distinct Form of Cellular Rejection.

O. AL-Badri, M. Alexander, F. Cosio, L. Cornell.
Acute Rejection Profoundly Impacts Graft Survival in Young but Not in Old Kidney Transplant Recipients.

C. Denecke,^1,3 M. Biebl,^1,3 J. Fritz,² A. Brandl,^1,4 S. Weiss,^1,4 T. Dziodzio,^1,3 F. Aigner,^1,3 R. Sucher,^1,3 C. Bösmüller,¹ J. Pratschke,^1,3,4 R. Öllinger.^1,3
Acute Rejection: A Major Cause of Death-Censored Kidney Allograft Failure.

M. Alkadi,¹ J. Kim,¹ C. Hartono,² M. Aull,¹ T. Muthukumar.¹
Adiponectin Is Produced by Leukocytes Infiltrating Renal Transplants.

S. Goparaju, R. Fan, K. Keslar, N. Dvorina, W. Baldwin III.
Age Gap Analysis Between Live Donor and Recipients in Kidney Transplantation: Opportunities to Improve Voluntary Exchange Programs and Kidney Paired Donation.

J. Rodriguez,¹ A. Patel,² M. Goggins.²
Age-Based High GFR Associates with Clinical Risk Among Potential Living Donors, but Only with Increased Nephron Number Among Approved Donors.

H. Chakkera,¹ E. Poggio,³ A. Denic,² J. Mathew,² W. Kremers,² J. Larson,² H. Amer,² F. Cosio,² M. Stegall,² S. Taler,² A. Rule.²
Alloantibody Suppression by Bruton Tyrosine Kinase Antagonist Ibrutinib Is Associated with a Moderate Splenic B-Cell Reduction.

N.-N. Chai, I. Kim, S. Jordan, A. Klein, G. Wu.
An Analysis of Factors Associated with Pancreas Allograft Thrombosis.

J. Steggerda, K. Bornhurst, A. Annamalai, A. Peng, J. Mirocha, D. Dafoe.
Analysis of T Cell Receptor Repertoire in Routine Renal Allograft Biopsy.

R. Reindl-Schwaighofer,¹ J. Weinberger,¹ R. Jimenez-Heredia,¹ J. Sunzenauer,¹ S. Schaller,² S. Winkler,² R. Oberbauer.¹
Appraisal of Alternative Immunosuppression Regimens in Intestinal Transplant Recipients: A Single Center Experience.

R. Patel, M. Keck, D. Collier, M. Vacha.
Arteriolar Hyalinosis on Renal Transplant Protocol Biopsies Is Not Associated with Tacrolimus Exposure.

S. Yilmaz,¹ D. Shaffer,² Y. Qazi,³ F. Shihab,⁴ K. McCague,⁵ D. Patel,⁵ F. Vincenti.⁶
Assessing the Induction of Tolerance to Vascularized Composite Allotransplantation in Miniature Swine.

J. Walch, J. Alonso-Escalante, H. Wang, B. Oh, M. Iglesias, A. Lee, G. Brandacher, G. Raimondi.
Assessing the Role of Everolimus in Reducing Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation for Patients within UCSF Criteria: Re-Inventing the Role of Mammalian Target of Rapamycine Inhibitors.

L.-B. Jeng, A. Thorat, H.-R. Yang, T.-H. Chen, S.-C. Hsu.
Association Between GFR Decline and Long Term Outcome in Renal Transplantation.

A. Delay,¹ O. Moranne,² N. Maillard,¹ E. Alamartine,¹ C. Mariat.¹
Association Between Pretransplant Body Mass Index and Outcomes in Patients Undergoing Living Kidney Transplantation: A Consideration of Gender Differences.

M. Okumi,¹ K. Unagami,¹ M. Furusawa,¹ T. Hirai,¹ Y. Okabe,² K. Masutani,³ T. Shimizu,¹ K. Omoto,⁴ H. Ishida,¹ T. Kitazono,³ K. Tanabe,¹ The Japan Academic Consortium of Kidney Transplantation (JACK).
Autologous BK-Specific T-Cell Lines in Kidney Transplant Recipients.

C. Lamarche,^1,2,3 O. Julie,^1,3 C. Carli,^1,3 J.-S. Delisle.^1,2,3
Barriers to the Wider Utilization of Living Donor Liver Transplantation (LDLT).

A. Yegiants, E. Przybyszewski, A. Fox, J. Emond, B. Samstein.
Biopsies for Delayed Graft Function After Alemtuzumab Induction in Kidney Transplantation: The Incidence of Early Rejection After Alemtuzumab Is Very Low but Not Negligible.

E. McGuire, C. Roufosse, T. Cook, D. Ashby, T. Cairns, J. Galliford, M. Willicombe, D. Taube, A. McLean.
Bone Allograft: An Unusual Cause of Sensitization.

J. Bloch,¹ V. Elsermans,² F. Provôt,¹ A. Lionet,¹ L. Wajbrot-Houzé,³ C. Noel,¹ M. Hazzan.¹
Bortezomib Impacts Tenascin mRNA in PBMNCs.

E. Bradley, O. Moussa, K. Twombley.
CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.

C. Cosentino, J. Kaiser, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
CD9+ Regulatory B Lymphocytes Control Chronic Lung Inflammation by Inducing Effector T Cell Apoptosis.

C. Brosseau,^1,2 M. Durand,¹ F. Braza,¹ E. Durand,² J. Loy,² P. Lacoste,² P. Royer,² M.-A. Cheminant,² A. Magnan,² S. Brouard.¹
CXCL12 as Innovative Immune Isolating Chemokine for Microencapsulated Allo and Xeno-Transplantation in NHPs.

M. Sremac,¹ A. Saraya,¹ O. Clemente,¹ M. Penson,¹ S. Chavan,³ N. Chronos,³ C. Schuetz,² J. Lei,² J. Markmann,² T. Brauns,¹ M. Poznansky.¹
Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epitheilal to Mesenquimal Transition.

V. Tubita,¹ J. Segui-Barber,⁴ M.-J. Ramírez-Bajo,¹ D. Moya-Rull,¹ P. Piselli,³ D. Verdirosi,³ F. Oppenheimer,^1,2,5 D. Serraino,⁶ H. Del Portillo,^4,7 F. Diekmann,^1,2,5 J. Campistol,^1,2,5 I. Revuelta.^1,2,5
Can We Predict New-Onset Diabetes After Transplantation Previously?

R. Imamura,¹ K. Tsutahara,² S. Nakazawa,¹ Y. Kakuta,¹ T. Abe,¹ T. Takao,² N. Ichimaru,³ S. Yamaguchi,² S. Takahara,³ N. Nonomura.¹
Center Level Analysis of Changes in Living Donor Transplant Rates in the United States.

D. Keith, A. Nishio Lucar, G. Vranic.
Center Volume Is Associated with Outcome Following Pancreas Transplantation within the Eurotransplant Region.

W. Kopp,^1,2 M. van Meel,² H. Putter,³ U. Samuel,² H. Arbogast,⁴ W. Schareck,⁵ J. Ringers,¹ A. Braat.¹
Center and Surgeons' Experience Improves Outcome in Adult-to-Adult Living Donor Liver Transplantation: Validation of the Report of the A2ALL Consortium.

S. Nagai, A. Yoshida, M. Rizzari, K. Collins, D. Kim, M. Abouljoud.
Characteristics Independently Associated with Kidney Candidates Having CPRA of 99-100%.

A. Kucheryavaya, D. Klassen, D. Stewart.
Characterization of T Regulatory Type 1 (Tr1) Cells in Naïve and Transplanted Non-Human Primates.

R. Yu, M. Tonsho, P. Spencer, S. Bernard-Stoecklin, G. Benichou, J. Madsen.
Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.

R. Anand, R. Hung, S. Frame, K. Bramham, M. Wain, A. Cronin.
Chronic Infection by Hepatitis C Virus and the Development of Transplant Glomerulopathy.

D. Regidor,¹ S. Alexandru,⁵ M. Martínez,³ N. Polanco,⁴ E. González,⁴ A. Serrano,² J. Morales.⁴
Cinacalcet Versus Pre-Transplant Parathyroidectomy in Renal Transplant Recipients: Single Centre Experience.

G. Lucisano,¹ R. Charif,¹ K. Koutroutsos,¹ D. Taube,¹ F. Palazzo,² M. Loucaidou.¹
Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.

D. Kim, G. Na, T. Hong, Y. You.
Clinical Impact of Pre-Transplant Serum 25-Hydroxyvitamin D Levels on the Post-Transplant Immunologic and Non-Immunologic Outcomes in Kidney Transplant Recipients.

T. Ban,^1,2 J. Kim,^1,2 Y. Lee,¹ B. Choi,^1,2 C. Park,^1,2 C. Yang,^1,2 Y.-S. Kim,^1,2 B. Chung.^1,2
Clinical Outcome in Pure T-Cell Mediated Acute Rejection of the Kidney with No Donor Specific Antibody or C4d Staining.

P. Randhawa,¹ G. Huang,² S. Randhawa,¹ G. Zeng,¹ X. Zhao.³
Clinical Outcome of Elderly Living Kidney Donors: A Single-Center Study in Japan.

J. Hasegawa, K. Unagami, M. Okumi, K. Omoto, M. Inui, H. Ishida, K. Tanabe.
Clinical Outcome on Kidney Retransplantation in Comparison with First Kidney Transplantation in Korea – Nationwide Cohort Study.

J. Kim,^1,2 T. Ban,^1,2 B. Jung,^1,2 B. Choi,^1,2 C. Park,^1,2 C. Yang,^1,2 Y.-S. Kim.^1,2
Clinical Significance of Solitary Pulmonary Nodules in Liver Transplant Recipients with Hepatocellular Carcinoma.

O. Serrano,¹ A. Bangdiwala,² D. Vock,² V. Kirchner,¹ K. Yadav,¹ A. Pugalendhi,¹ E. Minja,¹ T. Dunn,¹ E. Finger,¹ A. Matas,¹ R. Kandaswamy,¹ W. Payne,¹ T. Pruett,¹ S. Chinnakotla.¹
Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation.

C. Cho, K. Kim, S. Kim, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, N. Lee.
CoCl2 Induced ER Stress Protein Mediated Cytotoxicity in FK506 Treated Hepatoma HepG2 Cells.

S. Choi, S. Chung.
Cold Ischemia Induced Outcomes in Kidney Transplantation: A Meta-Analysis.

D. Bennett, M. Mustafa, M. Chiles, W. Skillen, S. Mohan.
Comparative Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma (HCC-CCA) Undergoing Liver Transplantation: A Single Center Matched Cohort Analysis.

K. Lunsford, M. Harlander-Locke, J. Gornbein, A. Zarrinpar, F. Kaldas, H. Yersiz, D. Farmer, R. Busuttil, V. Agopian.
Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.

P. Gatault,¹ N. Kamar,² M. Buchler,¹ C. Colosio,³ D. Bertrand,⁴ A. Durrbach,⁵ L. Albano,⁶ J. Rivalan,⁷ M. Essig,⁸ Y. Le Meur,⁹ N. Bouvier,¹⁰ B. Charpentier,⁵ E. Thervet,¹¹ L. Rostaing,² Y. Lebranchu.¹
Comparison of Once-Daily and Twice-Daily Low-Dose Tacrolimus in Living Related Kidney Transplantation – Prospective Trial of Once-Daily vs. Twice-Daily Tac – 5 Years Second Report.

T. Tsuchiya, H. Ishida, T. Nozaki, H. Shirakawa, T. Shimizu, K. Omoto, M. Okumi, K. Tanabe.
Comparison of Outcomes from Patients with Completion versus Total Pancreatectomy with Islet Autotransplantation: A Single-Institution Experience with 120 Consecutive Cases.

G. Yoshimatsu,¹ M. Takita,¹ R. Shahbazov,² M. Lawrence,¹ B. Naziruddin,³ P. Kim,³ M. Levy,⁴ N. Onaca.³
Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal^® with Prograf^® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.

W. Arns,¹ A. Huppertz,¹ T. Rath,¹ S. Ziefle,¹ L. Rump,¹ A. Hansen,¹ D. Baeumer,² K. Budde,¹ L. Lehner,¹ T. Klein,¹ P. Schenker.¹
Comparison of Renal Outcomes Between ABO-Incompatible and Kidney Paired Donation Transplantation In Living Donors.

N. Hashemi, M. Tavakol, B. Lee.
Complex Constellation of HLA Antibodies Contributes to Decreasing Trend of Transplant Rate in Candidates with 100% CPRA.

R. Rajalingam, D. Hyon Gae, D. Kopchaliiska, O. Buenaventura, K. Cunniffe, G. Da Gente, J. Roberts.
Computed Tomography Measures of Nutrition Deficits in Patients with Intestine Failure.

J. Davis, W. Bush, C. Kubal, R. Mangus.
Concordance Between Pancreatic Rejection and Kidney Rejection and Kidney Survival in Simultaneous Pancreas Kidney Transplantation.

I. Moinuddin, T. Taber, M. Yaqub, D. Mishler, O. Adebiyi, J. Chen, M. Goble, J. Powelson, J. Fridell, A. Sharfuddin.
Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.

S. Patel, R. Knight, S. Kuten, J. Nolte, A. Gaber.
Continuous Glucose Monitoring in the First 6 Weeks After Transplantation in Pancreas Transplant Recipients.

K. Bonner,¹ V. Dadlani,² P. Thapa,² M. Stegall,¹ Y. Kudva.²
Contributions of Naive vs. Endogenous and Induced Alloreactive Memory T Cells in Mixed Lymphocyte Reactions.

J. Lee, G. Benichou.
Correlation of the Shear Wave Elastography with Renal Function in Kidney Transplant Recipients: A Proof of Concept Study.

J. Dosal-Bañuelos, A. Flores-Mendoza, L. Morales-Buenrostro, M. Díaz-Zamudio.
Cross-Talk Between TLR and BCR Pathways Induces CNI-Resistance in B-Cells Responding to Blood Group A-Antigens: A Novel Paradigm for Treatment with TLR-Inhibitor for CNI-Resistant AMR.

H. Sakai, Y. Tanaka, H. Ohdan.
Cytokine Networks in Kidney Transplant Patients.

R. Sabat,¹ E. Witte,¹ P. Reinke,² K. Wolk,¹ N. Babel.^3,4
Cytokine Storm in Acute Post-Hepatectmy Phase Associates with Liver Injury and Impaired Liver Regeneration.

Y. Xu,^1,2 N. Navarro-Alvarez,¹ J. Dong,² J. Markmann,¹ H. Yeh.¹
Delayed Graft Function Is an Independent Risk Factor for Renal Allograft Rejection.

T. Dienemann, S. Weber, J. Jacobi, K.-U. Eckardt, A. Weidemann.
Detection of Venous Thrombi by Microdialysis Catheters and Angiographic Guided Thrombus Extraction in Two Solitary Pancreas Transplants.

G. Kjosen,¹ R. Horneland,² E. Aandahl,² O. Oyen,² T. Tonnessen,^1,3 H. Hakon.¹
Developing a PCR-Based System to Access the Correlation of Local Chimerism and Fate of the Vascularized Composite Allotransplant.

X.-T. Huang,¹ H.-Y. Cheng,¹ C.-F. Lin,¹ S.-S. Qiu,² L.-Y. Shih,¹ F.-C. Wei.^1,2,3
Development of Diabetic Glomerulosclerosis (DMGS) After Kidney Transplantation (KTX).

F. Cosio, L. Cornell, M. Stegall.
Diabetes Mellitus Predicts Outcome in Obesity After Kidney Transplantation.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
Differences in the Prevalence of Food Allergies After Liver and or Bowel Transplantation.

K. Khan, C. Desai, S. Kaufman, A. Kroemer, J. Hawksworth, R. Girlanda, T. Fishbein, C. Matsumoto.
Differential Characteristics of Kidney Transplant Recipients According to 1-Year Chronic Kidney Disease Stage 3a and Stage 3b Graft Function.

C. Baek,¹ H. Kim,¹ W. Yang,¹ D. Han,² S.-K. Park.¹
Do Highly Sensitized Recipients Benefit from the Immunological Advantages of Zero Mismatched (0MM) Deceased Donors (DD) Kidney Allografts?

N. Elfadawy,¹ S. Flechner,² J. Schold.²
Do Morbidly Obese Patients Have an Increased Risk of Infection Post-Kidney Transplant?

S. Strout, N. Pilch, T. Veasey, R. Miller, J. Fleming, H. Meadows, C. Mardis, B. Mardis, P. Baliga, A. Posadas, J. McGillicuddy, D. Taber.
Donor HLA Specific IgM Antibody Measured on Day 14 Post-Transplantation Predicts Poor Graft Survival in HLA-Incompatible Renal Transplantation.

A. Babu, A. Androeu, S. Daga, R. Higgins, D. Mitchell, D. Briggs, N. Khovanova, N. Krishnan.
Donor Risk Index for Intestinal & Multi-Visceral Transplantation.

G. Zeng,¹ M. Chen,² X. Zhao,³ D. Landsittel,² H. Sogawa.⁴
Donor-Candidate Mismatch in Age, Sex, HLA, and Body Size Inform a Calculator for Kidney Graft Survival.

J. Kalbfleisch,¹ V. Ashby,¹ A. Leichtman,² M. Rees,³ P. X.-L. Song,¹ A. Sakhuja,¹ M. Bray,¹ R. Eikstadt,¹ A. Goulding,¹ W. Wang.¹
Duodenal Graft Complications After Pancreas Transplant: Evolving Management.

D. Al-Adra,¹ J. Laurence,² A. Norgate,¹ N. Goldaracena,¹ M. Marquez,¹ A. Barbas,¹ M. Dib,¹ M. Selzner,¹ M. Cattral.¹
Dysfunctional Production of Adipocytokines in Obesity Results in Inferior Oncologic Outcomes from Hepatocellular Carcinoma Following Liver Transplantation.

A. Mathur, E. Presbyskowski, D. Carpenter, E. Zorn, J. Guarrera, B. Samstein, A. Griesemer, K. Halazun, Y. Veras, K. Tomoaki, J. Emond.
Early De Novo DSA with T Cell Mediated Rejection (TCMR) Is Associated with Allograft Dysfunction with Chronic Injury.

A. Cherukuri, R. Mehta, P. Sood, A. Zeevi, S. Hariharan, D. Rothstein.
Early Hospital Readmission Among Immunologically Vulnerable Kidney Transplantation Recipients.

E. King, B. Orandi, S. Bae, X. Luo, D. Segev.
Early Onset Hyperuricemia Is a Prognostic Marker for Kidney Allograft Dysfunction.

M. Han,¹ S. Yang,² I. Jung,³ S.-K. Park,⁴ Y. Kim,⁵ D. Han,⁵ Y. Kim,¹ S. Kim,⁶ J. Lee.⁷
Early Posttransplant Complications Following Abo-Incompatible Kidney Transplantation.

L. Rostaing,^1,2,3 A. Allal,¹ H. Naciri Benami,¹ Z. Abdulrahman,¹ L. Esposito,¹ F. Sallusto,¹ N. Doumerc,¹ X. Game,¹ B. Debiol,¹ N. Congy,¹ N. Kamar.^1,3,4
Eculizumab for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Randomized-Controlled Trial.

S. Kulkarni,¹ N. Kirkiles-Smith,² Y. Deng,³ R. Formica,⁴ M. Gilbert,⁵ V. Broeckner,⁶ L. Bow,¹ J. Pober.²
Effect of Isolated Intraperitoneal Sirolimus Treatment on the Kidneys of C57BL/6 Mice.

B. Kim,^1,3 Y. Cho,³ H. Lee,³ D. Joo,^2,3 K. Huh,^2,3 M. Kim,^2,3 Y. Kim.^2,3
Effect of Pylorus Preservation Procedure on Patient and Graft Outcome in Total Pancreatectomy with Islet Autotransplantation.

R. Shahbazov,¹ A. Dabous,² G. Yoshimatsu,² H. Fernandez,² G. Saracino,² B. Naziruddin,² N. Onaca,² P. Kim,² M. Levy.³
Effect on Endothelial function when Hyperglycemia Is Reversed by Single Pancreas Transplantation.

T. Halden,^1,2 I. Eide,^1,2 D. Dahle,¹ A. Åsberg,^1,3 A. Reisæter,¹ T. Jenssen,^1,4 A. Hartmann.^1,2
Elevated Lung Shunt Fraction as an Independent Predictor of Local Disease Progression and Metastasis in Hepatocellular Carcinoma.

T. Sandow,¹ D. DeVun,¹ P. Gulotta,¹ H. Bohorquez,² D. Kirsch.¹
Eliminating Xenoantigen Expression on Swine Red Blood Cells.

Z.-Y. Wang,¹ G. Martens,¹ R. Blankenship,¹ R. Sidner,¹ P. Li,¹ J. Estrada,¹ M. Tector,² A. Tector.^1,3
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.

E. Woodle, M. Pando Rigal, S. Tremblay, A. Girnita.
End Stage Renal Disease Patients Have a Skewed T Cell Receptor Vbeta Repertoire.

L. Huang,¹ A. Langerak,² I. Wolvers - Tettero,² R. Meijers,¹ C. Baan,¹ N. Litjens,¹ M. Betjes.¹
End-Stage Renal Disease Does Not Impair the Large-Scale Generation of Potent Alloantigen-Specific Regulatory T Cells for Immunotherapy.

N. Litjens, K. Boer, J. Zuijderwijk, M. Klepper, A. Peeters, W. Verschoor, R. Kraaijeveld, C. Baan, M. Betjes.
Endoscopic Polydimethylsiloxane Injection in Prevention of Recurrent Graft Pyelonephritis for Transplanted Kidney with Vesicoureteral Reflux.

L. Nison,¹ M. Hazzan,² P. Puech,³ S. Bouye.¹
Establishing a Learning Curve for Laparoscopic Living Donor Nephrectomy.

Z. Ahmed, R. Tamburrini, R. Uwechue, P. Chandak, F. Calder, N. Kessaris, N. Mamode.
Evaluating Associations Between Clinical and Psychosocial Risk Factors and Adverse Post-Transplant Events in High Risk Renal Transplant Recipients.

C. Yellman, D. Destiche, A. DeMers, I. Feurer, M. Via, C. Gamble, H. Schaefer.
Evaluating Delayed Graft Function After Kidney Transplantation as a Potential Surrogate Outcome.

S. Cramm, X. Luo, A. Massie, D. Segev.
Everolimus Decline Anti-ABO Blood Type Antibody Titer in Desensitization for ABO Incompatible Kidney Transplantation.

Y. Wada, N. Fukuzawa, H. Harada.
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.

S. Yeager, A. Carlson, C. Truax, N. Kenyon, F. Ahmed, J. Corbett, F. Shihab, L. Smith.
Ex Vivo Expansion of Human Alloantigen-Reactive Regulatory T Cells Using Monocyte-Derived Dendritic Cells versus CD40L-Stimulated B Cells.

H. Zhang,¹ Y. Zhao,¹ L. Lu,¹ Q. Tang,² M. Ezzelarab,¹ A. Thomson.¹
Exposure Analysis for the Composite Efficacy Endpoints in the US92 Phase 3 Kidney Transplantation Trial to Understand Center Effects.

F. Shihab, B. Kaplan, K. McCague, D. Patel, F. Vincenti.
Fatigue, Pain, and Other Physical Symptoms of Living Liver Donors.

Z. Butt,¹ A. DiMartini,² Q. Liu,³ M. Simpson,⁴ A. Smith,^3,5 J. Zee,³ B. Gillespie,⁵ S. Holtzman,⁶ D. Ladner,¹ K. Olthoff,⁷ R. Fisher,⁸ S. Hafliger,⁹ C. Freise,¹⁰ M. Mandell,¹¹ M. Dew.²
Fluctuation of Renal Function During the First Year Is Associated with Negative Impact on Long-Term Kidney Graft Survival: A Retrospective, Propensity Score-Matched Study.

H. Choi,¹ D. Joo,^2,3 M. Song,⁴ M. Kim,^2,3 Y. Kim,^2,3 B. Kim.^1,3
Functional Capacity Pre-Transplantation Measured by 6 Minute Walk Test and Clinical Outcomes.

T. Alhamad,¹ K. Lentine,² S. Anwar,³ T. Maw,¹ T. Horwedel,¹ J. Peng,¹ K. Saffaf,¹ J. Hagopian,¹ R. Delos Santos,¹ A. Malone,¹ D. Brennan.¹
Gender Bias and Kidney Transplantation in Nepal.

S. Rasmussen,¹ P. Paneru,² D. Segev,¹ A. Massie,¹ P. Shrestha.³
Gender Differences in Longitudinal eGFR of Living Kidney Donors in a Health Information Exchange.

M. Henderson,¹ T. McFarlane,¹ A. Massie,² D. Segev,² B. Dixon.^1,3
Gene Expression Microarray Analysis of Purified CD16-Stimulated Human NK Cells and Indication Biopsies Supports a CD16-Mediated Role for NK Cells in Antibody-Mediated Kidney Rejection.

M. Parkes,¹ P. Halloran,¹ L. Hidalgo.²
Graft Versus Host Disease (GVHD) in Patients with Pancreas Transplant Alone (PTA).

M. Mujtaba,¹ A. Sharfuddin,² A. Khalil,² T. Taber,² M. Goble,² J. Powelson,² J. Fridell.²
Gut Dysbiosis and Metabolic Disorders in Kidney Transplant Recipients.

M. Lecronier,¹ P. Tashk,¹ J. Aron-Wisnewsky,^2,3,4 E. Denamur,¹ O. Tenaillon,¹ B. Barrou,^4,5 J. Tourret.^1,4,5
HLA Antibody Clonality and Epitopes Dictate Complement Activation.

K. Thomas,¹ N. Valenzuela,¹ A. Mulder,² E. Reed.¹
Health Disparities in Pediatric Intestinal Transplantation: Before and After the Implementation of MELD/PELD.

V. Cohran,¹ S. Mohammed,¹ J. Prozialeck,¹ A. Gaddam,¹ J. Caicedo.²
Hepatitis C Patients in a Multicenter Study Who Received Living Donor Liver Transplants Are Likely to Have Increased Survival.

J. Kim,¹ K.-W. Lee,² G.-W. Song,³ B.-H. Jung,³ H. Lee,⁴ N.-J. Yi,² C. Kwon,¹ S. Hwang,³ K.-S. Suh,² J.-W. Joh,¹ S.-K. Lee,¹ S.-G. Lee.³
Higher Pre-Transplant Triglyceride Levels Are Associated with Increased Acute Cellular Rejection Risk Following Kidney Transplant.

J. Hagopian,¹ D. Brennan,² K. Lentine,³ T. Horwedel.¹
Highly Sensitized Patients Transplanted via the Eurotransplant Acceptable Mismatch Program Have Excellent Long-Term Graft Survival.

S. Heidt, M. Witvliet, G. Haasnoot, F. Claas.
Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.

B. Orandi, E. King, X. Luo, S. Bae, B. Lonze, R. Montgomery, D. Segev.
Hospitalization and Living Donor Kidney Transplantation Among Waitlisted End Stage Renal Disease Patients in the US.

K. Newman,^1,2 A. Adams,² S. Pastan,² R. Lynch,² R. Zhang,¹ R. Patzer.^1,2
IFN-γ and Contact-Dependent Cytotoxicity Are Rate-Limiting for NK Cells in a Model of Antibody-Mediated Chronic Rejection.

C. Lin,¹ R. Plenter,¹ R. Gill.²
IL2 and IL-15 Rescue TEMRA CD8 T Cells from Mitochondrial Dysfunction Associated Senescence Through a p38MAPK Dependent Pathway and Foster Their Pathogenic Potential.

G. Tilly,^1,2 M. Yap,^1,2 M. Giral,^1,2,3 C. Pecqueur,⁴ S. Brouard,^1,3 N. Degauque.^1,3
Ibrutinib Suppresses Alloantibody Responses in A Mouse Model of Allosensitization: A Preliminary Report.

G. Wu, I. Kim, N.-N. Chai, A. Klein, S. Jordan.
Identification of Biomarkers for Progressive Fibrosis in Renal Transplant Patients Using Novel Chemical Imaging Approaches.

V. Varma,¹ A. Kajdacsy-Balla,¹ S. Akkina,² S. Setty,¹ M. Walsh.¹
Immunologic Basis for Immunocloaking.

L. Brasile,¹ K. Kizjakina,¹ N. Henry,¹ B. Stubenitsky.²
Immunological Ageing-Related Expansion of Highly Differentiated CD4⁺CD28null T Cells Is Associated with a Lower Risk for Early Acute Rejection After Renal Transplantation.

B. Dedeoglu, R. Meijers, M. Klepper, D. Hesselink, C. Baan, N. Litjens, M. Betjes.
Impact of Allograft Dysfunction and Early Low Grade Proteinuria on Survival in Expanded Criteria Donor Kidney Transplant Recipients.

V. López, M. Cabello, P. Ruiz, C. Jironda, D. Burgos, M. González-Molina, D. Hernández.
Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo.

K. Bonner, N. Moore, M. Moreno Gonzales, M. Stegall.
Impact of Ideal Body Weight vs. Actual Body Weight for the Prediction of Small for Size Syndrome and Graft Loss After Living Donor Liver Transplantation.

M. Dib, N. Goldaracena, A. Barbas, M. Marquez, N. Alotaiby, G. Sapisochin, M. Cattral, L. Lilly, I. McGilvray, E. Renner, P. Greig, A. Ghanekar, N. Selzner, M. Selzner, D. Grant.
Impact of Immunosuppressants on Inducing Regulatory T Cells in Human Allo-Immune Responses.

Y. Tanaka, H. Ohdan.
Impact of Pre-Existing Comorbidities on Long-Term Patient and Graft Survival in Kidney Transplant Recipients.

F. Halleck, D. Khadzhynov, L. Lehner, E. Schrezenmeier, M. Duerr, A. Kleinsteuber, K. Budde, O. Staeck.
Impact of Preformed Anti-HLA Antibodies in the Outcomes of Kidney Transplantation.

S. Santos,¹ J. Malheiro,¹ M. Costa,² A. Campos,¹ S. Pedroso,¹ M. Almeida,¹ L. Martins,¹ L. Dias,¹ C. Henriques,¹ A. Cabrita.¹
Impact of Sarcopenia in Overweight/Obese Recipients on the Outcomes After Adult Living Donor Liver Transplantation.

A. Hammad,^1,2 Y. Hamaguchi,² S. Okumura,² A. Kobayashi,² S. Yagi,² S. Uemoto,² T. Kaido.²
Impact of Simultaneous Pancreas-Kidney Transplantation versus Kidney Transplant Alone on Patient and Graft Survival in Type 2 Diabetics with Elevated BMI.

S. Singh,^1,2 S. Kim.^1,2,3,4
Impact of Social Support on Feelings of Powerlessness and Attitudes Towards the Kidney Transplant in Long-Term Inner City Recipients.

S. Wu, A. Brar, M. Markell.
Impaired Outcome of Kidney Transplants from Donors with Acute Kidney Injury.

K. Schuette-Nuetgen,¹ G. Thölking,¹ H. Pavenstädt,¹ S. Ehlert,¹ B. Suwelack,¹ D. Palmes,² R. Bahde,² S. Reuter.¹
In Their Own Words: Living Kidney Donors Who Develop Kidney Failure.

L. Ross,¹ C. Halverson,² J. Wang,¹ M. Poulson,³ J. Karlin,⁴ M. Crowley-Matoka.⁵
In Vitro Induction of T Regulatory Cells by Multipotent Adult Progenitor Cells.

S. Stubblefield, N. Williams, A. Ting.
Incidence of Viral Infections in HLA-Sensitized Patients (HS Pts) Desensitized with IVIG + Rituximab (DES) Compared to Non-HS Pts Receiving Standard Immunosuppression.

S. Jordan, J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, M. Toyoda.
Incidence, Risk Factors, and Outcomes of Delayed Graft Function in Deceased Donor Kidney Transplantation in a Brazilian Center.

A. Ribeiro,¹ M. Helfer,² O. Costa,² A. Viccari,¹ R. Manfro.^1,2
Indirect Allo-Antigen Stimulation Identifies the Presence of Either Regulatory IL-10 or of Effector Cytokines IFN-g, IL-21, IL-17a Production by Human Blood Allo-Reactive Memory T_FH and T_CONV CD4⁺ T Cells.

C. Macedo, F. Paul, Y. Masaki, H. Kevin, M. Diana.
Influence of Inclusion of the Liver on the Outcome After Intestinal Transplantation.

E. Canovai,¹ D. Monbaliu,¹ I. Jochmans,¹ M. Sainz Barriga,¹ L. Ceulemans,¹ G. De Hertogh,² J. Pirenne.¹
Influence of Pancreas Import and Cold Ischemia on Outcomes Following Pancreas Transplantation.

M. Khan,¹ H. El-Hennawy,¹ J. Rogers,¹ A. Farney,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² R. Stratta.¹
Injurious Procoagulant Pathways During Prolonged Cold Storage of the Donor Pancreas.

B. Sandhu, S. Charitidou, N. Vallant, A. McLean, D. Taube, P. DiCocco, P. Herbert, J. Crane, V. Papalois.
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.

A. Konvalinka,¹ A. Chruscinski,² S. Kim,¹ K. Tinckam,¹ I. Jurisica,³ R. John.⁴
Intraoperative Blood Loss Is a Promoter of Early Tumor Recurrence in Liver Transplant Patients with High Risk Hepatocellular Carcinoma.

A. Kornberg,¹ U. Witt,¹ J. Kornberg,² H. Friess,¹ K. Müller,³ K. Thrum.⁴
Intravenous Immunoglobulins Failed to Prevent Acute Antibody-Mediated Rejection in Kidney Transplant Recipients with De Novo DSA within the First Year After Transplant.

M. Matignon,¹ C. Pilon,² M. Commereuc,¹ C. Grondin,² T. Kofman,¹ P. Lang,¹ F. Canoui Poitrine,³ J. Cohen,² P. Grimbert.¹
Is Delayed Graft Function in Simultaneous Kidney-Pancreas Transplant Recipients Associated with an Increased Risk of Pancreas Graft Failure?

S. Singh,^1,2 S. Kim.^1,2,3,4
Is Ketorolac Really Safe for Donor Nephrectomy?

K. Takahashi, K. Putchakayala, L. Malinzak, J. Denny, M. Abouljoud, D. Kim.
Isolating High Islet Mass Even from Alcoholic Pancreatitis Pancreases Intended for Clinical Islet Auto-Transplantation: Improved Strategies to Human Islet Isolation Technique.

A. Balamurugan, G. Loganathan, B. Tweed, W. Tucker, S. Mokshagundam, S. Williams, M. Hughes.
Kidney Allotransplantation Induces the Differentiation of Antigen-Experienced CD8 T Cells with Enhanced Metabolic Profiles.

G. Tilly,^1,2 M. Yap,^1,2 M. Giral,^1,2,3 S. Brouard,^1,3 C. Pecqueur,⁴ N. Degauque.^1,3
Kidney Survival Outcomes in Combined Intestinal-Kidney Transplant: An Analysis of the UNOS/OPTN Database 2000-2014.

A. Sharfuddin, T. Taber, M. Yaqub, I. Moinuddin, A. Khalil, O. Adebiyi, M. Mujtaba.
Kidney Transplant Patient Preferences and Trade-Offs for Outcomes After Transplantation.

M. Howell,^1,2 G. Wong,^1,2,3 J. Rose,⁴ A. Tong,^1,2 J. Craig,^1,2 K. Howard.²
Landscape of Hypertension Treatment in Former Kidney Donors.

L. Ferrara, O. Sanchez, D. Berglund, A. Matas, H. Ibrahim.
Laparoscopically Assisted Living Donor Hepatectomy Is Safe and Cost Effective.

M. Akoad, M. Simpson, E. Pomfret.
Late Outcome Surrogate Score (LOSS) for Kidney Allograft Failure.

B. Ho, L. Zhao, S. Montag, D. Ladner, M. Abecassis, A. Skaro.
Late Renal Xenograft Failure Is Antibody-Mediated: Description of the Longest-Reported Survival in Pig-to-Primate Renal Xenotransplantation.

L. Higginbotham,¹ S. Kim,¹ D. Mathews,¹ A. Stephenson,¹ C. Breeden,¹ C. Larsen,¹ M. Ford,¹ K. Newell,¹ A. Tector,² A. Adams.¹
Learning from Cancer: Using D-Lactate for Therapeutic Immunosuppression.

U. Beier,¹ J. Jiao,¹ H. Xiao,¹ A. Angelin,² D. Wallace,² M. Levine,³ W. Hancock.⁴
Limited Efficacy of Bortezomib on Desensitization via Rapid Humoral Compensation in a Sensitized Rhesus Model.

J. Kwun,¹ C. Burghuber,¹ N. Iwakoshi,² A. Gibby,² S. Knechtle.¹
Live Donor Kidney Transplantation of the Most Highly Sensitized Patients in the Era of Kidney Paired Donation.

A. Bingaman,¹ F. Wright,¹ M. Kapturczak,¹ L. Shen,¹ C. Murphey.²
Live Donor Liver Transplantation with Older Donors Only Impacts on a Late HCV Recurrence.

N. Goldaracena, G. Sapisochin, A. Barbas, M. Dib, D. Al-Adra, N. Selzner, M. Cattral, P. Greig, L. Lilly, I. McGilvray, G. Levy, A. Ghanekar, E. Renner, D. Grant, M. Selzner.
Live Kidney Donors Have Significant Out-of-Pocket Costs Associated with Donation.

J. Moore, J. Leanza, A. Massie, N. Dagher, D. Segev.
Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

E. Miner,¹ T. Atim,² M. Mamven,² N. Adjekughele,¹ I. Lawal,³ H. Nadey,⁴ O. Egbuna.⁵
Living Donor Liver Transplantation for Sick Patients with MELD Score ≥ 35.

R.-S. Soong,¹ Y.-C. Wang,¹ C.-H. Cheng,¹ T.-H. Wu,¹ C.-F. Lee,¹ T.-J. Wu,¹ H.-S. Chou,¹ K.-M. Chan,¹ C.-S. Lee,² W.-C. Lee.¹
Living Donor Rates Vary Greatly Among Organ Procurement Organizations in the United States.

D. Keith, A. Nishio Lucar, G. Vranic.
Living Related Small Bowel Transplantation in Children – Patient and Graft Survival at 10 Years.

S. Garcia Aroz,¹ I. Tzvetanov,¹ E. Hetterman,² J. Hoonbae,¹ M. Spaggiari,¹ J. Oberholzer,¹ G. Testa,³ E. John,¹ E. Benedetti.¹
Living Related Small Bowel Transplantation in Children, a Single-Center Experience – Growth, Development and Quality of Life 10 Years After Transplant.

S. Garcia Aroz,¹ I. Tzvetanov,¹ E. Hetterman,² J. Hoonbae,¹ M. Spaggiari,¹ J. Oberholzer,¹ G. Testa,³ E. John,⁴ E. Benedetti.¹
Long Term Follow Up of Kidney Donors with Asymptomatic Renal Stones.

D. Serur,¹ M. Charlton,² K. Juluru,³ G. Salama,³ E. LoCastro,³ G. Bretzlaff,² C. Hartono.¹
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.

L. Furian,¹ L. Di Maria,² G. Cappelli,³ M. Carmellini,⁴ G. Spagnoletti,⁵ G. Piredda,⁶ P. Todeschini,⁷ S. Chiaramonte,⁸ G. Tisone.⁹
Long Term Results on Pancreas Transplant Beyond the Standard Indications, at a Single Center.

D. Ramisch,¹ N. Aguirre,¹ F. Moss,² P. Farinelli,¹ R. Fortunato,² L. Gutierrez,² P. Barros Schelotto,¹ H. Fraguas,³ P. Raffaele,² G. Gondolesi.¹
Long-Term Deterioration of Graft Function (DeKAF) Study: Histologic Interpretation of Cross-sectional vs Prospective Cohorts.

A. Matas,¹ A. Fieberg,¹ L. Hunsicker,² J. Grande,³ For the DeKAF Group.
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).

R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
Long-Term Outcomes After Splenectomy for Small-for-Size Syndrome in Live Donor Liver Transplantation.

M. Dib, N. Goldaracena, A. Barbas, M. Marquez, G. Sapisochin, C. Beriault, N. Selzner, I. McGilvray, E. Renner, P. Greig, L. Lilly, A. Ghanekar, M. Cattral, M. Selzner, D. Grant.
Longitudinal Psychological Outcomes of Living Liver Donors.

Z. Butt,¹ M. Dew,² Q. Liu,³ M. Simpson,⁴ A. Smith,^3,5 J. Zee,³ B. Gillespie,⁵ S. Abbey,⁶ D. Ladner,¹ R. Weinreib,⁷ R. Fisher,⁸ S. Hafliger,⁹ N. Terrault,¹⁰ J. Burton,¹¹ A. DiMartini.²
Low Risk of Cytomegalovirus (CMV) Transmission in Clinical Islet Transplantation.

D. Kabbani,¹ K. Cheung,² P. Senior,² C. Cervera,¹ K. Doucette,¹ J. Preiksaitis.¹
Measuring Efficacy of Antibody Removal Therapies: Back to Titers.

A. Tambur,¹ D. Glotz,² N. Herrera,¹ E. Chatroop,¹ T. Roitberg,¹ J. Friedewald,¹ D. Gjertson.³
Mechanical Thrombectomy for the Treatment of Pancreas Transplant Venous Thrombosis: A Single Center Experience.

S. Shin,¹ H. Ko,² K. Ko,² Y. Kim,¹ J. Choi,¹ J. Jung,¹ D. Han.¹
Mechanism of FK506 Induced TNF Related Apoptosis in Jurkat T Cells.

S. Chung, S. Choi.
Membrane Proteome Profiling Reveals Molecular Changes Associated with Donor-Specific Tolerance to Vascularized Composite Allotransplants.

H.-Y. Cheng,¹ C.-L. Han,² F.-W. Jiang,² L.-Y. Shih,¹ C.-F. Lin,¹ Y.-J. Chen,³ F.-C. Wei.^1,4
Metabolomic Profiles of Hepatocellular Carcinoma and Cirrhotic Patients Before and After Transplantation.

C. Desai,¹ R. Varghese,² S. Robertazzi,¹ C. Di Poto,² A. Ferrarini,² C. Tu,² R. Girlanda,¹ K. Khan,¹ T. Fishbein,¹ H. Ressom.²
Metabolomic Profiling of Individuals with Failing Kidney Allograft.

R. Bassi,^1,2 M. Niewczas,³ L. Biancone,⁵ S. Bussolino,⁵ A. Lin,⁴ A. Chandraker,⁶ P. Fiorina.^1,2
MicroRNA-375 and -200c Are a Set of Novel Biomarkers That Can Predict Islet Autotransplantation Outcome.

G. Yoshimatsu,¹ M. Kanak,² M. Takita,¹ S. Prathab Balaji,¹ C. Chang,¹ M. Lawrence,¹ M. Levy,² N. Onaca,³ P. Kim,³ B. Naziruddin.³
Minimum Graft Size Avoiding Small-for-Size Associated Early Graft Failure in Living Donor Liver Transplantation.

S. Marubashi,¹ H. Nagano,³ H. Eguchi,² H. Wada,² K. Umeshita,² Y. Doki,² M. Mori,² N. Sato,¹ T. Kimura,¹ A. Kenjyo,¹ M. Gotoh.¹
Molecular Diagnosis of Antibody-Mediated Rejection in Routine Formalin-Fixed Paraffin-Embedded Nonhuman Primate Renal Allograft Biopsies.

B. Adam,¹ I. Rosales,² T. Oura,² R. Smith,² A. Cosimi,² T. Kawai,² R. Colvin,² M. Mengel.¹
Monocytic TNF-α Response to EBV Peptides as a Mean to Identify Over-Immunosuppressed Kidney Transplant Recipients.

P. Vallin,¹ O. Désy,¹ S. Béland,¹ E. Wagner,² S. De Serres.¹
Myeloid-Derived Suppressor Cells (MDSC) Accumulate in Intestinal Transplant (IT) Patients.

S. Okano,¹ K. Hashimoto,¹ K. Abu-Elmagd,¹ J. Fung,¹ D. Kish,² K. Keslar,² B. Min,² R. Fairchild,² C. Miller.¹
NEAD Chains Do Not Disadvantage Blood Type O, Black, or Highly Sensitized Patients.

M. Rees,¹ J. Roberts,² K. Lentine,³ A. Roth,⁴ A. Leichtman,⁵ H. Xiao,³ S. Rafizadeh,¹ E. Neidich,² M. Melcher.⁴
NanoString Detection of Gene Signatures in Urine During Acute Cellular Rejection of Kidney Grafts.

K. Keslar,¹ A. Zmijewska,² J. Andriga,² K. Newell,³ R. Mannon,² P. Heeger,⁴ R. Fairchild.¹
Natural Language Processing Methods Allow Reliable Extraction of Banff Scores and Grades.

K. Reilly,¹ L. Lenert,¹ H. Anwar,² J. Thompson,¹ D. Taber,¹ P. Mauldin,¹ T. Srinivas.¹
Negative Impact of Anticardiolipid Antibodies on 1-Year Renal Allograft Estimated Glomerular Filtration Rate: A Cohort Study.

M. Gauthier,¹ F. Canoui Poitrine,² S. Hue,³ D. Desvaux,⁴ T. Kofman,¹ P. Lang,¹ P. Grimbert,¹ M. Matignon.¹
No Significant Impact of KAS on Prior Living Kidney Donors' Access to Timely Transplant of High Quality Kidneys.

J. Wainright,¹ A. Kucheryavaya,¹ M. Aeder,² D. Klassen,¹ D. Stewart.¹
Number of Bacterial Isolates and Resistance Increases Mortality Risk in Intestinal Transplant Patients.

D. Patel, H. Shah, T. Schiano, J. Moon, K. Iyer, S. Huprikar.
Occult Multifocal Hepatocellular Carcinoma in Surgical Patients.

D. Aufhauser Jr,¹ E. Sadot,² D. Murken,¹ K. Eddinger,¹ D. Goldberg,³ E. Furth,⁴ P. Abt,¹ R. DeMatteo,² M. Levine.¹
Opioid-Sparing Pain Management Improves Outcomes and Safety in Living Liver Donors.

D. Ladner,¹ E. Pomfret,² M. Simpson,² J. Guarrera,³ R. Fisher,⁴ A. Skaro,¹ T. Baker,¹ T. Curtis,¹ A. Daud,¹ B. Platt,¹ R. Kang,¹ N. Salehitezangi,¹ J. Holl,¹ M. Abecassis,¹ D. Woods.¹
Outcomes for Kidney Allograft Recipients with Language Barriers Post-Transplantation – A Comparative Analysis.

S. Tahir,¹ F. Jackson-Spence,¹ H. Gillott,¹ F. Everson,² J. Nath,² A. Sharif.²
Outcomes of Donor Nephrectomy (DN) in the Obese.

O. Serrano,¹ A. Bangdiwala,² D. Vock,³ E. Minja,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ T. Pruett,¹ A. Matas,¹ R. Kandaswamy.¹
Outcomes of Donor Nephrectomy in the Elderly.

O. Serrano,¹ A. Bangdiwala,² K. Yadav,¹ A. Adamusiak,¹ D. Vock,³ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ T. Pruett,¹ A. Matas,¹ R. Kandaswamy.¹
Outcomes of Ductoplasty in Right Lobe Living Donor Grafts with More Than One Bile Duct.

S. Kapoor, V. Varma, B. Nath, V. Kumaran.
Outcomes of Kidney Transplantation in Obese Recipients – Single Center Experience.

A. El-Hinnawi, A. Rajab, G. Bumgardner, L. Haj Naser, R. Plews, I. James, M. Henry, R. Pelletier.
Outcomes of Small-for-Size Grafts in Adult Living Donor Liver Transplantation.

T. Klair,¹ E. Przybyszewski,¹ B. Samstein.²
Outcomes of Solid Organ Transplants Following Simultaneous Solid Organ and Vascularized Composite Allograft Procurements.

M. Alhefzi,¹ M. Aycart,¹ G. Sharma,² N. Krezdorn,¹ E. Bueno,¹ S. Talbot,¹ M. Carty,¹ B. Pomahac,¹ S. Tullius.³
Outcomes of Super Obese Patients Undergoing Kidney Transplantation: A Propensity Match Analysis from the UNOS Dataset.

R. Gedaly, P. Kanthawar, X. Mei, M. Daily, M. Shah, J. Berger, A. Castellanos, F. Marti.
Outcomes with Steroids Alone for Biopsy-Proven Pancreas Transplant Rejection.

S. Salahuddin,¹ B. Astor,¹ S. Parajuli,¹ A. Djamali,¹ J. Odorico,² D. Mandelbrot.¹
PD-L1/PD-L2-Expressing B-1a Cells Inhibit Allo-Reactive T Cells in Mice.

T. Hirose,^1,2 Y. Tanaka,¹ H. Ohdan.¹
Pancreas Retransplantation – Is It Worth It?

M. Kocik,¹ K. Lipar,¹ L. Janousek,¹ P. Girman,² J. Fronek,¹ F. Saudek.²
Pancreatic Allograft Failure in Latino Recipients: Diabetes Mellitus Type 2 Conversion?

H. Fernandez, G. McKenna, N. Onaca, R. Ruiz.
Pathogenic Role of Anti-HLA Antibodies on Endothelial Progenitor Cell Dysfunction of Highly Sensitized Kidney Transplanted Patients.

V. Cantaluppi,¹ S. Dellepiane,² D. Medica,² G. Tognarelli,² M. Quaglia,¹ C. Musetti,¹ A. Airoldi,¹ L. Biancone.²
Periodical Peer Review of a Pancreas Transplant Programme: Can It Enhance Performance?

Z. Moinuddin, A. Arif, O. Masood, A. Tavakoli, R. Pararajsingam, K. Poulton, J. Worthington, B. Forgacs, T. Augustine, R. Dhanda.
Peritransplant Costimulation Blockade Combined with a Short-Course of Rapamycin Prevents Rejection of Vascularized Composite Allografts.

B. Oh, G. Furtmüller, M. Fryer, P. Akre, D. Cooney, W. Lee, G. Raimondi, G. Brandacher.
Personal Relationships and Financial Outcomes in Living Liver Donors.

A. DiMartini,¹ M. Dew,¹ Q. Liu,² M. Simpson,³ D. Ladner,⁴ A. Smith,^2,5 J. Zee,² S. Abbey,⁶ B. Gillespie,⁵ R. Weinrieb,⁷ S. Mandell,⁸ R. Fisher,⁹ J. Emond,¹⁰ C. Freise,¹¹ Z. Butt.⁴
Planning Genitourinary Vascularized Composite Allotransplantation: A Pre-Operative Imaging Protocol.

I. Schol, T. Drijkoningen, G. Choy, R. Liu, C. Tanrikut, P. Holzer, D. Ko, C. Cetrulo.
Plasma Alemtuzumab Levels Show Great Interpatient Variability, but Are Not Associated with Late Acute Rejection in Simultaneous Pancreas-Kidney Recipients.

J. Bank,¹ M. Mallat,¹ C. Jol-van der Zijde,² R. Bredius,² P. van der Boog,¹ A. Braat,³ J. Ringers,³ M. Reinders,¹ J. de Fijter.¹
Plasma Endothelial Microvesicle Counts Indicate Allograft Rejection Following Kidney Transplantation.

D. Zecher,¹ A. Cumpelik,² B. Ruhland,¹ B. Banas,¹ H. Hopfer,³ M. Dickenmann,⁴ J. Schifferli.²
Poor HLA Matching May Reduce the Beneficial Effect of ABOi Pairs Entering the Paired and Pooled Scheme.

M. Willicombe, C. Lawrence, R. Charif, A. McLean, J. Galliford, D. Taube.
Portal Vein Complication After Living Donor Right Hepatectomy.

D.-H. Jung, S.-G. Lee, S. Hwang, K.-H. Kim, C.-S. Ahn, D.-B. Moon, T.-Y. Ha, G.-W. Song, W.-J. Kim, S.-H. Kim, W.-H. Kang, J.-H. Kwon, E.-K. Jwa, H.-D. Cho.
Post-Transplant Reduction of Long Lived Plasma Cells from Peripheral Circulation Is Associated with Acute Rejection in Kidney Transplant Recipients.

R. Minz,¹ R. Dhital,² M. Minz,² R. Nada,³ A. Sharma,² S. Singh,² D. Kenwar.²
Pre-Formed AT1R Antibodies Are Associated with Rejection After Kidney Transplantation.

D. Kim, P. Warner, K. Nelson, I. Gimferrer, C. Johnson, C. Blosser, R. Bakthavatsalam, N. Leca.
Pre-Transplant Intra-Arterial Liver Directed Therapy Does Not Increase the Risk of Hepatic Arterial Misadventures in Liver Transplantation.

J. Kallini,² A. Gabr,² R. Salem,² R. Lewandowski,² T. Baker.¹
Predicting Late Medication Non-Adherence in Adult Kidney Transplant Recipients.

D. Taber, A. Posadas, A. Chokkalingam, R. Browning, N. Salazar, M. Kamel, R. Pullalarevu, B. Kadri, K. Chavin, T. Srinivas, P. Baliga.
Predictive Value of Preoperation Serum Gamma-Glutamyltranspeptidase for Hepatocellular Carcinoma Prognosis After Liver Transplantation.

S. Fu, Q. Zhao, M. Chen, L. Wu, Q. Ren, F. Ji, Z. Guo, X. He.
Predictors of Outcomes After Kidney Transplantation in the Setting of Chronic Opiate Use.

R. Evans,¹ N. Neville,² A. Fugit,³ R. Gedaly,¹ T. Clifford.¹
Pretransplant Serum Hyaluronic Acid Can Be a Prognostic Predictor in Adult-to-Adult Living Donor Liver Transplantation.

S. Mizuno,¹ B. Das,² Y. Iizawa,¹ H. Kato,¹ Y. Murata,¹ A. Tanemura,¹ N. Kriyama,¹ Y. Azumi,¹ M. Kishiwada,¹ M. Usui,¹ H. Sakurai,¹ S. Isaji.¹
Prospective Long-Term Analysis of B- and Plasma Cell Subsets in Renal Transplant Patients After Combined Treatment with Rituximab and Bortezomib in Antibody Mediated Rejection.

M. Duerr, F. Halleck, O. Staeck, L. Lehner, D. Khadzhynov, S. Eva, J. Waiser, K. Budde.
Quality of Postoperative Pain Care in Living Liver Donors.

M. Mandell,¹ A. Smith,^2,6 D. Gordon,³ S. Holtzman,⁴ M. Dew,⁵ T. Howell,⁶ A. DiMartini,⁵ Z. Butt,⁸ M. Simpson,⁷ C. Freise,⁹ S. McCluskey,¹⁰ R. Fisher,¹¹ J. Guaerra,¹² K. Olthoff,¹³ E. Pomfret.⁷
Radiosensitive Cell Population Prolongs Graft Survival of Vascularized Composite Allografts in Non-Human Primates.

M. Uluer, J. Woodall, W. Hassanein, U. Drhu, B. Bojovic, A. Nam, S. Bartlett, R. Barth.
Rapamycin (RPM) Synergizes with CD154 mAb and DST to Promote Long-Term Vascularized Composite Allograft (VCA) Survival, but Prevents Induction of Donor-Specific Tolerance.

L. Wang, Z. Wang, R. Han, T. Bhatti, L. Levin, M. Levine, W. Hancock.
Rapid Emergence of CD28^null Cells Following Ex Vivo Restimulation Is Associated with Belatacept Resistant Rejection.

M. Cortes, S. Laurie, B. Sayed, M. Ford.
Recall Alloantibody Production Is Driven by CD138⁺ Cells Proliferating in the Spleens: An Indication for Long-Lived Plasma Cell Activities and Potential Therapeutic Target.

I. Kim, N.-N. Chai, A. Klein, S. Jordan, G. Wu.
Recipient Age and KDPI Are Potent Predictors of Early Acute Rejection in the Modern Era of Deceased Donor Kidney Transplantation.

D. Keith, G. Vranic, A. Nishio Lucar.
Recovery of eGFR in Both Donors and Recipients After Living Donor Kidney Transplantation.

J. Verbesey, A. Gilbert, A. Li, M. Reissmann, N. Foreman, M. Grafals, B. Javaid, P. Abrams, S. Ghasemian, M. Cooper.
Reduced Incidence of Rejection in AB0-incompatible Kidney Transplantation – Five Year Follow-Up in a Single Center.

A. Weidemann, F. Karpf, T. Dienemann, K. Birkner, J. Jacobi, K.-U. Eckardt.
Refill-Based Immunosuppression Non-Adherence Is Associated with Increased Death Censored Graft Loss.

K. Wen, S. Gourishankar, S. Shojai, A. Wong, M. Bae, D. Grynoch, P. Halloran.
Renal Fibroblast Activation and Survival by Anti-MHC Class I Antibody: The Role of mTOR Signaling Pathway.

J. Chen, A. Zmijewska, R. Mannon.
Renal Graft Survival According to Banff 2013 Diagnostic Categories in Indication Biopsies.

D. Redondo-Pachón,¹ C. Arias-Cabrales,¹ M. Pérez-Sáez,¹ J. Gimeno,² I. Sánchez-Güerri,² S. Bermejo,¹ A. Sierra,¹ C. Burballa,¹ M. Mir,¹ M. Crespo,¹ J. Pascual.¹
Results of Biopsies in Pancreas and Kidney-Pancreas Patients with Graft Dysfunction.

P. Uva, L. Leon, E. Minue, I. Cabrera, A. Giunippero, M. Norese, M. Toniolo, E. Chuluyan, D. Casadei.
Resveratrol Effectively Suppress Th17 Associated Allo-Immune Responses by the Modulation of AMPK/mTOR Pathway.

B. Chung, K. Doh, J.-W. Min, K. Kim, B.-M. Kim, M.-L. Cho, C. Yang.
Risk Factors for Early Readmission After Total Pancreatectomy with Islet Auto Transplantation.

R. Shahbazov,¹ N. Bashoo,² G. Yoshimatsu,² G. Saracino,² F. Azari,¹ N. Onaca,² P. Kim,² M. Levy.³
Role of Natural Killer Cells in Kidney Transplant Outcome.

E. Carta,¹ R. Littera,² M. Murgia,¹ M. Michittu,¹ B. Onano,¹ G. Piredda,¹ D. Argiolas.¹
Selection of Patients with Solitary Lesion of Hepatocellular Cancer for Liver Transplantation.

M. Grąt,¹ J. Stypułkowski,¹ W. Patkowski,¹ K. Wronka,¹ M. Wasilewicz,² K. Grąt,³ L. Masior,¹ M. Krasnodębski,¹ Z. Lewandowski,⁴ M. Krawczyk.¹
Sequential Analysis of Donor-Specific Antibodies and Pathological Findings Using Intravenous Immunoglobulin in a Highly Sensitized Rat Kidney Transplant Model.

Y. Sawada,¹ K. Omoto,² N. Kohei,⁴ K. Kawanishi,³ M. Okumi,² H. Ishida,² T. Kazunari.²
Sequential and Long-Term Protocol Biopsy Is Useful for the Detection of Subclinical Lesions of Clinical Interest in Kidney Allografts.

M. Miura,¹ H. Higashiyama,¹ T. Tsuji,² Y. Fukasawa.²
Serum Albumin Level Has Association with Both Graft Failure and Mortality in Kidney Transplant Recipients.

H. Jeon,¹ S. Rhee,¹ D. Shin,¹ J. Oh,¹ Y. Kim,² J. Lee.³
Serum Inflammatory Biomarkers in Kidney Transplant Recipients and Renal Donors.

J. Ramirez,¹ E. Cuevas,¹ J. Furuzawa,² L. Morales-Buenrostro,³ M. Lopez-Cervantes,² J. Alberu.¹
Should Obese Patients Undergo Renal Transplantation? A Retrospective Analysis to Assess Whether Body Mass Index Can Affect Transplant Outcome.

A. Mehta,¹ A. Marriott,¹ A. Ghazanfar.²
Should Renin Angiotensin Blockade Be the Mainstay of Hypertension Treatment in Kidney Donors?

O. Sanchez, L. Ferrara, D. Berglund, S. Reule, R. Spong, N. Issa, A. Kukla, A. Matas, H. Ibrahim.
Single Cell Profiling of Th9 Cells Allows Identification of Functionally Different Subsets.

K. Stanko, J. Schumann, K. Vogt, S. Schlickeiser, C. Appelt, B. Sawitzki.
Skin as a Harbinger of Rejection of Underlying Structures in Vascularized Composite Allografts: Concordance or Discordance?

L. Cendales,¹ M. Levine,² S. Bartlett,³ J. Cheeseman,¹ C. Drachenberg,³ W. Hancock,⁴ M. Joshi,¹ A. Kirk,¹ F. Leoopardi,¹ S. Levin,² M. Uluer,³ A. Selim,⁵ M. Song,¹ W. Twaddell,³ L. Wang,⁴ Z. Wang,² R. Barth.³
Soluble Fibrinogen-Like Protein 2 Regulates Differentiation and Enhances Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Allograft Immunity.

C. Yang,^1,4 L. Wang,³ R. Rong,^2,4 T. Zhu,^2,4 M. Xu.^2,4
Subnormothermic Machine Perfusion (SNMP) with a Novel Hemoglobin-Based Oxygen Carrier (HBOC) Solution for Ex Vivo Preservation in Vascularized Composite Allotransplantation (VCA).

S. Oksuz, R. Schweizer, M. Minervini, B. Banan, V. Gorantla, P. Fontes.
Successful Transplantation in ABO- and HLA-Incompatible Kidney-Transplant Patients.

L. Rostaing, N. Congy, A. Allal, L. Esposito, F. Sallusto, N. Congy, X. Doumerc, B. Debiol, N. Kamar.
Surgical Techniques in Modified Multiorgan Transplantation.

W. Ju, J. Lin, J. Zhou, M. Chen, A. Yang, D. Wang, Y. Ma, Z. Guo, M. Han, X. Wang, X. Zhu, X. He.
Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation.

H. Madariaga,¹ R. Ugarte,¹ C. Drachenberg,² N. Costa,¹ B. Thomas,¹ J. Bromberg,³ M. Weir,¹ A. Haririan.¹
Survey Results Show Strong Support for Allowing Patients Undergoing Desensitization to Keep Their Pre-Desensitization CPRA Allocation Priority.

A. Kucheryavaya,¹ R. Bray,² D. Tyan.³
Technique of “Loop V-Plasty” for Combined Reconstruction of the Middle Hepatic Vein and Multiple Inferior Right Hepatic Veins Using Single Polytetrafluoroethylene Graft in a Right Lobe Living Donor Liver Transplantation.

T.-H. Chen, L. Noriega, A. Thorat, P.-C. Li, H.-R. Yang, S.-C. Hsu, L. Jeng, M.-L. Li.
The Effect of Donor-Recipient Relationship on the Immunologic Outcome in Living Kidney Transplantation.

D. Khadzhynov, F. Halleck, L. Lehner, M. Duerr, J. Waiser, K. Budde, O. Staeck.
The Effect of Everolimus and Tacrolimus Exposure Levels on Renal Histology Parameters 6 Months Post-Transplantation.

S. Yilmaz,¹ D. Shaffer,² Y. Qazi,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ F. Vincenti.⁶
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.

J. Lee,¹ J. Park,² J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ K. Huh,¹ B. Kim,³ M. Kim,¹ S. Kim,¹ S. Ahn,² Y. Kim.¹
The Effect of Spironolactone on Calcineurininhibitor Induced Nephrotoxicity.

L. Mortensen,¹ H. Thiesson,¹ C. Bistrup,¹ F. Nielsen,³ U. Halekoh,² B. Jensen,³ N. Marcussen.⁴
The Impact of Allograft Rejection on DNA Methylation After Kidney Transplantation.

K. Boer, E. de Wit, D. Hesselink, L. Hofland, M. Betjes, C. Baan.
The Impact of Different Immunosuppressive Protocols on Early and Long Term Outcomes After Kidney and Pancreas Transplantation.

A. Rajab, R. Pelletier, A. El-Hinnawi, E. Elkhammas, G. Bumgardner, M. Henry.
The Impact of Graft Thin Upper Pole Arterial Branch Ligation on Adult Living Donor Kidney Transplantation.

T. Hiramitsu, M. Okada, T. Yamamoto, M. Tsujita, N. Goto, S. Narumi, Y. Watarai.
The Impact of Treating Borderline Cellular Rejections.

R. Mustafa,¹ Y. Al Azzi,¹ J. Crew,¹ G. Dube,¹ H. Morris,¹ M. Chiles,¹ J. Chang,¹ H. Fernandez,¹ D. Cohen,¹ I. Batal,² E. Campenot,² S. Mohan.¹
The Prevailing Preference for Left Nephrectomy in Living Donor Transplantation Does Not Adversely Affect Long Term Donor Outcome.

S. Robertson,¹ L. Garrard,¹ S. Farid,¹ R. Baker,¹ N. Ahmad,¹ M. Attia,¹ R. Feltbower,² M. Jameel,¹ H. Lutz.¹
The Property of Modulatory T Cells Generated by Mixed Lymphocyte Culture with CD154 Blockade.

K. Hotta, T. Oura, B. Cosimi, T. Kawai.
The Role and Mechanism of CD40/CD40L Expression on Different T-Cell Subsets.

N. Granofszky, K. Hock, B. Mahr, N. Pilat-Michalek, T. Wekerle.
The Role of B Cells in Liver Transplant Tolerance.

M. Morita,² G. Enyindah-Asonye,¹ N. Gupta,¹ J. Fung,² S. Qian,^1,2 L. Lu.^1,2
The Role of HLA Class II Antibody in Endothelial Cell Activation and Allograft Rejection.

G. Cantanhede,¹ V. Carter,² K. Giles,² J. Kirby,¹ S. Ali.¹
The Surgical Preconditioning in Patients with Ultra-Short Gut Using a Native Colonic Conduit for Anticipated Visceral Transplantation.

M. Fujiki, K. Hashimoto, A. Khanna, K. Abu-Elmagd.
The Urine Common Rejection Module (uCRM) Is a Sentinal Assay for Graft Rejection.

T. Sigdel,¹ T. Tran,¹ O. Bestard,² F. Vincenti,¹ M. Sarwal.¹
The Use of Kidney Donors Older Than 80 Years Does Not Affect Graft Survival in the Medium Term.

A. Fernández,¹ J. González,² C. Galeano,¹ S. Elias,¹ S. Jimenez,¹ F. Caravaca,¹ S. Pampa,¹ R. Marcen.¹
The In Vivo Non-Invasive Long-Term Functional Assessment of Neuronal Regeneration in Vascularized Composite Allotransplantation.

C.-J. Wen,^1,2 C.-H. Lin,¹ S.-L. Peng,^3,4 F.-N. Wang,³ L.-Y. Huang,³ H.-Y. Cheng,¹ H.-H. Hsu,¹ X.-T. Huang,¹ C.-H. Lin,¹ F.-C. Wei.¹
Time for the Grown Ups to Split the Difference? Outcomes of Two Adult Split Liver Transplants in the USA.

K. Halazun, E. Przybyszewski, B. Samstein, E. Verna, A. Fox, J. Guarrera, T. Kato, A. Griesemer, R. Brown, J. Emond.
Tolerance Induction in Vascularized Composite Allotransplantation with Peri-Transplant Combined Costimulation Blockade.

B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ G. Raimondi,¹ G. Brandacher.¹
Torque Teno Virus – Inverse Association with Late Silent Antibody Mediated Kidney Allograft Rejection.

G. Bond,¹ M. Schiemann,¹ F. Eskandary,¹ H. Herkner,² E. Puchhammer,³ R. Oberbauer,¹ G. Böhmig.¹
Total Pancreatectomy with Islet Autotransplantation for Chronic Pancreatitis: Considerations for Early Intervention.

J. Jolissaint,¹ L. Langman,¹ C. DeBolt,¹ A. Wang,² D. Strand,² V. Zaydfudim,¹ R. Adams,¹ K. Brayman.¹
Transcriptome Profiles in Peripheral Blood of Kidney Graft Recipients.

J.-W. Seo,¹ H. Moon,¹ Y.-G. Kim,¹ K.-H. Jeong,¹ S.-J. Ihm,² J.-Y. Moon,¹ S.-H. Lee.¹
Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).

A. Nejad, A. Vo, J. Choi, S. Jordan.
Transitional B Cell T1/T2 Ratio Is a Prognostic Marker for Human Renal Allograft Deterioration.

A. Cherukuri,¹ D. Rothstein,¹ R. Baker.²
Transplantation for Hepatocellularcarcinoma Is There a Tumor Size Limit?

A. Daoud, L. Teeter, M. Ghobrial, E. Graviss, S. Mogawer, A. Sholkamy, M. Alshazly, H. Monsour, A. Gaber.
United States versus Australia: Is "Percentage Decline in Estimated Glomerular Filtration Rate" Truly a Surrogate Outcome in Graft Survival?

K. Parker,² A. Rice,¹ A. Kirby,¹ M. Pinion,¹ K. Parker.²
Updated Experience of Living Donor Right Hepatectomy Using Mini-Incision Technique.

S. Nagai, A. Yoshida, M. Rizzari, K. Collins, D. Kim, M. Abouljoud.
Urinary Exosomal Annexin A1 Is a Predictive Biomarker of Post Kidney Transplant Complications.

H. Harada,¹ T. Murakami,² C. Yamamoto,² K. Hotta,¹ N. Fukuzawa,¹ M. Mitsuhashi.²
Urinary Expression of miRNA-155, miRNA-210, miRNA-142 and CXCL-10 Production Predicts the Risk of Acute Rejection and Graft Outcome in Renal Transplant Recipients.

O. Millan,¹ K. Budde,² C. Sommerer,³ I. Aliart,¹ O. Rissling,² B. Bardaji,⁴ M. Matz,² M. Zeier,³ I. Silva,⁴ L. Guirado,⁴ M. Brunet.¹
Urinary Markers of Proximal Tubular Dysfunction in Kidney Transplant as Predictors for CKD.

P. Garcia, V. Garcia-Nieto, J. Navarro, E. Martin, A. Rivero, A. Jarque, J. Gonzalez-Posadas, M. Macia.
Urine-Derived Cell Lines as a Novel Tool for Monitoring Allo-Reactivity in Kidney Transplant Patients.

C. Thieme,¹ B. Weist,¹ M. Schmück,¹ P. Reinke,¹ N. Babel.^1,2
Use of Autotransfusion During Liver Transplantation for Hepatocellular Carcinoma Does Not Increase Recurrence.

A. Gupta, M. Ramsay, G. Saracino, T. Anthony, R. Goldstein, G. McKenna, N. Onaca, R. Ruiz, G. Klintmalm, P. Kim.
Use of Integrated National Registry and Pharmacy Claims Data to Identify Diabetes Mellitus After Live Pancreas Donation.

K. Lentine,^1,7 N. Lam,² H. Randall,⁸ D. Axelrod,³ D. Segev,^4,1 G. Hess,⁵ A. Garg,⁶ D. Brennan,⁷ B. Kasiske,⁸ M. Schnitzler.^8,1
Utilization of Plasmapheresis and High Dose of Immunoglobulins in the Treatment of the High Level of De Novo Donor Specific Antibodies for the Successful Islet Allotransplantation.

J. Solomina,¹ Z. Tekin,¹ S. Matosz,¹ K. Golab,¹ C. Thomas,² J. Golebiewska,³ S. Ramachandran,¹ L. Schenck,¹ W. Chon,¹ M. Tibudan,¹ N. Marek-Trzonkowska,⁴ J. Millis,¹ P. Witkowski.¹
Utilizing HLA Single Antigen Flow Beads Assays to Evaluate Anti-MAMU Antibody in Sensitized Nonhuman Primate Model.

J. Kwun,¹ C. Burghuber,² M. Manook,¹ A. Clark,³ D. Chen,³ S. Knechtle.¹
Validation of SUITO Index and C-Peptide/Glucose Creatinine Ratio as Convenient Tools for the Evaluation of the Short and Long-Term Islet Allograft Function.

J. Gołębiewska,¹ J. Solomina,² S. Matosz,² C. Thomas,³ L. Schenck,² K. Golab,² W. Chon,³ S. Ramachandran,² M. Tibudan,² A. Dębska-ŚLizień,¹ B. Rutkowski,¹ P. Witkowski.²
Vascular Composite Allotransplantation Collaborative Initiative Biobank: Bringing the Power Back to Research.

J. Cheeseman, M.-B. Joshi, F. Leopardi, R. Osborne, D. Conlon, L. Stempora, M. Song, L. Cendales.
Virtual Crossmatch in Simultaneous Pancreas-Kidney Transplant.

E. Bevilaqua Rangel,¹ A. Miziara Gonzalez,¹ C. Santiago Melaragno,¹ J. de Sa,¹ M. Moura Linhares,¹ A. Salzedas-Neto,¹ R. de Marco,² M. de Lima,² J. Medina-Pestana.¹
Watch Out for the Guy with the Low EPTS Score: Nonadherence and Kidney Allograft Failure.

A. Liu, K. Balabhadrapatruni, J. Augustine.
What Is the Decline Rate of Pancreata Attributed to Donation After Cardiac Death When the Accompanied Kidney Is Transplanted?

T. Alhamad,¹ K. Lentine,² A. Taha,² J. Wellen,¹ D. Brennan.¹
Which Is the Predictable Value of Post-Transplant HCC Recurrence Between Tumor-Related Factors at the Initial Diagnosis and the Transplantation?

J. Lee,^1,2 J. Lee,¹ J. Lee,³ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ M. Ju,^1,2 M. Kim,^1,2 G. Choi,^1,2 J. Choi,^1,2 S. Kim,^1,2 D. Joo.^1,2
Which Is the Predictable Values of Post-Transplant Hepatocellular Carcinoma Recurrence in Patients Received Down Staging Therapy or Bridging Therapy?

S. Song, J. Lee, S.-K. Kwon, J. Lee, J. Lee, D. Han, G. Choi, M. Kim, J. Choi, S. Kim, D. Joo.
Why Do African American Patients Display Disparities in Renal Graft Function Following Renal Transplantation?

Y. Nyame, V. Gan, P. Aram, D. Greene, N. Yerram, C. Modlin, S. Flechner.
Widespread Weight Gain After Pancreas Transplantation May Worsen Metabolic Graft Function.

A. Gruessner, V. Whittaker, N. Ozden, R. Gruessner.
Young, Caucasian, Better Educated and Less Socially Deprived Patients Are More Likely to Be Transplanted with a Living Donor Kidney in the UK.

D. Wu,¹ M. Robb,² C. Watson,³ R. Ravanan,⁴ J. Forsythe,¹ W. Metcalfe,¹ C. Dudley,⁴ C. Bradley,⁵ H. Draper,⁶ A. Bradley,³ G. Oniscu.¹
Zero and One Mismathing for HLA DR10,14,16 Produces Increased Kidney Graft Survival.

J. Cicciarelli,^1,2 Y. Cho,² M. Altrich,¹ N. Kasahara,^1,3 N. Lemp.¹
Anti-Angiotensin II Type 1 Receptor Antibody Reduction with Proteasome Inhibitor-Based Desensitization.

A. Girnita, E. Portwood, P. Brailey, S. Tremblay, R. Alloway, E. Woodle.
Antithymocyte Globulin (ATG) versus Anti-interleukin-2 Receptor (Anti-IL-2R) as Induction Therapy for Kidney Transplantation After a Nonrenal Transplant.

H. Mai,¹ K. Trébern-Launay,¹ C. Legendre,² M. Kessler,³ L. Rostaing,⁴ V. Garrigue,⁵ E. Morelon,⁶ S. Brouard,¹ M. Giral,¹ J.-P. Soulillou.¹
Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.

A. Liu, N. Sarabu, A. Joshua.
Characterization of Human Islet Transplant Specific Exosomes in a Xenoislet Transplantation Model.

P. Vallabhajosyula, L. Korutla, M. Yu, S. Rostami, C.-X. Yuan, C. Liu, V. Korutla, S. Reddy, A. Habertheuer, A. Naji.
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.

X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
DNA Methylation Patterns and Association with Graft Injury Severity Post Liver Transplantation.

R. Gehrau, S. Bontha, V. Mas, D. Maluf.
Does Post-Transplant Adherence Come at a Cost?

K. Yadav, T. Nevins, D. Vock, W. Thomas, W. Robiner, A. Matas.
Donation After Cardiac Death Dose Not Impact Short and Long Term Graft Outcomes in Simultaneous Pancreas and Kidney Transplantation.

T. Alhamad,¹ A. Taha,² K. Lentine,² J. Wellen,¹ J. Garonzik-Wang,¹ D. Brennan.¹
Early Post-Transplant Patient, Graft Survival and Rejection Rates Under KAS.

A. Kucheryavaya, D. Stewart, D. Klassen.
Effect of Adipose Tissue-Derived Mesenchymal Stem Cells in a Rat Model of Chronic Renal Allograft Rejection.

R. Pepineli, F. Silva, P. Gouveia, G. Tavora, S. Gomes, I. Noronha.
Everolimus versus Mycophenolate Mofetil in Combination with Tacrolimus: A Propensity Score Matching Analysis in Liver Transplantation.

P. de Simone,¹ P. Carrai,¹ A. Precisi,² L. Coletti,¹ D. Ghinolfi,¹ F. Filipponi.¹
Fecal Microbiota Transplant Results in Durable Changes to Host Microbiota That Correlate with Allograft Outcome.

C. Brinkman, L. Hittle, W. Fricke, E. Mongodin, J. Bromberg.
Generation of Naïve Donor-Derived Lymphocytes from Graft-Resident Lymphoid Progenitors After Human Intestinal Transplantation.

J. Fu, J. Zuber, B. Shonts, S. Lau, A. Obradovic, T. Savage, M. Simpson, S. Yang, Y. Shen, M. Martinez, A. Griesemer, T. Kato, M. Sykes.
Geographic Variation in Liver Supply and Demand.

J. Pyke,¹ D. Schladt,¹ J. Zeglin,¹ H. Xiong,¹ S. Gentry,^2,1 W. Kim,^3,1 J. Lake,^4,1 A. Israni.¹
Hif-1α Stabilization in the Recipient Accelerates Cardiac Allograft Rejection.

Z. Ilyas, M. DeBerge, S. Dehn, J.-J. Wang, Z. Zhang, E. Thorp, M. Ansari.
Human Leukocyte Antigen-E Expression on Porcine GalTKO.hCD46 Cells Improves Ex-Vivo Xenograft Survival and Attenuates Injury.

C. Laird,¹ N. Kubicki,¹ L. Burdorf,¹ T. Zhang,¹ X. Chang,¹ G. Braileanu,¹ C. Phelps,² D. Ayares,² A. Azimzadeh,¹ R. Pierson.¹
Human MicroRNA Responses Are Predictive of CMV Reactivation Following Solid Organ Transplant.

S. Han,¹ D. Kumar,¹ V. Ferreira,¹ S. Husain,¹ N. Mueller,² A. Humar,¹ M. Mian,¹ P. Ashton.¹
Impact of Cold Ischemia Time on the Outcomes of Kidneys with KDPI >85%: Mate Kidney Analysis.

M. Sampaio, B. Chopra, K. Sureshkumar.
Implications of Subclinical Borderline Acute Cellular Rejection Detected in Protocol Biopsies on Graft Outcomes.

Z. Zaky,¹ C. Yu,¹ N. Elfadawy,² A. Chiesa-Vottero,¹ L. Herlitz,¹ S. Flechner,¹ E. Poggio.¹
Increased Access to Transplantation of Highly Sensitized Patients Facilitated by the New Kidney Allocation System.

A. Colovai, M. Ajaimy, C. Savchik, S. Chan, P. Masiakos, J. Rocca, E. Akalin.
Infectious Complication in Extremely Elderly Kidney Transplant (KT) Recipients: A Leading Cause of Death.

J. Cabrera,^1,3 M. Fernández-Ruiz,² M. Molina,¹ E. González,¹ N. Polanco,¹ F. López-Medrano,² J. Aguado,² M. Praga,¹ A. Andrés.¹
Is Prolonged Cold Ischemia a Contraindication to Using Kidneys from Acute Kidney Injury Donors?

M. Khan,¹ A. Carrier,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Kidney Structural Characteristics as Predictors of Long-Term Kidney Function in Living Kidney Donors.

J. Mathew,¹ A. Denic,¹ M. Alexander,² T. Vrtiska,³ H. Chakkera,⁴ S. Taler,¹ A. Rule.¹
Mechanisms of Alloantigen-Specific Regulation After Donor Specific Transfusion and Costimulatory Blockade in YFP-Foxp3/TdTomRed-Ebi3 Marker Mice.

Y. Tomita,¹ W. Bracamonte-Baran,¹ D. Vignali,² W. Burlingham.¹
Metallothionein Accelerates Anti-MHC Induced Small Airway Obliteration and Fibrosis by Negatively Regulating IL-10 and Regulatory Cells.

D. Nayak,^1,2 F. Zhou,¹ N. Benshoff,¹ T. Mohanakumar.^1,2
Optimal Donor/Recipient Pairing for High KDPI Grafts Can Yield Similar Survival to Medium KDPI Grafts.

M. Selim, E. Saad, M. Zimmerman, C. Johnson.
Pancreas After Islet Transplantation – A Successful Treatment Option After a Failed Islet Transplant.

R. Gruessner, N. Ozden, V. Whittaker, V. Aggarwal, A. Gruessner.
Peer Mentoring to Improve Access to Kidney Transplantation in the Southeast.

J. Gander,¹ S. McMath,² M. Rudd,² L. Sauls,³ S. Tripathi,¹ L. Plantinga,¹ L. McPherson,¹ T. Browne,⁴ S. Pastan,¹ R. Patzer.¹
Pre-Transplant Infusion of Extracorporeal Photopheresis Treated Donor Splenocytes Leads to Long-Term Liver Allograft Survival and Donor Specific Tolerance in Rats.

X. Kang,¹ Y. Xie,² X. Yeap,² J. Wang,² J. Schneiderman,² Z. Zhang.²
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.

D. Dahle,¹ T. Grotmol,² T. Leivestad,³ A. Hartmann,¹ G. Mjøen,¹ H. Pihlstrøm,¹ H. Næss,¹ H. Holdaas.¹
Smoking Exposure Among Kidney Allograft Recipients and Outcomes After Transplant.

H. Gillott,¹ S. Tahir,¹ F. Jackson-Spence,¹ F. Evison,² J. Nath,³ A. Sharif.³
Standardized Pre-Implantation Kidney Biopsies of Expanded Criteria Donors to Improve the Kidney Donor Profile Index (KDPI) for the Evaluation of Marginal Donors.

A. Sánchez-Escuredo,¹ A. Sagasta,² F. Diekmann,¹ I. Revuelta,¹ L. Rodas,¹ D. Paredes,³ M. Musquera,⁴ N. Esforzado,¹ M. Ricart,¹ F. Cofan,¹ V. Torregrosa,¹ J. Campistol,¹ M. Sole,² F. Oppenheimer.¹
Successful Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.

C. Ensor, R. Winstead, B. Johnson, M. Morrell, S. Kilaru, C. Moore, J. Hayanga, A. Zeevi, E. Lendermon, J. McDyer.
Survival Advantage with Older Live Donor Compared to Standard Criteria Deceased Donor Kidney Transplantation in Older Recipients.

P. Abrams, M. Cooper, J. Verbesey, R. Ghasemian, M. Grafals, A. Gilbert, J. Moore, J. Fenton, C. Cannon, J. Rapisurra, B. Javaid.
The Finances of Broader Sharing of Livers Following Share 35.

A. Harper,¹ E. Edwards,¹ R. Gilroy,² W. Chapman,³ D. Mulligan,⁴ G. Klintmalm.⁵
The Treatment of Borderline Lesion in Protocol Biopsies Did Not Improve the Outcome in Kidney Transplant Recipients.

A. Flores-Mendoza, L. Marino-Vazquez, A. Guichard-Romero, N. Uribe-Uribe, R. Rivera-Marfil, A. Nuñez-Abreu, J. Alberu, L. Morales-Buenrostro.
Urine Cell-Free Supernatant Metabolites Diagnostic of Antibody Mediated Rejection in Kidney Allografts.

M. Alkadi,¹ J. Lee,¹ D. Dadhania,¹ T. Muthukumar,¹ C. Snopkowski,¹ C. Li,¹ S. Salvatore,¹ S. Seshan,¹ K. Suhre,² M. Suthanthiran.¹
Visceral Adiposity Is Associated with Increased Recurrence of Hepatocellular Carcinoma Following Liver Transplantation.

A. Mathur, L. Boyangzi, M. Prince, J. Guarrera, B. Samstein, A. Griesemer, K. Halazun, T. Kato, J. Emond.
When Living Donor Liver Allografts Fail: Exploring the Pitfalls of Retransplantation Using Deceased Donor Organs.

T. Bittermann,¹ A. Shaked,² K. Lloyd,² D. Goldberg.¹
15-Years Experience with the EUROTRANSPLANT Senior Program.

H.-M. Tautenhahn,¹ S. Brückner,¹ H.-M. Hau,¹ H. Morgül,¹ J. Broschewitz,¹ C. Pipiale,¹ F. Pankow,¹ S. Erler,² M. Bartels.¹
6 Minute Walk Test and FVC Analysis: A New Method to Prioritize Organ Allocation for Patients with COPD.

I. Timofte, M. Terrin, M. Wijesinha, P. Sanchez, R. Pierson, E. Barr, J. Kim, Z. Kon, S. Pham, A. Iacono.
Clostridium difficile Infection in Patients with a Continuous Flow, Durable Left Ventricular Assist Device.

J. Glick Frasiolas, I. Li, H. Kim, D. Tsapepas.
Ex Vivo Expansion and Functional Characterization of Human Alloantigen-Specific Regulatory T Cells.

J. Mathew,¹ S. McEwen,¹ I. Konieczna,¹ X. Huang,¹ J. He,¹ R. Kornbluth,² J. Miller,¹ L. Gallon,¹ J. Leventhal.¹
In Vivo and In Vitro Characterization of 1.5 mm Ba²⁺-Alginate Macro-Encapsulated Cynomolgus Monkey Islets.

M. Bochenek,¹ J. McGarrigle,¹ J. Mendoza-Elias,¹ E. Marchese,¹ M. Nourmohammadzadeh,¹ Y. Wang,¹ A. Khan,¹ M. Omami,¹ C.-C. Yeh,¹ I. Lacik,² B. Strand,³ J. Oberholzer.¹
Pneumocystis jirovecii Pneumonia: Late and Serious Complication Among Kidney Transplant Recipients.

L. Viana, T. Sandes, M. Cristelli, A. Oliveira, D. Santos, H. Tedesco-Silva, J. Medina-Pestana.
Same Policy, Different Impact: Center and Regional Effects of SHARE 35 Liver Allocation.

D. Murken,¹ A. Peng,¹ D. Aufhauser Jr,¹ D. Goldberg,² M. Levine.¹
A 15-Year Retrospective Analysis of Acute Kidney Injury in Non Renal Solid Organ Transplant Recipients: Incidence, Outcome and Progression Toward End Stage Chronic Kidney Disease.

V. Cantaluppi,¹ A. Quercia,² S. Dellepiane,² D. Medica,² L. Biancone.²
A Call for a New Paradigm of Organ Allocation within the Confines of MELD for Those Who Are Not “the Sickest”.

T. Baker, A. Siarris, P. Accoh, D. Ladner.
A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus.

Y. Jung,¹ Y. Kim,¹ S. Kim,¹ H. Shin,¹ H. Rim,¹ H. Rhew.²
A Comprehensive Biomarker Study to Compare Tacrolimus and Mycophenolic Acid versus Half-Dose Tacrolimus and Everolimus in De Novo Kidney Transplant Patients in the Novartis US92 Study.

J. Klepacki,¹ J. Klawitter,¹ J. Klawitter,¹ A. Karimpour-fard,² E. Anderson,¹ G. Ingle,³ D. Patel,³ K. Johnson,⁴ D. Cibrik,⁴ U. Christians.¹
A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).

D. Kaul,¹ S. Tlusty,² A. Wilk,² C. Wolfe.¹
A Genome Wide Association Study of New Onset Diabetes After Transplant in Kidney Transplantation.

A. Giri,¹ M. Sanders,² D. Velez Edwards,¹ T. Ikizler,³ D. Roden,³ K. Birdwell.³
A Model to Explore the Potential Budget Impact of a Novel Screening Tool for the Detection of Subclinical Rejection Among Kidney Transplant Patients.

K. Jaglinski,¹ H. Uchida,¹ T. Inocencio,² K. Hughes.²
A Multi-Modular Approach for Training in Liver Procurement Accelerates Proficiency Gain.

I. Al Hasan,^1,2 H. Sharma,^1,2 M. Tun-Abraham,¹ D. Quan.^1,2
A Non-Hematopoietic Erythropoietin Analogue, ARA 290, Prolonged Allogeneic Pancreatic Islet Graft Survival in a Mouse Model.

M. Watanabe,¹ M. Yao,¹ D. Andersson,¹ M. Brines,² T. Lundgren,¹ M. Kumagai-Braesch.¹
A Novel Humanized Mouse Model Incorporating Non-Fetal Tissue.

M. Brown, I. Norman, Y. Zhou, W. Lou, J. Sullivan, W. Burlingham.
A Novel Inflammation-Targeting Tacrolimus Hydrogel for Liver Transplantation.

J. Jia,¹ J. Li,¹² Y. Zhou,¹ L. Jiang,¹ J. Zhang,¹ H. Lu,¹ H. Xie,¹ L. Zhou,¹ P. Kumur,³ S. Zheng.¹²
A Novel Intra-Abdominal Cooling System Prevents Graft Warming During Implantation for Robotic-Assisted Renal Transplantation.

R. Meier, M. Hagen, C. Joliat, J.-B. Buchs, A. Nastasi, R. Ruttimann, F. Lazeyras, P. Morel, L. Bühler.
A Novel Microfluidic Device for Purification of Pancreatic Islet Preparations.

W. Varhue,¹ L. Langman,² D. Bowers,³ S. Peirce-Cottler,³ N. Swami,¹ K. Brayman.²
A Novel Study to Determine the Association of Pre-Transplant Donor Specific Antibody and AT₁R Antibody with Kidney Transplant Outcomes Prior to Adoption of Solid Phase Antibody Assays.

R. Redfield, B. Astor, B. Jung-Hynes, D. Mandelbrot, D. Kaufman, A. Djamali, T. Ellis.
A Novel, Non-Viral mRNA Delivery System for Targeted Protein Translation in Human Islets.

J. Oberholzer,^1,2 D. Gutierrez,^1,2 E. Marchese,¹ M. Nourmohammadzadeh,^1,2 Y. Wang.^1,2
A Pilot Study of Donor: A Smart Phone Application for Identifying Live Kidney and Liver Donors.

K. Kumar,¹ E. King,¹ A. Muzaale,¹ J. Konel,¹ G. Segal,³ J. Arnold,³ K. Bramstedt,⁴ D. Segev,^1,2 A. Cameron.¹
A Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/Kg vs. 6mg/Kg in Kidney Transplant Patients Under Minimization Maintenance Immunosuppressive Regimen.

T. Sandes-Freitas, J. Junqueira Junior, M. Oliveira, C. Girão, R. Esmeraldo.
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.

H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
A Randomized-Controlled Trial Comparing the Efficacy of CYP3A5 Genotype-Based with Bodyweight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.

N. Shuker,^1,2 R. Bouamar,² R. van Schaik,³ M. Clahsen -van Groningen,⁴ J. Damman,⁵ C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ W. Weimar,¹ T. van Gelder,^1,2 D. Hesselink.¹
A Retrospective Analysis of Rabbit Antithymocyte Globulin Dosing, MELD, Race, and Weight on Infection and Rejection Rates in Liver Transplantation.

R. Imai, U. Wang.
A Successful Approach to Kidney Transplantation in Patients with Secondary Hyperoxaluria.

J. Roodnat,¹ A. Mik-van Egmond,² W. Visser,² S. Berger,³ W. van der Meijden,⁴ F. Knauf,⁵ M. Agteren van,¹ M. Betjes,¹ E. Hoorn.¹
A Visualization Software Platform for Managing a Kidney Paired-Donation Program.

M. Bray,¹ W. Wang,¹ M. Rees,² P. Song,¹ A. Leichtman,³ V. Ashby,¹ J. Kalbfleisch.¹
A Web-Based Survey of Academic Transplant Nephrologists in the U.S. on Relative Value Unit (RVU)-Based Productivity Assessment and Financial Compensation.

W. Chon,¹ M. Pavlakis,³ P. Witkowski,⁴ L.-X. Chen,¹ P. Kadambi.²
A Weighted Approach to Composite Efficacy Analysis in Kidney Transplantation.

B. Kaplan, K. MaCague, D. Patel, F. Vincenti.
Absence of Host CD137 Signaling Converts Chronic GVHD Toward Acute GVHD.

H. Cho,^1,3 J. Lee,^1,4 J. Kim,¹ U. Moon,¹ B. Kwon,^1,2 S. Park,³ K. Park.⁴
Accepted Mouse Kidney Allografts Are Characterized by Widespread Nitrosylation.

I. Aljabban, B. Jiang, C. Yang, D. Ndishabandi, R. White, P. Russell, J. Madsen, R. Colvin, A. Alessandrini.
Achieving Timely Therapeutic Mycophenolic Acid Levels in Pediatric Lung Transplant Patients.

C. Kam, S. Kim, E. Melicoff.
Acquired Down-Regulation of B Cell Function Induced by Donor Blood Group Antigens After ABO-Incompatible Kidney Transplantation.

M. Tasaki,¹ K. Saito,¹ Y. Nakagawa,¹ N. Imai,² T. Aoki,³ M. Kamimura,³ K. Takahashi,¹ Y. Tomita.¹
Activating Transcription Factor 5 (ATF5) Regulates Liver Ischemia/Reperfusion Injury.

G.-Q. Shen,² M. Morita,¹ J. Fung,² L. Lu,^1,2 S. Qian.^1,2
Activation of Alloreactive T Cells by Allogeneic Exosomes and Cells Cross-Dressed with Allogeneic MHC Molecules.

M. Babiker-Mohamed, J. Marino, P. Crosby, G. Benichou.
Activation of Innate Immunity During Human OLT-IRI Triggers Adaptive Immunity and Correlates with the Degree of IRI Injury.

A. Zarrinpar,¹ R. Sosa,² P. Rao,² C. Lassman,² R. Busuttil,¹ D. Gjertson,² J. Kupiec-Weglinski,¹ E. Reed.²
Acute Rejection by Belatacept (Bela) Dosing Frequency: Results from a Phase II Study of Kidney Transplant Recipients.

F. Vincenti,¹ G. Blancho,² A. Durrbach,³ G. Grannas,⁴ J. Grinyó,⁵ U. Meier-Kriesche,⁶ M. Polinsky,⁶ H. Zhao,⁶ C. Larsen.⁷
Acute Rejection, New-Onset Diabetes After Transplant and Transplant Outcomes in Pediatric Kidney Recipients: Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) Database.

A. Mehrnia, T. Le, T. Tamer, S. Bunnapradist.
Acute Rejections and Incidence of De Novo DSA Depend on Donor Factors and Deceased Donor Kidney Associated Risk Assessed by the Kidney Donor Profile Index (KDPI).

O. Staeck, D. Khadzhynov, L. Lehner, A. Kleinsteuber, M. Duerr, E. Schrezenmeier, K. Budde, F. Halleck.
Acute-on-Chronic Liver Failure Admissions Cost 3 Times More Than Non-ACLF Related Admissions.

S. Leffingwell, J. O'Leary, S. Asrani.
Adding Anti-Inflammatory Agents During Normothermic Ex-Vivo Liver Perfusion Improves the Preservation of Pig Liver Grafts Before Transplantation.

N. Goldaracena, E. Juan, K. Moritz, V. Spetzler, A. Barbas, D. Grant, M. Selzner.
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.

A. Karim, D. Conway, G. Leverson, J. Mezrich, L. Fernandez, A. D'Alessandro, D. Foley.
Adenovirus Infection in Kidney Transplant Recipients: Report of a Case Series.

C. Simancas-Ruiz, L. Marino-Vazquez, A. Meraz-Muñoz, A. Nuñez-Abreu, R. Rivera-Marfil, N. Uribe-Uribe, J. Alberu, L. Morales-Buenrostro.
Adopting the Kidney Donor Profile Index (KDPI)/Kidney Donor Risk Index (KDRI) for Japanese Donors After Cardiac Death.

M. Kusaka,¹ A. Kawai,¹ N. Fukami,¹ H. Sasaki,¹ H. Takahashi,² T. Ito,³ T. Kenmochi,³ R. Shiroki,¹ K. Hoshinaga.¹
Advantages of Computerized Dosing Strategy in Tacrolimus Treatment of Renal Transplant Patients.

S.-Y. Kim,¹ S. Cho,¹ M.-J. Cho,¹ C. Lee,¹ A. Han,¹ C. Choi,¹ S. Ahn,¹ S.-I. Min,¹ S.-K. Min,¹ M. Park,² I. Jung,³ S. Kim,⁴ J. Ha.^1,2
African Americans Have Greater Odds of Late Stage Diagnosis of Hepatocellular Carcinoma in Mississippi.

M. Aru, S. Seals, B. Ingram, A. Seawright, C. Anderson, T. Earl.
African Americans and Organ Donation: Where Do We Go After Moving from the Bottom to the Top?

C. Callender,¹ N. Koizumi,² P. Miles,³ J. Melancon.³
After Alemtuzumab Induction, Tac+MMF Is Superior to CsA+MMF in Pediatric Kidney Transplantation.

M. Kaabak,¹ N. Babenko,¹ A. Zokoyev,¹ R. Shapiro.²
Age Adapted Immunosuppression for Elderly Kidney Allograft Recipients: Balancing Risks for Cancer versus Rejection.

F. Jackson-Spence,¹ H. Gillott,¹ S. Tahir,¹ F. Evison,² J. Nath,³ A. Sharif.³
Age and Education Level Are Predictors of Patient Preferences for Educational Formats in ESRD Patients Undergoing Transplant Education.

K. Leick,¹ J. Jones,¹ S. Witte,² L. Hunsicker,³ Z. Stewart.¹
Aging Is Critically Impacting the Efficacy of Immunosuppressants.

J. Schuitenmaker, K. Edtinger, M. Seyda, H. Uehara, M. Quante, A. ElKhal, S. Tullius.
Air Pollution – An Additional Risk Factor for Developing Cardiac Allograft Vasculopathy.

C. Bara, D. Böthig, Y. Scheibner, D. Bobylev, B. Przybylek, A. Haverich.
Airway Inflammation and Symptoms in Children Following Liver and Heart Transplantation.

A. Redmann,¹ J. Bucuvalas,² R. Wood,³ C. Chin,⁴ C. Hart.¹
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.

V. Siddagangaiah,¹ H. Sharma,² N. Lal,¹ J. Rai,¹ M. Howse,¹ D. Ridgway,¹ A. Sharma,¹ A. Hammad,¹ S. Mehra.¹
Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.

I. Yakubu,¹ B. Masters,¹ B. Ravichandran,¹ T. Sparkes,¹ M. Moss,¹ F. Rasetto,¹ S. Jonchhe,¹ B. Thomas,² N. Costa,² D. Leeser,² S. Bartlett,² A. Haririan.²
Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.

I. Kim,¹ J. Choi,¹ A. Vo,¹ A. Kang,¹ M. Toyoda,¹ J. Mirocha,² E. Kamil,¹ S. Louie,¹ O. Galera,¹ S. Jordan,¹ D. Puliyanda.¹
Alkaline Phosphatase a New Marker for Graft Outcome and High Pulse Wave Velocity in Renal Transplant Recipients.

S. Sezer,¹ E. Tutal,¹ Z. Bal,¹ B. Demirci,¹ M. Haberal.²
Allograft TLR4 Receptor Signaling Induces Specific Early Inflammatory Events in Promotes Allografts Subjected to Prolonged Cold Ischemic Storage.

T. Yagisawa, N. Kohei, D. Kish, R. Fairchild.
Alloimmunity Through Non-HLA Epitopes in Kidney Transplantation.

R. Reindl-Schwaighofer,¹ A. Kainz,¹ B. Cole,² J. van Setten,² K. Jelencsics,¹ B. Keating,² R. Oberbauer.¹
Alterations in Central Carbohydrate Metabolism in Porcine Liver Allografts Preserved with a Subnormothermic Machine Perfusion (SNMP) System.

B. Banan, A. Cyr, R. Lopez, G. Michalopoulos, P. Fontes.
Altruistic Kidney Donation: A Single US Transplant Center Experience.

A. Aguire-Alarcon,¹ M. Lubetzky,¹ M. McKinney,¹ L. Kayler.²
Altruistic Kidney Donation: From the Donor's Perspetive.

R. Burge,¹ S. Potts,^2,3 S. Lundie.⁴
American and European Transplant Surgeons: Research, Teaching, and Burnout.

M. Jesse,¹ M. Abouljoud,¹ A. Eshelman,¹ C. DeReyck,² J. Lerut.²
Amino Acid (AA) Metabolism During Liver Allograft Preservation Comparing Subnormothermic Machine Perfusion (MP) Against Cold Storage (CS).

B. Banan, R. Lopez, C. Hughes, G. Michalopoulos, P. Fontes.
An Analysis of Non-Tuberculous Mycobacteria (NTM) Infection and Colonization in Lung Transplant Recipients (LTRs) Post-Transplant: A Single Center Matched Cohort Study.

H. Kozlowski,^1,2 D. Kabbani,³ C. Chaparro,^1,2 L. Singer,^1,2 C. Rotstein,^1,2 S. Keshavjee,^1,2 S. Husain.^1,2
An Assurance of Insurance: Should Living Kidney Donors Be Required to Have Health Insurance?

J. Siegel,¹ A. Humar,² P. Gianaros,¹ J. Steel.²
An Epidemiological Update of Non-Melanoma Skin Cancer in Immunosuppressed Organ Transplant Recipients with Skin of Color.

C. Shaver, C. Cusack, C. Chung.
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.

J. Chen,¹ R. Hoffman,² M. Thomas,² J. Gervasio.²
An Improved Flow Cytometry Based Platelet Counting in Xeno Perfusion Models.

S. Sendil,¹ G. Braileanu,¹ W. Sun,¹ W. Hassanein,¹ D. Parsell,¹ H. Crum,² L. Burdorf,¹ R. Pierson,¹ A. Azimzadeh.¹
An In-Situ Treatment of Donor Skin Induces MARCH1 and Decreases MHC II Expression on Donor Dendritic Cells, Promoting Skin Allograft Acceptance.

T. Borges,^1,2 F. Machado,¹ C. Bonorino,¹ L. Riella.²
Analysis of a Large Single-Center Cohort of Renal Transplant Recipients with Histoplasmosis.

M. Mashayekhi, A. Langone.
Angiotensin II Blockade and Fibroblast Growth Factor-23 in Stable Kidney Transplant Recipients.

O. Sanchez, S. Reule, S. Li, D. Berglund, R. Spong, H. Ibrahim.
Angiotensin II Type-1 Receptor Antibodies in Renal Transplant Recipients Associated with Ventricular and Endothelial Dysfunction: Preliminary Results.

L. Figuerola-Chaparro,¹ F. Davila-Radilla,¹ E. Cuevas,² L. Castillo-Martínez,¹ A. Orea-Tejeda,¹ J. Arreola-Guerra,² J. Alberu.²
Anterior Rectus Sheath Approach for Renal Transplant: An Open Minimal Incision with Decreased Wound Complications.

S. Phillips,¹ S. Hill,¹ L. Lipscomb,¹ B. Sankari,² S.-C. Chueh,² J. Africa.²
Anti-BTLA Antibody (6B2) Induced Prolongation of Fully MHC-Mismatched Murine Cardiac Allograft and Generation of Foxp3+ Regulatory T Cells.

M. Uchiyama,^1,2 E. Yin,^2,3 X. Jin,^2,4 T. Shimokawa,¹ H. Yagita,⁵ M. Niimi.²
Anti-HLA Antibodies in Allogeneic and Autologous Hematopoietic Stem Cell Transplantation.

A. Bertocchi, L. Requiao-Moura, M. Torres, E. Tonato, M. Durao Junior, A. de Matos, N. Hamershclak, A. Pacheco-Silva.
Anti-HLA Antibody Composition and Outcomes in Pediatric Heart Transplant Recipients with a Positive Cross-Match.

P. Jindra,¹ S. Nicholas,² J. Chappelle,¹ T. Humlicek,² K. Hosek,² J. Heinle,² S. Denfield,² A. Jeewa,² R. Kerman,¹ W. Dreyer.²
Anti-Inflammatory Effects of AAV-Mediated TIMP-1 Gene Transfer in Hepatic Ischemia-Reperfusion Injury.

S. Duarte, T. Fujii, G. Lipshutz, R. Busuttil, A. Coito.
Anti-LG3 Antibodies Enhance Renal Microvascular Rarefaction, Fibrosis and Dysfunction Associated with Ischemia-Reperfusion Injury.

B. Yang,^1,3 K. Hamelin,^1,3 M. HÉnault-Rondeau,^1,3 N. Patey,^1,2,3 J. Turgeon,^1,3 S. Lan,^1,3 L. Pomerleau,¹ J. Peng,¹ J. Tremblay,¹ M. DieudÉ,^1,3 M.-J. HÉbert,^1,3 H. Cardinal.^1,3
Anti-Thymocyte Globulin Induced Thrombocytopenia and Bleeding After Kidney Transplantation.

M. Dokus,¹ A. Patel,¹ J. Iuppa,² E. Venniro,³ A. Danzig,¹ J. Cooley,² J. Taylor,³ R. Kashyap,¹ M. Orloff.¹
Anti-Thymocyte Globulin Induction Does Not Increase the Risk of Thrombotic Events in Kidney Transplantation: A Matched Case-Control Study.

J. Iuppa,¹ M. Dokus,² E. Venniro,³ A. Patel,² A. Danzig,⁴ J. Hahn,¹ R. Kashyap,² M. Orloff,² J. Taylor.³
Antibody Titers as Predictors of Kidney Graft Outcomes.

A. Gilbert,¹ M. Zaheer,¹ O. Timofeeva,² S. Rosen-Bronson,² M. Awwad,² D. Li,² M. Grafals,¹ B. Javaid,¹ P. Abrams,¹ J. Verbesey,¹ M. Cooper.¹
Antibody-Mediated Rejection Can Be Assessed by Histology When DSA Is Unknown or Negative.

J. Reeve,¹ P. Halloran.²
Antithymocyte (ATG) Dose Density in Renal Transplant Recipients (RTR) with Early Graft Dysfunction (EGD).

S. Kuten, S. Patel, R. Knight, D. Nguyen, E. Graviss, H. Podder, A. Gaber.
Are Random Tacrolimus Levels in the Emergency Department Costing You Money?

B. Lee, D. Jain, M. Campara.
Arterial Hypertension After Renal Transplantation in Pediatric Patients: An Analysis of CERTAIN Registry.

R. Sugianto,¹ E. Wühl,² B. Schmidt,¹ K. Krupka,² B. Höcker,² B. Tönshoff,² A. Melk.¹
Aryl Hydrocarbon Receptor Expression Increases in Skin Graft-infiltrating Th1 and Treg Cells.

J. Fechner, W. Julliard, L. Owens, J. Mezrich.
Assessing Vaccination Status in Transplant Candidates and Recipients: Current Status and Challenges to Successful Implementation.

H. Leung, K. Cameron, B. Ho, M. Ison.
Assessment of Molecular Mechanisms of Non-Transplant Cardiac Hypertrophy in Cardiac Allograft Hypertrophy – An Exploratory Gene Array Study of Myocardial Biopsy Samples.

R. Araujo-Gutiérrez,^1,2 S. Ibarra-Cortez,^1,2 M. Park,¹ J. Estep,¹ G. Ashrith,¹ B. Trachtenberg,¹ G. Torre-Amione,¹ K. Youker,^1,2 A. Bhimaraj.¹
Assessment of Postoperative Glycemic Control in Orthotopic Heart Transplant Recipients.

J. Glick Frasiolas, J. Matthew, D. Tsapepas.
Assessment of Transplant Health Literacy of Liver Transplant Candidates and Their Caregivers.

Y. Bababekov,¹ Z. Fong,^1,2 J. Adler,¹ H. Yeh,¹ D. Chang,^1,2 J. Pomposelli.³
Assessment of mRNA Gene Profiles in Plasma Exosome to Predict Risk for Antibody-Mediated Rejection (ABMR) of Renal Allografts.

H. Zhang,¹ J. Kahwaji,¹ P. Li,² S. Ge,¹ D. Thomas,¹ C. Nast,³ A. Vo,¹ M. Haas,³ S. Jordan,¹ M. Toyoda.¹
Association Between Delayed Graft Function and Long-Term Outcomes After Kidney Transplantation from Donors After Circulatory Death.

P. Clayton,^1,2,3 G. Russ,^1,2,3 S. McDonald,^1,2,3 S. Chadban.^1,4,5
Association of Genetic Polymorphisms in Complement Independent Pathways with Donor Specific Antibodies in Kidney Allograft Recipients.

Y. Chang,^1,2 T. Shah,^1,3 D. Min.¹
Association of Genetic Polymorphisms of Angiopoietin-Like 4 with Proteinuria in Kidney Allograft Recipients.

Y. Chang,^1,4 T. Shah,^2,4 Y.-T. Chuang,³ D. Min.⁴
Association of Smoking Habits with Comorbidity 15 Years After Liver Transplantation.

S. Pischke,³ M. Lege,¹ L. Fischer,² U. Herden,² A. Lohse,³ B. Nashan,² M. Sterneck.¹
Associations of Perfusate Biomarkers and Pump Parameters with Delayed Graft Function and Deceased-Donor Kidney Allograft Function.

C. Parikh,¹ I. Hall,¹ R. Bhangoo,² J. Ficek,¹ P. Abt,³ H. Thiessen-Philbrook,¹ H. Lin,¹ M. Bimali,¹ P. Murray,⁴ V. Rao,¹ B. Schröppel,⁵ M. Doshi,⁶ F. Weng,⁷ P. Reese.³
Attenuation of Warm Hepatic Ischemia-Reperfusion Injury by Bruton's Tyrosine Kinase Inhibition.

A. Zarrinpar,¹ T. Palumbo,¹ K. Nakamura,¹ C. Lassman,² R. Busuttil,¹ J. Kupiec-Weglinski.¹
Attitudes Toward Living Kidney Transplantation Among Potential Transplant Candidates.

K. Yu,¹ S. Kulkarni,¹ J. Gannon,¹ P. Reese,² E. Gordon,³ C. Thiessen.¹
B Lymphocyte-Induced Maturation Protein-1 Promotes Allograft Survival via Modulation of T Cell Development.

A. Wang,¹ C. Loh,^1,3,4 S.-J. Chen,² C.-H. Lin,¹ H.-K. Sytwu,² S.-H. Chuang,¹ F.-C. Wei.^1,4
BK Viremia Surveillance and Management in Simultaneous Pancreas-Kidney Transplants.

S. Westphal, C. Miles.
Bariatric Surgery and Increased Risk of Death After Listing for Liver Transplantation.

S. Asrani, F. Khan, G. Saracino, G. McKenna, J. Hasse, G. Klintmalm, J. Trotter.
Barriers to Living Donor Kidney Transplant in the Pediatric Population.

S. Taormina,¹ M. Galloway,² A. Jain.³
Baseline Donor Specific Antibody (DSA) More Predictive of Chronic Antibody Mediated Rejection (CAMR) Than the Change in DSA Over Time.

D. Mitema,¹ W. Cheungpasitporn,¹ M. Stegall,¹ F. Cosio,¹ M. Gandhi,² C. Schinstock.¹
Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.

J. Clark,¹ T. Sparkes,¹ B. Masters,¹ J. LaMattina,² R. Barth,² M. Moss.¹
Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.

M. Savic,¹ M. Cruz,² A. Rossi,¹ J. Vella.¹
Belatacept Immunotherapy Is Not Augmented by Blockade of Activated LFA-1 in a Nonhuman Primate Renal Transplant Model.

K. Samy,¹ M. Mulvihill,¹ B. Collins,¹ D. Lo,² M. Song,¹ F. Leopardi,¹ A. Kirk.^1,2
Benefit of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation with 2 Years Follow-Up.

Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ T. Nagai,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
Benefit of Protocol Biopsies in Pediatric Kidney Transplant Patients.

M. Nazario, O. Moussa, S. Self, K. Twombley.
Bile Acid Signaling Affects Metabolism and Prolongs Allograft Survival in Obese Recipients.

M. Quante, A. ElKhal, M. Seyda, J. Schuitenmaker, H. Uehara, S. Tullius.
Bioinformatic Analysis of Pathways Mediating Clusterin Functions in Kidney Cells Under Normoxia and Hypoxia.

G. Dairi, Q. Guan, C. Collins, C. Ong, M. Gleave, C. Nguan, C. Du.
Biopsy-Proven Rejection in Children After Liver Transplantation Is Associated by an IL-12p40-Mediated Innate Immune Response Followed by Th1 T Cell Activation.

C. Falk,¹ I. Goldschmidt,² F. Mutschler,² E. Pfister,² F. Lehner,³ J. Keil,¹ C. Neudörfl,¹ A. Karch,⁴ R. Mikolajczyk,⁴ U. Baumann.²
Breadth of HLA-Specific B Cell Reactivity and Frequency Assessed by a Novel Multiplex Bead Based Assay Predicts and Correlates with Rejection in Kidney Transplant Recipients.

A. Akl, Z. Ilyas, O. Traitanon, L. Gallon, A. Tambur, M. Ansari.
C1-Inhibitor Abrogated Ischemia/Reperfusion (I/R) Induced Inflammaging by Inhibiting Senescence-Associated Secretory Phenotype (SASP) in Tubular Epithelial Cells (TEC).

G. Castellano,¹ R. Franzin,¹ A. Stasi,¹ C. Divella,¹ M. Gigante,¹ S. Simone,¹ A. Intini,¹ A. Picerno,¹ P. Pontrelli,¹ A. Crovace,¹ M. Battaglia,¹ B. Oortwijn,² E. Amersfoort,² G. Grandaliano,³ L. Gesualdo.¹
C1q Assays Are Not Associated with Clinical or Serologic Endpoints.

A. Gilbert,¹ M. Zaheer,¹ O. Timofeeva,² M. Awwad,² D. Li,² S. Rosen-Bronson,² B. Javaid,¹ M. Grafals,¹ J. Verbesey,¹ P. Abrams,¹ M. Cooper.¹
C1q Donor Specific Antibody Associates with Post Transplant Biopsy Findings in Highly Sensitized Kidney Transplant Recipients.

S. Kuppachi,¹ D. Holanda,² S. Gallegos,³ E. Field.^3,4
C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains.

C. Blosser,¹ Y. Zhang,² T. Dhawale,³ C. Johnson,¹ P. Hendrie,³ R. Smith.²
CD8⁺TCR^– Facilitating Cells in Mobilized Peripheral Blood Mononuclear Cells Are Enriched with IL-10 Producing B Cells.

Y. Wen, E. Yolcu, Y. Huang, L. Kahn, S. Ildstad.
CMV Monitoring Reduces Risk of Clinical Complications in Kidney Transplant Recipients.

A. Gilbert, M. Cooper, J. Verbesey, R. Ghasemian, P. Abrams, J. Moore, M. Grafals, J. Chahine, S. Punnett, E. Hall, I. Anzak, B. Javaid.
CMV-Accelerated Cardiac Allograft Rejection Is Associated with Dysregulation of Sphingolipid Metabolomics.

J. Burg,¹ T. Andoh,² N. Haese,² C. Kreklywich,² K. Watters,³ T. Metz,³ S. Orloff,¹ D. Streblow.²
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.

A. Aliabadi,¹ J. Goekler,¹ O. Salameh,¹ T. Haberl,¹ B. Steinlechner,² P. Opfermann,² A. Kaider,¹ K. Uyanik-Uenal,¹ G. Laufer,¹ A. Zuckermann.¹
Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.

A. Zmijewska, J. Chen, J. Zmijewski, R. Mannon.
Can OPTN/UNOS Policies Be Effectively Transferred to Another Country's Healthcare System? Russian Case.

B. Yaremin,¹ A. Mironov,⁴ A. Kolsanov,² A. Navasardyan,¹ R. Akhmetshin,³ A. Starostina.²
Can Qrisk Be Useful to Predict Future Cardiovascular Co-Morbidites and Type II Diabetes in Living Kidney Donors Prior to Donation?

S. Bhutani, R. Chinnadurai, G. Bernal-Blanco, B. Patel, A. Summers, D. Van Dellen, M. Morton, P. Michael.
Cardiovascular Prognosis and Adverse Cardiac Events After Orthotopic Liver Transplantation.

L. Potena, V. Manfredini, P. Prestinenzi, R. Alabrese, V. Bertuzzo, L. Borgese, M. Masetti, C. Morelli, F. Grigioni, A. Pinna.
Caval Replacement versus Piggyback Liver Transplantation: The Toronto Experience.

A. Barbas, M. Dib, N. Goldaracena, M. Marquez, G. Sapisochin, D. Al-Adra, S. McCluskey, I. McGilvray.
Changes in Fatigue After Kidney Transplantation.

H. Ying, I. Olorundare, N. Dagher, B. Lonze, R. Montgomery, M. McAdams-Demarco, D. Segev.
Characteristics and Outcome of Patients Placed on Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation.

E. Batchelor, J. Bland, D. Douglass, J. Mullins, M. Mohanka, S. Bollineni, V. Kaza, M. Wait, F. Torres, A. Banga.
Characteristics of Human Rhinovirus (HRV) Infections in Transplant Recipients.

H. Crossman,¹ M. Barron,¹ M. Levi.¹
Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era.

S. Hammad, L. Shah, M. Restivo, H. Robbins, J. Scheffert.
Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies.

F. Tinney Jr,¹ L. Yessayan,² M. Abouljoud,³ A. Patel.³
Chemokine Receptor CXCR4 Antagonist, a Novel Pathway to Prevent Chronic Allograft Nephropathy.

Y. Xu, Q. Zhang, X. Hu.
Children Listed as Status 1B for Liver Transplantation Are Disenfranchised by MARS Therapy.

A. Bakshi,¹ M. Kueht,¹ A. Rana,^1,2 A. Akcan Arikan,³ J. Goss.^1,2
Chimeric Cell Transplantation for Treatment of Duchenne Muscular Dystrophy: A Preliminary Report.

E. Szilagyi, E. Bryndza Tfaily, J. Cwykiel, M. Siemionow.
Cholangioscopy in Liver Transplant Recipients.

U. Agbim,¹ E. Verna,¹ R. Brown, Jr,² A. Sethi.¹
Chronic High Epstein-Barr Viral Load Carriage in Pediatric Kidney Transplant Recipients.

M. Yamada,¹ P. Fadaker,¹ C. Nguyen,¹ A. Ganoza,² A. Humar,² M. Michaels,^1,2 M. Green.^1,2
Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I Is a Predictive Marker for Graft Loss in Patients Positive for IgA aB2GPI.

J. Morales, M. Serrano, J. Martínez-Flores, D. Perez, M. Sevilla, O. Cabrera, A. Serrano.
Circulating Soluble-Klotho Levels Modestly Increase After Renal Transplantation.

S.-J. Tan,¹ A. Crosthwaite,² D. Langsford,³ V. Obeysekere,⁴ F. Ierino,^2,5 M. Roberts,^5,6 S. Holt,¹ T. Hewitson,¹ K. Dwyer,^3,5,7 N. Toussaint.¹
Circulating miR-215, miR-let-7c miR-154, miR-193a, NR_036506.1 and NR_027669.1 as Biomarkers Predict Fungal Infection in Post-Transplanted Recipients.

A. Yang, Z. Guo, W. Ju, C. Zhang, Z. Li, X. Yuan, Q. Zhao, H. Ye, Y. Liao, X. Zhu, X. He.
Citrate-Based Thermoresponsive Hydrogel as a Versatile Platform for Extrahepatic Islet Transplantation.

Y. Zhu,¹ X. Zhang,² A. Guillermo,¹ X. Luo.²
Clinical Correlation Between Pairs of Kidneys Transplanted from the Same Donor.

A. Baheerathan, H. Beckwith, A. McLean, D. Taube, M. Willicombe.
Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.

S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, D. Segev.
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.

S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, F. Al Ammary, D. Segev.
Clinical Measures to Reduce Early Urinary Tract Infections Following Kidney Transplantation: A Single Center Experience.

B. Chopra, T. Ko, C. Webster, J. Sheyman, A. Arumgarajah, V. Katragadda, R. Marcus, K. Sureshkumar.
Clinical Outcomes of Kidney Allograft Recipients with Apolipoprotein L1 (APOL1) Risk Alleles from Living Kidney Donors.

C. Dorr,^1,2,3 A. Hart,^1,2,3 D. Schladt,¹ A. Muthusamy,¹ R. Mannon,⁴ W. Oetting,² A. Matas,² P. Jacobson,² A. Israni.^1,2,3
Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Kidney Recipients.

C.-K. Oh,¹ S.-J. Kim,² K. Huh,³ S. Kim,⁴ H. Cho,⁵ S. Lee.⁶
Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.

A. Alghamdi, A. Humar, Y. Natori, S. Husain, L. Singer, E. Renner, C. Rotstein, D. Kumar.
Clinical Risk Factors for the Recurrence of Clostridium difficile Infection (CDI) in Solid Organ Transplant Recipients (SOTR).

Y. Natori, M. Shiotsuka, L. Oen, E. Renner, L. Singer, J. Kim, H. Ross, D. Kumar, C. Rotstein, A. Humar, S. Husain.
Clinical Significance of C3d Binding Donor Specific Anti-HLA Antibodies (DSA) Detected by Single Antigen Beads (SAB) After Kidney Transplantation.

R. Pelletier,¹ I. Balazs,² P. Adams,³ P. Steller,³ N. DiPaola,⁴ L. Rankin,³ A. Diez,⁵ M. Henry.¹
Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.

C.-D. Kim, J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim.
Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.

M. Tseng,¹ S. Ge,¹ R. Roberts,² C. Kuo,² J. Choi,¹ N. Nissen,¹ M. Chu,¹ I. Kim,¹ B. Shin,¹ M. Toyoda,¹ S. Jordan.¹
Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies.

S. Olson, A. McCann, S. Kumer, T. Schmitt, B. Floyd, R. Taylor, R. Gilroy.
Combined Liver-Kidney Transplantation for Polycystic Liver and Kidney Disease: Analysis from the UNOS Dataset.

C. Coquillard, J. Berger, M. Daily, X. Mei, F. Marti, M. Shah, R. Gedaly.
Combined Liver-Kidney Transplantation in Children: Long-Term Follow-Up in 27 Children.

M. Kemper,¹ B. Nashan,² L. Fischer,² F. Brinkert.¹
Common Iliac Artery Stenosis: An Often Overlooked Cause of Graft Dysfunction.

E. Christie, P. Campbell, K. Wen.
Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.

C. Santos, M. Saeed, D. Brennan, M. Olsen.
Comparing Renal Function After Liver Transplantation: Modified Piggyback versus Conventional Techniques without Venovenous Bypass.

J. Lee, J. Lee, S. Song, J. Lee, S.-K. Kwon, D. Han, M. Ju, G. Choi, J. Choi, M. Kim, S. Kim, D. Joo.
Comparison of Actual versus Goal Tacrolimus Levels Post Cardiothoracic Transplant.

E. Milas, I. Feurer, C. Truscott, J. Gray, N. Wilson, S. Bala, T. Dreher, M. Wigger, M. Steele, A. Shah, E. Lambright, D. Hanto.
Comparison of Clinical Outcomes in Lung Transplant Patients with and without Preoperative Pulmonary Hypertension.

A. Kalya, M. Boga, S. Dasyam, R. Walia, M. Smith, R. Bremner, A. Omar, V. Patel, E. Kuo, J. Huang, S. Hashimi.
Comparison of De Novo Donor Specific Antibody Formation for Kidney Transplant Recipients Induced with Thymoglobulin or Basiliximab.

A. Gong, K. Lee, S. Patel, M. Brande, R. Dhawan, C. Parke, M. Smogorzewski, L. Aguirre, B. Duong, S. Alexopolus, Y. Qazi.
Comparison of EDTA, DTT and Dilutions to Abrogate the Prozone Effect in Luminex-Based HLA Antibody Assays.

M. Pando, S. Franklin, L. Nelson, Y. Desmarteau, A. Jaramillo.
Comparison of Efficacy of Different Regimens for Treating Recurrent IgA Nephropathy After Kidney Transplantation.

G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang, J. Fei, S. Deng, J. Li, G. Huang, Q. Fu.
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.

Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ T. Nagai,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
Comparison of Outcomes of Kidney Transplantation from DBD, DCD or DBCD Donors: A Single Center Experience from China.

G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang.
Comparison of Surgical Correction Techniques for Post-Kidney Transplantation Vesicoureteral Reflux.

V. Turunç,¹ A. Eroğlu,² B. Tabandeh,¹ H. Dheir,² E. Basok,³ A. Erol.³
Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.

J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, E. Kwon, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim, C.-D. Kim.
Compensating Live Kidney Donors: The Views of United States Voters.

J. Fisher,¹ T. Peters,² R. Gish,³ R. Howard.⁴
Complement Receptor C5aR2 Deletion in Kidney Transplantation in Mice Attenuates Renal Damage.

A. Thorenz,¹ R. Chen,¹ K. Hueper,² B. Hensen,² C. Klemann,³ M. Meier,⁴ A. Klos,⁵ F. Gueler.¹
Complications of Dual Antiplatelet Therapy Among Recipients of Kidney Transplants.

F. Weng, A. Athavale, K. Hussain, K. Tibaldi, G. Rogal.
Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.

K. Patel,¹ B. Stephany,² J. Barnes,¹ S. Bauer,¹ M. Spinner.¹
Contrasting Effects of Tacrolimus and Everolimus on Regulatory T Cell Activation and Mixed Hematopoietic Chimerism Induced by Natural Killer T Cell Stimulation.

S. Miyairi,^1,2 T. Hirai,¹ R. IShii,¹ M. Okumi,¹ Y. Ishii,³ S. Nunoda,² K. Yamazaki,² K. Tanabe.¹
Controlled Cardiac Death Donor Program for Kidney Transplantation – Spanish Multicenter Experience with Two Years of Follow-Up.

J. Portoles,¹ M. Perez-Saez,² D. Hernandez-Marrero,² O. Lafuente,¹ F. Diekmann,² N. Maruri Kareaga,² M. Rodriguez-Ferrero,² F. Llamas,² M. Mazuecos,² J. Juega,² E. Melilli,² A. Rodriguez-Benot,² A. Alonso,² J. Pascual.²
Conversion from Tacrolimus (TAC) to Sirolimus (SLR)-Based Immunosuppression in Pediatric Patients Who Underwent Liver Transplantation for Unresectable Hepatoblastoma – 2 Year Follow-Up.

R. Hendrickson,¹ W. Andrews,¹ M. Davis,¹ R. Cisneros,¹ R. Fischer,² J. Daniel.²
Conversion to Belatacept as Rescue Therapy in Kidney Transplant Recipients with Severe Graft Dysfunction.

F. Oldhafer,¹ M. Hiss,² A. Schwarz,² H. Haller,² G. Einecke.²
Conversion to Once-Daily Tacrolimus in Stable Pediatric Liver Transplantation Recipients.

N. Lee, S. Lee, C.-W. Cho, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, S.-K. Lee.
Cost-Effectiveness of Machine Perfusion Use After Long Cold Ischemic Time in a Kidney Transplantation Program.

A. Matos, D. Malheiros, S. Morgado, L. Requiao-Moura, M. Borrelli, M. Nogueira, M. Durao, E. Tonato, A. Pacheco-Silva.
Creation of a Small Animal Model of Ex-Vivo Normothermic Perfusion (EVNP) for Treatment of Kidney Ischemia-Reperfusion (I/R) Injury.

Y. Smolin, I. Palma, C. Pivetti, S. Kabagambe, J. Woloszyn, Y. Chen, T. Boyer, I. Palma, J. Sageshima, C. Santhanakrishnan, R. Perez.
Culture Specific Interventions to Increase Organ Donation Advocacy in a Hispanic Serving Institution.

Y. Tasnif,¹ S. Ghaddar,² S. Saladin,³ A. Alaniz.¹
Cytomegalovirus Infection After Cardiac Transplantation.

O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.
De Novo DQA/DQB Donor Specific Antibodies (DSA) Is Associated with Allograft Dysfunction in Pediatric Liver Transplantation (LT).

U. Ekong, L. Bow, R. Morotti, J. Gannon, P. Valentino, P. Yoo, M. Rodriguez-Davalos, S. Emre.
De Novo Proliferative Glomerulonephritis with Monoclonal IgG Deposits of the IgG1κ Subtype in a Kidney Allograft: Protocol Biopsy Findings.

T. Tsuji,¹ M. Miura,² M. Yanai,¹ H. Itami,¹ Y. Ishii,¹ M. Akimoto,¹ Y. Fukasawa.¹
Deceased Donor ABO-Incompatible Kidney Transplantation Has the Potential to Reduce Blood Group Disparity.

M. Manook,¹ L. Bradbury,² D. Osei-Bordom,¹ B. Sandhu,¹ T. Maggs,¹ O. Shaw,¹ N. Kessaris,¹ S. Shah,³ A. Dorling, N. Mamode.¹
Deceased Donor Kidney Transplantation in the Setting of Positive Donor-Specific Antibodies.

B. Orandi,¹ J. Montgomery,² E. Kraus,¹ D. Segev,¹ R. Montgomery,¹ N. Alachkar.¹
Deceased Non-A₂ Donor ABO-Incompatible Liver Transplantation – Promising Results with Anti-A/B Antibody Reduction Both Pre- and Post-Transplant.

U. Dahlgren,¹ G. Herlenius,¹ J. Mölne,² L. Rydberg,³ O. Samuelsson,⁴ W. Bennet.¹
Deceased Organ Donor Factors Influencing Pancreatic Graft Transplantation and Survival.

M. Sally, M. Ellis, T. Groat, X. Gao, S. De la Cruz, M. Patel, D. Malinoski.
Deceased Organ Donors with Zero Organs Transplanted: Why and How Can We Improve?

P. Lange,¹ S. Rudich,¹ N. Obaseki,¹ J. Punch.²
Decellularized Rat Liver Scaffolds Support Multilineage Xenogenic and Heterogenic Cell Growth.

W. Hassanein, U. Dhru, J. Woodall, M. Uluer, A. Cimeno, D. Parsell, C. Rivera, S. Klepfer, C. Drachenberg, R. Barth, J. LaMattina.
Defining Frailty in Liver Transplant Recipients.

L. Louwers,¹ K. Eid,¹ J. Plescia,¹ N. Presser,¹ J. Muntean,¹ M. Kattan,² K. Chagrin,² C. Miller,¹ D. Kelly.¹
Defining Ischemic Time in Lung Donation After Circulatory Determination of Cardiac Death.

D. Pratt,¹ Z. Kon,² A. Iacono,² J. Kim,² R. Reed,² I. Timofte,² J. Gammie,² S. Pham,² B. Griffith,² P. Sanchez.²
Delayed Graft Function (DGF) Doesn't Affect Adversely the Long-Term Survival of Renal Transplantations (RT) from Uncontrolled Donation After Cardiac Death (UDCD) as Compared with RT from Standard Criteria Donor (SCD).

M. Molina,¹ J. Cabrera,² E. Gonzalez,¹ E. Gutierrez,¹ E. Morales,¹ E. Hernandez,¹ M. Praga,¹ A. Andres.¹
Delaying the Induction of Mixed Chimerism Until Two Months After NHP Heart and Kidney Cotransplantation Results in Long Term Survival.

K. Huh,¹ M. Tonsho,¹ P. Spencer,¹ J. Paster,¹ X. Wu,¹ I. Hanekamp,¹ T. Kawai,^1,3 R. Smith,² A. Cosimi,¹ A. Dehnadi,¹ G. Benichou,¹ R. Colvin,^1,2 J. Madsen.^1,4
Dendritic Cells and Damage-Associated Molecular Patterns in Aging.

M. Seyda, H. Li, G. Liu, M. Quante, H. Uehara, J. Schuitenmaker, A. Elkhal, S. Tullius.
Descriptive Epidemiology and Trends of Community Parenteral Antimicrobial Therapy Utilization Among Solid Organ Transplant Recipients at a High Volume Transplant Center 2008 to 2014.

S. Mawhorter, N. Shrestha.
Detection of Endothelial Cell Specific Molecule-1 According to Allograft Status After Kidney Transplantation.

J.-W. Seo, S.-Y. Kim, Y.-G. Kim, Y.-H. Jeong, Y.-H. Lee, J.-Y. Moon, T.-W. Lee, C.-G. Ihm, S.-H. Lee.
Determinants of 1 Year Graft Loss After Pre Kidney Transplant Bariatric Surgery.

G. Mour, J. Zhang, Z. Su, D. Taber, P. Mauldin, T. Srinivas.
Development of a Sequencing-Based Cytomegalovirus UL55 Glycoprotein B (gB) Genotyping Assay.

S. Cowden, K. Grantham, I. Caton, J. Hester, M. Altrich, S. Kleiboeker.
Development of an Integrated Transplant Data Mart for Customized Data Reporting.

R. Patzer, K. Little, J. Kirsch, J. Weaver, A. Adams.
Diabetes Mellitus Status of the Donor and Prolonged Cold Ischemia Time Have a Synergistic Negative Effect on Graft Survival After Liver Transplantation.

I. Brüggenwirth,^1,2 N. Dolgin,¹ P. Martins,¹ B. Movahedi,¹ A. Ahearn,¹ R. Porte,² A. Bozorgzadeh.¹
Diabetes Mellitus and Kidney Transplant Outcomes.

A. Mehrnia,¹ A. Wang,¹ W. Chaiwatcharayut,² E. Huang,¹ S. Bunnapradist.¹
Diagnosis of Pulmonary Nocardiosis: A Single Center Study.

D. Wray,¹ S. Win,² M. Heincelman,¹ L. Steed,¹ J. Cantey.¹
Differences in Reported Barriers to Immunosuppression Adherence Among a Cohort of Pediatric Renal Transplant Recipients from the United States and Canada.

O. Bignall II,^1,2 A. Pai,² S. Amaral,³ S. Furth,³ N. Bergman,² J. Goebel,⁴ The TAKE-IT Study Investigators, B. Foster.⁵
Differences in Tacrolimus Troughs and Doses Between Caucasians and African Americans with Two CYP3A5 Loss-of-Function Alleles: Looking Beyond CYP3A5 Expression.

W. Oetting,¹ D. Schladt,² W. Guan,¹ R. Remmel,¹ C. Dorr,² K. Sanghavi,¹ A. Matas,¹ R. Mannon,³ A. Israni,² P. Jacobson,¹ For DeKAF Genomics,¹ GEN-03 Investigators.¹
Differential Effect of Delayed Graft Function (DGF) on Kidney Transplant Outcomes: When Does DGF Not Make a Difference?

M. Khan,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Difficult to Place Livers: Implications for Expanding the Donor Pool.

E. Edwards,¹ A. Harper,¹ J. Rosendale,¹ J. Eason.
Diffuse Extent of Peritubular Capillaritis in Late Antibody Mediated Rejection Is Associated with More Severe Chronic Allograft Damage.

Z. Kikić,¹ F. Eskandary,¹ H. Herkner,² R. Oberbauer,¹ G. Bond,¹ H. Regele,³ G. Böhmig,¹ N. Kozakowski.³
Digital Kidney Biopsy Evaluation: Quantification of Macrophage Prevalence in a Cross Sectional Study.

J. Schmitz,¹ A. Khalifa,¹ H. Haller,² H. Kreipe,¹ F. Feuerhake,¹ J. Bräsen.¹
Direct Alloimmunity Is Driven by Recipient APCs Displaying Donor MHC Molecules.

J. Marino,¹ J. Paster,¹ P. Crosby,¹ M. Uehara,² S. Mordecai,¹ R. Abdi,² G. Tocco,¹ G. Benichou.¹
Direct Detection of T and B Memory Lymphocytes Reveals HCMV Exposure That Serum Antibodies Fail to Identify.

S. Sundararaman, F. Terlutter, T. Nowacki, R. Caspell, P. Lehmann.
Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.

N. Goyal, W. Huepfel, A. Tierney, N. Issa, J. Lake, J. Thompson, M. Hassan, H. Ibrahim, A. Kukla.
Distinct Effects of Chronic Hyperglycemia on Cellular and Humoral Alloresponses In Vivo.

N. Bishop,¹ K. Beard,² R. Gill.²
Distinctive Roles of Gsk3 Inhibitory Phosphorylation in Liver Inflammatory Immune Response and Hepatocellular Injury Against Ischemia Reperfusion.

H. Zhou,^1,2 J. Zhu,¹ S. Yue,¹ R. Busuttil,¹ J. Kupiec-weglinski,¹ L. Lu,² Y. Zhai.¹
Do All cPRA 100% Candidates Have Equal Access to Organ Allocation?

H. Gebel,^1,2 S. Gustafson,¹ D. Segev,^1,3 B. Kasiske,¹ A. Israni.¹
Do Powerful Induction Antibodies Increase Post Renal Transplant Infections?

M. John, I. Dortonne, B. Kim, C. Li, M. Killackey, A. Paramesh, B. Lee, R. Zhang, G. Parker, J. Buell.
Do We Need Radioisotope Renography in Evaluation of Split Renal Function in Living Kidney Donors?

Y. Yoon,¹ H. Lee,¹ D. Joo,² K. Huh,² M. Kim,² S. Kim,² Y. Kim,² W. Han.¹
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.

S. Bhutani,¹ A. Ponnusamy,² Q. Tak,¹ S. Shah,¹ J. Worthington,¹ A. Summers,¹ K. Poulton,¹ D. Van Dellen,¹ M. Morton,¹ M. Picton.¹
Does Donor and Recipient Age Disparity Make a Difference with Expanded Criteria Donors?

M. Khan,¹ K. Jones,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Does Drain Placement Reduce the Risk of Peri-Graft Collections and Wound Complications After Kidney Transplant?

S. Cimen,¹ S. Cimen,¹ K. Tennankore,² A. Imamoglu,³ I. Alwayn.¹
Does Location Matter for Withdrawal of Donation After Cardiac Death Donors ?

K. Mekeel,¹ W. Garrison,² J. Trageser,² J. Berumen,¹ L. Stocks,² A. Hemming.¹
Does Pre-Emptive Transplantation Improve Survival Compared to Transplantation After Dialysis Among Deceased Donor Kidney Recipients?

J. Tao, C. Wu, W. Bannister, M. Schnitzler, A. Bonagura, B. Laihinen, F. Irwin.
Does Pre-Operative Transarterial Chemoembolization(TACE) Increase the Risk of Early Post-Operative Pancreatitis After Liver Transplantation(LT)?

V. Kirchner, L. Zhang, T. Dunn, E. Finger, M. Hassan, R. Kandaswamy, J. Lake, P. Liu, E. Minja, O. Serrano, A. Pugalenthi, J. Thompson, K. Yadav, W. Payne, T. Pruett, S. Chinnakotla.
Does Rising MELD Score Convey Worse Liver Transplant Outcome?

A. Rahnemai-Azar, J. Perkins, M. Montenovo, T. Pearson, R. Bakthavatsalam, S. Rayhill, A. Dick, J. Reyes, L. Sibulesky.
Does Social Support Predict Clinical Outcomes Post-Transplantation? A Systematic Review and Meta-Analysis.

K. Ladin,¹ A. Daniels,¹ M. Osani,² R. Bannuru.²
Don't Judge a Book by Its Cover: Normal Liver Enzymes After Transplantation Can Be Associated with Pathologies Requiring Intervention.

C. Sanchez,¹ S. Kumer,² S. Olson,¹ R. Gilroy,¹ T. Schmitt,² B. Kane,² R. Taylor.¹
Donor AKI Does Not Adversely Affect the Outcome Following DCD Kidney Transplant.

I. Qaqish, D. Haakinson, K. Reddy, M. Smith, H. Khamash, R. Heilman.
Donor Interstitial Fibrosis and Tubular Atrophy (IFTA) Are Not Independent Risk Factors for a Lower GFR at One Year.

R. Heilman, I. Qaqish, M. Smith, H. Khamash, B. Kaplan, K. Reddy.
Donor Sharpin Expression Modulates TNFα Mediated Inflammation and Cardiac Allograft Rejection in Mice.

R. Ang,¹ P. Heeger,² A. Ting.¹
Donor Smoking Increases Kidney Allograft Recipient Mortality in a National Population Cohort Analysis.

H. Gillott,¹ F. Jackson-Spence,¹ S. Tahir,¹ F. Evison,² J. Nath,³ A. Sharif.³
Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.

L. Requião-Moura,¹ M. Afonso,² A. Sakashita,³ M. Silva,¹ A. Matos,¹ A. Pacheco-Silva.¹
Donor Specific Antibody Used to Predict Crossmatch Results: A Clinically Useful Algorithm Derived from the College of American Pathologists Survey.

S. Wrenn,¹ D.-S. Hain,² S. Harm,² S. Hillyard,² D. Shah,² P. Hammond,² C. Marroquin,¹ M. Fung.²
Donor Transmited Rabies Outbreak Involving Four Transplant Recepients in Kuwait and Saudi Arabia.

H. Elsiesy,^1,2 I. Hussain,³ F. Abaalkhail,^1,2 W. Al-Hamoudi,¹ H. Elbeshbeshy,¹ M. Al Sebayel,¹ D. Broering,¹ A. Elgohary,¹ S. Al Fawaz,⁴ S. Althawadi,⁵ J. Alotaibi,⁴ H. AlHindi,⁵ P. Nair,⁶ T. Al- Otaibi,⁶ N. Nampoory,⁶ L. Orciar,⁷ A. Velasco-Villa,⁷ P. Yager,⁷ T. Smith,⁷ W. Carson,⁷ M. Niezgoda,⁷ A. Wadhwa,⁷ R. Edgar Condori,⁷ Y. Li,⁷ R. Franka,⁷ M. Halim,⁴ R. Willoughby.⁸
Donor-Derived Toxoplasmosis in Solid Organ Transplant 2008 – 2015: Opportunities for Improvement.

C. Wolfe,¹ A. Wilk,² S. Tlusty,² C. Sifri,¹ M. Morris,¹ A. Mehta,¹ D. Kaul.¹
Donor-Recipient Race Matching Is Not Associated with Recipient Survival Following Heart Transplantation.

C. Evans,¹ P. Sanchez,¹ Z. Kon,¹ E. Feller,² B. Griffith,¹ S. Pham.¹
Donor-Specific Antibodies in a Single-Center Pediatric Kidney Transplant Population – Incidence and Risk Factors.

M. Bock,¹ L. Starkey,¹ C. Buchanan,² E. Steinberg,² A. Sikora,² K. McKinnon,² M. Wachs,² J. Goebel.¹
Down-Regulated of Circulating miR-29b, miR-185 and NR_073415.2 in Post-Transplanted Patients with Cytomegalovirus Infection May Serve as Novel Biomarkers for Early Diagnosis.

A. Yang, W. Ju, Z. Guo, C. Wu, J. Lin, M. Chen, R. Deng, E. Chen, Y. Gao, X. Zhu, X. He.
Dual Kidney Transplants as Policy to Optimize the Allocation of Marginal Donor Kidneys: Analysis of the French Cohort Since 2002.

E. Savoye,¹ R. Snanoudj,² C. Hiesse,³ M.-N. Peraldi,⁴ A. Durrbach,⁵ N. Ouali,⁶ M. Durand,⁷ L. Badet,⁸ M.-A. Macher.¹
Dynamic Detection of Anti-HLA Antibodies Can Predict aGVHD and OS in HLA-12/12 Matched Unrelated-Donor Allo-HSCT for Hematological Malignancies.

J. He,¹ Z. Pan,¹ X. Yuan,¹ Y. Li,¹ X. Wu,² W. Zhu,² X. Bao,¹ Q. Zhao.²
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).

J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.
ER Stress and Loss of GRP78 Expression Provides a Link Between Renal Ischemia/Reperfusion Injury and the Urinary Metabolome.

C. van Kooten,¹ T. Pacchiarotta,² P. van der Pol,¹ J. de Fijter,¹ N. Schlagwein,¹ D. van Gijlswijk,¹ O. Mayboroda.²
ESAT-6 Inhibits Donor-Specific Memory CD8+ T Cell Generation and Alloimmune Responses.

Z. Dai,¹ H. Dai.²
ESM1 Gene Promotes Hepatocyte Proliferation Through NF-κB Signal Pathway.

J. Zhou, W. Ju, X. Jiao, X. Zhu, X. He.
Early Changes to Kidney Distribution Under the New Kidney Allocation System.

A. Massie,¹ X. Luo,¹ B. Lonze,¹ N. Desai,¹ A. Bingaman,² M. Cooper,³ D. Segev.¹
Early Enteral Feeding After Living Donor Liver Transplantation Prevents Infectious Complications: A Prospective Pilot Study.

J. Kim,¹ D. Sinn,² S. Lee,¹ G.-S. Choi,¹ J. Park,¹ C. Kwon,¹ S. Kim,¹ J.-W. Joh,¹ S.-K. Lee.¹
Early Hospital Readmisison Among Older Kideny Transplant Recipients.

E. King, L. Kucirka, M. McAdams-DeMarco, F. Al-Ammary, D. Segev.
Early Hospital Readmission After Kidney Transplantation: Seasonality, Causes and Prognosis.

M. Tavares, M. Cristelli, L. Viana, M. de Paula, H. Silva Junior, J. Medina Pestana.
Early Impact of the New Kidney Allocation System (KAS) in Highly Sensitized Patients.

D. Mompoint-Williams, R. Gaston, G. Jeremy, J. Locke, V. Kumar.
Early Onset Acute Antibody Mediated Rejection (ABMR) Is More Common in Female Than in Male Recipients of a Living Unrelated Donor (LURD) Renal Transplant and Is Associated with the Presence of Preformed Donor Specific Antibodies (DSA).

D. Soonawala,¹ K. Groeneweg,¹ F. van der Toorn,¹ S. Heidt,² D. Roelen,² F. Claas,² J. de Fijter.¹
Early Tacrolimus Exposure in Patients Treated De Novo with Once-Daily Tacrolimus After Liver Transplantation: Relationship with Acute Rejection and Long-Term Outcome.

M. Gastaca, A. Valdivieso, J. Bustamante, P. Ruiz, J. Fernandez, A. Ventoso, M. Testillano, I. Palomares, M. Prieto, P. Salvador, A. Matarranz, M. Suarez, J. Ortiz de Urbina.
Eary Use of Statins Associated with Improved Death-Censored Graft Survival Following Kidney Transplant.

T. Horwedel,¹ D. Brennan,² K. Lentine,³ J. Hagopian.¹
Economic Analysis of Survival for Patients Undergoing Kidney Transplant in a Philanthropic Hospital of Sao Paulo, Brazil.

A. Matos,¹ D. Malheiros,² S. Morgado,¹ L. Requiao-Moura,¹ A. Kanamura,³ M. Cendoroglo,³ O. Pavao Santos,³ A. Pacheco-Silva.¹
Effect of Baseline Co-Morbidity on Mortality in Living Kidney Donors – 10 Year UK Cohort Study.

N. Krishnan,¹ L. Bradbury,² N. Raymond.¹
Effect of Baseline Proteinuria on Long- and Short-Term Outcomes in Live Kidney Donors – 10 Year U.K Cohort Study.

N. Krishnan,¹ L. Bradbury,² N. Raymond.¹
Effect of Conversion to mTOR Inhibition on Allograft Fibrosis in Pediatric Liver Transplantation.

R. Fischer,¹ S. Foster,² A. Kats,¹ W. Andrews,¹ R. Hendrickson,¹ J. Daniel.¹
Effect of Donor-Recipient Gender Mismatch in Liver Transplant Recipients: A Post-Hoc Analysis of the H2304 Study.

L. Fischer, P. de Simone, G. Dong, P. Lopez, P. Bernhardt, F. Saliba.
Effect of Early Tacrolimus Trough Variability on Graft Outcomes in Lung Transplantation.

K. Boyle, M. Moranville, P. Shah.
Effect of Inflammation on Concentration of Intracellular Tacrolimus.

E. Bae,¹ S. Yang,² S. Han,¹ J.-Y. Park,¹ H. Lee,¹ Y. Kim.¹
Effect of Modifying Life Support Withdrawal Practices on Outcomes of Donation After Circulatory Death in Liver Transplantation: A Meta-Analysis.

Y. Cao,^1,2 S. Shahrestani,³ H. Chew,^2,4 M. Crawford,⁵ P. Macdonald,^1,2,4 J. Laurence,^3,5,7 W. Hawthorne,^3,6 K. Dhital,^1,2,4 H. Pleass.^3,5,6
Effect of Telehealth Monitoring on Early Hospital Readmission After Renal Transplantation.

K. Noon,¹ N. Sarabu,¹ J. Augustine,¹ D. Hricik,¹ B. Deleva,¹ K. Woodside,² M. Aeder,¹ J. Foote,¹ A. Bruno,¹ K. Walsh,¹ M. Johnston,¹ V. Humphreville,¹ E. Sanchez.¹
Efficacy of Nine National Policies Reimbursing and Incentivizing Live Organ Donation.

V. Apte, S. Fry-Revere.
Elderly Kidney Transplant Recipients Need Optimized Immunosuppression According to Comorbidity and Infection.

E. Kang,¹ S. Park,¹ S. Park,¹ S. Yang,² I. Jung,³ S.-K. Park,⁴ Y. Kim,⁵ D.-J. Han,¹ Y. Kim,¹ J. Lee.⁶
Elevated De Novo Donor Specific Antibody After Alemtuzumab Induction in Renal Transplant Recipients.

K. Fabbri, J. Descourouez, M. Jorgenson, R. Redfield.
Elevation of Peripheral IL-6 in Kidney Transplant Recipients with Antibody Mediated Rejection.

N. Wilson, A. Djamali, R. Redfield.
Elucidating Clinical Factors Implicated in Primary Graft Dysfunction After Heart Transplantation.

R. Quintana-Quezada, I. Rajapreyar, Y. Yeh, S. Choi, I. Gregoric, P. Loyalka, B. Kar.
End Stage Renal Disease (ESRD) Patients' Willingness to Accept Risks to Living Kidney Donors.

J. Gannon,¹ C. Thiessen,¹ K. Yu,¹ L. Skrip,¹ P. Reese,² E. Gordon,³ S. Kulkarni.¹
Enhanced Natural Killer Responsiveness Is a Potent Cytotoxic Mechanism Associating to Kidney Allograft Dysfunction and Pathogenic Effects of Donor-Specific Antibodies (DSA).

P. Paul,^1,2 T. Legris,³ C. Picard,⁴ D. Todorova,^1,2 L. Lyonnet,¹ L. Daniel,⁵ B. Dussol,^3,6 V. Moal,³ H. Vacher Coponat,³ Y. Berland,³ F. Dignat-George,^1,2 S. Burtey.^2,3
Eomesodermin Expression by CD8+ Alloreactive T Cells in Human and Nonhuman Primate Allograft Recipients.

A. Perez-Gutierrez, L. Lu, A. Zahorchak, Y. Ono, A. Thomson, M. Ezzelarab.
Epidemiology of Surgical Site Infections After Liver Transplantation: 4 Year Prospective Study.

Y. Natori, R. Kassar, A. Iaboni, S. Hosseini-Moghaddam, D. Vu, S. Husain, E. Renner, C. Rotstein.
Establishment of SCID Pigs Cell Lines to Prevent Immunodeficiency Using RGEN System.

D.-H. Kim,¹ J.-S. Ahn,¹ S. Hwang,² J.-W. Lee.¹
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.

M. McRae, T. How, A. Kirk, H. Xu.
Evaluating the Influence of Liver Donor and Recipient Race on Tacrolimus Dose Requirements.

J. Knorr, J. Vidal, V. Navarro, R. Zaki.
Evaluation According to Donor Source: 24-Month Results from Post-Hoc Analysis of the ELEVATE Study in Kidney Transplant Recipients.

J. de Fijter, H. Holdaas, P. Lopez, P. Bernhardt, D. Gaohong, J. Cruzado, M. van der Giet.
Evaluation of Conformational Diversity of a Single HLA-I Molecule Coated on Single Antigen Beads: Potential Impact on Organ Allocation?

V. Jucaud, M. Ravindranath, P. Terasaki.
Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.

I. Gutman, M. Misel, D. McKay, A. Hemming, J. Kerr, K. Mekeel.
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.

H. Yang, A. Thorat, L. Jeng, C.-C. Yeh, T.-H. Chen, S.-C. Hsu, K.-S. Poon.
Evaluation of Patient-Reported Nonadherence with Tacrolimus Level Variability in Renal Transplant Recipients.

N. Parrish,¹ T. Kaiser,² A. McCann,¹ J. Aladimi,² J. Harris,³ A. Govil,² B. Abu Jawdeh,² G. Mogilishetty,² R. Alloway,² E. Woodle.²
Evaluation of Perioperative Anemia and Associated Transfusion Requirements in Adult Liver Transplant Recipients.

E. Aldag, P. Moghimi, R. Pedersen, A. Sahajpal, J. Clendenon, V. Gunabushanam, M. Irani, D. Kramer.
Evaluation of Polyomavirus (BK) Treatment and Clinical Outcomes in Pediatric Kidney Transplant Recipients: A >10 Year Single Center Retrospective Experience.

R. Liverman,¹ E. Kraus,¹ R. Garro,² B. Warshaw,² P. Winterberg,² R. George.²
Evaluation of T Cell Immunity in Elderly Solid Organ Transplant Recipients.

J. Schaenman,¹ Y. Korin,² T. Sidwell,² V. Groysberg,² E. Lum,¹ E. Huang,¹ S. Bunnapradist,¹ T. Pham,¹ G. Danovitch,¹ E. Reed.²
Evaluation of an Early Steroid Withdrawal Maintenance Regimen in African American Renal Transplant Recipients.

S. Gabardi, M. Kim, R. Alsheikh, K. Townsend, A. Chandraker.
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).

E. Aldag, T. Pedone, R. Pedersen, S. Besur, K. Safdar, A. Sahajpal.
Evaluation of the Utilization of Filgrastim in Kidney Transplant Recipients.

T. Poon,¹ C. Guerra.²
Everolimus Abrogates C5a and TGFβ Mediated Perycite-to-Myofibroblast Transition (PMT) Inhibiting Vascular Rarefaction.

G. Castellano, R. Franzin, A. Stasi, C. Divella, L. Gesualdo.
Everolimus and Low Dose Cyclosporine Immunosuppressive Regimen and Development of Anti HLA Donor Specific Antibodies.

E. Minetti,¹ L. Di Maria,¹ L. Caroti,¹ E. Buti,² P. Carta.¹
Eversion Endarterectomy of the Deceased Donor Renal Artery to Prevent Kidney Discard.

M. Khan, K. Jones, H. El-Hennawy, A. Farney, J. Rogers, G. Orlando, R. Stratta.
Evolution of Donor Nephrectomy: Long-Term Outcomes with Four Different Techniques Between 1963 and 2014 at a Single Institution.

O. Serrano,¹ A. Bangdiwala,² D. Vock,³ E. Minja,¹ A. Pugalendhi,¹ K. Yadav,¹ V. Kirchner,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ T. Pruett,¹ A. Matas,¹ R. Kandaswamy.¹
Ex Vivo Perfusion of Porcine Forelimbs to Prolong Allowable Ischemia Time.

N. Krezdorn,¹ M. Kueckelhaus,² A. Dermietzel,² M. Alhefzi,¹ M. Aycart,¹ S. Fischer,³ T.-S. Win,¹ H. Kiwanuka,¹ E. Bueno,¹ B. Pomahac.¹
Ex-Vivo Normothermic Perfusion (EVNP) Attenuation of Kidney Ischemia-Reperfusion Injury (IRI): A Proposed Mechanism.

I. Palma,¹ S. Kabagambe,¹ Y. Smolin,¹ T. Boyer,¹ I. Palma,¹ O. Fiehn,² Y.-J. Chen,¹ J. Sageshima,¹ C. Santhanakrishnan,¹ C. Troppmann,¹ R. Perez.¹
Ex-Vivo Normothermic Perfusion for Assessment of High Risk Deceased Donor Kidneys for Transplantation.

S. Kabagambe, I. Palma, Y. Smolin, T. Boyer, I. Palma, J. Sageshima, C. Santhanakrishnan, C. Troppmann, J. McVicar, R. Perez.
Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Taclorimus with CsA for Two Years Result by a Japanese Multicenter Study.

N. Yoshimura, K. Nishimura, K. Akioka, M. Shimazu, K. Nose, T. Nishioka, N. Nakamura, K. Uchida, T. Nakatani, H. Ushigome.
Exome Sequencing and HLA-Independent Prediction of Long-Term Kidney Allograft Function.

L. Mesnard,^1,3,6 T. Muthukumar,^2,9 M. Burbach,² C. Li,² H. Shang,⁴ D. Dadhania,^2,3 J. Lee,^2,3 V. Sharma,² J. Xiang,⁴ M. Carmagnat,⁵ C. Suberbielle,⁵ N. Ouali,⁶ E. Rondeau,^6,1 J. Friedewald,⁸ M. Abecassis,⁷ M. Suthanthiran,^2,9 F. Campagne.³
Exosome-Like Vesicles Released in Association with Tissue Injury Trigger Anti-LG3 Production.

M. Dieudé,^1,2,3 J. Turgeon,^1,3 B. Yang,^1,2,3 L. Pomerleau,^1,3 K. Hamelin,^1,3 S. Lan,^1,2,3 S. Qi,^1,3 D. Gingras,^1,3 W. Dhari,¹ A. Rivard,¹ M.-J. Hébert.^1,2,3
Exosomes Expressing Cardiac Self-Antigens (Myosin and Vimentin) and Immuno-Regulatory miRNA Induce Graft Rejection.

M. Sharma,^1,2 M. Gunasekaran,^1,2 Z. Xu,^1,2 N. Steward,¹ W. Liu,^1,2 N. Benshoff,¹ T. Mohanakumar.^1,2
Expansion of Anti-HLA Antibodies After Renal Transplantation and Prognosis in Those Which Fix C1q.

P. Ruiz-Esteban,¹ M. Gonzalez-Molina,¹ A. Caballero,² A. Torio,² M. Leon,³ E. Palma,¹ D. Burgos,¹ M. Cabello,¹ V. Lopez,¹ M. Rodriguez,⁴ D. Hernandez.¹
Experience of Short-Term Preemptive Treatment for Cytomegalovirus Infection in Seropositive Patients After Liver Transplantation – Ten Years Result of a Single Institution.

T.-J. Wu, Y.-C. Wang, C.-H. Cheng, T.-H. Wu, R.-S. Soong, C.-F. Lee, H.-S. Chou, K.-M. Chan, W.-C. Lee.
Extraperitoneal Placement of the Kidney Prevents Graft Vascular Kinking or Rotation in Simultaneous Pancreas-Kidney Transplant (SPK).

M. Maraschio, A. Alcaraz, E. Giordano Segade.
Extreme Hyperoxia During Pre-Implant Normothermic Liver Perfusion (PINLiP) Is Associated with Post-Reperfusion Syndrome and Vasoplegia.

C. Watson, V. Kosmoliaptsis, L. Randle, M. Hamed, J. Klinck, A. Butler.
FGF and Wnt Signaling in Pancreatic Progenitor and Beta-Cell Growth.

S. Afelik,¹ N. Yonan,¹ B. Pool,² J. Jensen,² J. Oberholzer.¹
Factors Affecting Mortality During Waiting Time for Kidney Transplantation: A Nationwide Population-Based Cohort Study Using the Korean Network for Organ Sharing (KONOS) Database.

S. Lee,¹ K. Yoo,² J. An,³ Y. Oh,³ C. Lim,³ Y. Kim,¹ J. Lee.³
Factors Associated with Increased Risk of MELD Progression Among a Large Population of Patients with Cirrhosis and an Initial Low MELD Score (<15).

K. Atiemo, L. Zhao, A. Skaro, L. VanWagner, S. Goel, A. Kho, B. Ho, R. Kang, S. Montag, J. Holl, M. Abecassis, D. Ladner.
Factors Associated with Prolonged Warm Ischemia Time Among Deceased Donor Kidney Transplant Recipients.

A. Miller,¹ B. Kiberd,¹ I. Alwayn,² S. Kim,³ K. Tennankore.¹
Factors Associated with Response to Plasmapheresis in Patients with Recurrent FSGS.

J. Shoji,¹ V. Tatapudi,² Z. Laszik,¹ A. Jones,³ J. Wolf,⁴ D. Adey,¹ F. Vincenti.¹
Factors Mediating Kidney Rejection in Patients of Simultaneous Liver-Kidney Transplants.

R. Dong, A. Tambur, L. Gallon, J. Levitsky.
Factors Predicting Risk for Antibody-Mediated Rejection in Highly Sensitized Pediatric Renal Transplants.

I. Kim,¹ J. Choi,¹ A. Vo,¹ S. Louie,¹ J. Mirocha,² S. Jordan,¹ E. Kamil,¹ D. Puliyanda.¹
Factors Predicting Tacrolimus Trough Variability After Lung Transplantation.

K. Boyle, M. Moranville, P. Shah.
Factors in a Successful Transfer of Pediatric Liver Transplant Recipients to Adult-Based Care.

J. Bilhartz, M. Lopez, J. Magee, V. Shieck, S. Eder, E. Fredericks.
Fatty Liver in Non-Hepatic Organ Transplantation.

N. Kemmer, A. Alsina.
Fifty Is the New 40? An Argument to Uncap the MELD Score.

J. DiNorcia,¹ Y. Genyk,¹ K. Andreoni,⁴ W. Kim,³ J. Levitsky,⁵ D. Mulligan,⁶ R. Sung,⁷ M. Nadim.¹
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.

J. Choi, S. Jordan, A. Vo.
Focal C4d Staining in Biopsies of Kidney Transplant Recipients Is Not Associated with Antibody Mediated Rejection and Does Not Correlate with Graft Survival.

R. Prashar, M. Goggins, L. Yessayan, A. Patel, M. Goggins.
Four-Factor Prothrombin Complex Concentrate as a Strategy to Rapidly Reverse Anticoagulation in Patients Undergoing Cardiac Transplantation: Better Than the Conventional Approach?

T. Sam,¹ G. Gonzalez-Stawinski,² G. Saracino,³ A. Jamil,³ S. Hall,² K. Cox,¹ B. Lima.²
Fractional Excretion of NGAL Instead of ^99mTcMAG₃Renography to Monitor Resolution of Delayed Graft Function.

J. Bank, M. Reinders, L. Noordermeer, M. Mallat, S. van der Kooij, C. van Kooten, J. de Fijter.
Frequency and Utility of Donor-Specific Antibody Testing in Simultaneous Liver Kidney Transplant.

A. Morrison,¹ D. Sawinski,² M. Kamoun,³ P. Porrett.¹
Function of Sertoli Cells in Regulating Allogeneic T Cell Differentiation into Treg and Th17 In Vitro.

L. Xie,¹ W. Jiang.²
Gastric Bypass Does Not Negatively Affect Kidney Transplant Outcomes.

N. Goyal, O. Sanchez, N. Issa, A. Matas, H. Ibrahim, A. Kukla.
Gender Mismatch in the UNOS Heart Transplant Database: Not a Factor in Younger Heart Transplant Patients.

J. Kobashigawa, M. Kittleson, L. Czer, T. Aintablian, E. Passano, D. Chang, F. Esmailian, J. Patel.
Gene Expression Levels of Advanced Heart Failure Patients in Terms of Coagulation and Its Effect within Multiple Organ Dysfunction Syndrome.

R. Togashi, E. Chang, N. Wisniewski, M. Cadeiras, G. Bondar, E. Reed, M. Deng.
Gene Expression Profiling Score and the Risk of Infection in Heart Transplant Recipients.

J. Teuteberg,¹ D. Budge,² M. Shullo,¹ S. Hall,³ J. Kobashigawa.⁴
Genetic TIM-4 Deletion Promotes Immunoregulatory Tissue-Resident Macrophage Survival and Lowers the Barrier to Cardiac Allograft Tolerance.

T. Thornley,¹ P. Kyriazis,¹ K. Agarwal,¹ Z. Fang,¹ L. Ma,¹ V. Chipashvili,¹ M. Koulmanda,^1,2 T. Strom.^1,2
Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.

E. Rhone,¹ R. Gehrau,² S. Bontha,² P. Walker,³ C. Dumur,⁴ D. Maluf,² V. Mas.²
Geographic Variability in Access to Transplant Centers for Children with End-Stage Renal Disease.

C. Toro,¹ M. Ross,^1,2 D. Wiebe,² S. Amaral.^1,2
Give One and Done? Evaluating a Change in Surgical Prophylaxis in Kidney Transplant Recipients.

K. Bliven, C. Truax, K. Snow, N. Kenyon, A. Carlson, S. Yeager, L. Smith.
Glomerular Capillary C4d Staining without Evidence of Rejection Is Associated with Worse Graft Function in ABO-Incompatible Kidney Transplantation.

D. Toki,¹ M. Inui,¹ M. Okumi,² H. Ishida,² K. Setoguchi,¹ T. Shimizu,² K. Unagami,² K. Tanabe.²
Good Livers with a Bad Reputation: Favorable Outcome with Imported Grafts.

M. Akoad, M. Simpson, J. Pomposelli, E. Pomfret.
Graft Loss Due to Recurrence of Focal Segmental Glomerulosclerosis in Second Renal Transplant.

V. Aggarwal, A. Gruessner, R. Gruessner, V. Whittaker, S. Narsipur.
Graft Survival in Sensitized and Non-Sensitized Patients: Role of the Combination of Donor-Specific Antibodies and Acute Rejection.

P. Souza,¹ A. Aguirre,¹ G. Bezerra,² H. Rodrigues,² F. Agena,¹ D. David,¹ F. de Paula,¹ E. David-Neto,¹ M. Castro.¹
Growth of Liver Allografts in Pediatric Transplant Recipients.

S. Chaudhry, J. Stern, S. Lobritto, M. Martinez, J. Vitorrio, J. Emond, T. Kato, B. Samstein, S. Bentley-Hibbert, A. Griesemer.
HCK Is a Potential Mediator of Renal Fibrosis.

C. Wei,¹ M. Menon,¹ L. Li,² Z. Yi,¹ K. Keung,³ C. Woytovich,¹ I. Greene,¹ W. Zhang,¹ J. He,¹ B. Murphy.¹
HCV, Acute Rejection, and the New Direct-Acting Antivirals in Deceased Donor Kidney Transplant Recipients.

C. Liao, A. Massie, S. Bae, D. Segev.
Hand-Assisted Laparoscopic Donor Nephrectomy: Experience with Over 2400 Cases at a Single Center.

H. Li,^1,2 M. Stegall,¹ G. Chow,¹ P. Dean,¹ J. Heimbach,¹ T. Taner,¹ M. Prieto.¹
Health Insurance Trends in United States Living Kidney Donors.

J. Rodrigue,^1,2 A. Fleishman.¹
Heart and Kidney Transplants in Patients with Mechanical Circulatory Support: Who Needs a Kidney?

J. Neyer, J. Patel, M. Kittleson, D. Chang, M. Luu, T. Aintablian, E. Passano, L. Czer, F. Esmailian, J. Kobashigawa.
Heat Shock Protein 90 Inhibitor 17DMAG Is a Potential New Therapeutic Agent Against Acute Allograft Rejection.

T. Maehana,¹ T. Tanaka,¹ H. Kitamura,² N. Masumori.¹
Hematopoietic Progenitor Cells and Monocyte Subsets and Hepatic Decompensation in Patients Referred for Liver Transplant Evaluation.

K. Forde,¹ K. Krok,² M. Patel,¹ M. Krowka,³ M. Fallon,⁴ S. Kawut.¹
Heparanase: A New Factor Involved in the Pro-Fibrotic Renal Biological Machinery Activated by the Ischemia/Reperfusion (I/R) Injury.

G. Zaza,¹ V. Masola,¹ G. Gambaro,² M. Onisto,³ G. Bellin,¹ I. Vlodavsky,⁴ Z. Abassi,⁵ A. Lupo.¹
Hepatitis B Immune Globulin Withdrawal in HBsAg Positive Liver Transplant Patients.

A. Nolan,¹ C. Onwudiwe,¹ A. Rangnekar,² R. Satoskar,² T. Fishbein.²
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.

A. Gonzalez, F. Forouton, A. Humar, S. Husain.
Hepatitis C Eradication with Sofosbuvir Based Regimens Leads to Significant Metabolic Changes in Post Orthotopic Liver Transplant Patients.

A. Morales,¹ M. Singla,² H. Greenwald,¹ S. Robertazzi,¹ C. Rodigas,¹ V. Washington,¹ R. Satoskar,¹ C. Smith.¹
Here Comes the Sun: Industry's Payments to Transplant Physicians.

R. Ahmed,¹ E. Chow,² S. Bae,² A. Massie,² E. King,² B. Orandi,² J. Lopez,² B. Lonze,² D. Segev.²
Heterologous Persistent and Latent Viral Infections Do Not Impact Graft Survival.

J. Espinosa,^1,2 M. McRae,¹ J. Wang,¹ A. Kirk.¹
High Concentrations of CXCL9 and CXCL10 Chemokines but Not CXCL8 (IL-8), IL-6, TNF-a or IFN-g in Biopsy Tissue Are Associated with Pathological Staging of Rejection After Kidney Transplantation.

C. Falk,¹ C. Neudörfl,¹ K. Daemen,¹ J. Keil,¹ F. Lehner,² H. Haller,³ J. Schmitz,⁴ C. Blume,⁵ J.-H. Bräsen.⁴
High KDPI Is a Predictor of Acute Rejection in Delayed Graft Function.

B. Muth,¹ J. Turk,¹ S. Parajuli,¹ D. Mandelbrot,¹ M. Mohamed,¹ R. Redfield,² D. Kaufman,² A. Djamali.^1,2
High Resolution Detection of Human Pancreatic Islet Damage During and After Isolation Procedure Using MicroRNAs.

S. Prathab Balaji,¹ M. Kanak,² G. Yoshimatsu,¹ C. Chang,¹ M. Levy,² M. Lawrence,¹ P. Kim,³ N. Onaca,³ B. Naziruddin.³
High Tacrolimus Dose Requirements at Month 6 Are Associated with Inferior Graft Function in Renal Transplant Patients.

O. Rissling, S. Brakemeier, L. Lehner, F. Halleck, O. Staeck, D. Schmidt, K. Budde.
Higher Functional Capacity Prior to Kidney Transplant Confers Lower Risk of New Onset Diabetes After Transplantation.

I. Qaqish, S. Behmen, R. Heilman, H. Khamash, J. Huskey, S. Nair, H. Chakkera.
Higher Pre-Transplant HDL Levels Are Associated with Decreased Acute Rejection Following Kidney Transplant.

J. Hagopian,¹ D. Brennan,² K. Lentine,³ T. Horwedel.¹
Histone Deacetylase-2 Gene Deletion in Mice Mitigates Liver Ischemia/Reperfusion Injury.

D. Murken,¹ D. Aufhauser Jr,¹ Z. Wang,² G. Ge,² W. Hancock,^2,3 M. Levine.^1,4
Hospital Readmissions Following Discharge After Liver Transplantation (LT).

E. Minja, S. Chinnakotla, K. Yadav, A. Pugalenthi, O. Serrano, R. Kandaswamy, W. Payne, T. Pruett, V. Kirchner.
Hospital Readmissions in the First Year Post Transplant Over a 12-Year Span at a Single Center.

C. Avila, I. James, G. Phillips, A. El-Hinnawi, A. Rajab, R. Pelletier, M. Henry, G. Bumgardner.
Hospitalizations for Cardiovascular Disease After Kidney Transplantation: The Role of Facility Characteristics on Outcomes and Costs.

A. Mathur, Y.-H. Chang, D. Steidley, N. Katariya, A. Singer, W. Hewitt, K. Reddy, N. Wasif, D. Etzioni, A. Moss.
Hospitalizations, Survival, and Complications: 1-Year Outcomes for Elderly Lung Transplant Recipients.

N. Casciello, A. Fuentes, J. Krisl, N. Sinha, T. Kaleekal.
How Small Is Too Small: A Comparison of Access and Survival by Weight in Pediatric Liver Transplant Recipients.

E. Steen, R. Cotton, A. Rana.
How Tacrolimus Variability Affects Donor Specific Antibodies, Rejection and Outcome After Kidney Transplantation.

S. Papachristos, A. John Velvet, A. Summers, A. Tavakoli, R. Dhanda, R. Pararajasingam, B. Forgacs.
Human Epineural Allograft Conduits Supported with Mesenchymal Stem Cells Enhance Peripheral Nerve Regeneration: A Preliminary Report.

M. Siemionow, M. Strojny, W. Malewski, J. Cwykiel, M. Cyran.
Human Leukocyte Antigen (HLA) Mismatch Impact on Lung transplants outcomes.

G. Chery,¹ L. Snyder,¹ M. Durheim,¹ S. Palmer,¹ M. Neely.²
Human Multipotent Mesenchymal Stromal Cells Improve Survival and Function of Pancreatic Islets by Cell-to-Cell Contact.

E. Montanari,¹ R. Meier,² D. Bosco,¹ R. Mahou,³ P. Morel,² J. Seebach,⁴ C. Wandrey,³ C. Gonelle-Gispert,¹ L. Bühler.²
Human PDL1⁺ SLA-DR^–Swine Vascular Endothelial Cells Suppress Pig-Human PBMC Xeno-MLR(Mixed Lymphocyte Reaction) by Inducing Human Regulatory IL-10⁺Tr1(Type 1 Regulatory T Cells) Subset for Suppression of Xenogeneic Reactions.

Q. Shao, Q. Diag.
Hydrogen Sulfide Supplementation Helps Mitigate Effects of Ischemia Reperfusion Injury in a Murine Model of Donation After Cardiac Death Renal Transplantation.

J. Grewal,¹ I. Lobb,¹ M. Saha,² J. Jiang,² A. Haig,¹ A. Sener.^1,2
Hydrogen Sulfide Treatment Mitigates Donor Tissue Necrosis During Prolonged Cold Storage and Improves Survival Following Allogeneic Renal Transplantation.

I. Lobb,^1,3 W. Liu,² J. Jiang,³ D. Lian,³ A. Sener.^1,3,4
Hydrogen Sulphide Is an Important Regulator of Erythropoietin Synthesis in Patients with Anemia of Chronic Kidney Disease.

J. Leigh,¹ P. Shao,¹ M. Saha,¹ I. Lobb,¹ A. Pasch,⁵ H. van Goor,⁴ M. Feelisch,² R. Wang,³ A. Sener.¹
Hyponatremia in Early Post Lung Transplantation Predicts Patient and Hospital Outcomes.

E. Tantisattamo,¹ A. Chokechanachaisakul,² O. Traitanon,³ A. Shetty,² B. Ho,² J. Friedewald,² S. Bhorade,² A. Haynes,² A. Nieland,² L. Gallon.²
Hypothermic Machine Perfusion Ameliorates Vasospasm and Edema of Podocytes and Renal Tubular Epithelial Cells Through Upregulating Expression of Krüppel-Like Factors 2.

Z. Zhong,¹ D. Ko,² Y. Wang,¹ Q. Ye.¹
IL-10 Expression of In Vitro Activated B Cells as A Biomarker for B Cell Tolerance.

T. Oura, K. Hotta, K. Crisalli, B. Cosimi, T. Kawai.
IL-17A Preactivated Mesenchymal Stem Cells (MSC-17) Are Enriched for Genes Involved in T Cell Chemotaxis to Mediate Superior Immunosuppression.

K. Sivanathan,^1,2,3 D. Rojas-Canales,^1,2 S. Gronthos,⁴ S. Grey,⁵ P. Coates.^1,2,3
IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.

K. Sablik,¹ C. Looman,² M. Clahsen-van Groningen,³ J. Damman,³ D. Roelen,⁴ M. van Agteren,¹ M. Betjes.¹
Ideal Outcome After Liver Transplantation: An Exploratory Study Using Machine Learning Analyses to Leverage Long-Term Registry Data from Studies in Pediatric Liver Transplantation (SPLIT).

E. Hsu,¹ M. Shaffer,^1,2 R. Anand,³ V. Ng,⁴ J. Bucuvalas.⁵
Identification of Donor HLA-Specific Antibodies as a Risk Factor for Graft Dysfunction and Failure Following BK Virus Associated Nephropathy.

E. Abuhelaiqa, S. Salvatore, J. Lee, J. Lee, V. Sharma, T. Muthukumar, S. Seshan, M. Suthanthiran, D. Dadhania.
Identifying Social Barriers to Health Literacy in ESRD Patients Undergoing Kidney Transplant Evaluation.

K. Leick,¹ J. Jones,¹ S. Witte,² L. Hunsicker,³ Z. Stewart.¹
IgM Treatment Successfully Prevents Type 1 Diabetes by Dysregulation of Pancreatic MicroRNAs with Immunomodulatory Roles.

P. Chhabra, R. Gehrau, V. Mas, D. Bower, D. Maluf, K. Brayman.
Imaging Cell Biology In Vivo with Intravital-Microscopy.

T. Ueno,¹ M. Yeung,¹ N. Igarashi,³ T. Yokoyama,² Y. Kihara,² O. Konno,² Y. Nakamura,² H. Iwamoto,² T. Ikeda,³ M. McGrath,¹ M. Sayegh,¹ A. Chandraker.¹
Imminent Death Donation: Potential Effects on Organ Donation Numbers and Clinical Outcomes.

V. Potluri,¹ S. Nazarian,² M. Levine,² P. Reese.³
Immune Tolerance Monitoring in Renal Allograft Tolerance Induced by Transient Mixed Chimerism in Nonhuman Primates and Humans.

K. Hotta, T. Oura, K. Crisalli, D. Sachs, B. Cosim, T. Kawai.
Immunosuppressive Actions of CLI95 and CORM401 on TLR4 in Renal Ischemia Reperfusion Injury.

P. Luke,^1,2,5 G. Cepinskas,^1,4 H. Alharbi,^3,5 A. Haig,^3,5 R. Bhattacharjee.^1,2,5
Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).

A. Vo,¹ C. Boutsicaris,¹ X. Zhang,² N. Reinsmoen,² J. Choi,¹ S. Jordan.¹
Impact of BKV Subtype Distribution on BKV Nephropathy, Viremia, and Renal Outcome in Patients After Renal Transplantation.

S. Anke,¹ L. Silvia,¹ H. Hermann,¹ H. Albert,² S. Corinna.²
Impact of C3d and C1q-Binding DSA Detected Long-Term After Kidney Transplantation.

M. Crespo,^1,2 D. Redondo,^1,2 C. Garcia,³ J. Gimeno,⁴ M. Perez,^1,2 M. Mir,¹ J. Hernandez,³ J. Yelamos,² A. Faura,^1,2 J. Pascual.^1,2
Impact of Donor AKI on Outcome Following High KDPI Deceased Donor Kidney Transplantation.

D. Haakinson,¹ I. Qaqish,² M. Smith,³ H. Khamash,² K. Reddy,¹ R. Heilman.²
Impact of Donor Specific Antibodies on Cardiac Allograft Vasculopathy.

A. Vu,¹ A. Althouse,² A. Zeevi,³ J. Teuteberg,² M. Shullo.²
Impact of Early Hospital Readmissions After Kidney Transplantation on Graft Function.

I.-K. Kim, M. Ju, S. Son.
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.

T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
Impact of Ethnicity on Tacrolimus Trough/Dose Ratios Following Solid Organ Transplantation.

A. Santeusanio, A. Owusu-Obeng, J. Jeff.
Impact of Everolimus and Low-Dose Ciclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.

B. Höcker,¹ S. Zencke,¹ L. Pape,² K. Krupka,¹ L. Kösters,¹ A. Fichtner,¹ L. Dello Strologo,² I. Guzzo,² R. Topaloglu,² B. Kranz,² J. König,² M. Bald,² N. Webb,² A. Noyan,² H. Dursun,² S. Marks,² Z. Ozcakar,² F. Thiel,² H. Billing,² M. Pohl,² H. Fehrenbach,² P. Schnitzler,¹ T. Bruckner,¹ L. Weber,² R. Feneberg,² T. Ahlenstiehl-Grunow,² B. Tönshoff.¹
Impact of HLA-DR Compatibility on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients Following Early Switch from Calcineurin Inhibitor to Everolimus: Subanalysis from the ELEVATE Study.

J. Cruzado, H. Holdaas, P. Lopez, J. Aguilar, G. Dong, F. Claas, W. Arns, M. van der Giet, J. de Fijter.
Impact of Left Ventricular Diastolic Dysfunction on Patients Being Evaluated for Liver Transplantation.

K. Forde,¹ R. McLean,¹ W. O'Donnell,¹ K. Krok,² M. Patel,¹ G. Lin,³ J. Oh,³ M. Krowka,³ M. Fallon,⁴ S. Kawut.¹
Impact of Mixed Xenogeneic Chimerism on Human B Cell Response to Pig Antigens.

H. Li, S. Shao, P. Vishwasrao, M. Holzl, M. Sykes.
Impact of New Kidney Allocation System on Transplant Rates for Highly Sensitized Patients-Center Specific Study.

X. Zhang, M. Naim, A. Vo, S. Jordan, N. Reinsmoen.
Impact of Transfusion Requirements on Likelihood of Heart Transplantation After Total Artificial Heart.

J. Cook,¹ L. Kang,¹ M. Flattery,² I. Tchoukina.²
Impact of the National Overdose Death Epidemic on the Deceased-Donor Pool.

M. Bowring, A. Massie, L. Kucirka, E. Chow, M. Sulkowski, D. Segev, C. Durand.
Impact of the New Kidney Allocation System on Highly Sensitized Patients: Single Center Report.

A. Mattiazzi,¹ W. Kupin,¹ D. Roth,¹ L. Chen,² G. Burke,² G. Ciancio,² P. Ruiz,² R. Vianna,² G. Guerra.¹
Impact on Wound Healing Events After Early Conversion to Everolimus in De Novo Renal Transplant Recipients: 24-Month Results from the Randomized ELEVATE Study.

B. Nashan,¹ M. van der Giet,¹ H. Holdaas,¹ M. Zeier,¹ J. Pascual,¹ Y. Avihingsanon,¹ P. Lopez,² J. Aguilar-Sanchez,² J. Kochuparampil,² Z. Wang,³ J. Cruzado,¹ J. De Fijter.¹
Impediments to Timely Listing for HIV+ Patients Being Evaluated for Kidney Transplantation.

D. Lee,¹ A. Aldea,¹ M. Harhay,² S. Akshay,² G. Malat,³ N. Law,¹ S. DeBellis,² T. Bias,¹ S. Boyle,² K. Ranganna,² A. Doyle.²
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.

M. Cote,¹ M. Pavlakis,² J. Ethridge,¹ C. Currier,² M. Curry,² E. Khankin,² F. Cardarelli,² K. Richards,^1,2 C. Rogers.^1,2
Implicit Bias in Dialysis Providers' Transplant Education Practices for Low-Income and Racial/Ethnic Minority Patients.

C. Gonzalez,^1,2 A.-M. McSorley,¹ J. Peipert,¹ K. Norris,¹ C. Goalby,¹ L. Peace,³ P. Lutz,³ A. Waterman.¹
Improved Regeneration of the Remnant Liver After Extended Hepatectomy or Partial Liver Transplantation by Pharmacologic Mobilization of Endogenous Stem Cells in Rats.

M. Chen, R. Zhai, L. Qi, A. Cameron, B. Philosophe, Z. Sun.
Improving Donor Comfort: Perioperative Dexamethasone Decreases Nausea, Vomiting, and Pain After Laparoscopic Donor Nephrectomy.

S. Yamanaga,^1,2 A. Posselt,¹ C. Freise,¹ S.-M. Kang.¹
Improving Kidney Allocation System with Higher Resolution.

M. Cusick, J. Friedewald, K. Haarberg, J. Leventhal, A. Tambur.
In Situ Aortic Flush with Lactated Ringer's (LR) Solution During Donation After Brain Death (DBD) Organ Procurement Provides Similar Outcomes and Significantly Decreases Costs in Kidney and Liver Transplantation Compared to Standard Preservation Solutions.

S. Rudich, P. Lange.
In Vitro Reactivity of CD4⁺ T Cells Subsets from Hosts with Antigen Specific Transplant Tolerance Mediated by CD4⁺CD25⁺T Cells.

B. Hall, C. Robinson, K. Plain, N. Verma, G. Tran, N. Carter, M. Nomura, R. Boyd, S. Hodgkinson.
In Vitro and In Vivo Characterization of Human Hematopoietic Chimeric Cells – A Novel Approach for Tolerance Induction in Transplantation.

M. Siemionow, E. Tfaily, M. Cyran, R. Gendek, M. Strojny, E. Szilagyi, J. Cwykiel.
Incidence and Factors Associated with De Novo DSA After BK Viremia in Renal Transplant Recipients.

S. Patel, S. Kuten, R. Knight, D. Nguyen, E. Graviss, A. Gaber.
Incidence of Anxiety Following Live Kidney Donation.

J. Leanza, A. Massie, D. Segev.
Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.

E. Schrezenmeier,¹ T. Doerner,² O. Staeck,¹ K. Budde,¹ F. Halleck.¹
Incidence of Polyoma Virus Associated Nephropathy in a Single Transplant Center Employing a Reduction of Immunosuppression at a Lower Threshold of BK Viremia.

M. Azar, A. Valika, D. Banach, I. Hall, M. Malinis.
Incidence of Post-Transplant Cardiovascular Disease After Pediatric Kidney Transplantation.

O. Serrano,¹ A. Bangdiwala,² D. Vock,² W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ B. Chavers.³
Incidence of Post-Transplant Lymphoproliferative Disorder in First, Kidney-Only Transplant Recipients Remains Stable.

J. Molony,¹ Y. Peng,¹ N. Baker,² U. Meier-Kriesche,³ J. Snyder.¹
Incidence of Post-Transplant Malignancy (PTM) After Pediatric Kidney Transplantation (PKTx).

O. Serrano,¹ A. Bangdiwala,² D. Vock,² W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas,¹ B. Chavers.³
Incidence of and Risk Assessment for Adverse Cardiovascular Outcomes Following Liver Transplantation: A Systematic Review.

M. Konerman,¹ D. Fritze,² R. Weinberg,³ E. Spengler,¹ C. Sonnenday,² P. Sharma.¹
Incidence, Risk Factors and Treatment of Incisional Hernia After Kidney Transplantation – An Analysis of 1564 Consecutive Patients.

L. Ooms,¹ J. Verhelst,¹ J. Jeekel,² J. IJzermans,¹ J. Lange,¹ T. Terkivatan.¹
Inconsistent HLA Antibody Reactivity Detected with Different Solid-Phase Assays.

A. Jaramillo,¹ L. Nelson,¹ Y. Desmarteau,¹ B. Labuda,² K. Barrios,² J. Lunz,² R. Heilman,³ M. Pando.¹
Increased Frequency of Post-Recovery Liver Reallocation: The Law of Unintended Consequences?

J. Orlowski, C. Muse, J. Whaley, R. Squires.
Increased Gene Expression of TGF-β in Peripheral Blood Mononuclear Cells from Renal Transplant Patients with Polyomavirus BK Viremi.

W. Yin,¹ M. Lu.²
Increased Incidence of Clostridium difficile Infections with Proton Pump Inhibitor Use Post-Kidney Transplant.

M. Spinner,¹ K. Patel,¹ E. Neuner,¹ B. Stephany.²
Increased Utilization of High Risk Deceased Donors with Share 35 Does Not Affect Outcomes in Liver Transplantation.

M. Boktour, A. Saharia, D. Victor, S. Gordon-Burroughs, C. Mobley, R. McFadden, V. Ankoma-Sey, J. Galati, A. Gaber, H. Monsour, R. Ghobrial.
Increasing Volume and Improved Survival in Solid Organ Transplantation for Amyloidosis – An Analysis of the UNOS Database.

J. Jaramillo,¹ J. Stehlik,¹ J. Fang,¹ R. Al-Dulaimi,¹ E. Gilbert,¹ S. Drakos,¹ O. Wever-Pinzon,¹ C. Selzman,¹ S. McKellar,¹ T. Kovacsovics,² J. Abraham,² M. Maurer,³ J. Nativi-Nicolau.¹
Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allografts by Combination of Anti-BTLA mAb (6B2) and Anti-PD-1 mAb (PIM-2).

E. Yin,^1,2 M. Uchiyama,^1,3 X. Jin,^1,4 T. Shimokawa,³ H. Yagita,⁵ M. Niimi.¹
Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.

M. McAdams-DeMarco, Q. Huang, X. Luo, B. Orandi, S. Dorry.
Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.

F. Al Ammary,¹ S. Bae,¹ A. Massie,¹ N. Dagher,¹ E. King,¹ A. Wiseman,² D. Segev.¹
Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.

H. Dave, L. Wolfe, H. Fattah, D. Kumar, A. King, M. Levy, A. Cotterell, A. Sharma, C. Bhati, G. Gupta.
Ineligible: Attitudes and Follow-Up of Individuals Ruled Out of Living Kidney Donation.

D. Dobosz,¹ C. Thiessen,¹ J. Gannon,¹ S. Li,¹ K. Kennedy,² D. Gray,³ A. Mussell,³ E. Gordon,² S. Kulkarni,¹ P. Reese.³
Infection-Related Mortality After Kidney Transplantation in the Current Era.

I. Helanterä,¹ S. Kinnunen,² P. Karhapää,² A. Juutilainen,² P. Finne.³
Infections in De Novo Kidney Transplant Recipients Treated with the RANKL Inhibitor Denosumab: A Post-Hoc Analysis of the POSTOP Clinical Trial (NCT01377467).

M. Bonani,¹ D. Frey,² J. Brockmann,³ T. Fehr,¹ T. Müller,¹ N. Graf,⁴ R. Wüthrich.¹
Inferior Outcomes in Hepatitis C Virus Positive Donors to Hepatitis C Virus Negative Kidney Recipients: Analysis of National Data.

H. Fattah, L. Kang, H. Dave, D. Kumar, A. King, C. Bhati, A. Sharma, G. Gupta.
Inflammation Amplifier, a Chemokine Inducer in Non-Immune Cells in Kidney Transplantation Graft.

H. Higuchi,^1,2 H. Bando,² J. Jing-Jing,² T. Atsumi,² D. Iwami,¹ K. Morita,¹ N. Shinohara,¹ M. Murakami.²
Inflammatory Conditions Switch the Effect of MSC on B Cells from Pro-Tolerogenic to Anti-Proliferative.

M. Franquesa,^1,2 F. Luk,¹ S. Korevaar,¹ L. Boon,³ F. Borras,² M. Betjes,¹ C. Baan,¹ M. Hoogduijn.¹
Influence of Cold Ischemia Time in Kidney Transplants from Small Pediatric Donors.

L. Kayler,¹ M. Lubetzky,² P. Friedman.³
Influence of Country-Associated Geographical Variables in the Ouctomes of Kidney Transplantation in Patients with HIV-Infection.

M. Cristelli,¹ F. Cofán,² H. Tedesco-Silva,¹ J. Trullas,³ D. Santos,¹ C. Manzardo,⁴ F. Aguero,⁴ A. Moreno,⁴ F. Oppenheimer,² F. Dieckmann,¹ J. Miro,⁴ J. Medina-Pestana.¹
Influence of Donor and Recipient CYP3A4, CYP3A5 and ABCB1 Genotypes on Outcomes in Liver Transplants.

M. Debette-Gratien,¹ J. Woillard,² N. Picard,² M. Sebbagh,⁴ D. Sautereau,⁵ V. Loustaud-Ratti,¹ D. Samuel,³ P. Marquet.²
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.

C. Burton, Y. Tong, J. Preiksaitis.
Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.

A. Weick, O. Sadiq, S.-M. Jafri, D. Moonka.
Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.

S. Jordan,¹ J. Choi,¹ X. Zhang,¹ M. Haas,² A. Peng,¹ J. Kahwaji,¹ R. Villicana,¹ A. Vo.¹
Innate Immune Signaling During Ischemia-Reperfusion Injury in Human Orthotopic Liver Transplantation.

R. Sosa,¹ A. Zarrinpar,² C. Lassman,¹ R. Busuttil,² D. Gjertson,¹ J. Kupiec-Weglinski,¹ E. Reed.¹
Intra-Operative Hepatic Arterial Flow Predicts Hepatic Artery Complications After Deceased Donor Liver Transplantation.

H. Fernandez, G. Testa, G. Klintmalm, P. Kim.
Intragraft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation.

L. Gallon,¹ J. Leventhal,¹ C. Dumur,² J. Mathew,¹ L. Nadimpalli,¹ A. Shetty,¹ S. Ildstad,³ V. Mas.²
Introducing a Mobile Phone Application to Transplant Patients to Encourage Medication Compliance and Education in This At-Risk Cohort.

A. Zanetti Yabur, A. Rizzo, J. Graham, J. Rocca.
Is CMV Prophylaxis Effective in CMV-Seropositive Patients Receiving Thymoglobulin as Induction Therapy?

E. Feitosa, F. Agena, J. Reusing Jr, F. Lemos, E. David-Neto.
Is Donor Methamphetamine Use a Contraindication in Heart Transplantation?

M. Kittleson, J. Patel, L. Czer, A. Velleca, T. Aintablian, D. Chang, F. Esmailian, J. Kobashigawa.
Is Early Endoscopic Retrograde Cholangiopancreatography (ERCP) Safe Post Liver Transplant?

B. Wolk,¹ A. Shiani,² S. Lipka,² A. Kumar,² N. Kemmer,¹ H. Pinkas,² A. Alsina,¹ P. Brady,² A. Turner.¹
Is It Worth Risking Lives of Multiple Procurement Surgeons to Save One Life in Extreme Weather Conditions?

H. Sharma, I. Al-Hasan, M. Richard, O. Ali, A. Sener, D. Quan, V. Macillister.
Is MELD Score a Significant Predictor of Post-Transplant Mortality? An Old Issue with Simple Answer.

A. Rahnemai-Azar,¹ J. Perkins,¹ M. Montenovo,¹ S. Rayhill,¹ R. Bakthavatsalam,¹ N. Leca,² C. Blosser,² I. Di Castro,² R. Bhattacharya,³ J. Reyes,¹ L. Sibulesky.¹
Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?

A. Modi,¹ J. Hermann,¹ H. Nazario,² S. Gonzalez,¹ J. Gripshover,³ M. Gautam,¹ J. Weinstein,² D. Potosky,³ M. Barnes,² A. Habib,² P. Mantry,² J. Trotter.¹
Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?

T. Zens, G. Leverson, R. Redfield, P. Chlebeck, L. Zitur, D. Kaufman, L. Fernandez.
Is There a Link Between Proteinuria and Increased FGF-23 Levels in Renal Transplant Patients.

E. Tutal,¹ S. Sezer,¹ Z. Bal,¹ B. Demirci,¹ M. Haberal.²
Ischemia-Reperfusion Injury Following Transplantation: Implications for the Modulation of CXCL8 Chemokine Function.

B. Martinez Burgo,¹ S. Ali,¹ J. Kirby,¹ N. Sheerin,¹ S. Cobb,² D. Kashanin.³
Japanese Multicenter Study of Hepatopulmonary Syndrome in Living Donor Liver Transplantation.

H. Egawa, S. Ogata.
KDPI Outcomes and Discard Rates – The Contradiction of the U.S. and European Approach.

L. Lehner, A. Kleinsteuber, F. Halleck, D. Khadzhynov, M. Duerr, K. Budde, O. Staeck.
Kidney Donor Profile Index and Recipient BMI Are Potent Predictors of Six Month Deceased Donor eGFR as Opposed to EPTS.

A. Agarwal, W. Ally, D. Maluf, S. Pelletier, K. Brayman.
Kidney Graft Homing of De Novo Donor Specific HLA Antibodies Is an Early Step within the Antibody-Mediated Graft Damage Process.

A. Nocera,¹ M. Cioni,² A. Tagliamacco,¹ A. Innocente,³ I. Fontana,⁴ A. Magnasco,² A. Nocco,³ A. Sementa,² G. Garibotto,¹ G. Ghiggeri,² M. Cardillo,³ P. Comoli,⁵ F. Ginevri.²
Kidney Outcomes in Patients with Liver Cirrhosis and Chronic Kidney Disease Receiving an Orthotopic Liver Transplant Alone.

N. Singh,^1,2 S. Ahmadzadeh,¹ B. Amin,² R. Marahatta,² H. Shokouh-Amiri,¹ R. McMillan,¹ G. Zibari.¹
Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer.

N. Koyawala,¹ J. Silber,² P. Rosenbaum,¹ R. Bloom,¹ W. Wang,² A. Hill,² S. Nazarian,¹ D. Sawinski,¹ J. Trofe,¹ M. Lim,¹ J. Schold,³ P. Reese.¹
Kidney Transplant Outcomes in Patients with CPRA Values >98% After Implementation of the New OPTN/UNOS Kidney Allocation System (KAS): A Single Center Study Update.

N. Kaur,¹ S. Goral,¹ J. Kearns,² P. Abt,³ A. Naji,³ P. Porrett,³ M. Levine,³ M. Kamoun.²
Kidney Transplant Recipient Adherence Measured by Proportion of Days Covered Is Associated with Late Biopsy Proven Acute Rejection.

B. Hofmeyer, K. Look, J. Fose, A. Pulvermacher, A. Djamali, D. Hager.
Kidney Transplant with Low Level DSA and Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly Sensitized Transplant Candidates.

C. Schinstock, W. Cheungpasitporn, F. Cosio, D. Mitema, M. Gandhi, M. Prieto, P. Dean, M. Stegall.
Kidney Transplantation Offers a Significant Survival Advantage Compared to Waitlisting, a Single Centre Experience.

G. Spanos,¹ N. Duncan,¹ P. Brookes,¹ S. Singh,¹ D. Goodall,¹ D. Moutzouris,¹ E. Evangelou,² M. Loucaidou.¹
Kidney Transplantation from Thin Basement Membrane Nephropathy Donor.

C. Choi,¹ A. Han,¹ S.-Y. Kim,¹ S. Cho,¹ M.-J. Cho,¹ C. Lee,¹ S. Ahn,¹ S.-K. Min,¹ J. Ha,¹ M. Park,² S. Kim,³ I. Jung,¹ S.-I. Min.¹
Kidney Transplantation with Strong Preformed Donor-Specific Antibodies: Impact of C1q-Binding Ability.

J. Malheiro,¹ S. Tafulo,² S. Santos,¹ M. Costa,¹ L. Martins,¹ L. Dias,¹ A. Henriques.¹
Kidney Transplantation: Do Early Urinary Tract Complications Influence Long-Term Graft Survival?

E. Arpali, D. Kaufman, H. Sollinger.
Kidney Transplants from Anuric Deceased Donors on Renal Replacement Therapy.

W. Bry, J. Bellingham, S. Katznelson, P. Patel, K. Ueda, H. Mahanty, N. Neidlinger, A. Hassoun, V. Peddi.
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.

G. Basso, C. Felipe, A. Ferreira, M. Cristelli, N. Oliveira, T. Sandes-Freitas, J. Mansur, L. Viana, W. Aguiar, E. Campos, M. Gerbasi-DeLima, H. Tedesco-Silva, J. Medina-Pestana.
LACE Index Risk Assessment Tool Predicts Liver Transplant Readmissions.

A. Masoumi,¹ R. Barth,² J. LaMattina,² D. Bruno,² L. Hebert,¹ N. Schluterman,³ S. Hanish.²
Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels.

D. Goodall, M. Willicombe, A. McLean, D. Taube.
Late-Onset Pneumocystis Jirovecii Pneumonia After Renal Transplantation: A Case-Control Study.

J. Lee,¹ J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ B. Kim,² M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
Left Renal Vein Ligation for Management of Portal Hypoperfusion in Liver Transplantation.

K. Putchakayala, W. Kane, K. Takahashi, M. Rizzari, A. Yoshida, M. Abouljoud.
Life-Years Saved After Pediatric Liver Transplantation.

R. Gruessner, A. Gruessner.
Limited Hepatitis B Immune Globulin Following Liver Transplant for Hepatitis B.

T. Sievers, J. Thompson, J. Lake.
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.

K. Ayasoufi, V. Gorbacheva, F. Ran, A. Valujskikh.
Lipid Metabolism and Preservation of Discarded Steatotic Human Livers Using 24 Hours Ex-Vivo Normothermic Machine Perfusion.

Q. Liu, A. Nassar, G. Iuppa, B. Soliman, L. Buccini, M. Blum, T. Okamoto, T. Uso, A. Bennett, W. Baldwin, K. Abu-Elmagd, J. Fung, C. Miller, C. Quintini.
Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy?

R. Mohan, J. Patel, M. Kittleson, D. Chang, T. Aintablian, L. Czer, F. Esmailian, J. Kobashigawa.
Liver Graft Rejuvenation Prior to Transplantation: A Bench-to-Bedside Approach.

A. Zarrinpar,¹ B. Ke,¹ H. Ji,¹ E. Reed,² R. Busuttil,¹ J. Kupiec-Weglinski.¹
Liver Graft Steatosis Associates with an Increase of Circulating Immune Response Chemokines.

R. Gehrau, V. Mas, A. Sharma, V. Bontha, D. Maluf.
Liver Ischemia Induces Kupffer Cell Necroptosis to Facilitate Liver Inflammatory Immune Activation.

S. Yue,¹ H. Zhou,^1,2 R. Busuttil,¹ J. Kupiec-Weglinski,¹ X. Wang,² Y. Zhai.¹
Liver Recipient with Renal Dysfunction: Liver Only or Simultaneous Liver-Kidney Transplant?

K. Yadav, T. Pruett, R. Kandaswamy, W. Payne, L. Zhang, S. Chinnakotla.
Liver Transplantation (LT) Using Liver Allografts from Deceased After Cardiac Death (DCD) Donors: Opinions, Practices and Reality.

L. Sher,¹ P. Abt,² Y. Genyk,¹ M. Lo,¹ P. Yan,¹ L. Ji,¹ C. Marsh.³
Liver Transplantation for Propionic Acidemia: A Review of the United States Scientific Registry for Transplant Recipients (SRTR) and Non-US Case Series.

N. Celik, K. Soltys, G. Bond, Q. Sun, G. Vockley, R. Sindhi, G. Mazariegos.
Liver Transplantation in Patients Actively Drinking Less Than 6 Months Before Transplant Presenting with Acute Decompensation: A Single-Center Experience.

H. Monsour, D. Victor, M. Boktour, J. Galati, J. Ontiveros, L. Theriot, R. McFadden, C. Mobley, A. Saharia, S. Gordon-Burroughs, A. Gaber, R. Ghobrial.
Living Donor Kidney Transplantation: How Do Recipients Benefit Psychologically?

H. Maple,¹ J. Chilcot,² J. Weinman,² N. Mamode.¹
Living Donor Liver Transplantation for Children With Biliary Atresia in the Pediatric End-Stage Liver Disease Era: The Role of Age and Insurance Status.

J. Chu,^1,2 R. Annunziato,³ R. Aviles,³ R. Arnon.^1,2
Living Kidney Donor Preferences: A Novel Use of a Visual Instrument to Quantify ESRD Risk Acceptance.

C. Thiessen,¹ J. Gannon,¹ D. Dobosz,¹ S. Li,¹ D. Gray,² A. Mussell,² K. Kennedy,³ L. Skrip,¹ E. Gordon,³ P. Reese,² S. Kulkarni.¹
Living Kidney Donor Priorities for Outcomes: A Nominal Group Technique Study.

C. Hanson,^1,2 J. Kanellis,^3,4 G. Wong,^1,2 J. Pinter,² S. Chadban,^5,6 J. Chapman,⁷ J. Craig,^1,2 J. Gill,⁸ A. Garg,⁹ J. Lewis,^1,2 A. Tong.^1,2
Local Infusion of MyD88 Inhibitor Inhibits Ischemia-Reperfusion Kidney Injury.

H. Cho,^1,3 J. Lee,^1,4 H. Kim,^1,2 Y. Han,² B. Kwon,^1,2 S. Park,^1,3 K. Park.⁴
London Criteria for Listing Potential Liver Transplant Jehovah's Witness (JW) Patients. A Single Centre Results of Listing and Liver Transplant (LT) in JW Patients in Canada.

H. Sharma, I. Al-Hasan, K. Pineda-Solis, M. Tun, P. Marotta, D. Quan, M. Levstik.
Long Term Heterotopic Cardiac Xenograft Survival from Donor Pigs with Six Gene Modifications.

M. Mohiuddin,¹ A. Singh,¹ J. Chan,¹ P. Corcoran,¹ M. Thomas III,² B. Lewis,² D. Ayares,³ K. Horvath.¹
Long Term Outcomes Following Antibody Mediated Rejection (AMR) in Renal Transplant Recipients.

R. Crew, S. Patel, H. Morris, M. Chiles, L. Ratner.
Long Term Safety of Intravenous Ketorolac Use After Donor Nephrectomy.

P. Tabrizian,¹ M. Giacca,¹ J. Prigoff,² E. Chin,² M. Palese,² D. Herron,² A. Arvelakis,¹ D. LaPointe Rudow,¹ S. Florman,¹ R. Shapiro.¹
Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 7 Years Follow-Up.

Y. Watarai, M. Okada, K. Futamura, T. Nagai, T. Yamamoto, M. Tsujita, T. Hiramitsu, N. Goto, S. Narumi, T. Kobayashi.
Long-Term Islet Xenograft Survival Requires Effective Control of Early Xenogeneic IL-17 Response and Late Xenogeneic IFN-γ Response.

H. Kang,¹ S. Wang,² X. Zhang,³ A. Singh,⁵ L. Zhang,¹ W. Suarez-Pinzon,⁵ S. Miller,⁴ B. Hering,⁵ X. Luo.^1,3,4
Long-Term Liver Function of Deceased Liver Transplantation Using Hepatitis B Surface Antigen Positive Grafts.

W.-C. Lee,¹ Y.-C. Wang,¹ C.-H. Cheng,¹ T.-H. Wu,¹ C.-F. Lee,¹ R.-S. Soong,¹ T.-J. Wu,¹ H.-S. Chou,¹ K.-M. Chan,¹ C.-S. Lee.²
Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,¹ J. Medina Pestana,² M. del C Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ A. Matas,⁶ T. Wekerle,⁷ J. Grinyó,⁸ U. Meier-Kriesche,⁹ M. Polinsky,⁹ H. Zhao,⁹ A. Durrbach.¹⁰
Long-Term Outcomes in Pediatric Live-Donor Liver Transplantation.

N. Celik,¹ A. Ganoza,² F. Vyas,¹ J. Squires,³ V. Venkat,³ G. Bond,¹ K. Soltys,¹ R. Sindhi,¹ R. Squires,³ A. Humar,² G. Mazariegos.¹
Long-Term Renal Allograft Outcome After Parathyroidectomy.

M. Patecki, I. Scheffner, H. Haller, W. Gwinner.
Long-Term vs Short-Term Valganciclovir Prophylaxis Use for Cytomegalovirus and Epstein-Barr Virus Infections in Pediatric Living Related Liver Transplantation.

T. Ueno,¹ H. Yamanaka,¹ Y. Takama,¹ N. Tanaka,¹ Y. Tazuke,¹ K. Bessho,² H. Okuyama.¹
Low Pretransplant BMI/Weight and Changes in Posttransplant T Cell Exhaustion Levels Are Associated with Viremia/Viral Infection in Pediatric Kidney Transplantation in the First Post-Transplant Year – A Report from the IMPACT Study Consortium.

R. Ettenger,¹ H. Chin,² P. Grimm,³ K. Kesler,² E. Reed,⁴ M. Sarwal,⁵ B. Warshaw,⁶ E. Tsai,¹ A. Kirk.⁷
Low-Pressure Pneumoperitoneum in Living Kidney Donors: An Age-Dependent Analysis of Recipient Outcomes.

S. Kulkarni,¹ S. Douglas,² E. Cohen,¹ S. Swift,¹ I. Hall.²
Lysosome Ativity Regulates LG3 Export by Apoptotic Cells.

D. Beillevaire,^1,2,4 J. Turgeon,^1,2,4 E. Boilard,^3,4 M. Dieudé,^1,2,4 M.-J. Hébert.^1,2,4
MELD as a Metric for Survival Benefit of Liver Transplantation.

X. Luo, A. Massie, S. Bae, M. Bowring, D. Segev.
MHC/HLA-Specific IgE in Allotransplantation.

A. Farkas,¹ U. Baranyi,¹ L. Unger,¹ B. Mahr,¹ K. Hock,¹ N. Pilat,¹ H. Regele,² M. Wahrmann,³ G. Böhmig,³ R. Valenta,⁴ T. Wekerle.¹
Management and Outcomes of Upper Extremity Deep Venous Thrombosis in Heart Transplant Patients.

A. Panakos,¹ D. Kramer,¹ M. McCarey,¹ P. Mather.²
Management of Recurrent aHUS After Adult Kidney transplantation Despite Eculizumab Prophylaxis.

M. Morton,¹ R. Chinnadurai,¹ S. Ahmed,² A. Sharma,² T. Dutt,² S. Bhutani,¹ H. Denley,¹ T. Augustine,¹ T. Goodship,³ N. Sheerin,³ M. Picton.¹
Managing the Kidney Waiting List: Pride and Prejudice.

F. Smith,¹ C. Sheehan,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² R. Stratta.¹
Marked Alterations in Gene Expression in Peripheral Blood Leukocytes of Kidney Transplant (tx) Recipients Following Mycophenolic Acid (MPA) Treatment.

K. Sanghavi,¹ B. Wu,¹ C. Dorr,² A. Muthuswamy,² W. Guan,¹ D. Schladt,² R. Remmel,¹ D. Ilke,³ A. Matas,¹ A. Israni,² W. Oetting,¹ P. Jacobson.¹
Markers of Activation of Microvascular Endothelial Cells Predict a Poor Long-Term Graft Outcome in Early Renal Graft Biopsies Displaying Acute Tubular Necrosis.

Y.-C. Dubois-Xu,¹ P. Ahmadpoor,¹ A. Corchia,¹ D. Buob,² P. Galichon,¹ I. Brochériou,¹ C. Suberbielle,³ A. Hertig,¹ E. Rondeau.¹
Mass Cytometry Reveals NK Cell and T Cell Subsets in Pediatric Liver Transplant Patients with Acute Rejection.

A. Lau,^1,2 K. Haas,¹ T. Shawler,² C. Esquivel,² O. Martinez,² R. Castillo,¹ S. Krams.²
Matrix Metalloproteinase-2 (MMP-2) Activity Protects Against Hepatic Ischemia Reperfusion Injury Through MMP-9-Dependent and MMP-9-Independent Mechanisms.

S. Duarte, P. Matian, H. Kato, R. Busuttil, A. Coito.
Measured Glomerular Filtration Rate of the Remaining Kidney Divided by Its Volume Prior to Donation Is a Predictor of the Long-Term Gain of Function in Living Kidney Donors.

M. Courbebaisse,¹ F. Gaillard,² A. Le Nestour,⁴ J.-M. Correas,³ H. Slimani-Thevenet,⁵ C. Leon,² D. Eladari,¹ M.-O. Timsit,⁶ P. Otal,⁷ G. Friedlander,¹ P. Houillier,¹ N. Kamar,⁸ C. Legendre.²
Mechanisms of Cellular Repopulation within Healthy or Intrinsically Scarred Kidney Extracellular Matrix Scaffolds.

J. Uzarski,¹ C. Deaton,⁵ H. Ward,² A. Wandinger-Ness,³ W. Miller,⁴ J. Wertheim.¹
Medicaid Insurance Is Associated with Shorter Time to Transplant Listing After LVAD Implantation.

W. Schultz, M. Yin, Y.-A. Ko, J. Vega, A. Morris.
Membranoproliferative Glomerulonephritis Pattern without Immunoglobulin and Complement Deposition in Renal Allograft Was Related to the Injury of Antibody-Mediated Rejection.

J. Wen, F. Xu, J. Chen, X. Li, M. Zhang, Z. Zhang, Z. Liu.
Memory Regulatory T Cell: A Potential Actor in Immunological Operational Tolerance in Kidney-Transplant Patients via the ATP Degradation into Adenosine.

M. Durand,^1,2 F. Braza,¹ N. Degauque,¹ F. Dubois,² M. Chesneau,¹ P. Guérif,^1,3 M. Giral,^1,3 S. Brouard.¹
Mesenchymal Stem Cells Reprogram Macrophage Polarization and Attenuate Liver Ischemia and Reperfusion Injury by Regulating Notch/Cox2/PGE2 Signaling Pathway.

C. Li,¹ S. Yue,¹ R. Busuttil,¹ J. Kupiec-Weglinski,¹ B. Ke.¹
Metabolic Dysregulation and Mitochondrial Dysfunction Are Key Features of Injury Profiles of Donor Kidneys After Brain Death.

M. Lo Faro,¹ M. Akhtar,¹ H. Huang,¹ M. Kaisar,¹ R. Robolledo,² K. Morten,¹ L. Heather,¹ A. Dona,³ H. Leuvenink,² S. Fuggle,¹ B. Kessler,¹ C. Pugh,¹ R. Ploeg.¹
Metabolic Recovery and Ex Vivo Simulation of Early Liver Reperfusion.

B. Bruinsma,¹ J. Avruch,² G. Sridharan,¹ P. Weeder,¹ N. Karimian,¹ J. Markmann,² K. Uygun,¹ H. Yeh.²
MiRNA-200b Inhibits Epithelial-Mesenchymal Transition in TGF-β1 Induced Human Bronchial Epithelial Cells.

S. Ladak, C. Ward, S. Ali.
MicroRNA let-7i Regulates Dendritic Cells Maturation Targeting Interleukin-10 via JAK1-STAT3 Signal Pathway Subsequently Induces Prolonged Cardiac Allograft Survival in Rats.

X. Jin,¹ Y. Sun,² X. Liu,² J. Wang,¹ S. Xu,¹ L. Yao,¹ Z. Zhao,³ L. Jiang,⁴ Q. Wu,⁵ J. Wu.²
Missed Opportunities After Cardiac Death: Should Every Donation After Cardiac Death (DCD) Referral Be Pursued? A Large Single US Organ Procurement Organization (OPO) Experience.

S. Rudich, R. Messer, R. Pietroski, P. Lange.
Mitochondrial Membrane Potential Correlates with Ischemic Injury and Kidney Graft Function in Rats.

M. Chen, J. Huang, L. Qi, S. Kwon, R. Montgomery, Z. Sun.
Monocyte Recruitment to HLA Class I Antibody-Activated Endothelial Cells Is Dependent Upon mTOR.

S. Salehi, E. Reed.
Morbidity and Mortality of Early Post-Operative Acute Kidney Injury in Cardiothoracic Transplant Recipients.

J. Casale, A. Logan, C. Doligalski.
Multifactorial Prediction of Biliary Stricture After Liver Transplantation: The Impact of Platelet Counts.

K. Takahashi, K. Putchakayala, M. Rizzari, K. Collins, S. Nagai, A. Yoshida, M. Abouljoud, G. Schnickel.
Multiorgan Procurement a Learning Tool in General Surgical Resident Education.

J. Bayer, R. Goldstein, G. McKenna, G. Testa, R. Ruiz, T. Anthony, N. Onaca, G. Klintmalm, P. Kim.
Multiplex Profiling of Plasma Proteins After Xenogenic Lung Exposure.

A. Azimzadeh,¹ N. Cheng,¹ X. Cheng,¹ E. Schwartz,¹ L. Burdorf,¹ S. Dahi,¹ N. Kubicki,¹ D. Parsell,¹ T. Zhang,¹ D. Cooper,² C. Phelps,³ D. Ayares,³ R. Pierson III.¹
Muscle Density Is Associated with Mortality Among Kidney Waitlist Candidates.

R. Reed,¹ S. Nair,² G. Smith,¹ C. Lewis,¹ J. Terry,² J. Carr,² J. Locke.¹
Mycophenolate Mofetil Dose Reduction Are Associated with the Risk of Acute Rejection and Graft Failure After Renal Transplantation.

A. El-Agroudy,¹ A. Taher,² A. Alaradi,² B. Alhayki,² S. Gareeb,² E. Farid.²
Mycophenolate Mofetil Single Dose Pharmacokinetics Following Laparoscopic Sleeve Gastrectomy.

A. Leino,¹ A. Lichvar,¹ T. Kaiser,¹ U. Christians,³ T. Mizuno,² T. Fukuda,² R. Alloway,¹ A. Vinks,² E. Woodle,¹ T. Diwan.¹
NFκB Inhibitor Withaferin A Blocks IBMIR In Vitro: miRNA 375 Analysis.

M. Kanak,¹ M. Takita,² G. Yoshimatsu,² M. Lawrence,² M. Levy,¹ B. Naziruddin.³
NKG2A-Expressing Natural Killer Cells Dominate the Response to Latent Epstein-Barr Virus Infection.

O. Hatton,¹ D. Strauss-Albee,² S. Krams,¹ C. Blish,² O. Martinez.¹
National Trends in Liver Discards: The Weekend Effect.

D. Carpenter,¹ S. Mohan,² K. Halazun,³ E. Verna,⁵ M. Chiles,² G. Charak,¹ L. Ratner.⁴
National Trends of Acute Myocardial Infarction and Percutaneous Interventions in Liver Transplant Hospitalizations from 2006-2012.

G. Nadkarni, M. Menon, R. Kent, S. Patel, A. Patel, T. Schiano, S. Florman, P. Heeger.
Natural Killer Cells Display Functional and Receptor Diversity in Response to Alloantigen.

O. Hatton,¹ T. Shawler,¹ C. Blish,² O. Martinez,¹ S. Krams.¹
NecroX-7 Attenuates Ischemia-Reperfusion Renal Injury.

K. Lee,¹ Y. Ham,¹ J. Jeon,¹ Y. Chang,² S. Chung,¹ K. Na,¹ D. Choi.¹
Necroptosis Is Involved in CD4⁺ T-Cell Mediated Microvascular Endothelial Cell Death and Chronic Cardiac Allograft Rejection.

C. Kwok,^1,2 N. Montwill,^1,2 A. Pavlosky,^1,2 A. Haig,² X.-Y. Huang,¹ A. Jevnikar,^1,3 Z.-X. Zhang.^1,2,3
Neighborhood Poverty and Gender Disparities in Access to Live Donor Kidney Transplantation.

T. Purnell, X. Luo, S. Bae, L. Kucirka, D. Segev.
Neighborhood Socioeconomic Characteristics Influence Access to Kidney Transplantation Independently of Individual Socioeconomic Status.

J. Adler, J. Markmann, D. Chang, H. Yeh.
Neonatal Tolerance to Blood Group A-Antigen in a Mouse Model of ABO-Incompatible Heart Transplantation (ABOi HTx).

B. Motyka,¹ B. Lamarche,¹ K. Labonte,¹ S. Wang,¹ J. Pearcey,¹ K. Tao,¹ M. Mengel,¹ B. Sis,¹ P. Cowan,² L. West.¹
Neuro-invasive Saint Louis Encephalitis Virus (SLEV) Infection in Solid Organ Transplant Recipients in a Non-Endemic Area.

C. Hartmann, I. Qaqish, T. Grys, H. Vikram, M. Seville, R. Orenstein, S. Kusne, J. Blair, R. Patron.
Neuromuscular Stimulation Leads to Improved Lower Limb Edema and Blood Flow Compared to Standard Compression Devices Following Kidney and Pancreatic Transplantation.

B. Alharbi, O. Ali, M. Saha, M. May, P. Luke, A. Sener.
Neutrophil-to-Lymphocyte Ratio as a Predictor of Polyomavirus BK Nephropathy in Kidney Transplant Patients.

K. Masutani,¹ A. Tsuchimoto,¹ Y. Matsukuma,¹ K. Kaku,² K. Kurihara,² Y. Okabe,² K. Tsuruya,¹ M. Nakamura,² T. Kitazono.¹
Never Events and Hospital Acquired Conditions After Kidney Transplant.

Z. Moghadamyeghaneh, M. Alameddine, G. Burke, G. Ciancio, L. Chen.
New England BK Consortium: Regional Survey of BK Screening and Management Protocols in Comparison to Published Consensus Guidelines.

S. Gabardi, M. Pavlakis, C. Tan, J. Francis, F. Cardarelli, W. Asch, K. Bodziak, M. Chobanian, H. Gilligan, R. Gohh, S. Kung, L. Inker, S. Martin, N. Rodig, A. Rossi, A. Chandraker.
New Kidney Allocation System: Friend or Foe?

F. Cabeza,² A. Dejman,¹ A. Torres,³ J. Gaynor,² P. Ruiz,² D. Roth,² W. Kupin,² G. Burke,² G. Ciancio,² L. Chen,² R. Vianna,² A. Mattiazzi,² G. Guerra.²
Non-adherence to Appointments Is a Strong Predictor of Medication Non-Adherence and Outcomes in Kidney Transplant Recipients.

M. Posadas Salas, R. Pullalarevu, M. Kamel, A. Chokkalingam, R. Browning, B. Kadri, M. Salazar, T. Srinivas, D. Taber.
Nontuberculous Mycobacterial Infection Among Allogeneic Hematopoietic Stem Cell Transplant Recipients: A 16-Year Cohort Study.

A. Alghamdi, J. Lipton, C. Rotstein, D. Kumar, A. Humar, T. Mazzulli, S. Husain.
Normothermic Perfusion of Livers Donated After Circulatory Death: A New Clinically Relevant Experimental Model.

Y. Cao,¹ H. Chew,^1,2 K. Fernandez,¹ L. Gao,¹ J. Villanueva,¹ M. Hicks,¹ P. Macdonald,^1,2 K. Dhital,^1,2 H. Pleass.³
Novel Approaches to Medication Teaching in Solid Organ Transplantation.

D. Tsapepas, N. Jandovitz, S. Dulanya, D. Salerno, S. Hammad, P. Jordan.
Novel Effect of miR-26a:Mdm2:p53 Pathway on Mouse Liver Regeneration.

J. Zhou, W. Ju, X. Yuan, X. Jiao, D. Wang, X. Zhu, X. He.
Novel Nuclear Factor-κB Activation Inhibitor, Dehydroxymethylepoxyquinomicin, Prevents the Development of Chronic Cyclosporine Nephropathy in Rats.

S. Morita,¹ K. Shinoda,¹ S. Tamaki,¹ H. Kono,² Y. Kanno,³ K. Umezawa,⁴ K. Nakagawa,² M. Oya.¹
Nuclear Factor of Activated T-Cells Post-Renal Transplant.

K. Tornatore,^1,4 K. Attwood,² O. McGuire,³ K. O'Loughlin,³ R. Venuto,⁴ H. Minderman.³
Older Patients Reliably Participate in Automated Living Donor Follow Up Rather Than Avoiding This New Technology.

H. Braun, M. Parente, R. Hirose, G. Roll.
One-Year Graft Loss Risk in Kidney Transplants – A Big Data Approach.

T. Srinivas, D. Taber, J. Zhang, Z. Su, J. Marsden, A. Tripathi, W. Moran, P. Mauldin.
Only 13% of Liver Transplant (LT) Recipients with Moderate to Severe Kidney Disease (KD) Tolerate Conversion to Everolimus and Reduced Tacrolimus (EVR/rTac).

S.-H. Pan, I. Kim, A. Klein, A. Annamalai, T. Todo, N. Nissen.
Optimal Integration of Kidney Exchange Programs with Antibody Reduction Therapy to Increase Successful Transplant in Difficult to Match Recipients.

K. Melancon,¹ N. Koizumi,² M. Gentili,³ C. Callender.⁴
Optimal Measures for Timely Transplantation: Reviewing Correlation Between Early Transplantation Wait-Listing and Transplantation Outcomes.

M. Brown, K. Polkinghorne, J. Kanellis.
Optimized Flow Cytometry Crossmatch with Increased Sensitivity and Specificity.

K. Barrios,¹ J. Lunz,¹ B. Labuda,¹ D. Magas,¹ D. Freedom,¹ K. Szewczyk,¹ M. Jendrisak,¹ A. Jaramillo.^1,2
Optimizing CPRAs for Sensitized Kidney Waitlist Candidates: The Devil Is in the KAS Details.

J. Houp,¹ R. Vega,¹ B. Lonze,² N. Desai,² R. Montgomery,² A. Jackson.¹
Optimizing the Immunogenicity and Immunomodulatory Properties of MSC for Cellular Therapy.

S. de Witte,¹ M. Franquesa,¹ T. Strini,¹ S. Korevaar,¹ F. Luk,¹ S. Elliman,² P. Newsome,³ M. Gargesha,⁴ D. Roy,⁴ A. Merino,¹ C. Baan,¹ M. Hoogduijn.¹
Original KDRI Predicts Kidney Graft Failure in a Brazilian Cohort.

J. Reusing Jr.,¹ C. Nihei,¹ A. Lino de Souza,² E. David-Neto,¹ C. Ventura.³
Outcome After Kidney Transplant (KTx) in Patients with Chronic Hypotension on Haemodialysis (HD).

O. Manolitsi, N. Kessaris, J. Olsburgh, I. Loukopoulos.
Outcome of Partial Reconstruction of Multiple Hepatic Arteries in Pediatric Living Donor Liver Transplantation Using Left Lateral Section Grafts.

K. Lee, K. Kim, S. Kim, J. Lee, J. Lee, N. Lee, C. Cho, S. Lee, G. Choi, C. Kwon, J.-W. Joh, S.-K. Lee.
Outcome of the Various Pathology Grades of Antibody-Mediated Rejection After Heart Transplantation.

J. Patel, M. Kittleson, D. Chang, T. Aintablian, L. Czer, A. Trento, J. Kobashigawa.
Outcomes Following Appendectomy in Kidney Transplant Recipients.

S. DiBrito, I. Olorundare, C. Landazabal, D. Segev, N. Dagher.
Outcomes Following Appendectomy in Liver Transplant Recipients.

N. Dagher, S. DiBrito, I. Olorundare, C. Landazabal, D. Segev.
Outcomes Following Inguinal Hernia Repair in Liver Transplant Recipients.

N. Dagher, S. DiBrito, I. Olorundare, C. Landazabal, D. Segev.
Outcomes Following Inguinal Hernia Repair in Patients with End Stage Liver Disease.

N. Dagher, S. DiBrito, I. Olorundare, C. Landazabal, D. Segev.
Outcomes for Liver Transplantation Using Organs from Donation After Cardiac Death Donors: A Single Center Experience.

J. Vanatta, X. Zhao, V. Puri, R. Helmick, S. Nair, S. Satapathy, J. Eason.
Outcomes from De Novo Tacrolimus Weight-Based Dosing Compared to Conservative Dosing in Kidney Transplant Recipients.

B. Summers,² K. Szempruch,¹ M. Harris,² A. Quidley,¹ C. Haisch,¹ A. Maldonado.¹
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.

S. Florman,¹ A. Durrbach,² V. Duro Garcia,³ K. Calderon,⁴ U. Meier-Kriesche,⁴ M. Polinsky,⁴ H. Zhao,⁴ J. Medina Pestana.⁵
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT.

F. Vincenti,¹ J. Medina Pestana,² M. Abouljoud,³ B. Bresnahan,⁴ V. Duro Garcia,⁵ L. Mulloy,⁶ K. Rice,⁷ L. Rostaing,⁸ C. Zayas,⁹ K. Calderon,¹⁰ U. Meier-Kriesche,¹⁰ M. Polinsky,¹⁰ H. Zhao,¹⁰ C. Larsen.¹¹
Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.

N. Jasiak,¹ J. Thielke,¹ J. Chen,² N. Hilal,¹ S. Salah,¹ D. Wu,¹ E. Benedetti,² P. West-Thielke.^1,2
Outcomes in Lung Transplant Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) in the Perioperative Period.

A. Habertheuer, M. Williams, S. Miller, E. Cantu, C. Bermudez, P. Vallabhajosyula.
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.

N. Jasiak,¹ C. Stromayer,¹ J. Thielke,¹ J. Chen,² J. Chen,¹ B. Talon,¹ R. Rubin-Tobar,¹ E. Benedetti,² P. West-Thielke.^1,2
Outcomes of Anticoagulation Use for Portal Vein Thrombosis in University of Wisconsin Liver Transplant Patients.

M. Falls,¹ A. Said,² L. Fernandez,² D. Foley,² K. Frith,¹ D. Hager,² H. Hoy,¹ G. Leverson,² J. Mezrich,² T. Prickette,² M. Wakefield,² A. D'Alessandro.²
Outcomes of Aorto-Hepatic Conduit During Liver Transplantation – A 31-Year, Single Center Experience.

A. Gupta, T. Anthony, R. Goldstein, G. McKenna, N. Onaca, R. Ruiz, G. Testa, G. Klintmalm, P. Kim.
Outcomes of Arterial and Venous Conduits for Vessel Reconstruction in Liver Transplantation.

J. Tan,¹ G. Oniscu.²
Outcomes of Deceased Donor Kidney Transplantation from Diabetic Donors: Does Presence of Recipient Diabetes Matter?

J. Rogers,¹ A. Farney,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² H. El-Hennawy,¹ M. Khan,¹ M. Gautreaux,¹ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Outcomes of EVAR in Kidney Transplant Recipients: Results form a National Quality Initiative.

I. Bostock,¹ D. Zarkowsky,¹ D. Stone,¹ M. Eslami,² M. Malas,³ P. Goodney.¹
Outcomes of Hispanic Kidney Transplant Recipients Under a Cyclosporine versus Tacrolimus Based Immunosuppression Protocol.

P. West-Thielke, A. Lasky, J. Thielke, M. Campara, E. Benedetti.
Outcomes of Liver Grafts from Donors with Very High Transaminases.

P. Martins, A. Rawson, P. Mahboub, B. Movahedi, N. Dolgin, I. Bruggenwirth, A. Bozorgzadeh.
Outcomes of Living and Deceased Donor Liver Transplant Recipients According to the MELD Score.

J. Lee, J. Lee, S. Song, J. Lee, S.-K. Kwon, D. Joo, M. Ju, G. Choi, J. Choi, S. Kim, M. Kim.
Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1 , Hepatitis C Infection Post Liver Transplant.

D. Jones,¹ S. Baggett,¹ M. Shoreibah,² O. Massoud.²
Outcomes of Second Kidney Transplantation Compared Primary Transplantation According to Donor Specific Antibody.

J. Lee,^1,2 K. Lee,¹ J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ D. Joo,^1,2 K. Huh,^1,2 M. Kim,^1,2 S. Kim,^1,2 Y. Kim.^1,2
Outcomes of Sequential and En Bloc Transplants in the Elderly: 10 Year Review of UNOS Data.

V. Whittaker,¹ R. Gruessner,¹ A. Vikram,² A. Gruessner.
Outcomes of Solid Organ Transplantation from an HIV Positive Donor to Negative Recipients.

S.-N. Lin,¹ M.-K. Tsai,¹ C.-Y. Luo,² C.-Y. Lee,¹ R.-H. Hu,¹ J.-M. Lee,¹ H.-S. Lai.¹
Outcomes of Transplant Recipients Treated with Cidofovir for Resistant or Refractory Cytomegalovirus Infection.

S. Mehta, M. Alfares, A. Valsamakis, S. Shoham, R. Boger, L. Lees, D. Ostrander, R. Avery.
Outcomes of Untreated Asymptomatic Bacteriuria in Renal Transplant Recipients: A Single-Center Experience.

W. Davis, R.-A. Lee, L. Daniels, S. Todd, K. True, P. Chong.
Outcomes with the Use of Pediatric Donor Livers in Adult Recipients: Review of the UNOS Database.

K. Croome, D. Lee, J. Burns, J. Nguyen, D. Perry, C. Taner.
Parainfluenza-3 Infections Early After Kidney Transplantation.

I. Helanterä,¹ V.-J. Anttila,² M. Lempinen.¹
Parameters of Uremia-Associated Premature Ageing of Peripheral T Cells Do Not Predict Infectious Complications After Renal Transplantation.

B. Dedeoglu, R. Meijers, M. Klepper, D. Hesselink, C. Baan, N. Litjens, M. Betjes.
Patients Treated with Belatacept Show Low Levels of APRIL and HLA Antibodies.

M. Rial,¹ N. Ambrosi,² F. Caro,² D. Curcio,¹ J. Salaberry,² O. Guardia,¹ A. Dotta,¹ D. Guerrieri,² K. Padros,³ E. Chuluyan,² D. Casadei.
Patients with ESRD Due to Diabetes Have Higher Variability of Their Tacrolimus Levels and Worse Outcomes.

D. Goodall, M. Willicombe, A. McLean, D. Taube.
Pediatric Critical Care Education Impacts Pediatric Organ Donation.

D. Lebovitz,¹ T. Nakagawa,² C. Wright.³
Pediatric En Bloc Kidney Transplants Reduce DGF and Are Misrepresented by the KDPI.

M. Khan,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
Pediatric Kidney Transplantation and Mortality: Distance to Transplant Center Matters.

J. Adler, Y. Bababekov, J. Markmann, D. Chang, H. Yeh.
Pediatric Liver Transplant Exception Request Narratives – How Do We Justify Requests?

H. Braun,³ S. Rhee,¹ J. Dodge,² J. Roberts,² E. Perito.¹
Pediatric Patients Benifit from Steroids Free Regimen After Kidney Transplantation: A Meta-Analysis.

R. Deng, H. Zhang, Y. Zheng, L. Liu, C. Wang.
Pediatric Split Liver Transplantation: Single Center Experience.

A. Elsabbagh,^1,2 C. Williams,¹ R. Girlanda,¹ C. Desai,¹ J. Hawksworth,¹ A. Kroemer,¹ C. Matsumoto,¹ T. Fishbein.¹
Peri-Operative Events and Complications in Minimally-Invasive Live Donor Nephrectomy: What Should We Tell Potential Donors?

K. Kortram, J. Ijzermans, F. Dor.
Persufflation Improves Viability and Function of Porcine Kidneys Relative to Static Cold Storage.

C. Min,¹ L. Steyn,² A. Pandey,³ R. Harland,² J.-P. Galons,⁴ K. Papas.²
Pharmacokinetic Evaluation of Astagraf XL® and Prograf® in Renal Transplant Candidates Following Laparoscopic Sleeve Gastrectomy.

A. Lichvar,¹ A. Leino,¹ T. Kaiser,¹ T. Mizuno,² T. Fukuda,² U. Christians,¹ R. Alloway,¹ A. Vinks,² E. Woodle,¹ T. Diwan.¹
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.

K. Unagami,¹ M. Okumi,² M. Furusawa,² T. Hirai,² T. Shimizu,² K. Omoto,² M. Inui,² H. Ishida,² K. Nitta,¹ K. Tanabe.²
Physical Disability on the Liver Transplant Waitlist: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study.

M. Samoylova, M. Haftek, S. Shiboski, K. Covinsky, J. Roberts, J. Lai.
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.

L. Mugge, A. Zimmerman, N. Varshney, A. Gohara, M. Rees, J. Ortiz.
Pneumocystis Pneumonia Following Solid Organ Transplantation, Systematic Review and Meta-Analysis.

S. Hosseini-Moghaddam,^1,2 R. Krishnan.²
Polyfunctionality of CD8 T Cell Responses to Cytomegalovirus in Transplant Patients.

L. Higdon,¹ K. Margulies,² J. Maltzman.^1,3
Porcine Islets Engineered with SA-FasL Protein Induces Robust Tolerance in Mice through CD4⁺CD25⁺FoxP3⁺ Treg Cells.

K. Woodward,¹ H. Zhao,¹ H. Shirwan,¹ F. Wang,¹ M. Graham,² B. Hering,² E. Yolcu.¹
Portal Venous Flow Volume Measurements May Aid Intraoperative Management of Large Portosystemic Shunts During Pediatric Liver Transplantation.

T. Pshak,¹ J. Roach,² F. Karrer,² M. Wachs.²
Positive Impact of a Pilot Pharmacist-Run Diabetes Pharmacotherapy Clinic in Solid Organ Transplant Recipients.

D. Newland, A. Edwards, R. Hall, P. Maxwell.
Post-Donation eGFR and Hypertension in Living Kidney Donors.

A. Massie,¹ A. Muzaale,¹ S. Anjum,¹ J. Leanza,¹ J. Alejo,¹ J. Locke,² D. Segev.¹
Post-Transplant Vaccine Initiative Collaboration (VIC) in a Multidisciplinary, Transplant Ambulatory Setting.

G. Malat,⁴ S. DiLollo,¹ D. Lee,² A. Sharma,³ T. Bias,² M. Harhay,³ K. Ranganna,³ A. Doyle.³
Post-Transplantation Hypomagnesemia as a Predictor of Survival Among the Kidney Transplant Population.

T. Hod, B. Patibandla, A. Chandraker.
Post-Trial Experience with Belatacept: A Large Single Center Experience.

A. Adams, C. Garrett, J. Goldstein, R. Zhang, A. Guasch, S. Pastan, R. Patzer, A. Kirk, T. Pearson, C. Larsen.
Posterior Reversible Encephalopathy Syndrome After Pediatric Heart Transplantation: Increased Risk for Children with Preexisting Glenn/Fontan Physiology.

M. Kemna,¹ B. Eilers,² E. Albers,¹ Y. Law.¹
Postoperative Rebound of Anti-Blood Type Antibodies and Antibody-Mediated Rejection After ABO-Incompatible Living Related Kidney Transplantation – Is Prophylactic Treatment Necessary?

H. Ishida, T. Kondo, T. Shimizu, T. Nozaki, K. Tanabe.
Posttransplant AT1Rabs Precede De Novo HLA-DSA Development.

J. Arreola-Guerra,³ E. Cuevas,¹ E. Hernandez-Mendez,¹ M. Vilatoba,¹ A. Contreras,¹ J. Ramirez,¹ D. de Rongs,¹ J. Granados,¹ L. Morales-Buenrostro,² J. Alberu.¹
Potential Biomarkers and Treatment for BK Virus Associated Nephropathy.

M. Borkar,¹ V. Srivastava,² R. Cunnington,¹ T. Sharma,¹ L. Tibbles.¹
Pre-Emptive Kidney Transplantation with Living- Donor and Concomitant Unilateral Nephrectomy in Patients with Autosomal-Dominant Polycystic Kidney Disease: A Safe Strategy?

C. Michel,¹ F. Audenet,¹ M. Ariane,¹ C. Legendre,² D. Joly,² A. Méjean,¹ M.-O. Timsit.¹
Pre-Existing Chronic Heart Failure in Kidney Transplantation: An Underestimated Risk Factor for Graft Loss?

F. Halleck, D. Khadzhynov, L. Lehner, E. Schrezenmeier, M. Duerr, A. Kleinsteuber, K. Budde, O. Staeck.
Pre-Existing Diabetes Mellitus Type 2 and Insufficiently Controlled Post-Transplant HbA1c in Kidney Transplantation.

F. Halleck, D. Khadzhynov, L. Lehner, E. Schrezenmeier, M. Duerr, A. Kleinsteuber, K. Budde, O. Staeck.
Pre-Mortem Cannulation and NECMO Preservation for DCD Liver Transplantation.

P. Ruiz,¹ M. Gastaca,¹ A. Valdivieso,¹ A. Ventoso,¹ I. Palomares,¹ M. Prieto,¹ J. Bustamante,² P. Salvador,² J. Ortiz de Urbina.¹
Pre-Transplant Anti-A Titers in Waitlisted A2 to B Kidney Transplant Candidates.

D. Moore, I. Feurer, R. Forbes, A. DeMers, D. Shaffer.
Pre-Transplant Cardiovascular Risk Factors Affect Kidney Allograft Survival: A Multi-Center Study in Korea.

J. An,^1,2 S. Ahn,³ E. Bae,² E. Kang,² H.-L. Kim,⁴ Y.-J. Kim,⁵ Y. Oh,^1,2 C. Lim,^1,2 Y. Kim,² Y. Kim,⁶ J. Lee.^1,2
Pre-Transplant Coronary Artery Disease: An Underestimated Risk Factor for Post-Transplant Mortality?

D. Khadzhynov, F. Halleck, L. Lehner, M. Duerr, A. Kleinsteuber, K. Budde, O. Staeck.
Pre-Transplant Prostate Cancer in Lung Transplant Recipients and Impact on Post-Transplant Morbidity and Mortality.

S. Ajani, M. Valapour, M. Budev.
Pre-Transplant Risk Factors: Predicting Nonadherence and Rejection in Adult Liver Transplant Recipients.

S. Lieber,¹ J. Helcer,¹ E. Leven,¹ C. Knight,² C. Wlodarkiewicz,² A. Shenoy,¹ E. Shemesh,¹ S. Florman,³ T. Schiano,³ R. Annunziato.¹
Predicting Delayed Kidney Graft Function with Gene Expression in Preimplantation Biopsies.

T. Mourão,^1,3 K. Mine,¹ E. Campos,^1,3 J. Medina-Pestana,^2,3 H. Tedesco-Silva,² M. Gerbase-De Lima.
Predicting Early Cardiac Death After Kidney Transplantation.

K. Balabhadrapatruni, A. Liu, N. Sarabu, E. Sanchez, J. Augustine.
Predicting Emergence of Anti-HLA Class I and II Antibodies by Time Dependent Phenomapping in Heart Transplant Patients.

M. Bakir, N. Jackson, E. Chang, D. Henriquez-Ticas, C.-H. Tseng, T. Khuu, J. Zhang, E. Reed, M. Deng, M. Cadeiras.
Predicting Survival to Listing for Liver Transplantation: Do MELD and Race Interact?

M. Jesse, E. Goldstein, N. Rebhan, C.-X. Ho, T. Macaulay, M. Bebanic, L. Shkokani, D. Moonka, M. Abouljoud, A. Yoshida.
Predicting and Reducing 30-Day Readmission After Liver Transplant (OLT).

K. Eid, M. Elshamy, L. Louwers, B. Eghtesad, C. Quintini, K. Snyder, F. Aucejo, K. Hashimoto, M. Fujiki, C. Miller, D. Kelly.
Predicting the Ability of Anti-HLA Antibodies to Activate Complement.

D. Bekbolsynov, C. Baum, B. Mierzejewska, A. Malebari, M. Rees, S. Stepkowski.
Prediction of Patient Survival After Kidney Transplantation: Construction, Validation and Evaluation of Decision Models Using Data Mining Approaches.

I. Scheffner,¹ K. Hua,² D. Simovici,² T. Abeling,¹ H. Haller,¹ W. Gwinner.¹
Predictive Factors of Early Hospital Readmission in Liver Transplant Recipients.

A. Hilliard, M. Brokhof, J. Geyston, J. DeMott, E. Chan, M. Hertl, N. Alvey.
Predictive Model of Delayed Graft Function in Machine Perfused Kidney Transplantation: Model Validation Using Decision Curve Analysis.

K. Ravindra,¹ S. Sanoff,¹ D. Vikraman,¹ U. Patel,¹ M. Ellis,¹ E. Squires,² D. Sudan,¹ W. Irish.¹
Predictors of Donor Heart Utilization in United States.

J. Trivedi, A. Cheng, E. Schumer, M. Black, H. Massey, M. Slaughter.
Predictors of Post Transplant Lymphoprolipherative Disorder Among Adult Kidney Transplant Recipients.

M. Mohamed, S. Parajuli, B. Muth, A. Djamali, B. Astor.
Predictors of Postoperative Cardiovascular Complications Until Three Months After Kidney Transplantation.

M. Slot,^1,2 J. van de Wetering,¹ M. Kho,¹ M. Betjes,¹ J. Roodnat.¹
Predictors of Urologic Complications After Pediatric En-Bloc Donor Kidney Transplantation.

S. Kabagambe,¹ A. De Mattos,² R. Perez,¹ C. Santhanakrishnan,¹ J. Sageshima,¹ C. Troppmann,¹ J. McVicar.¹
Prednisone Wean After Dual Heart and Kidney Transplantation: Is There a Risk?

D. Chang, J. Patel, M. Kittleson, T. Aintablian, L. Czer, D. Ramzy, J. Kobashigawa.
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.

G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli.
Preformed Antibodies Against AT₁R and EDNRA Correlate with Rejection Post-Transplant.

A. Gareau,¹ C. Wiebe,^1,2 D. Pochinco,² I. Gibson,³ D. Rush,¹ P. Nickerson.^1,2,4
Pregnancy in the Renal Transplant Recipient: Pregnancy Viability and Effects on Graft Function.

A. Lima, M. Cristelli, C. Teixeira, I. Pietrobom, G. Basso, L. Viana, M. de Paula, C. C[acirc]ndido, H. Tedesco-Silva, J. Pestana.
Preimplant Donor Histology Does Not Improve Discrimination of 5 Year Kidney Allograft Outcomes.

C. Traynor,¹ T. Dorman,² D. de Freitus,² P. Conlon,² C. O'Seaghdha.²
Preimplantation and Post-Transplant Serial Biopsies of Standard and Extended Criteria Donor Kidneys: Intragraft Molecular Profiles and Effect of Different Immunosuppressive Protocols.

C. Mazeti,¹ H. Caldas,¹ I. Fernandes-Charpiot,² M. Baptista,² M. Abbud-Filho.^1,2,3
Preoperative Cytokine Storm in High MELD Patients Accentuates Incidence of Rejection Following Liver Transplantation.

A. Mathur, E. Presbyskowski, E. Zorn, K. Rogers, J. Guarrera, B. Samstein, A. Griesemer, K. Halazun, T. Kato, J. Emond.
Presence of Highly Immunogenic Mismatch Eplets Is Associated with Development of Chronic Active Antibody-Mediated Rejection: A First Report from Japan.

D. Iwami, K. Morita, H. Sasaki, H. Higuchi, Y. Takada, N. Shinohara.
Preservation of Alloreactive and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.

J. Schaenman,¹ Y. Korin,² T. Sidwell,² V. Groysberg,² J. Gadzhyan,¹ E. Lum,¹ U. Reddy,¹ E. Huang,¹ T. Pham,¹ G. Danovitch,¹ E. Reed,² S. Bunnapradist.¹
Probability of Transplant (POT) Index: A Novel Method to Predict the Likelihood of an Adult Liver Transplant.

J. Moffett,¹ M. Kueht,¹ H. Petrowsky,² I. Riaz,³ C. Nalty,⁴ S. Khaderi,¹ C. O'Mahony,¹ J. Goss,¹ A. Rana.¹
Profiling of T Cell Subsets in a Primate Cardiac Transplant Model.

N. O'Neill, T. Zhang, G. Braileanu, W. Sun, X. Cheng, C. Evans, R. Pierson, A. Azimzadeh.
Prognosis Value of the Presence and Persistence of C1q Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.

E. Bailly,¹ B. Proust,² M. Giral,³ V. Vuiblet,⁴ V. Chatelet,⁵ E. Morelon,⁶ P. Malvezzi,⁷ S. Caillard,⁸ B. Barrou,⁹ L. Couzi,¹⁰ J. Sayegh,¹¹ C. Mousson,¹² D. Anglicheau,¹³ P. Grimbert,¹⁴ M. Hazzan,¹⁵ G. Mourad,¹⁶ R. Purgus,¹⁷ P. Westeel,¹⁸ Y. Lebranchu,^1,19 M. Büchler.^1,19
Projection versus Reality: KPSAM and KAS.

S. Gustafson, A. Israni, J. Pyke, N. Salkowski, J. Snyder, B. Kasiske.
Prolonged Cold Ischemia Time Negatively Impacts Graft and Recipient Survival in a Murine Orthotopic Hindlimb Transplant Model.

N. Datta, S. Devaney, A. Allen, R. Busuttil, K. Azari, J. Kupiec-Weglinski.
Prolonged Normothermic Ex Vivo Kidney Perfusion Is a Safe Preservation Technique for Kidney Transplantation: A New Opportunity for the Storage, Assessment and Repair of Kidney Grafts.

J. Kaths,^1,2,3 J. Echeverri,¹ N. Goldaracena,¹ K. Louis,¹ Y.-M. Chun,¹ I. Linares,^1,3 A. Wiebe,¹ P. Yip,⁵ R. John,⁵ I. Mucsi,⁶ A. Ghanekar,¹ D. Bagli,^7,3 D. Grant,¹ L. Robinson,^2,3 M. Selzner.^1,3
Prolonged Pre-Transplant Dialysis Duration Reverses the “Nephroprotective Effect” in Simultaneous Liver-Kidney Transplant Recipients.

M. Casey, X. Wen, A. Santos, S. Rehman, K. Womer.
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?

G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang.
Prospective Investigation of the Reliability and Validity of the Live Donor Assessment Tool (LDAT).

D. LaPointe Rudow, A. Shenoy, J. Hunt, Z. Filipovic-Jewell, B. Haydel, B. Iacoviello.
Prospective Randomized Controlled Study Evaluating the Relationship Between Electronic Adherence Data and Tacrolimus Concentration Data.

B. Kane,¹ M. Lockwood,¹ L. Potter,¹ L. Lourenco,¹ A. Bodzin,¹ D. Covington,² K. Mayer,³ J. Millis.¹
Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.

A. Shetty, O. Traitanon, M. Ansari, J. Mathew, J. Leventhal, V. Mas, L. Gallon.
Prospective Single Antigen Bead Epitope-Based Clustering for Early Detection of Antibody Mediated Rejection.

A. Lichvar, S. Tremblay, P. Brailey, A. Girnita, R. Alloway, E. Woodle.
Prostate Cancer Characteristics and Outcome in Renal Transplant Recipients: Results from a Contemporary Monocentric Study.

C. Pettenati,¹ A.-S. Jannot,² V. Verkarre,³ S. Hurel,¹ H. Kreis,⁴ M. Housset,⁵ C. Legendre,⁴ A. Méjean,¹ M.-O. Timsit.¹
Protective Effects of Nrf2 Over-Activation in Myeloid Cells During Hepatic Ischemia Reperfusion Correlates with Stat3 Signaling in Hepatocytes.

C. Harberg,¹ L.-Y. Lee,¹ S. Werner,² D. Johnson,³ J. Johnson,³ D. Foley.¹
Protocol for Health Information Exchange Living Donor Cohort Discovery.

M. Henderson,¹ A. Roberts,² A. Massie,³ D. Segev,³ W. Goggins,¹ C. Stone,¹ B. Dixon.^1,2
Psychiatric Characteristics of Acute Liver Failure Patients: Acetaminophen Overdose versus Other Etiologies.

N. Rebhan, M. Bebanic, A. Yoshida, T. Macaulay, E. Goldstein, C.-X. Ho, A. Eshelman, M. Abouljoud, M. Jesse, M. Rizzari.
Psychosocial Factors Associated with Medication Adherence Based on Self Reports in Kidney Allograft Recipients: Baseline Findings from the PRIMA (ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application) Study.

A. Han,¹ C. Choi,¹ S.-Y. Kim,¹ S. Cho,¹ M.-J. Cho,¹ C. Lee,¹ S. Ahn,¹ S.-I. Min,¹ S.-K. Min,¹ I. Jung,¹ S. Kim,² M. Park,³ J. Ha.^1,3
Pulmonary Hypertension in Renal Transplant Candidates: A Systematic Review and Meta-Analysis of the Available Evidence.

A. Moza,¹ A. Khan,² R. Prashar,³ S. Khan,¹ S. Khouri,¹ S. Vetteth,¹ D. Malhotra,¹ M. Rees,¹ G. Moukarbel,¹ J. Ortiz.¹
Pulse Wave Velocity Amongst African-American Kidney Transplant Recipients Randomized to Once-Daily MeltDose Tacrolimus Tablets (Envarsus XR) vs. Traditional Twice-Daily Tacrolimus Capsules: Exploratory Results from a Phase III Trial.

J. Trofe-Clark,^1,2 R. Townsend,² R. Neubauer,² M. Lim,² L. Callahan,³ R. Bloom.²
Quadruple Induction Regimen with Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Improves Graft Function without Increase in the Incidence of Microvascular Inflammation or De Novo Donor Specific Antibody Compared to the Standard Triple Regimen.

M. Miura, H. Higashiyama.
Qualitative Assessment of Patient-Perceived Treatment Burden Following Cardiac Transplantation.

K. Deininger,¹ J. Reich,¹ J. Hirsch,² S. Graveline,² A. Feist,² J. LaFleur,³ S. Smith,⁴ A. Ambardekar,¹ J. Lindenfeld,⁵ C. Aquilante.¹
Quality Assessment and Process Improvement of Thymoglobulin Dosing.

H. Sarumi, L. Beck, C. Borscheid, B. Fast, S. Hogan, M. James, K. Vassar, D. Vock, T. Pruett.
Quality Improvement Initiative to Provide Comprehensive Pharmacy Services to Kidney Transplant Patients at a Small Transplant Center.

J. Dickson,¹ W. Vincent III,¹ L. Wu,² J. Thurman,¹ J. Francis,³ M. Nuhn.⁴
Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.

H. Lee,¹ K. Park,² J. Ryu,² J. Yu,³ B. Chung,³ C. Yang,³ E.-J. Oh.¹
Quantitative Hepatitis C Virus (HCV) RNA in Plasma and Kidney Tissue in HCV Antibody Positive Donors.

H. Shike,¹ Z. Kadry,² R. Shah,² Y. Imamura,¹ W. Greene,¹ J. Gaspari,¹ T. Riely,¹ H. Nathan,³ R. Hasz,³ A. Jain.¹
Racial Differences Amongst Infants Undergoing Intestine Transplants.

K. Khan, C. Desai, S. Kaufman, R. Girlanda, J. Hawksworth, A. Kroemer, T. Fishbein, C. Matsumoto.
Racial Disparities in Cognitive and Social Requirements Prior to Listing for Liver Transplant.

M. Jesse, E. Goldstein, T. Macaulay, N. Rebhan, C.-X. Ho, M. Bebanic, L. Shkokani, M. Abouljoud, A. Eshelman, A. Yoshida.
Racial Disparities in the Evaluation for Liver Transplantation.

M. Jesse, E. Goldstein, N. Rebhan, C.-X. Ho, T. Macaulay, M. Bebanic, L. Shkokani, D. Moonka, M. Abouljoud, A. Yoshida.
Randomized Controlled Trial of Mixed Acute Rejection Therapy in Renal Allografts: 3 Year Follow Up.

A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells.

T. Nakamura, K. Masuda, T. Matsuyama, H. Ushigome, N. Yoshimura.
Rapid Detection of Acute Infection in Immunosuppressed Renal Patients with IRIDICA: A Pilot Study.

S. Hassan,¹ A. Adwaney,¹ A. Massiah,² R. Murphy,² S. Law,¹ S. Mohd-Afzal,¹ M. Wilks,² R. Thuraisingham.¹
Rapid Discontinuation of Prednisone (RDP) in Kidney Transplant (KTx) Recipients: 15-Year Outcomes.

O. Serrano,¹ R. Kandaswamy,¹ K. Gillingham,¹ W. Payne,¹ T. Dunn,¹ S. Chinnakotla,¹ E. Finger,¹ H. Ibrahim,² A. Kukla,² R. Spong,² N. Issa,² T. Pruett,¹ A. Matas.¹
Rapid Withdrawal of Donation After Cardiac Death Donors.

K. Mekeel,¹ J. Trageser,² W. Garrison,² J. Berumen,¹ L. Stocks,² A. Hemming.¹
Rare Presentation of PTLD as Parotitis.

R. Pullalarevu, A. Posadas Salas, G. Mour, T. Srinivas, N. Salazar, P. Mohan.
Re-Examining the Role of B-1 Cells in a Murine Model of Renal Ischemia Reperfusion Injury.

D. Firl,^1,2,3 A. Das,¹ J. Fung,² M. Carroll.¹
Real Time Assessment of Kidney Transplant Indication Biopsies by Microarrays: First Results of the INTERCOMEX Study.

P. Halloran,^1,2 J. Reeve,¹ INTERCOMEX Study Group.
Really Old (>84 Years) Deceased Donor Livers Can Save Lives.

A. Friedman, E. Marquez, K. DelliCarpini.
Recapitulating Peripheral T Cell Development in Neonatal Mice to Induce Transplant Tolerance.

R. Bascom, K. Tao, L. West.
Recipient Outcomes in U.S. Cases of Post-Donation Living Donor Malignancy.

A. Wilk,¹ S. Taranto,¹ M. Nalesnik.³
Reciprocal Effects of HDAC1 and HDAC2 Deletion on Renal Cold Ischemia Survival and Nuclear Co-Repressor Complex Expression.

D. Aufhauser Jr,¹ D. Murken,¹ Z. Wang,¹ A. Samanta,² G. Ge,¹ T. Bhatti,³ W. Hancock,^2,3 M. Levine.¹
Recombinant TSGL-Ig Protects Liver Endothelial Cells Against Prolonged Cold Preservation Injury in Mouse Liver Transplantation.

C. Zhang,^1,2 H. Ji,¹ Y. Liu,^1,2 Y. Zhang,^1,2 X.-D. Shen,¹ F. Gao,¹ R. Busuttil, G. Shaw, J. Kupiec-Weglinski.
Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.

M. Paula, C. Felipe, M. Cristelli, P. Orlandi, L. Viana, G. Basso, P. Carvalho, C. Montenegro, A. Lima, I. Pietrobom, H. Tedesco-Silva, J. Medina-Pestana.
Reduced Incidence and Level of De Novo Donor-Specific Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results from BENEFIT.

R. Bray,¹ H. Gebel,¹ R. Townsend,² M. Polinsky,² L. Yang,² U. Meier-Kriesche,² C. Larsen.¹
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus: A Cost-Effectiveness Analyses.

H. Tedesco-Silva, C. Felipe, A. Brigido, M. Cristelli, M. Paula, A. Bessa, P. Ruppel, J. Medina-Pestana.
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.

S. Patel, S. Kuten, J. Snyder, R. Knight, A. Gaber.
Reducing Non-Anastomotic Biliary Strictures After Donation After Circulatory Death Liver Transplantation, a Matter of Time?

N. Gilbo, I. Jochmans, M. Sainz, J. Pirenne, D. Monbaliu.
Regression of Asymptomatic Cardiomyopathy and Clinical Outcome of Renal Transplant Recipients: Long-Term Extension of Two Randomized Controlled Trials.

E. Paoletti, D. Bellino, L. Marsano, R. Russo, F. Masarino, G. Garibotto.
Relationship Between Changes in Brain Natriuretic Peptide Levels and Cardiac Allograft Rejection Early After Heart Transplantation.

J. Dann,¹ K. Deininger,¹ D. Reinhold,¹ R. Page II,¹ A. Ambardekar,¹ J. Lindenfeld,² C. Aquilante.¹
Relationship Between Dialisys Duration and Prevalence of Cardiovascular Diseases in Kidney Transplantation Recipients.

K. Unagami,¹ M. Okumi,² T. Hirai,² Y. Okabe,³ K. Masutani,⁴ T. Shimizu,² K. Omoto,² M. Inui,² H. Ishida,² T. Kitazono,⁴ K. Nitta,¹ K. Tanabe,² The Japan Academic Consortium of Kidney Transplantation (JACK).
Renal Allograft Outcomes with Renal Artery Angioplasty and/or Stenting in Transplant Renal Artery Stenosis.

E. Tantisattamo,¹ A. Chokechanachaisakul,² S. Pitukweerakul,³ P. Ratanasrimetha,⁴ A. Shetty,² O. Traitanon,⁵ L. Gallon.²
Renal Dysfunction at 12 Months Is Not Associated with Everolimus Exposure in De Novo Renal Transplant Recipients.

F. Shihab,¹ Y. Qazi,² S. Mulgaonkar,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ D. Shaffer.⁶
Renal Efficiency: A New Metric for Evaluating Kidneys in Living Donors.

A. Diez, K. Rima, J. Von Visger, U. Nori, T. Pesavento, A. Rajab, M. Henry, R. Pelletier.
Renal Function Decline Is Higher in the First Year After Liver Transplantation: Final Results from the Italian Observational Study SURF.

A. Giacomoni,¹ M. Cescon,² G. Magini,³ F. Picciotto,⁴ U. Cillo,⁵ M. Senzolo,⁵ G. Vennarecci,⁶ P. De Simone.⁷
Renal Outcomes of Pediatric Kidney Transplant Recipients Following a Previous Solid Organ Transplantation.

G. Hamdani,¹ B. Zhang,² J. Goebel,³ E. Nehus.¹
Renal Risk Index and Acute Kidney Injury in Liver Transplant Patients.

J. Neal, Y. Sun, J. Erley, J. Shen, C. Sonnenday, P. Sharma, J. Park.
Renal Transplant in Obese Recipients: Consideration of Donor and Recipient Factors Can Improve Outcomes.

P. Stahler, J. Mezrich, G. Leverson, D. Kaufman, H. Sollinger.
Renal Vein Thrombosis Incidence in 3976 Consecutive Kidney Transplants: Retrospective Analyses Focusing on Intraoperative Risk Factors.

H. Marinho Neto, B. Leslie, J. Neves Neto, J. Offerni, A. Pessoa, M. Almeida, M. Nogueira, S. Ximenes, W. Aguiar, H. Tedesco, J. Medina Pestana.
Replacing Cold Storage with Normothermic Ex Vivo Kidney Perfusion Improves Function of Grafts Retrieved After Circulatory Death (DCD).

J. Kaths,^1,2 Y.-M. Chun,¹ D. Cen,¹ J. Echeverri,¹ I. Linares,¹ P. Yip,³ R. John,³ D. Bagli,⁴ I. Mucsi,⁵ A. Ghanekar,¹ D. Grant,¹ L. Robinson,² M. Selzner.¹
Replicative Senescence and Arteriosclerosis After Kidney Transplantation.

K. De Vusser,¹ D. Martens,² E. Lerut,³ D. Kuypers,¹ T. Nawrot,² M. Naesens.¹
Resolution of Donor Non-Alcoholic Fatty Liver Disease Following Liver Transplantation.

A. Posner,¹ W. Twaddell,² S. Hanish,² D. Bruno,² W. Hutson,² L. Hebert,² R. Barth,² J. LaMattina.²
Resource Utilization and Cost Analysis of Early Hospital Readmissions Following Kidney Transplantation.

M. Au, O. Famure, Y. Li, J. Kim.
Results from 100 Consecutive Donation-After-Circulatory Death (DCD) Liver Transplants Using a Thrombolytic Protocol.

J. Seal, H. Bohorquez, N. Battula, E. Ahmed, D. Bruce, I. Carmody, R. Trevor, G. Tyson, S. Joshi, N. Bzowej, G. Therapondas, N. Girgrah, A. Cohen, G. Loss.
Results of a Biopsy Based, Early Intervention Treatment Protocols for BK Viraemia and BK Virus Associated Nephropathy.

S. Jones,¹ S. Waller,¹ K. Lai,^2,3 A. Hibbard,¹ P. Trevillian,¹ M. Heer.¹
Resveratrol Attenuates Liver IRI by Regulating Macrophage Activation Through SIRT1/p19/p53 Pathway.

K. Nakamura,¹ M. Zhang,² B. Ke,¹ S. Kageyama,¹ R. Busuttil,¹ J. Araujo,² J. Kupiec-Weglinski.¹
Retroperitoneal versus Intraperitoneal Hand Assisted Laparoscopic Donor Nephrectomy: A Case Matched Study.

Z. Ahmed, M. Sait, R. Tamburrini, R. Uwechue, P. Chandak, N. Kessaris, N. Mamode.
Review of Aborted Hepatectomy of Liver Transplantation in a Single Center Study.

J. Lee, G. Choi, W. Cho, J.-W. Joh, S.-K. Lee, S.-J. Kim, C. Kwon, J. Park, J. Kim.
Review of Organ Utilization from Increased Infectious Risk Donors.

A. L'Huillier,¹ A. Humar,² C. Payne,³ D. Kumar.²
Risk Factors for Clinical Urinary Tract Infections in Kidney Transplant Recipients with Asymptomatic Bacteriuria.

S. Medani, M. Dorais, A. Tavares-Brum, H. Mawad, A. Duclos, C. Lemieux, A. Barama, H. Cardinal.
Risk Factors for Early vs. Late Onset Clostridium difficile Infection(CDI) in Solid Organ Transplant Recipients (SOTR).

Y. Natori, M. Shiotsuka, L. Oen, E. Renner, L. Singer, H. Ross, D. Kumar, C. Rotstein, A. Humar, S. Husain.
Risk Factors for Hospitalization Among Waitlisted End Stage Renal Disease Patients.

K. Newman,^1,2 A. Adams,² S. Pastan,² R. Lynch,² R. Zhang,¹ R. Patzer.^1,2
Risk Factors for Short and Long Term Mortality in High MELD Recipients.

A. Bertacco,^1,2 M. Rodriguez-Davalos,¹ M. Schilsky,³ P. Yoo,¹ S. Kulkarni,¹ B. Fortune,³ A. Liapakis,³ S. Emre,¹ D. Mulligan.¹
Risk Factors for Single and Recurrent Symptomatic Urinary Tract Infections within the First Year After Kidney Transplantation.

K. Bourgi, W. Choi, A. Nakhle, Z. Abdel-Rahman, O. Abreu-Lanfranco, M. Ramesh, A. Patel, R. Del Busto, G. Alangaden.
Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis.

J. Thielke,¹ N. Jasiak,¹ N. Hilal,¹ S. Salah,¹ E. Benedetti,² P. West-Thielke.²
Risk Stratification for Optimized Utilization of Deceased Donor Kidneys with Acute Kidney Injury by KDIGO Criteria.

B. Yu,¹ T. Koo,² J. Lee,³ J. Yang,² J. Ha,⁴ C. Ahn,¹ Y. Kim,¹ H. Lee.¹
Risk of Acute Rejection Among ABO Incompatible Living Donor Kidney Recipients.

P. MacLennan, V. Kumar, R. Reed, D. Mompoint-Williams, K. Stegner, J. Locke.
Risk of Peritoneal Dialysis Catheter-Associated Peritonitis Following Kidney Transplant.

A. Rizzi,¹ S. Ruitta,¹ J. Peterson,¹ G. Gagin,¹ D. Fritze,¹ R. Sung,¹ Y. Lu,² K. Woodside.¹
Robotic Kidney Transplantation in Obese Recipients Can Lead to Superior Outcomes in Terms of Wound Infection and Graft Survival – 48 Months of Follow-up.

I. Tvetanov, S. Garcia Aroz, M. Spaggiari, J. Hoonbae, J. Oberholzer, E. Benedetti.
Robotic-Assisted Laparoscopic Donor Nephrectomy with Transvaginal Extraction of the Kidney.

C. Champy,¹ L. Salomon,¹ I. Cholley,¹ A. Hoznek,¹ R. Yiou,¹ D. Vordos,¹ P. Grimbert,² P. Lang,² A. De La Taille.¹
Role of Donor Hemodynamic Trajectory in Determining Graft Survival in Liver Transplantation from Donation After Circulatory Death Donors.

D. Firl, K. Hashimoto, C. O'Rourke, J. Fung, B. Eghtesad.
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.

B. Chopra, K. Sureshkumar.
Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.

A. Andreou, A. Babu, T. Barber, R. Higgins, D. Briggs, D. Mitchell, N. Khovanova, T. Shaikhina, S. Daga.
Role of TGF-β in Ischemia and Reperfusion Injury Induced Renal Fibrosis in Human Proximal Tubular Epithelial Cells.

R. Kapoor, N. Sheerin, J. Kirby.
Rurality Status Does Not Affect Kidney Transplant (KTP) Rates Among Veterans Compared to Medicare, Medicaid, and Private Insurance (PrivIns) Beneficiaries.

R. Kalil,^1,2 C. Franciscus,² A. O'Shea.^1,2
Safety and Efficacy of Ledipasvir/Sofosbuvir (LS) with or without Ribavirin (RBV) for Treatment of Recurrent Hepatitis C Infection Post-Liver Transplant.

K. Gutierrez, J. Scheuermann, I. Goldvarg, S. Joshi, G. Tyson, N. Bzowej, N. Girgrah, S. Anders, G. Loss, G. Therapondos.
Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.

R. Miller,¹ H. Meadows,¹ S. Strout,¹ T. Veasey,¹ A. Mardis,¹ J. Fleming,¹ C. Mardis,¹ N. Pilch,¹ K. Chavin,² D. Taber.²
Schisandra Sphenanthera Extract Facilitates Anti-Tuberculosis Treatment Post Renal Transplantation Through Increasing Bioavailability of Tacrolimus.

R. Deng,¹ L. Zhang,¹ L. Liu,¹ H. Fu,² J. Li,¹ Q. Fu,¹ C. Wang.¹
Sepsis Prolongs Allograft Survival Compared with Non-Septic Infection in a Murine Model of Skin Transplantation and Pseudomonas aeruginosa Pneumonia.

L. Margoles, S. Laurie, C. Coopersmith, M. Ford.
Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation.

I. Striz, E. Cecrdlova, A. Sekerkova, J. Slatinska, V. Svachova, O. Viklicky.
Shifts of Etiology in Patients with in Bacteremic Liver Transplant Recipients.

S. Kim,¹ Y. Kim,¹ J. Choi,¹ S. Yoon,¹ G. Na,² J. Kim,² I. Moon,² Y. Yoo,² D. Kim.²
Short, Cool and Well Oxygenated – HOPE for DCD Kidneys.

P. Kron, A. Schlegel, O. de Rougemont, C. Oberkofler, P.-A. Clavien, P. Dutkowski.
Short-Term Starvation Attenuates Liver Ischemia Reperfusion Injury by SIRT1-Autophagy Signaling in Mice.

J. Rao,¹ H. Zhou,¹ F. Zhang,¹ X. Wang,¹ Y. Zhai,² L. Lu.¹
Should HLA DR and DQ Eplet Mismatching Replace Traditional DR and DQ Mismatching for Deceased Donor Offers in Pediatric Renal Transplantation?

C. Bryan, V. Chadha, B. Warady.
Significance of Preservation Fluid Cultures in Solid Organ Transplantation.

H. Nam, N. Perni, K. Galen, M. Campara, R. Roca-Garcia, V. Yeldandi.
Significant Association of Innate Immune Related Genes Polymorphism on Infectious Complications Following Early Post Renal Transplantation phase.

L. Das, K. Ide, Y. Tanaka, S. Shimizu, N. Tanimine, S. Verma, H. Ohdan.
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.

H.-P. Chang,¹ C.-Y. Lee,² C.-C. Si,¹ M.-K. Tsai,² F.-L. Lin Wu.^1,3
Signs of a Dying Organ: Beyond Resistance in Subnormothermic Kidney Perfusion.

M. Blum, D. Urcuyo, Q. Liu, B. Soliman, T. Okamoto, D. Goldfarb, C. Quintini.
Similar Kidney Allograft and Patient Survival in Native Americans Despite Lower Rates of Living Donation and Longer Wait on the Deceased Donor List.

H. Khamash,¹ K. Reddy,² H. Chakkera,¹ J. Huskey,¹ S. Sukumaran-Nair,¹ A. Mathur,² A. Moss,² N. Katariya,² A. Singer,² R. Heilman.¹
Simulating Alternative Bayesian Criteria to Identify Transplant Center Performance Outliers.

J. Schold,¹ C. Miller,¹ M. Henry,² L. Buccini,¹ S. Flechner,¹ D. Goldfarb,¹ E. Poggio,¹ K. Andreoni.³
Simultaneous En-Bloc Dual Transplantation: A New Approach.

D. Nghiem.
Simultaneous Pancreas/Kidney Transplantation Increases the Risk of Late-Onset BKV-Associated Nephropathy.

T. Schachtner,^1,2 M. Zaks,¹ A. Kahl,¹ P. Reinke.^1,2
Single Center Experience with Robotic Kidney Transplantation for Recipients with BMI >40 kg/m²: A Comparison with the UNOS Registry.

I. Tvetanov, S. Garcia Aroz, M. Spaggiari, J. Hoonbae, J. Oberholzer, E. Benedetti.
Slipping Through the Cracks: Late Onset BK Viremia.

J. Gandhi,¹ M. Mackenzie,¹ D. DeWolfe,² F. Cardarelli,³ M. Pavlakis,³ C. Tan.^1,4
Social Support Does Not Predict Medication Adherence Post-Transplantation: A Systematic Review and Meta-Analysis.

K. Ladin,¹ A. Daniels,¹ R. Bannuru,² M. Osani.²
Socioeconomic Status and Readmission Following Kidney Transplant.

S. DiBrito, E. King, M. O'Hare, D. Segev.
Sofosbuvir-Based Regimen in Treatment Experienced-Post Liver Transplant Patients with Hepatitis C Recurrence.

A. Ajlan,¹ A. Aljedai,¹ H. Elsiesy,² D. Alkortas,¹ R. Alarieh,² W. Alhumodi,² D. Broring,² M. Alsebayel,² F. Aba Alkhail.²
Soluble ST2 and Cardiovascular (CV) Outcomes and Mortality in Kidney Transplant Candidates.

M. Keddis,¹ Z. El-Zoghby,² A. Gray,² J. Meeusen,² L. Donato,² F. Cosio,² D. Steidley.¹
Some DCD Livers Function as Well as DBD Livers: The Implications of Discarding Usable Livers.

J. Scalea, R. Redfield, D. Foley.
Sphingosine-1 Phosphate Receptor 1 Agonist SEW2871 Ameliorates Hepatocellular Injury on Ischemic Reperfusion in Mice: A New Therapeutic Target.

T. Ito, N. Kuriyama, A. Matsuda, H. Kato, Y. Iizawa, Y. Murata, A. Tanemura, Y. Azumi, M. Kishiwada, S. Mizuno, M. Usui, H. Sakurai, S. Isaji.
Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.

Y. Huang, J. Park, A. Naik, D. Kaul.
Stem Cell-Mediated Regeneration of Ischemically Damaged Renal Allografts During Ex Vivo Warm Perfusion.

L. Brasile,¹ N. Henry,¹ B. Stubenitsky.²
Steroid Free Immunosuppression and Clinical Outcomes in Recipients of Deceased Donor Kidney Transplant with Positive Flow Cytometry Crossmatch.

O. Adebiyi, T. Taber, W. Goggins, D. Mishler, M. Yaqub, A. Sharfuddin.
Steroid Use May Not Increase Risk of Fracture in Kidney Transplant Patients.

N. Sarabu, K. Kucharski, D. Hricik, A. Padiyar, A. Huml, J. Augustine.
Storage Kidneys Prior to Transplantation Using First Polish Preservation Solution "Biolasol" – Preliminary Report.

A. Jozwik,¹ P. Domagala,¹ R. Kieszek,¹ M. Wszola,¹ M. Bieniasz,¹ M. Serwanska-Swietek,¹ M. Durlik,² F. Ryszka,³ A. Chmura,¹ A. Kwiatkowski.¹
Strategies to Prevent Ischemic Cholangiopathy After Donation After Circulatory Death Donor Liver Transplantation.

C. Kubal,¹ R. Mangus,¹ J. Fridell,¹ B. Ekser,¹ N. Rush,² R. Saxena,² J. Tector.¹
Stratification of Kidney Transplant Recipients into Those with Low and High Alloreactive T-Cells May Allow Safe Conversion to mTOR-Inhibitor-Based Immunosuppression.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
Stratifying Skin Versus Non-Skin Cancer Risk Post-Kidney Transplantation According to Patient Characteristics.

F. Jackson-Spence,¹ H. Gillott,¹ S. Tahir,¹ F. Evison,² J. Nath,³ A. Sharif.³
Stress Cardiomyopathy in the Perio-Perative Period After Liver Transplant.

N. Presser, B. Barzilai.
Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.

K. Barker,¹ N. Cook,¹ P. Kevan,² I. Frank.¹
Sublingual Tacrolimus in Liver Transplantation: A Valid Option?

M. Moreno Gonzales,¹ L. Myhre,² T. Taner.¹
Subnormothermic Machine Perfusion (SNMP) of Liver Allografts with a Novel Hemoglobin-Based Oxygen Carrier (HBOC) Increases β-Oxidation of Fatty Acids and Decreases Lipid Peroxidation (LP).

B. Banan, R. Lopez, C. Hughes, G. Michalopoulos, P. Fontes.
Subnormothermic Machine Perfusion (SNMP) with a Hemoglobin Based Oxygen Carrier (HBOC) Solution Reprograms Dynamic Inflammation Networks When Compared to Cold Storage (CS) in a Porcine Liver Allograft Model.

D. Sadowsky, R. Zamora, B. Banan, D. Barclay, J. Yin, Y. Vodovotz, P. Fontes.
Successful Human-to-NonHuman Primate Pancreatic Islet Intraportal Xenotransplantation Using a Human Allo-Based Immunosuppression Regimen and Its Potential Pre-Clinical Application.

J. McGarrigle,¹ M. Bochenek,¹ E. Marchese,¹ A. Khan,¹ D. Gutierrez,^1,2 A. Mikalauskaite,¹ B. McCracken,¹ M. Reedy,¹ M. Omami,¹ C.-C. Yeh,¹ M. Spaggiari,¹ M. Nourmohammadzadeh,^1,2 D. Isa,¹ S. Ghani,¹ L.-J. Wang,¹ J. Mendoza-Elias,^1,2 Y. Wang,¹ J. Oberholzer.^1,2
Successful Prophylactic Use of Eculizumab in aHUS Kidney Transplant Patients: A Report of 9 Cases.

A. Kumar,¹ Z. Stewart,³ A. Reed,³ D. Orozco,² R. Smith,^1,2 C. Nester,^1,2 C. Thomas.^1,2
Survival Advantage in the Elderly with Kidney Transplantation.

G. Spanos,¹ N. Duncan,¹ P. Brookes,¹ D. Goodall,¹ K. Koutroutsos,¹ E. Evangelou,² M. Loucaidou.¹
Survival After Second Kidney Transplant: Are We Being Good Stewards?

C. Jay, J. Pugh, G. Halff, G. Abrahamian, F. Cigarroa, N. Stephens, K. Washburn.
Survival Benefit from Kidney Transplantation Using Kidneys from Deceased Donors Over 75 Years.

M. Pérez-Sáez,¹ E. Arcos,² J. Comas,² M. Crespo,¹ J. Lloveras,¹ J. Tort,² J. Pascual,¹ Catalan Renal Registry Committee.²
Survival Benefit of Kidney Transplantation in US Adults with Sickle Cell Nephropathy.

T. Purnell, X. Luo, S. Bae, A. Massie, D. Segev.
Susceptibility Patterns of Pre-Transplant Pseudomonas and Post-Lung Transplant Outcomes in Patients with Cystic Fibrosis.

S. Pouch,¹ E. Lease,² T. Bogdanovich,³ D. Ho,⁴ R. Miller,⁵ M. Estabrook,⁶ T. Babu,⁷ C. Kotton,⁷ C. Shaver,⁸ L. Thomas,⁸ S. Aslam,⁹ T. McCarty,¹⁰ J. Garcia-Diaz,¹¹ K. Doucette,¹² S. Kirkby,¹³ D. van Duin.¹⁴
Systematic Review and Meta-Analysis of the Impact of Computed Tomography Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation.

J. van Vugt,¹ S. Levolger,¹ R. de Bruin,¹ J. van Rosmalen,² H. Metselaar,³ J. IJzermans.¹
TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.

M. Wahrmann,¹ J. Mühlbacher,¹ H. Regele,¹ F. Eskandary,¹ J. Gilbert,² S. Panicker,² G. Böhmig.¹
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.

M. Henry.
Tacrolimus (Tac), Rather Than Cyclosporine (CsA), Interacts with Insulin Resistance (IR) to Alter Key Transcription Factors for β-Cell Identity & Function without Altering NFAT Localization.

J. Triñanes,¹ A. Rodriguez,² E. de Koning,¹ J. de Fijter,¹ F. Carlotti,¹ A. Torres,² A. de Vries,¹ E. Porrini.²
Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.

D. Taber, V. Phan, A. Wilton, N. Pilch, H. Meadows, J. Fleming, C. Mardis, A. Mardis, C. Bratton, K. Chavin, J. McGillicuddy, S. Nadig, P. Baliga.
Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.

J. Wiegel, T. Egbuka.
Tacrolimus Precision Medicine: Antibiotics Increase Intra-Patient Variability in Tacrolimus Trough Concentrations in Kidney Transplant Recipients.

Y. Zheng, J. Lee, A. Masand, D. Dadhania, M. Thangamani, M. Suthanthiran.
Tacrolimus as a Tool for Intracellular Assessment of von Willebrand Factor Production by Activated Human Glomerular Endothelial Cells.

S. Béland, P. Vallin, O. Désy, S. De Serres.
Telemedicine to Reduce Readmissions Post Liver Transplant: Compliance and Feasibility Results.

T. Kaiser,¹ P. Kimmel,² S. Osborn,² S. Diersing,² B. Boswell,² J. Huff,² J. Garrett,¹ N. Anwar,¹ S. Shah.¹
Text Messaging Facilitates Follow-Up Communication with Live Donors.

J. Moore, A. Massie, J. Berger, J. Montgomery, S. Dorry.
Th17 Development Is Critical for Airway Epithelial Injury After Transplantation.

J. Xu, Y. Zhang, L. Wang, X. Li, R. Chen, R. Zhang, Y. Ding.
The Apoptosis of the Tracheal Epithelia Increase the Recipient's MSCs Derived Myofibroblasts in Allografts to Exacerbate Obliterative Bronchiolitis After Tracheal Transplantation in Mice.

C. Wang,¹ T. Xia,¹ X. Zhang,² K. Jiang,¹ J. Wang,¹ J. Nie.¹
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.

E. Woodle,¹ D. Kaufman,² A. Shields,¹ J. Leone,³ A. Matas,⁴ A. Wiseman,⁵ P. Thielke,⁶ R. Alloway.¹
The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.

S. Ge, M. Chu, J. Choi, S. Jordan, M. Toyoda.
The Burden and Outcomes of Fractures in Kidney Transplant Recipients.

N. Atagu, T. Nguyen, N. Phan, O. Famure, Y. Li, J. Kim.
The Clinical Differences Between First and Second Kidney Transplant in IgA Nephropathy: A Multicenter Retrospective Study.

C. Baek,¹ J. Lee,² J. Park,³ H. Kim,¹ Y. Kim,² W. Huh,³ J. Yang,⁴ D. Han,⁵ S.-K. Park.¹
The Coefficient of Variability of Tacrolimus Levels Can Predict Antibody-Mediated Rejection After Renal Transplantation.

P. Ruiz-Esteban,¹ M. Gonzalez-Molina,¹ A. Caballero,² E. Palma,¹ D. Burgos,¹ M. Cabello,¹ J. Alonso-Titos,¹ A. Duarte,¹ D. Hernandez.¹
The Combined Effect of Acute Rejection and De Novo Donor-Specific Antibodies on Kidney Allograft Survival.

S. Davis, J. Gralla, A. Wiseman, J. Cooper.
The Correlation of Hepatic and Systemic Hemodynamics During Liver Transplantation: Quantification of Hepatic Resistance as an Actual Value.

A.-C. Feng, T.-W. Chen, H.-L. Fan, J.-C. Yu, C.-B. Hsieh.
The Distance Between Us: The Landscape of Recipient-Specific Loss-of-Function in Solid Organ Transplantation and Association with Rejection-Free Graft Survival.

B. Cole,^1,2,5 J. van Setten,^3,5 B. Keating.^1,4,5
The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.

J. Choi, J. Jung, S. Shin, Y. Kim, D. Han.
The Effect of Body Mass Index on Lung Transplant Outcomes.

M. Kashem,¹ A. Shiose,¹ J. Abraham,¹ N. Dean,¹ S. Breves,¹ F. Cordova,² N. Patel,² T. Yoshizumi,¹ G. Criner,² Y. Toyoda.¹
The Effect of Bortezomib on DSA Reduction During the Treatment of AMR in Pediatric Kidney Transplant Patients.

O. Moussa, S. Self, K. Twombley.
The Effect of Families on Organ Donation Among Native Americans.

T. Bongiovanni,^1,3 J. Rawlings,² J. Trompeta.¹
The Effect of Immunosuppression Regimen on Iga Nephropathy Recurrence Post Kidney Transplantation.

K. Koutroutsos,¹ A. Kousios,¹ L. Leighton,¹ R. Charif,¹ D. Goodall,¹ T. Cook,² J. Galliford,¹ D. Taube,¹ M. Loucaidou.¹
The Effect of Maternal Graft in Early Acute Cellular Rejection After Pediatric Living Donor Liver Transplantation.

Y. Noguchi,¹ T. Ueno,¹ K. Bessho,² Y. Takama,¹ H. Yamanaka,¹ N. Tanaka,¹ Y. Tazuke,¹ H. Okuyama.¹
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.

B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
The Effect of Tocilizmab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.

B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
The Effect of the Use of a TNF-Alpha Inhibitor in Hypothermic Machine Perfusion on Kidney Function After Transplantation.

P. Diuwe,¹ P. Domagala,¹ R. Kieszek,¹ M. Wszola,¹ M. Serwanska-Swietek,¹ L. Paczek,² M. Durlik,³ A. Chmura,¹ A. Kwiatkowski.¹
The Effects of Brain Death and Ischemia on Tolerance Induction Are Organ-Specific.

S. Michel,^1,2 M. Madariaga,¹ G. LaMuraglia II,¹ R. Colvin,³ E. Farkash,³ J. Allan,^1,4 D. Sachs,¹ K. Yamada,¹ J. Madsen.^1,5
The Environmental Impact of Dialysis vs Transplantation.

M. Grafals,¹ R. Sanchez.²
The Epidemiology of Clostridium difficile Infection in a National Kidney Transplant Center.

C. Kennedy,¹ C. Waldron,¹ M. Scally,² K. Burns,² C. Magee,¹ F. Fitzpatrick.²
The Fine-Tuning of CXCL8 Protects Kidney Against Ischemia-Reperfusion Injury in Mice Lacking MicroRNA-146a.

L. Amrouche,^1,2 G. Desbuissons,¹ M. Rabant,^1,2 C. Legendre,^1,2 F. Terzi,² D. Anglicheau.^1,2
The First 48 Months of an Australian Renal and Liver Organ Transplant Dermatology Database.

L. Ge,^1,2 P. Lowe.^1,2
The Function of CD8⁺TCR^– Facilitating Cells and Regulatory T Cells Is Impaired in Flt3-Ligand Knockout Mice.

Y. Huang, H. Xu, T. Miller, Y. Wen, S. Ildstad.
The Heterogenous Genomic Landscape of Unresectable Hepatoblastoma Requiring Liver Transplantation: Prognostic Implications.

M. Ningappa, B. Higgs, S. Ranganathan, C. Ashokkumar, R. Sindhi.
The IFN-Gamma-Inducible Protein (IP-10/CXCL10) Is a Promising Target to Improve Endocrine Function Following Islet Transplantation.

G. Yoshimatsu,¹ M. Kanak,² P. Balaji S,¹ C. Chang,³ C. Darden,³ M. Takita,¹ M. Lawrence,¹ B. Naziruddin.⁴
The Immunologic Profile of Brain Death in Humans: A Whole-Body Analysis.

D. Carpenter,^1,2 N. Matsuoka,¹ J. Thome,^1,3 T. Granot,^1,3 C. Gordon,^1,3 B. Kumar,^1,3 T. Senda,^1,3 M. Miron,^1,3 J. Weiner,² A. Griesemer,^1,2 D. Farber.^1,2,3
The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation.

O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.
The Impact of Donor Procurement Characteristics in Contemporary Live Donor Pediatric Renal Transplantation Outcomes: An Analysis of 282 Cases.

Z. Ahmed,¹ R. Uwechue,¹ P. Chandak,¹ J. Stojanovic,² N. Kessaris,¹ N. Mamode.¹
The Impact of Etiology of Liver Disease and Indication for Transplantation on Access to the Liver Transplant Waiting List in the United States.

D. Goldberg,^1,2 B. French,² C. Newcomb,² Q. Liu,² J. Lewis,^1,2 S. Halpern.^1,2
The Impact of Gender Discordance on Graft Survival Among Liver Transplant Recipients.

J. Moore, X. Luo, A. Massie, T. Purnell, D. Mogul, D. Segev.
The Impact of Kidney Donor Profile Index (KDPI) on Rates of Delayed Graft Function (DGF).

T. Zens, G. Leverson, R. Redfield, P. Chlebeck, L. Zitur, D. Kaufman, L. Fernandez.
The Impact of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx) Is Independent of Time Post-Transplant.

R. Gaston,¹ J. Grande,² R. Leduc,³ The DeKAF Study Group.
The Impact of Non-Adherence on Disparities in African-American Kidney Transplant Recipients.

D. Taber, A. Chokkalingam, A. Posadas, R. Browning, N. Salazar, M. Kamel, R. Pullalarevu, B. Kadri, T. Srinivas, K. Chavin, P. Baliga.
The Impact of Pre-Donation eGFR on Recipient Outcomes, as a Function of Donor Age.

J. Gill,¹ J. Dong,² O. Djurdjev,² J. Lesage,¹ C. Rose,¹ J. Gill.¹
The Impact of Thromboelastography on Resuscitation in Pediatric Liver Transplantation.

K. Gonzalez,¹ K. Curiel,¹ B. Dalton,¹ V. Fioravanti,¹ W. Andrews,¹ B. Wicklund,² R. Hendrickson.¹
The Impact of Total Ischaemic Time, Donor Age and the Pathway of Donor Death on Graft Outcomes After Deceased Donor Kidney Transplantation.

G. Wong,¹ A. Teixeira-Pinto,¹ C. Jeremy,¹ C. Jonathan,¹ M. Stephen,² L. Wai.³
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.

D. Fantus,¹ Y. Ono,¹ S. Yokota,¹ C. Komatsu,¹ H. Turnquist,^1,2 A. Thomson.^1,2
The Importance of KDPI in Simultaneous Liver and Kidney Transplant.

E. Chan,¹ M. Hertl,¹ J. Perkins.²
The Incidence of Symptomatic Pericardial Effusion with Long-Term Sirolimus Therapy.

N. Chandolias,¹ S. Wang,¹ A. Hahn,¹ R. Lyubarova,² R. Lopez-Soler,¹ D. Conti.¹
The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation.

Z. Baris, F. Ozcay, G. Moray, M. Haberal.
The Increase of Serum MiR-142-3p Level in Acute Cardiac Rejection as a Reflection of Exosome-Mediated Genetic Exchange Between T Cells and Endothelial Cells.

I. Dewi,¹ Z. Hollander,² B. McManus,² O. Gidlöf,¹ J. Öhman.¹
The Influence of Static versus Machine Dynamic Perfusion Kidney Graft Preservation on Delayed Graft Function Incidence: A Prospective, Randomized Study.

H. Marinho Neto, V. Aires, J. Offerni, W. Luconi, P. Luconi, S. Braga, I. Noronha, R. Barsante, J. Moreira, A. Savina, L. Kuschnaroff, F. Lemos, A. Cuvello, P. Chocair, L. Moura, A. Silva Filho, I. Charpiot, M. Abbud Filho, M. Cunha, P. Malafonte, D. Demetrio, L. Miorin, A. Duboc Filho, A. Claudini, W. Aguiar, H. Tedesco, J. Medina Pestana.
The Intrarenal Resistive Index Measured After Transplantation Is Determined by the Upstream Vascular System of the Recipient.

L. Heylen,¹ M. Naesens,¹ B. Sprangers,¹ S. Heye,² P. Verhamme,³ I. Jochmans,⁴ D. Monbaliu,⁴ J. Pirenne,⁴ D. Kuypers,¹ K. Claes.¹
The Long and Short of Old and Cold on Renal Allograft Outcomes.

A. Naik,¹ D. Luan,¹ K. Lentine,² P. Rao,¹ A. Sakhuja,¹ Y. Huang,¹ M. Samaniego,¹ S. Norman,¹ A. Ojo,¹ D. Cibrik.¹
The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.

F. Eskandary,^1,2 J. Reeve,^1,3 H. Regele,⁴ L. Hidalgo,^1,3 D. Yoo,¹ N. Kozakowski,⁴ K. Famulski,¹ G. Böhmig,² P. Halloran.^1,5
The Prediction of Molecular ABMR by Anti-HLA Donor-Specific Antibody Properties.

F. Eskandary,^1,2 J. Reeve,^1,3 D. Yoo,¹ H. Regele,⁴ L. Hidalgo,^1,3 G. Böhmig,² P. Halloran.^1,5
The Preventive and Therapeutic Effect of Immunoglobulin on Infectious Complications in Donation After Cardiac Death Liver Transplant Recipients: A Prospective Randomized Controlled Study.

A. Yang, Z. Guo, W. Ju, Y. Chen, M. Han, X. Wang, D. Wang, Y. Ma, A. Hu, X. Zhu, X. He.
The Role of Obesity in Survival Outcomes of Liver Transplant Recipients with High MELD Score.

S.-H. Chang,¹ N. Carlsson,¹ X. Liu,² J. Wellen,³ J. Hagopian,⁴ T. Horwedel,⁴ T. Alhamad.⁵
The Role of Palliative Care in the Thoracic Transplant Multidisciplinary Care Team: Barriers and Benefits.

A. Manfredi,¹ C. Toevs.²
The Role of Short-Term Ventricular Assist Device in Patients with Cardiogenic Shock – Is It Really a Solution?

A. Popov, M. Zeriouh, S. Anton, W. Alexander, Z. Bartlomiej, D. Garcia, P. Mohite, A. Padukone, A. Koch, O. Ananiadou, L. Fazekas, A. Simon.
The Safety and Efficacy of Suspended Gasless Laparoscopy Living-Donor Nephrectomy in Renal Transplantation.

J. Tian.
The Significance of Microvascular Inflammation in Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.

H. Ishihara,¹ H. Ishida,¹ K. Unagami,² T. Hirai,¹ M. Okumi,¹ K. Omoto,¹ T. Shimizu,¹ K. Tanabe.¹
The Simplified EPTS Score: Who Wins and Who Loses?

J. Schold, E. Poggio, R. Fatica, S. Flechner, L. Buccini, D. Goldfarb.
The Therapeutic Potential of Human Liver-Derived Stem Cell Transplantation in a Cirrhotic Liver Rat Model.

S. Lee,¹ J.-H. Lee,² H.-J. Park,² Y.-A. Kim,² M.-N. Park,² S.-K. Lee.¹
The UK Kidney Donor Risk Index Score Predicts the Development of TRAS Post Deceased Donor Transplantation.

M. Willicombe, A. Baheerathan, S. Moser, A. McLean, M. Hammady, W. Gedroyc, D. Taube.
The UK ONE Study: Safety and Feasibility of Regulatory T Cell Therapy in Renal Transplantation.

A. Bushell,¹ J. van der Net,^1,2 D. Game,³ R. Hilton,³ S. Thirkell,⁴ P. Friend,² E. Geissler,⁵ K. Wood,¹ P. Harden,² G. Lombardi.⁴
The UKKDRI Score Predicts Outcomes of Deceased Donor Transplantation Using a Steroid Sparing Immunosuppressive Protocol.

A. Wardle, M. Willicombe, D. Goodall, A. McLean, D. Taube.
The Use of Kidneys with Acute Kidney Injury: The Good, the Bad and the Ugly.

C. Boffa,^1,2 F. van de Leemkolk,¹ E. Curnow,³ J. Gilbert,² E. Sharples,^1,2 R. Ploeg.^1,2
The Use of Perioperative Lactate Values as Markers for Adverse Outcomes in Liver Transplantation.

B. Rao,¹ A. Yoshida,³ M. Ibrahim,² S.-M. Jafri.²
The Use of Thromboelastography (TEG) in Preoperative Pediatric Liver Transplantation to Predict Postoperative Thrombotic Complications.

K. Curiel,¹ B. Wicklund,² K. Gonzalez,¹ W. Andrews,¹ V. Fioravanti,¹ R. Hendrickson.¹
The mTORC2 Activation Is Critical for Hepato-Cytoprotection Against Ischemia and Reperfusion Injury.

H. Zhou,^1,2 J. Zhu,^1,3 S. Yue,¹ R. Busuttil,¹ J. Kupiec-Weglinski,¹ X. Wang,² Y. Zhai.¹
Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using ASTAGRAF XL^® Despite a Higher Degree of HLA Mismatch : A Post-Hoc Analysis of Phase III Data from Over 2000 Patients.

J. Schwartz, S. Wilson, F. Shi, N. Undre, M. Kumar.
Thoracic Simulated Allocation Modeling (TSAM) of Broader Sharing.

M. Colvin,¹ M. Skeans,¹ L. Robbins Callahan,² L. Edwards,² J. Zeglin,¹ S. Silvestry,³ R. Davies,⁴ M. Farr,⁵ A. Israni,¹ J. Rogers.⁶
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.

W. Yin.^1,2
Three Months of Weekly Rifapentine Plus Isoniazid for Latent Tuberculosis Treatment in Solid Organ Transplant Candidates.

B. Knoll,¹ R. Nog,¹ Y. Wu,² A. Dhand.¹
Three-Year Outcome After HSCT with Subsequent KT from the Same Haploidentical Donor without Immunosuppression.

C. Schwarz,¹ A. Lawitschka,² G. Böhmig,³ E. Dauber,⁴ H. Greinix,⁵ N. Kozakowski,⁶ F. Mühlbacher,¹ G. Berlakovich,¹ T. Wekerle.⁷
Thrombalexin: Detection & Efficacy of a Membrane-Bound Anti-Thrombin Agent.

M. Manook,^1,2 J. Kwun,¹ J. Yoon,¹ S. Sacks,² A. Dorling,² N. Mamode,² R. Smith,² S. Knechtle.¹
Thrombolytic Protocol in Organ Procurement from Donation After Circulatory Death Donors Reduces Ischemic Cholangiopathy in Liver Transplantation.

J. Fan, G. Selvaggi, W. De Faria, S. Nishida, A. Tekin, T. Beduschi, Y. Yushkov, R. Vianna.
Thrombotic Microangiopathy After Kidney Transplantation: A Rare but Serious Complication.

C. Teixeira, I. Pietrobom, A. Lima, N. Tenório, G. Basso, M. Cristelli, L. Viana, G. Kirsztajn, H. Tedesco-Silva, J. Medina-Pestana.
Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients.

Q. Huang, X. Luo, M. McAdams-DeMarco, D. Segev.
Tipping the Scales: Liver Transplant Outcomes of the Super Obese.

R. Gedaly, J. Berger, X. Mei, F. Marti, L. Turcios, M. Shah.
Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Protects Against Loss of Hepatic Integrity After Ischemia-Reperfusion Injury.

T. Fujii, S. Duarte, R. Busuttil, A. Coito.
Tissue Priming of Plasmacytoid Dendritic Cells Enhances Their Phagocytosis and Lowers the Threshold for Subsequent Toll-Like Receptor 7/9 Activation.

J. Ruben,¹ G. Garcia-Romo,¹ E. Breman,¹ S. van der Kooij,¹ A. Redeker,² R. Arens,² C. van Kooten.¹
Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.

H. Fernandez, S. Patel, M. Chiles, L. Ratner, R. Crew.
Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.

J. Budihardjo,¹ M. Iglesias,¹ J. Walch,¹ X. Calderon-Colon,² W. Lee,¹ G. Brandacher,¹ J. Patrone,² G. Raimondi.¹
Tool to Assess Risk of Non-Adherence in Renal Transplant Candidates.

T. Kaiser,¹ K. Daley,² L. Dick,² L. Deye,² N. Parrish,² J. Huff,² A. Govil,¹ B. Abu Jawdeh,¹ G. Mogilishetty,¹ R. Alloway,¹ E. Woodle.¹
Transcatheter Aortic Valve Replacement (TAVR) for Severe Aortic Stenosis as a Bridge to Liver Transplantation.

R. Syed, P. Cox-Alomar, H. Bohorquez, G. Therapondos, N. Girgrah, S. Joshi, G. Tyson, T. Reichman, I. Carmody, G. Loss, A. Cohen, D. Bruce, E. Ahmed, J. Seal, P. Parrino, S. Ramee, N. Bzowej.
Transplant Specialized Community Pharmacists' Role in Care Transitions for Transplant Patients.

D. Nguyen,^1,2 N. Rickles,² C. Rogers,³ K. Richards,³ J. Thomas,¹ A. Loring,¹ H. Kirkham,¹ M. Kang,¹ K. Poliskey.¹
Transplantation of Islet Preconditioned with Hydrogen Sulfide Enhances the Graft Function in Diabetic Mice.

D. Wang, M. Ding, J. Xue, J. Zheng, S. Feng, H. Tian, Y. Li.
Transplanting the Extremely Sensitized Patient: The University of Wisconsin Experience with the New Kidney Allocation System.

E. Grodstein, R. Bennett, J. Anderson, G. Press, A. Djamali, D. Kaufman, R. Redfield.
Transplants without Borders – A Project for In Locus Training of New Transplants Centers in Brazil.

M. Perosa,¹ J. Branez,¹ L. Mota,¹ B. Zeballos,¹ H. Noujaim,¹ L. Ianhez,¹ L. Alvim,¹ D. Machado,¹ M. Moreno,¹ T. Genzini,¹ R. Kandaswamy.²
Treatment for AMR and DSA: A Center Based Review of Pediatric Orthotopic Heart Transplant Recipients.

D. Drogalis-Kim,¹ M. Hickey,² J. Alejos,¹ E. Reed,² N. Halnon.¹
Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.

G. Einecke,¹ J. Bräsen,² A. Schwarz,¹ H. Haller,¹ F. Njau.¹
Treatment of Post-Transplant Focal Glomerulosclerosis: The Effect on Histopathology Lesions and Podocyte Foot Process Effacement.

K. Koutroutsos,¹ J. Moss,² L. Moran,² T. Cook,² R. Charif,¹ D. Taube,¹ C. Roufosse,² M. Loucaidou.¹
Treg-Rich Organized Lymphoid Structures (TOLS) in Spontaneously Accepted Mouse Kidney Allografts.

C. Yang,¹ E. Farkash,² D. Ndishabandi,¹ R. White,¹ B. Jiang,¹ I. Aljabban,¹ P. Russell,¹ J. Madsen,¹ R. Colvin,¹ A. Alessandrini.¹
Trends in Aspergillus Infection After Liver Transplantation, 1988-2014.

R. Al Masri, L. Jennings, S. Asrani, G. Klintmalm, C. Spak.
Trends in Liver Transplant Rates and Waitlist Survival.

M. Bowring, A. Massie, X. Luo, L. Kucirka, E. Chow, A. Cameron, D. Segev.
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.

R. Parekh, M. Segovia, N. Kaur.
Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study.

S. Steinberg,¹ R. Gedaly,² L. Chan,³ A. Langone.⁴
Type of Sensitization Does Not Impact Kidney Graft Outcome in Weakly Sensitized Patients.

A. Morrison,¹ D. Sawinski,² M. Lim,² M. Levine,¹ M. Kamoun,³ P. Porrett.¹
Understanding the Dynamics of a Suddenly Plateauing Kidney Waiting List.

A. Wilk, D. Stewart, E. Edwards.
Underweight BMI Is Associated with Graft Failure and Increased Mortality in Liver Transplant Recipients.

T. Alhamad,¹ N. Carlsson,² X. Liu,³ J. Wellen,⁴ J. Garonzik-Wang,⁴ S.-H. Chang.²
Unexpected Early Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.

M. Yanik,¹ R. Mannon,² M. Seifert.¹
Universal Stenting of Renal Transplants Associated with a Low Complication Rate When Quality Assurance Program Ensures Stent Removal.

C. Yeast, J. Riley, C. Ashbaugh, G. Ross, M. Wakefield.
Ureteroenterostomy in Kidney Transplant: Retrospective Analysis of 30 Consecutive Cases.

H. Marinho Neto, B. Leslie, J. Neves Neto, M. Almeida, A. Pessoa, J. Offernni, M. Nogueira, S. Ximenes, W. Aguiar, H. Tedesco, J. Medina Pestana.
Urgent Kidney Transplantation as Successful Treatment of Calciphylaxis in Three Patients with End-Stage Kidney Failure.

E. Nordheim,¹ D. Dahle,¹ I. Syse,¹ A. Åsberg,^1,2 A. Reisæter,¹ H. Holdaas,¹ T. Jenssen,^1,3 A. Hartmann.^1,4
Urinary CXCL9 Protein as Biomarker for BK Polyoma Viremia.

N. Sarabu,¹ R. El-Rifai,² J. Augustine,¹ A. Padiyar,¹ A. Huml,¹ T. Young,¹ V. Rodriguez,¹ D. Hricik.¹
Urinary Neutrophil Gelatinase-Associated Lipocalin in Living Kidney Donor Nephrectomy.

Y. Yoon,¹ H. Lee,¹ D. Joo,² K. Huh,² M. Kim,² S. Kim,² Y. Kim,² W. Han.¹
Urinary Tract Infections During the First Year After Renal Transplantation: Risk Factors and Nomograms.

C. Jironda, V. López, M. Cabello, A. Duarte, C. Gutiérrez, P. Ruiz, D. Burgos, D. Hernández.
Urinary Virome in Human Kidney Transplants Reveals Multiple Virus Subtypes with Distinct Genome Polymorphisms.

R. Ranjan,¹ A. Rani,¹ H. McGee,¹ D. Brennan,² P. Finn,¹ D. Perkins.^1,3
Urine IP-10 as the Biomarker for ABMR in Kidney Transplant Recipient with DGF.

N. Townamchai,¹ A. Leelahavanichakul,² J. Supapol,³ S. Wattanatorn,¹ Y. Avihingsanon,¹ K. Praditpornsilpa.¹
Use of Elderly Donors in Liver Transplantation: A Paired-Match Analysis at a Single Center.

D. Ghinolfi, Q. Lai, P. DeSimone, D. Pezzati, G. Cirillo, F. Filipponi.
Use of En-Bloc Vascularized Rectus Sheath Allograft to Achieve Abdominal Closure in Pediatric Liver and Multivisceral Transplantation.

J. Reddy, A. Rege, D. Vikraman, B. Collins, T. Brennan, S. Knechtle, D. Sudan, K. Ravindra.
Use of Preoperative Embolization Prior to Transplant Nephrectomy.

C. Yeast, J. Riley, J. Holyoak, S. Weinstein, G. Ross, M. Wakefield.
Use of the Psychosocial Assessment Tool to Identify Risk in Families of Pediatric Liver Transplant Recipients.

E. Fredericks, T. Smith, J. Sevecke, S. Eder, C. Limke, C. Shneider, M. Lopez.
Using 3D Printing in Complex Pediatric Renal Transplantation.

P. Chandak,¹ N. Byrne,² N. Karunanithy,³ C. Callaghan,¹ I. Mushtaq,⁴ S. Marks,⁴ J. Stajonovic,¹ Z. Ahmed,¹ N. Kessaris,¹ N. Mamode.¹
Using Gastrointestinal Biopsy to Predict Outcome in Patients Evaluated for Cardiac Transplantation for Amyloidosis: A Report from the International Consortium on Cardiac Amyloidosis Transplantation (iCCAT).

Y. Li,¹ K. Verkouw,¹ S. Tabtabai,¹ R. Barrios,² R. Gill,³ J. Koo,⁴ C. Marboe,⁵ E. Rodriguez,⁶ C. Tan,⁶ T. De Marco,³ J. Estep,² M. Hanna,⁶ M. Maurer,⁵ J. Patel,⁴ V. Selby,³ M. Semigran,¹ J. Stone.¹
Utility of a Scoring Tool for Living Kidney Donor Volunteers.

S. Lien,¹ L. Willey,² A. Lecuyer-Koich,² M. Voges,² T. Dunn.²
Utilization of Parenteral Nutrition in Patients Undergoing Liver Transplantation.

D. Liang,¹ S. Gordon Burroughs,¹ J. Nolte,¹ M. Boktour,¹ J. Ensor,¹ A. Ali,¹ T. Hirase,¹ J. Hall,¹ S. Spear,¹ L. Moore,¹ C. Mobley,¹ A. Saharia,¹ S. Hai,² A. Gaber,¹ R. Ghobrial.¹
Utilization of Subacute Rehabilitation Facility Early After Kidney Transplantation.

F. Luan, M. Ben-Israel, S. Mulgaonkar.
VO_2peak Outperforms Troponin T for Risk Prediction of Cardiovascular Disease and All-Cause Mortality in Patients with End Stage Renal Disease Being Evaluated for Kidney Transplant.

H. Chakkera,¹ C. Lee,² J. Dickinson,^1,2 B. Kaplan,^1,2 I. Qaqish,¹ S. Behmen,¹ R. Heilman,¹ H. Khamash,¹ J. Huskey,¹ S. Nair,¹ R. Scott,¹ D. Steidley,¹ M. Temkit,¹ S. Angadi.^1,2
Vaccination Compliance in Listed Kidney Transplant Candidates: A Retrospective Chart Review.

I. Tawhari,¹ C. Staffeld-Coit,² J. Garcia-Diaz.¹
Vaccination Status and Titers Before and After Pediatric Renal Transplantation: An Analysis of the CERTAIN Registry.

B. Höcker,¹ M. Aguilar,¹ P. Schnitzler,² L. Pape,² L. Dello Strologo,² N. Webb,² M. Bald,² G. Genc,² H. Billing,² J. König,² A. Büscher,² F. Thiel,² S. Marks,² M. Pohl,² M. Wigger,² R. Topaloglu,² A. Fichtner,¹ S. Rieger,¹ K. Krupka,¹ B. Tönshoff.¹
Vaccination of the Pediatric Patient After Transplantation – Attitudes and Knowledge of the General Pediatrician.

B. Gonzalez,¹ S. Worley,² A. Tang,² C. Saracusa,¹ J. Goldfarb.¹
Validation of the Kidney Donor Risk Index (KDRI) in the Australian and New Zealand Kidney Transplant Population.

P. Clayton,^1,2,3 S. White,^1,4 S. McDonald,^1,2,3 S. Chadban.^1,4,5
Validation of the Newly Developed North America Islet Donor Scoring System in the Medium Volume Islet Transplant Center.

J. Solomina,¹ S. Matosz,¹ M. Sledzinski,² J. Golebiewska,³ O. Savaril,¹ L.-J. Wang,⁴ T. Kin,⁵ K. Golab,¹ S. Ramachandran,¹ M. Tibudan,¹ L. Schenck,¹ W. Chon,⁶ C. Thomas,⁶ P. Witkowski.¹
Vascular Endothelial Cell Activation by Mitochondria Links Innate and Adaptive Immune Responses to Allograft Injury.

F. Feng, H. Xu, L. Lin, A. Kirk, T. Brennan.
Virological Profile of Deceased Organ Donors in the UK.

M. Lawrance,¹ K. Davison,¹ I. Ushiro-Lumb,² S. Lattimore (deceased),¹ S. Brailsford.^1,2
Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.

T. Pastrana-Camacho,¹ M. Bradley,¹ H. Winters,¹ S. Black,² K. Porter,³ K. Mumtaz.⁴
Virtual Crossmatching Under the New KAS: Safely Bypassing a Physical Crossmatch When Allocating Kidneys to Highly Sensitized Candidates.

R. Bray,¹ R. Parsons,² N. Turgeon,² H. Gebel.¹
Waitlist versus Population-Based Metrics of Access to Liver Transplantation: Comparing UNOS Waitlist Data and Nationally-Representative Data of Patients with End-Stage Liver Disease.

D. Goldberg,^1,2 B. French,² J. Lewis,^1,2 S. Halpern.^1,2
What Are the Benefits of Transvaginal Route for Kidney Extraction in Laparoscopic Living Donor Nephrectomy ?

S. Hurel,¹ M. Ariane,¹ F. Audenet,¹ C. Legendre,² A. Mejean,¹ M.-O. Timsit.¹
What Living Organ Donors See as Their Unmet Needs in the United States.

S. Fry-Revere, M. Middelman.
What if Mycophenolic Acid Product Is Discontinued Less Than 6 Weeks Before Pregnancy?

N. Sifontis,¹ L. Coscia,² D. Armenti,² S. Constantinescu,^2,3 M. Moritz.^2,4
When Liver Transplants and Procurement Occur at One Location – A National Study of Graft Survivals.

J. Ortiz,¹ N. Koizumi,² C. Kwon,² Y. Zhang,² C. Ortiz.³
Which Post-Transplant Complications Are More Common in Elderly Renal Recipients?

F. Agena, F. Paula, B. Reichert, P. Neves, A. Piovesan, W. Nahas, E. David-Neto.
Why Are Pancreas Transplants Declining in the United States in the Past Decade?

R. Stratta,¹ A. Gruessner,² J. Odorico,³ J. Fridell,⁴ J. Rogers,¹ A. Farney,¹ G. Orlando,¹ R. Gruessner.²
Will the New Kidney Allocation System Negatively Impact Future Organ Donation in States Mandated to Export a Large Number of Kidneys?

D. Mital,¹ E. Hull,¹ J. Brown,¹ C. Karmell,² M. Jendrisak.²
Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.

P. Ueno,¹ H. Tedesco,¹ A. Brigido,¹ C. Felipe,¹ P. Hannun,¹ M. Cristelli,¹ W. Aguiar,² J. Medina-Pestana.¹
Young Recipients Receiving Kidneys from Older Donors Have Poorer Allograft Outcomes.

A. Wardle, M. Willicombe, D. Goodall, A. McLean, D. Taube.
aPC Pretreatment of hEPCR-Expressing PAECs Attenuates Endothelial Cell Damage and Thrombosis.

C. Laird,¹ B. French,¹ D. Harris,¹ X. Chang,¹ D. Ayares,² R. Pierson,¹ A. Azimzadeh.¹
c-Kit⁺ Cells Are Kidney-Specific Progenitor/Stem Cells with Regenerative Potential.

S. Abreu Gomes,¹ G. Goss,² B. Goldstein,² B. Seidler,³ D. Saur,³ J. Hare,² E. Bevilaqua Rangel.¹
iNKT Cell Activation Under Co-Stimulatory Blockade Establishes Mixed Chimerism Through Thymic Regulatory T Cell Activation.

T. Hirai,¹ Y. Ishii,² R. Ishii,¹ S. Miyairi,¹ M. Ikemiyagi,¹ M. Okumi,¹ K. Tanabe.¹
iNKT Cell Ligands Administered with Bone Marrow Cells Expand Allo-Specific Regulatory T Cells In Vivo and Establish Transplant Tolerance.

S. Miyairi,^1,2 T. Hirai,¹ M. Okumi,¹ Y. Ishii,³ K. Yamazaki,² K. Tanabe.¹
Avoidance of CNI and Steroids Using Belatacept – A Preliminary Report of CTOT-16.

R. Mannon,¹ P. Stock,² A. Mehta,³ D. Ikle,⁴ N. Watson,⁵ N. Bridges,⁵ M. Robien,⁵ K. Newell.³
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.

S. Pol,¹ A. Aghemo,² L. Lin,³ R. Hyland,³ C. Yun,³ J. Spellman,³ M. Natha,³ D. Brainard,³ J. McHutchison,³ M. Bourlière,⁴ M. Peck-Radosavljevic,⁶ M. Michael,⁵ M. Colombo.²
Three-Year Graft Loss Risk in Kidney Transplants: Dynamic Patient Level Data Improve Predictive Efficacy.

T. Srinivas, J. Zhang, Z. Su, D. Taber, J. Marsden, K. Reilly, D. Northrup, J. Long, L. Lenert, W. Moran, P. Mauldin.
Would Transplanting Kidneys Currently Being Discarded in the US Place Programs at Risk for Regulatory Review?

J. Snyder, N. Salkowski, B. Thompson, A. Wey, A. Israni, B. Kasiske, S. Leppke.
A Single Histone/protein Acetyltransferase, Tip60, Is Absolutely Essential for Treg Survival and Function, and Its Inhibition Abrogates Induction of Treg-Dependent Allograft Tolerance.

L. Wang,¹ A. Beeler,² S. Dahiya,¹ R. Han,¹ W. Hancock.¹
Donor-Derived Toll-Like Receptor-Dependent Intravascular Monocytes Cause Primary Lung Graft Dysfunction.

S. Chiu, Z. Zheng, H. Sun, M. DeCamp, Jr, G. Budinger, H. Perlman, A. Misharin, A. Bharat.
Non-Human Primate Lung Allograft Survival Is Prolonged by IL-6 Inhibition and ATG Treatment Possibly Through Expansion of Peripheral Regulatory T Cells.

A. Aoyama, M. Tonsho, R.-N. Smith, R. Colvin, A. Dehnadi, J. Madsen, A. Cosimi, G. Benichou, T. Kawai, J. Allan.
Regulatory T Cell Infusion Can Enhance Memory T Cell and Alloantibody Responses in Lymphodepleted Nonhuman Primate Heart Allograft Recipients.

M. Ezzelarab,¹ H. Zhang,¹ L. Lu,¹ H. Guo,¹ A. Zahorchak,¹ R. Wiseman,² M. Nalesnik,³ J. Bhama,¹ D. Cooper,¹ A. Thomson.^1,4
Acute Rejection in Non-Human Primates Treated with Belatacept Is Mediated by a Unique CD8 Memory Subset.

D. Mathews,¹ W. Wakwe,¹ M. Lowe,¹ C. Breeden,¹ F. Leopardi,¹ A. Farris,¹ M. Song,¹ E. Strobert,² J. Jenkins,² C. Larsen,¹ R. Townsend,³ A. Adams.¹
Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the SIMCER Study.

F. Saliba,¹ C. Duvoux,² S. Dharancy,³ J. Dumortier,⁴ Y. Calmus,⁵ F. Di Giambattista,⁶ F. Conti.⁵
Novel Function of CD4⁺ T Cell DEPTOR in Treg Homeostasis and Alloimmunity.

J. Wedel,^1,2 S. Bruneau,^1,2 K. Liu,^1,2 N. Kochupurakkal,^1,2 M. Laplante,³ D. Briscoe.^1,2
Short Duration Perioperative Administration of Ledipasvir/Sofosbuvir Is Safe and Effective in Preventing HCV Recurrence After Liver Transplant.

E. Verna,¹ J. Levitsky,² J. O'Leary,³ N. Bzowej,⁴ D. Moonka,⁵ R. Hyland,⁶ D. Brainard,⁶ J. McHutchison,⁶ N. Terrault.⁷
HLA Identical Renal Transplant Tolerance Using Donor Hematopoietic Stems Cells (DHSC): Role of Immunoregulation.

J. Leventhal,¹ J. Mathew,¹ D. Salomon,² S. Kurian,² J. Friedewald,¹ L. Gallon,¹ X. Huang,¹ A. Tambur,¹ Y. Kanwar,¹ J. Charette,¹ M. Abecassis,¹ J. Miller.¹
Prevalence of Polyreactive Innate-Like B Cells Among Graft-Infiltrating B Cells in Human Cardiac Allograft Vasculopathy.

D. Chatterjee,¹ C. Moore,² B. Gao,³ K. Clerkin,¹ S. See,¹ D. Shaked,¹ K. Rogers,¹ S. Nunez,¹ Y. Veras,¹ L. Addonizio,¹ M. Givertz,⁴ Y. Naka,¹ D. Mancini,¹ R. Vasilescu,⁵ C. Marboe,⁵ S. Restaino,¹ J. Madsen,² E. Zorn.¹
Thoracic Simulation Allocation Modeling (TSAM) of a 6-Tier Allocation Strategy.

M. Colvin,¹ M. Skeans,¹ L. Robbins Callahan,² L. Edwards,² J. Zeglin,¹ S. Silvestry,³ R. Davies,⁴ M. Farr,⁵ A. Israni,¹ J. Rogers.⁶
A 5-Year Multicenter Evaluation of Seasonal Influenza Infection in Transplant Recipients.

D. Kumar,¹ E. Cordero,⁴ E. Blumberg,² A. Limaye,⁵ M. Levi,⁷ L. Danziger-Isakov,⁹ J. Englund,⁸ S. Husain,¹ F. Silveira,¹⁰ G. Reid,⁶ T. Sharma,³ A. Humar.¹
Outcomes Associated with Carbapenem-Resistant Enterobacteriaceae Infection After Solid Organ Transplantation in a Multicenter Study.

S. Huprikar,¹ L. Casner,¹ L. Camera Pierrotti,² A. Nellore,³ R. Madan,⁴ J. Garcia-Diaz,⁵ S. Jacobs,⁶ D. Lee,⁷ W. Trindade Clemente,⁸ G. Alangaden,⁹ R. La Hoz,¹⁰ N. Theodoropoulos,¹¹ M. Miceli,¹² G. Santoro-Lopes,¹³ D. Banach,¹⁴ D. Simon,¹⁵ G. Patel.¹
Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.

A. Chandraker, J. Kobashigawa, J. Stehlik, M. Givertz, R. Pierson, S. Pinney, M. Joren, S. Nissen, I. Guleria, Y. Morrison, B. Armstrong, N. Bridges, M. Sayegh, R. Starling.

« View all sessions from the 2016 American Transplant Congress